<SEC-DOCUMENT>0001493152-25-011971.txt : 20250814
<SEC-HEADER>0001493152-25-011971.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814160114
ACCESSION NUMBER:		0001493152-25-011971
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		251218435

	BUSINESS ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:GTBP="http://gtbiopharma.com/20250630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_031_GTBP_gtbiopharma.com_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20250101_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000005" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000007" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-04-012025-06-30" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-04-012025-06-30" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-04-012025-06-30" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0282" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0380" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IssuanceOfWarrantsForVrtWaiver" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:GainOnSettlementOfDebt" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:DividendOnSeriesLConvertiblePreferredStock" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_SeriesLConvertiblePreferredStockMember" id="xdx2ixbrl0757" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0800" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="xdx2ixbrl0833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0886" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0888" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1049" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1051" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1233" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1235" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1237" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1239" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1241" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl1243" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20250630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_SeriesLConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-04</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-14</xbrli:startDate>
        <xbrli:endDate>2025-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-14_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_InducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-22</xbrli:startDate>
        <xbrli:endDate>2025-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-22</xbrli:startDate>
        <xbrli:endDate>2025-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-11</xbrli:startDate>
        <xbrli:endDate>2025-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember14125843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-31</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_VestingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-172025-02-17_custom_ZOneLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:ZOneLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-17</xbrli:startDate>
        <xbrli:endDate>2025-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-07-08_custom_CobySilberfeinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-092025-07-09_custom_CobySilberfeinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-09</xbrli:startDate>
        <xbrli:endDate>2025-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember14126828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-20</xbrli:startDate>
        <xbrli:endDate>2024-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-18</xbrli:startDate>
        <xbrli:endDate>2025-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-28</xbrli:startDate>
        <xbrli:endDate>2025-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-27_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000756" toRefs="Footnote000767"/>
  <ix:relationship fromRefs="xdx2ixbrl0757" toRefs="Footnote000767"/>
  <ix:relationship fromRefs="Fact000783" toRefs="Footnote000820"/>
  <ix:relationship fromRefs="Fact000784" toRefs="Footnote000820"/>
  <ix:relationship fromRefs="Fact000786" toRefs="Footnote000820"/>
  <ix:relationship fromRefs="Fact000788" toRefs="Footnote000820"/>
  <ix:relationship fromRefs="Fact000870" toRefs="Footnote000893"/>
  <ix:relationship fromRefs="Fact000872" toRefs="Footnote000893"/>
  <ix:relationship fromRefs="Fact000874" toRefs="Footnote000894"/>
  <ix:relationship fromRefs="Fact000876" toRefs="Footnote000894"/>
  <ix:relationship fromRefs="Fact000878" toRefs="Footnote000895"/>
  <ix:relationship fromRefs="Fact000880" toRefs="Footnote000895"/>
  <ix:relationship fromRefs="Fact000882" toRefs="Footnote000895"/>
  <ix:relationship fromRefs="Fact000884" toRefs="Footnote000895"/>
  <ix:relationship fromRefs="xdx2ixbrl0886" toRefs="Footnote000896"/>
  <ix:relationship fromRefs="xdx2ixbrl0888" toRefs="Footnote000896"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20250101__20250630_zikTFUPnOrmh"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentQuarterlyReport_c20250101__20250630_zsULSmQNl7Ge"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarterly
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20250101__20250630_zPYXV3RqSqlc"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_903_edei--DocumentFiscalYearFocus_c20250101__20250630_zm6MjHXfDJO"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000016" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentTransitionReport_c20250101__20250630_zPXQqNyNGMV1"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transition
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from __________ to ____________.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_908_edei--EntityFileNumber_c20250101__20250630_zJpVUrpsFTLj"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000018" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20250101__20250630_zBG7pOJPJASh"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000019" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20250101__20250630_zMUezMPhTfqi"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250101__20250630_z8PmfQyHD4f2"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000021" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
                                            or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
                                            Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A<sup>1</sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--CityAreaCode_c20250101__20250630_zn6q8EVv0mCf"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000022" name="dei:CityAreaCode">415</ix:nonNumeric></span>-<span id="xdx_904_edei--LocalPhoneNumber_c20250101__20250630_zGSVRenfLxWg"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000023" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20250101__20250630_zb9eZqnjriEd"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000024" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20250101__20250630_zka8jzxK6lqk"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000025" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20250101__20250630_znZFQu6UmDoi"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:exchnameen" id="Fact000026" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20250101__20250630_z2WhjSm6Yz1j"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000027" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_902_edei--EntityInteractiveDataCurrent_c20250101__20250630_zWDpyiqPvX1a"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000028" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20250101__20250630_zenHHq7bdY02"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000029" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_903_edei--EntitySmallBusiness_c20250101__20250630_zafnCZpSNQ1b"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000030" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20250101__20250630_zyF1vL4IujW"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000031" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_903_edei--EntityShellCompany_dbF_c20250101__20250630_zf0iNihKTn48"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000032" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 8, 2025, the registrant had <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250808_zSWH03UVUIk5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-08-08" id="Fact000033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,557,502</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><sup>1</sup></b></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of July 1, 2024, the Company became a fully remote
company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act
of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company&#8217;s
principal executive offices may be directed to <span id="xdx_900_edei--EntityAddressAddressLine1_c20250101__20250630_z1F61UngoQWk"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000034" name="dei:EntityAddressAddressLine1">505 Montgomery Street</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20250101__20250630_z0fvyZJG5uJe"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000035" name="dei:EntityAddressAddressLine2">10th Floor</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20250101__20250630_zksqAsjfsuFb"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000036" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20250101__20250630_zfsz77Ijbrkk"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:stateprovnameen" id="Fact000037" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250101__20250630_z1tDuiwSIAy6"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000038" name="dei:EntityAddressPostalZipCode">94111</ix:nonNumeric></span>, or by email to auditcommittee@gtbiopharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-Q</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Six Months Ended June 30, 2025 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Condensed
    Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Condensed
    Statements of Operations for the three and six months ended June 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Condensed
    Statements of Stockholders&#8217; Equity (Deficit) and Mezzanine for the three and six months ended June 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Condensed
    Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Notes
    to Unaudited Condensed Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">PART
    II OTHER INFORMATION</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Item 1A.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#b_001">Risk Factors</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Item 2.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#b_002">Unregistered Sales of Equity Securities and Use of Proceeds</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Item 3.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#b_003">Defaults Upon Senior Securities</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Item 4.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#b_004">Mine Safety Disclosures</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Item 5.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#b_005">Other Information</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Condensed
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zcHRBXMw1dTi" summary="xdx: Statement - Condensed Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250630_zh9MjdOijgmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zPyU8osjQrk7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_z3BZcarb1YU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zna7NRuRsjRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzFeu_zBXRNxTinDx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,228,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,951,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_i02I_maCzFeu_zLQDTfipxrb4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2025-06-30" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2024-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredOfferingCosts_i02I_maCzFeu_z5PtrH9ImE9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred offering costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-06-30" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0053">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzFeu_zGMvwrnFsla8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,043,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzFeu_zDYx6W3ShXjj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,124,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zO8HDd083QH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES, MEZZANINE
    EQUITY AND STOCKHOLDERS&#8217; DEFICIT</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_z1wXD6n4zBo9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCz1PN_zIBJ41U8blQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz1PN_zY3bOvZ9Shci" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,797,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPayableCurrent_i02I_maCz1PN_ziajnXUsm3Kh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2025-06-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0074">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilityCurrent_i02I_maCz1PN_zSuHb0DhAp6d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrant
    liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i01TI_mtCz1PN_maLASEz75V_z7FlRThdc882" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,307,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,902,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_i01B_zTPNUx9L0tCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Mezzanine Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_maLASEz75V_zlUuDxurrId9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Preferred stock,
    par value $<span id="xdx_902_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zRQEx5FeHDBg" title="Convertible Preferred stock, par value"><span id="xdx_90D_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zisjtw4ZhGZd" title="Convertible Preferred stock, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember" id="Fact000088" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000090" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z3xA3UPiBEJ9" title="Convertible Preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z0vOih5HJBjg" title="Convertible Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember" id="Fact000092" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000094" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized Series L - <span id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_ztZOHibdIyI3" title="Convertible Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zmiU8Ab4rFc1" title="Convertible Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember" id="Fact000096" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember" id="Fact000098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,301</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90C_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zUYPhFwdv9X5" title="Convertible Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zeSnHX9Q5Rij" title="Convertible Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2025 and December
    31, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0086">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; Equity (Deficit)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_maSEzD3S_z37IVsaP8cY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Preferred stock,
    par value $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ze78M2zfDFG" title="Preferred stock, par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zD67o4ZejA63" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXSJ44DhziS7" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z1MSgMTnQpr9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized Series C - <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z6KspVqAaeN3" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zeiG5HrU8Bkg" title="Preferred stock, shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zfPFA3MBoVRh" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXEnwMVxkF6d" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of June 30, 2025 and December 31,
    2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maSEzD3S_zToMKiPSAwHl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250630_zygSlGjb9vV6" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_ztYIqfw2ftk6" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_zLsdBv9LFal7" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zt9AKJlxZmo7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20250630_zOIH8hmVarC2" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250630_zUWnxpfxE39l" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,272,995</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zRtKaD41BYxc" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zqul8BagpME3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapital_i02I_maSEzD3S_zQTujaqqMwZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,378,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzD3S_zuSWMTQTOII2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000148" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">697,521,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_mtSEzD3S_maLASEz75V_z1e4zWPDXhG3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders&#8217; Equity (Deficit)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,861,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz75V_zGJu4N38mI64" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,124,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Condensed
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zGk7YtCubilj" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20250401__20250630_zmltfgq68F2g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240401__20240630_zN6w6lexAxeg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20250101__20250630_zrQi2xMcq9b6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20240630_zjJNTqoZUSo4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The Three
    Months</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the Six
    Months</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ended
    June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ended
    June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCziGa_zBteizmwvxid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0157">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0158">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0159">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zVPwuHmgQFy6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_msCziGa_zFadb3cLb1Yg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and
    development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-012025-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,784,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,462,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,561,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_msCziGa_zzU7c757AWf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Selling,
    general and administrative (including $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zw5Yl2VSZ2dc" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zoiy1ZREopr6" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> from stock compensation for the three months ended June 30, 2025 and 2024,
    respectively, and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zY9UyFhuAcWb" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_z5yVUiKrDucd" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span> for the six months ended June 30, 2025 and 2024, respectively)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-04-012025-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,122,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,983,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,436,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCziGa_maNILzSIF_zlp5rtRRp5l8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss from Operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000185" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,513,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,906,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,445,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,997,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z85zOZRhhV3l" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--InterestIncomeOther_i01_maNIEzVlj_zYPG3tMOfmi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-04-012025-06-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-04-012024-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-01-01to2025-06-30" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-012024-06-30" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzVlj_zTeGSDNsMj0h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value of
    warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-04-012025-06-30" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-04-012024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">117,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-06-30" id="Fact000203" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">775,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzVlj_zUnFCNu6DQ41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of vendor
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0208">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzVlj_zrPKVOJCLND7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-012025-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_maNIEzVlj_zW1HnWotu0h3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    gain on short-term investments</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-04-012024-06-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-06-30" id="Fact000218" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_maNILzSIF_mtNIEzVlj_zTamZ89jvnU9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Other Income (Expense), Net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-04-012025-06-30" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-06-30" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtNILzSIF_maNILATzw02_zrNRCfvUGj45" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,433,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,209,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILATzw02_zh287R7SpA43" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividends on preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2025-04-012025-06-30" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2025-01-01to2025-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzw02_zslXL0Y7bpUk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss attributable to common stockholders&#8217;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-04-012025-06-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,518,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-012024-06-30" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,294,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-06-30" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Per Share - Basic and Diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20250401__20250630_zxVXp1Lwste7" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pid_c20250401__20250630_zH9g56o3qSB2" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-04-012025-06-30" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-012025-06-30" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.55</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20240401__20240630_zmygftPrk9G5" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20240401__20240630_z4UVU5m1UdD1" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.17</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250630_zOozajTbJst2" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250630_zxgUWALonqhh" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-06-30" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.90</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240630_zvgtjX15rNC9" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240630_zV52CvrYoUOc" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.86</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - basic and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250401__20250630_zZMlvyTZS1S4" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250401__20250630_zOp6kqiw78yd" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,771,765</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240401__20240630_zKZzXmcd1mr2" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240401__20240630_zcAzeZsVm6o6" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,711,955</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250630_zng7YfKgLVw1" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250630_za2L2NPkL2qg" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-06-30" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,559,604</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240630_zgBihj7kqV96" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240630_zSYsdj84UZ7i" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,546,294</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>CONDENSED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) and MEZZANINE EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Three and Six Months Ended June 30, 2025 and 2024 (Unaudited):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_ztGy2INgei57" summary="xdx: Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zziObHGDoKqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zfybLQmwodh2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zuQpV0Dl3W3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zzQoHZtPwBH" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_zq5ahTxKd987" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="13"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>
                     <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Mezzanine
    Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            C </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span><span style="font-family: Times New Roman, Times, Serif"><br/>
                                            <b>Equity</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            L </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_435_c20250401__20250630_eus-gaap--StockholdersEquity_iS_zEgHaJzimhxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zUGhGEVHgPq1" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFStt05zuqIe" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,536,397</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,019,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">696,003,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">980,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zRELqbB352W3" title="Mezzanine equity balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z5nFMWJQ9Gkf" title="Mezzanine equity balance" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_zwVyjYhrfrw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants for
    cash and inducement warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6g6wt48prpk" title="Exercise of warrants for cash and inducement warrants, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-04-012025-06-30" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zHp9WQ6QWv28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series L convertible preferred
    stock and warrants issued for cash, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250401__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember_zJIAykVPx5Oe" title="Series L convertible preferred stock and warrants issued for cash, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z5PsYW1giRE3" title="Series L convertible preferred stock and warrants issued for cash, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zSfqOlYY5IH5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series L
    convertible preferred stock into common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLN63k1TJJG" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zGsod6Qb15R5" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000312" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">310</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfeEFBYfuOG" title="Conversion of Series L convertible preferred stock into common stock" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_zb17PwGm8we4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance and exercise of
    prefunded warrants for ELOC fee</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVZV6k2uVZj4" title="Issuance and exercise of prefunded warrants for ELOC fee, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-04-012025-06-30" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zehITGmqT6t3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    and warrants for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsMu5HUUxSe2" title="Issuance of common stock and warrants for services, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-012025-06-30" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueOther_zzQipcau3Fjg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants for
    VRT waiver</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-04-012025-06-30" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DividendsPreferredStock_iN_di_zjgGGCg8xpbj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend on Series L convertible
    preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-04-012025-06-30" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zfN1PKsC2xb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-04-012025-06-30" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zrz8NXrpemog" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,433,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,433,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20250401__20250630_eus-gaap--StockholdersEquity_iE_zzqRoLsnnpcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zL5AMfJT5SGg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxnw5wViF3p9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,272,995</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,378,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">697,521,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,861,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZsCTNXHkIbd" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,301</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zgeor1n4btp" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,956,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Mezzanine
    Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            C </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span><span style="font-family: Times New Roman, Times, Serif"><br/>
                                            <b>Equity</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            L </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_431_c20250101__20250630_eus-gaap--StockholdersEquity_iS_zVRlLqv3BzRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zMkVcgXfCZf9" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9JM2PaxOkI4" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zx7nHfQfsLla" title="Mezzanine equity balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zGqlKBRNqZy8" title="Mezzanine equity balance" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_zrZGJHZRMmO4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants for
    cash and inducement warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbtWAVBSIL2d" title="Exercise of warrants for cash and inducement warrants, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">537,069</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,051,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-01to2025-06-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zI08ohwRSLZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series L convertible preferred
    stock and warrants issued for cash, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-01to2025-06-30" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember_z5cxgTBoRHfb" title="Series L convertible preferred stock and warrants issued for cash, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z4ptLfBqs4De" title="Series L convertible preferred stock and warrants issued for cash, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zgKch1QfX9J7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series L
    convertible preferred stock into common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMUnfdLh9j7" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-01to2025-06-30" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zdexGztyEBQl" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">310</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z0d7I6YYuRG7" title="Conversion of Series L convertible preferred stock into common stock" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_ztuFNhMxLIx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of prefunded warrants
    in settlement of vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-01to2025-06-30" id="Fact000418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_zGbAIrBoKfe2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance and exercise of
    prefunded warrants for ELOC fee</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z10h434XoJn4" title="Issuance and exercise of prefunded warrants for ELOC fee, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-01to2025-06-30" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zuEb2ZyM8xqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    and warrants for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgigVxgQX2ul" title="Issuance of common stock and warrants for services, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-06-30" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueOther_zaw2Zd3zSGxd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants for
    VRT waiver</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-01to2025-06-30" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DividendsPreferredStock_iN_di_zwIBn2T3aVse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend on Series L convertible
    preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-01to2025-06-30" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zo3rOjwMpfn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-06-30" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zjJJIpBA2Od2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,209,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,209,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_431_c20250101__20250630_eus-gaap--StockholdersEquity_iE_zj2qPRW5KlGb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zt3ekOBZOW29" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPQaYmYars31" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,272,995</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,378,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">697,521,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,861,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zxcXe43WUTxk" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,301</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_ztsfQ6pLt5D1" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000472" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,956,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Three and Six Months Ended June 30, 2025 and 2024 (Unaudited):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zAHeIc6mdxG4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zHPaKN20oLUk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zIy3JRFGls7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zaZMNmiadv67" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_zb0iRVlZXHUk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            C </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_431_c20240401__20240630_eus-gaap--StockholdersEquity_iS_zDq2azI7pe51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbQExla3sOB5" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000480" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZmpoN5zRqQc" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,653</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,641,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,331,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,312,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_zQOn08e48aAg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    and warrants for cash, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIpsSOsAEwV6" title="Issuance of common stock and warrants for cash, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">740,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,975,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-04-012024-06-30" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_iN_di_zfYavo71VhPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cancellation of common
    stock previously issued to prior CFO</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iN_pid_di_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znm4F6OnyO5l" title="Cancellation of common stock previously issued to prior CFO, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,902</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_zoMMH6om3Ok8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    in settlement of vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2vSeYNMQPSj" title="Issuance of common stock in settlement of vendor payable, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-06-30" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_ze88VZZc2QA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-04-012024-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zA8tjanLh2sd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0516">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000518" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,710,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43A_c20240401__20240630_eus-gaap--StockholdersEquity_iE_zOc0wgo6dFs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zyCUoVxA7bW3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztEScMEQwjbg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000523" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">688,041,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,508,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
                                            C </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
                                            Shares</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid
                                            in</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43D_c20240101__20240630_eus-gaap--StockholdersEquity_iS_zAoyA8O2Us5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zhE5QOfjrzL7" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXAsGmr3xx86" title="Balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000538" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,653</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000532" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000533" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43E_c20240101__20240630_eus-gaap--StockholdersEquity_iS_z29t3ZN4pwwa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znN93wZmfJUh" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000546" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRNAld2EI0zc" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,653</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_zo3IctQbX5Ji" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    and warrants for cash, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z31eLQXjVlAk" title="Issuance of common stock and warrants for cash, net, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">740,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,975,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-06-30" id="Fact000554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_iN_di_zSRW9iC1YbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cancellation of common
    stock previously issued to prior CFO</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iN_pid_di_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4TO4Fcnrxy7" title="Cancellation of common stock previously issued to prior CFO, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000564" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,902</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_zlivqKQ2Rw28" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock
    in settlement of vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPnoSPNIVJz3" title="Issuance of common stock in settlement of vendor payable, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zNqmEGA3Pt8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair value of vested stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0575">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zmL0QjhaYp6c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000583" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000584" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_439_c20240101__20240630_eus-gaap--StockholdersEquity_iE_zCh60LNoPmU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zgqJoNjeV2Oh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000592" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSeVwiY5q1qf" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000589" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">688,041,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,508,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43C_c20240101__20240630_eus-gaap--StockholdersEquity_iE_zVlDU0Yc8lul" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zrGNka0wiD6g" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJsjA9QWeiZf" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000599" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">688,041,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,508,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Condensed
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zBc4Rxge5mlc" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20250101__20250630_zvvhorDR5vX6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240630_zrCn6tgu3IZ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For The Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zb429pVVqStl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maNCPBUzih0_z5EZM2N8nxDd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000609" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,209,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000610" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ztVYalPx8md4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_maNCPBUzih0_zvOLebTsBBY3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-06-30" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfWarrantsForVrtWaiver_i02_maNCPBUzih0_zpBpcNY54eN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants for
    VRT waiver</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:IssuanceOfWarrantsForVrtWaiver" contextRef="From2025-01-01to2025-06-30" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzih0_zGwVQiZtAy44" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value of
    warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-06-30" id="Fact000621" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-06-30" id="Fact000622" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">775,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzkoF_msNCPBUzih0_zY7qaTems4gh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-06-30" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainOnSettlementOfDebt_i02N_di_msNCPBUzkoF_msNCPBUzih0_zPIBjkjmLYb4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain on extinguishment
    of debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="GTBP:GainOnSettlementOfDebt" contextRef="From2025-01-01to2025-06-30" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0628">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DebtSecuritiesUnrealizedGainLoss_i02N_di_msNCPBUzih0_zfgaxTlC9lrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain on short-term
    investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-06-30" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z6YXwLoCaK7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzih0_zXYuhUsLXJ36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Increase) Decrease in
    prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-06-30" id="Fact000637" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzih0_zaAu1TSQuv9d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease in accounts payable
    and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-06-30" id="Fact000639" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,623,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-06-30" id="Fact000640" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,231,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInOperatingLeaseRightofuseAssets_i03N_di_msNCPBUzih0_zQlv0Sbj7JF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">(Increase)
    in operating lease right-of-use assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="From2024-01-012024-06-30" id="Fact000643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCz2Bm_mtNCPBUzih0_zqXpwOdHhQcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Used in Operating
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000645" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,216,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-06-30" id="Fact000646" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,699,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z83FjlOYqkg5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForProceedsFromInvestments_i01N_di_msCzXLW_zUcq9fMTooqd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Sale of investments</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0651">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2024-01-012024-06-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,893,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzXLW_maCCERCz2Bm_z81Y90qSUgXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Provided by Investing
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-06-30" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,893,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zVy2u67axFf3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUznTA_zzTw3zUPiYk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants and
    issuance of inducement warrants for cash, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-06-30" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0661">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maNCPBUznTA_zLoEqnv7nq9i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from issuance
    of common stock and warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-06-30" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_i01_maNCPBUznTA_zzw2gtF6f3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from issuance
    of Series L convertible preferred stock and warrants, net</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-01-01to2025-06-30" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,441,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUznTA_maCCERCz2Bm_ztV1Ww3EQkBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net Cash Provided by Financing
    Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,493,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-06-30" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz2Bm_zKzXGUzFiSS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Increase in Cash and Cash Equivalents and
    Restricted Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-06-30" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,277,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-06-30" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,170,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zPt5L20iGVP1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents
    and Restricted Cash at Beginning of Period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,044,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,079,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z8DQMKeMB3Hk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and Cash Equivalents
    and Restricted Cash at End of Period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,321,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,249,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zmu1QtHCxw97" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF CASH FLOW INFORMATION:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--CashPaidDuringYearFor_i01B_zyhVVkYyFZH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid during the period for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InterestPaid_i02_zgIz9QR6n0yk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxesPaidNet_i02_zGaiM4vz2ts9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zFIwC34qIcY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF NON-CASH INVESTING AND FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction_i01_zB794rS0dGjb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair
    value of vested warrants issued in Series L conv. preferred stock transaction</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" contextRef="From2025-01-01to2025-06-30" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--FairValueOfPrefundedWarrantsIssuedForElocFee_i01_zbMFO28rxlD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value of prefunded warrants issued for ELOC fee</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee" contextRef="From2025-01-01to2025-06-30" id="Fact000699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssued1_i01_z0tchkF7nEu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value of common stock and warrants issued for services</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2025-01-01to2025-06-30" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable_i01_zkiWUXBUPHTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value of prefunded warrant or common stock to settle vendor payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" contextRef="From2025-01-01to2025-06-30" id="Fact000705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" contextRef="From2024-01-012024-06-30" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DividendOnSeriesLConvertiblePreferredStock_i01_zVH7E9bTQLQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Dividend
    on Series L convertible preferred stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:DividendOnSeriesLConvertiblePreferredStock" contextRef="From2025-01-01to2025-06-30" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ConversionOfStockAmountIssued1_i02_zlCoSBoXhjN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Conversion
    of Series L convertible preferred stock into common stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2025-01-01to2025-06-30" id="Fact000711" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
and Six Months Ended June 30, 2025 and 2024 (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000714" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zLEV62EVlkn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_z9TKPvbm3UX3">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The
Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future.
Historically, the Company has financed its operations through public and private sales of common stock, the issuance of preferred
and common stock, the issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30,
2025, the Company recorded a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zpENKaWznPqb" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000716" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">2.2</ix:nonFraction></span>
million and used cash in operations of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zlO6G3zoUVT3" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000718" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.2</ix:nonFraction></span>
million. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of
the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm,
in its report on the Company&#8217;s December 31, 2024, financial statements, raised substantial doubt about the Company&#8217;s
ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000720" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zbhqx6OdlYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_824_z2ZMo578HY9a">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000722" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_84B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1yDj5UG7pt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zR6OwY5RDU07">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000724" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_zhEdzgSn4ROd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z7BcxPB2Ntg2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000726" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4SjGrr2hpN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zC5etwP6Mndk">Cash
Equivalents</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At June 30, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_zlw5dHhPhBak" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000728" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zTHlkxQTmVR6" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span> million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000732" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zuLfr8H4lvzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zpLohf8KFOt1">Restricted
Cash</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The
Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the
same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000734" name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"><p id="xdx_84E_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zrw9QSB92Pmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z9tYdQmnwDFj">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses.&#160;As of June 30, 2025, there was $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250630_z39qRWhw9aui" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-06-30" id="Fact000736" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span>&#160;million of deferred offering costs on the consolidated balance
sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000738" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBNOjN3ZtlO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zNr1pr6PKkog">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_900_ecustom--WarrantLiabilityCurrent_iI_c20250630_zeY6Pis1mQQg" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_z95d9INiBjZ6" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span> at June 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000744" name="GTBP:WarrantLiabilityPolicyTextBlock"><p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zzjREssO3MYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z0SMOmeygsmk">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000746" name="GTBP:MezzanineEquityPolicyTextBlock"><p id="xdx_84B_ecustom--MezzanineEquityPolicyTextBlock_zhhC9ZWZiqCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfB9zpdQRTsf">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000748" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z5VdWMBCHuWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zdDJNBitkyR">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000750" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVFnZfwbYQCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B5_zSKXQcRn5Ve">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000752" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z79HEwK8goC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zTcM4jjU8cec">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000754" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z8nUnOa1arL9" style="display: none">Schedule of Anti-dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible
    preferred stock <b><sup id="xdx_F4E_zNIpjxvAfxFj">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,084,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,751,669</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,133,762</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-06-30" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,960,651</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,260,027</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000767" xml:lang="en-US">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-06-30" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, as of June 30, 2025</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AB_zHlsfpWsJME3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000771" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z68Myz1d8pI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ztAeaEzQPvtf">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20250630_zxroiafA4Vy7" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-06-30" id="Fact000773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000775" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2yEebsh9Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zp5MBuogswXa">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000777" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztoQDRMqA6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zabjQIR5FpHc">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

</ix:nonNumeric><p id="xdx_854_zSphDe2DYUz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000779" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFyidnjsY8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82F_zeNVb29eQlfi">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000781" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLoADPOTcSZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z5xdaPWmqwL6" style="display: none">Schedule of Accounts Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250630_zqT9xxd4ApCb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zAQeoUhxNx27" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, <br/>
    2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zn3m6wkeYMui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to Cytovance, a related party <b><sup id="xdx_F42_zWvCot73Bpz4">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">598,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zlF7tyJeMuH7" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zn43xrZCRtr1" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zNbhlRSfuPb5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University
    of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30_custom_UniversityOfMinnesotaMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zD4p7hdqONKa" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-06-30_custom_UniversityOfMinnesotaMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zx9a0O4DQCL3" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z3qTuviRILM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zYBl9cG3c2xf" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zi6GWXtUKJge" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000802" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zRjY8xRkQrs5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zMdk2AEfa6f1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2025-06-30_custom_OtherAccountsPayableMember" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zcWnGQ4VuzWb" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-06-30_custom_OtherAccountsPayableMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNUhi0cHgKul" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zyUoH1ArR81a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630_zzldxFzUBNx7" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-06-30" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zfUyh2Qpl2Hg" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F02_zzW27guC4jY5">1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zS1vfydUx7A3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000820" xml:lang="en-US">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8AA_zIHPIENRySpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000822" name="GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zfPzkRmitlG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B7_z2szJcyXcmNk">Schedule of Accounts Payable to Related Party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250101__20250630_zeZOS0OUYWXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240630_z5rRWGsXn3Nc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zbQUuhGvsRSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,515,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9GeCP6JTmU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">626,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTM2XvgnEZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,641,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zH6PoVGKIThl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in common stock,
    at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIcmYJ9ZRH57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments
    in pre-funded warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zBF3iIgEViI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">598,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zIhslV6GwNO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and June 2024, the Company issued an aggregate of <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB8ZdmFhN50d" title="Issuance of prefunded warrant to settle vendor payable, shares"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></span> shares of common stock with a fair value of approximately $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20240101__20240630_zXo5H3a32y47" title="Issuance of prefunded warrant to settle vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2024-01-012024-06-30" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span> to
Cytovance as partial payment of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjDXuHDRqfm2" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares of common stock exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7vYly99QAUd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share
with a fair value of approximately $<span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zzVzGpSsxzn3" title="Payments in pre-funded warrants, at fair value"><ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></span> to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpLm4km7m4O5" title="Prior year unpaid fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember" id="Fact000852" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million. The Company classified this transaction as other income during the period ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000854" name="GTBP:WarrantLiabilityTextBlock"><p id="xdx_808_ecustom--WarrantLiabilityTextBlock_zOlz8YeTr0Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_82E_zyauPDLekUS2">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate
of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zovNsnTgRgDk" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,667</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zWtWlFYy0kL1" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_z4lKmWtLNMLg" title="Volatility amount utilized in the value calculation percentage"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zsyEGhgEAUGl" title="Warrant  fair value"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000862" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember" escape="true" id="Fact000864" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zvN0uJtHZ0Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zj5GFkPO6bY1" style="display: none">Schedule of Warrant Liability Assumptions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zMRaoSHMbGci" title="Warrants measurement input" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-06-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.58</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zOEchUvwyMma" title="Warrants measurement input" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zR4NEA7W5L54" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.68</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zUghOTnWsWWi" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z7DEEYXKYyrh" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-06-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zUiUML0kgpkj" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____z8DPmaUwmuz6" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000878" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.5</ix:nonNumeric></span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zXBAlpEzUHif" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000880" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.0</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zP2IqcNqlPej" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000882" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.0</ix:nonNumeric></span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zb5TRxpqlamj" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000884" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.50</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zHDWhiBMoW8l" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zVd24N3s9O86" title="Warrants measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zSBeyTu8ftGi" title="Fair value of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zx5PEV1dsO5b" title="Fair value of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0B_zMY6SPzd685c"><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1D_zPSDqIoGOGi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000893" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zbMpmvqZUpyf" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F18_zM3f9fFjxWu3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000894" xml:lang="en-US">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0F_z7vjk12pZ6Sa"><sup>3</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1B_z4fCAsr4Xz53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000895" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F00_z6cW6eqbfiDa">4</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F18_zfI28UCMF0N6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000896" xml:lang="en-US">Based on no dividends
paid or expected to be paid</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A6_zGCiIYluZunb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000898" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLe24w7itmB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zQqix48w7G1l" style="display: none">Schedule of Warrant Liability Transactions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20250630_zhVN18dsfG8j" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20240630_zPEwsW5r4H1e" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zH5wLvB2rDkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_z94fK3t2S4zf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at
    fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zn1u4FH4ak8b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2025-01-01to2025-06-30" id="Fact000906" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2024-01-012024-06-30" id="Fact000907" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">775,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zcihmlUBCKf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zd0T0KijeE01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zcMXOpmsNzE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000915" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9LePaa2nNHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_827_zspFBQN2pBwk">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of June 30, 2025 was <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_zmTL5pJtTJIf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250630_zpHuDjFmZ4fc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250630_zEVcGcYZERth" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630_zmtZZfO8SmW3" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Equity Facility</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#8220;Purchase
Agreement&#8221;) with investors (collectively, the &#8220;Investors&#8221;) relating to a committed equity facility (the
&#8220;Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to
the Investors up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF7eF2GrWFK8" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember" id="Fact000925" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span>
million of its common stock subject to certain conditions and limitations set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the
Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market
conditions, the trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of
such shares of common stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and
prices at, which the shares of common stock are sold to the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be <span id="xdx_90C_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7ddTMl6SBce" title="Weighted average volume price of common stock percentage"><ix:nonFraction name="GTBP:WeightedAverageVolumePriceOfCommonStockPercentage" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span>% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to
purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCv1LOuVrsOd" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span>
shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zZ30HP9Ugi3i" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-02-262025-02-26" id="Fact000931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">686,000</ix:nonFraction></span> before deducting placement agent fees and other offering expenses
of $<span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zge4LiRJJlec" title="Other offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-02-262025-02-26" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span> in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zW0ZQlglhOAi" title="Issuance of warrants, exercisable"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2025-02-26" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of the Company&#8217;s common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zectYv7kG3tj" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-02-26_us-gaap_CommonStockMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span> per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zep4Qz0Hgg6j" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span> per share in exchange for the Company&#8217;s agreement to issue the holders new warrants
(the &#8220;Inducement Warrants&#8221;) exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zYlSb9FEM1fi" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,138</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zb96CDLdLc7" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zGQqpzO5dZt" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zD47LyZzbrhe" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000947" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zczLTEjo14Ef" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zXylTgIAvtB7" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately
upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zbzA4hNPEAXd" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000953" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen months</ix:nonNumeric></span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_z1OESNPFBh17" title="Placement agents"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zRlrlaV0737g" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zcTUxLso45Nd" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26" format="ixt-sec:durwordsen" id="Fact000959" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250630_zD6aQk1WrWEl" title="Equity issuance cost"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-06-30" id="Fact000961" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Series L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, and as amended on May 21, 2025, the Company entered into a securities purchase agreement (the &#8220;Securities
Purchase Agreement&#8221;) with the purchasers identified therein (collectively, the &#8220;Purchasers&#8221;) providing for the
issuance and sale to the Purchasers of (i) <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zarCk86s68qi" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000963" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">6,611.11</ix:nonFraction></span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Series L Convertible Preferred Stock&#8221;),
(ii) warrants to purchase up to a number of shares of common stock of the Company equal to 100% of the shares of the Company&#8217;s
common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock (the &#8220;Common Warrants&#8221;), and
(iii) warrants to purchase up to a number of shares of Company&#8217;s common stock equal to the number of Greenshoe Conversion
Shares (as defined in the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the
&#8220;Vesting Warrants&#8221; and together with the Common Warrants, the &#8220;Warrants&#8221;), with an aggregate stated value of
$<span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zIctUc4ICvI9" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,611,111</ix:nonFraction></span>,
for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zys4wTWv0qE" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,950,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an
aggregate stated value of up to $<span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_z1KC69dSYb51" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,018,349</ix:nonFraction></span>
(the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zKTNo8NprII9" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,616,514</ix:nonFraction></span>,
subject to adjustments, as further described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its
respective Greenshoe Rights for an amount of Series L Convertible Preferred Stock equal to the ratio of such Purchaser&#8217;s
original subscription amount to the original aggregate subscription amount of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
filed with the Secretary of State of the State of Delaware a Certificate of Increase (the &#8220;Certificate of Increase&#8221;) increasing
the shares of Series L 10% Convertible Preferred Stock as designated in the Certificate of Designations from <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zjqBiuyFCbG9" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,056</ix:nonFraction></span> shares to <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zl6BkDZuGUL4" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,630</ix:nonFraction></span>
shares. The Certificate of Designation creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms
and conditions on which shares of such preferred stock would convert into shares of our common stock, as well as its liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be
converted at any time at the option of the Purchasers into shares of the Company&#8217;s common stock at an initial conversion price
of $<span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zCMTE1mMQBi5" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>,
subject to certain conditions, as further described in the Certificate of Designation. In addition, the holders of the Series L
Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value
per share) of <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztSReXVKfFRb" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
per annum until May 11, 2026, increasing to <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z4PBmYYRKa2l" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%
per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date of
issuance of the Series L Convertible Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in
cash, shares of the Company&#8217;s common stock (subject to the Company&#8217;s satisfaction of the conditions set forth in the
Certificate of Designation), or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right
to require the Company to redeem the Preferred Shares at a premium, in accordance with and subject to certain conditions as further
described in the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#8217;s common stock equal to 100% of the Conversion Shares (as defined in the Securities Purchase Agreement) underlying
the Preferred Shares issued to such Purchaser and (ii) a Vesting Warrant (the exercisability of which shall vest ratably from time
to time in proportion to the Purchaser&#8217;s (or its permitted assigns&#8217;) exercise of such Purchaser&#8217;s Greenshoe Rights
pursuant to Section 2.4 of the Purchase Agreement), each to purchase up to a number of shares of the Company&#8217;s common stock
equal to the number of Greenshoe Conversion Shares (as defined in the Securities Purchase Agreement) applicable to such Purchaser,
in accordance with the Securities Purchase Agreement. An aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zeKMbz6a5lf7" title="Aggregate number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember" id="Fact000983" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">3,235,978</ix:nonFraction></span>
Common Warrants were issued with an initial exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z0aleKWOeapf" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zaimnRnnO2he" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt-sec:durwordsen" id="Fact000987" name="us-gaap:WarrantsAndRightsOutstandingTerm">five
years</ix:nonNumeric></span>. An aggregate of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zYMPm5YBwpI1" title="Aggregate number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember" id="Fact000989" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">11,576,406</ix:nonFraction></span>
Vesting Warrants were issued with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zZ9QsUoJyeJd" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $<span id="xdx_90C_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zy4EIPDm1CFb" title="Floor price"><ix:nonFraction name="us-gaap:DerivativeFloorPrice" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.454</ix:nonFraction></span> per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration
statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the
Series L Convertible Preferred Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement
within 30 days after the initial closing and after each closing of the exercise of a Greenshoe Right in accordance with the
Securities Purchase Agreement, to become effective no later than 90 days after filing. If these deadlines are not met, <span id="xdx_90C_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8uPmJVJoJf" title="Liable of liquidated damage percentage, description"><ix:nonNumeric contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember" id="Fact000995" name="GTBP:LiableOfLiquidatedDamagePercentageDescription">the
Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the Securities
Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_908_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc70S6wPsKbb" title="Common stock shares outstanding percentage"><ix:nonFraction name="GTBP:CommonStockSharesOutstandingPercentage" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% of the number of shares of the Company&#8217;s common stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). In connection with the required Shareholder Approval, all of the Company&#8217;s officers and directors (each a &#8220;Voting
Agreement Party&#8221;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval. Shareholder Approval was obtained on July 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zfxeuClwKSj3" title="Dividends to holders unpaid"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember14125843" id="Fact000999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span> were declared and unpaid as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqQixzlzdl4d" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAc1AjdiuT45" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></span></span> shares of series C preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9yvFiItTky4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4vBEy8ioKVe" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mezzanine
Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Series L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May 12, 2025 private placement of Series L Convertible Preferred Stock and Warrants produced net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfWHUntL7L5j" title="Proceeds from issuance of Series L convertible preferred stock and warrants, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,441,000</ix:nonFraction></span>,
which was allocated to mezzanine equity and additional paid in capital based on the relative fair value of the Series L Convertible
Preferred Stock and Warrants at issuance, respectively. Series L Convertible Preferred Stock is classified as mezzanine equity as it is
conditionally redeemable upon the occurrence of certain events that are not solely within the control of the Company, and upon such
event, the Series L Convertible Preferred Stock would become redeemable at the option of the holders, while Warrants are classified
as additional paid in capital. The relative fair values and allocation of net proceeds is below:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001011" name="us-gaap:ScheduleOfConversionsOfStockTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfConversionsOfStockTextBlock_z4eXOwBTwrta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ztAV5Hmk04k2" style="display: none">Schedule of fair values and allocation of net proceeds</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250512__20250512_zoK18SsbtBfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relative
    Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZUKKfTWedoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series L Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember" id="Fact001013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,688,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDixMPeB8Pji" title="Convertible preferred stock and warrants fair value percentage" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">37.7</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdz5utsYe719" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-122025-05-12_us-gaap_WarrantMember" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,089,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ivnyYMac1a" title="Convertible preferred stock and warrants fair value percentage" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-122025-05-12_us-gaap_WarrantMember" id="Fact001019" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.3</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zBTmFcgTcKBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-122025-05-12" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,777,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512_zE7CVK7xIZxf" title="Convertible preferred stock and warrants fair value percentage" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-122025-05-12" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49F_20250512__20250512_zYihwjyeE2e3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation
                                                                                                                                                                          of Net Proceeds</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zxyeobCFgYGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Mezzanine equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-122025-05-12_custom_MezzanineEquityMember" id="Fact001025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,025,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zORHzGTl2Fi" title="Convertible preferred stock and warrants net proceeds percentage" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-122025-05-12_custom_MezzanineEquityMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">37.7</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zUZLCKFpD2x6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember" id="Fact001029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zEkicuT39JCl" title="Convertible preferred stock and warrants net proceeds percentage" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.3</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_z5DFcgIRmWW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-122025-05-12" id="Fact001033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,411,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512_zjp40NXazyE9" title="Convertible preferred stock and warrants net proceeds percentage" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-122025-05-12" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_znFb3FxML5fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Series L Convertible Preferred Stock is converted into common stock it is reclassified from mezzanine equity to additional paid in capital
based on a pro-rata basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001037" name="GTBP:CommonStockWarrantsAndOptionsTextBlock"><p id="xdx_80A_ecustom--CommonStockWarrantsAndOptionsTextBlock_zyfxNdUrAs64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_zwzcaLLtxo4d">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001039" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFRRZXXlycMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the six months ended June 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zud5tta1Phy6" style="display: none">Schedule of Warrant Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_z37492ouCh32" title="Warrants outstanding, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,429</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zOovBpyVmDqc" title="Weighted average exercise price, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.85</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zc0TWRY0dmE8" title="Number of warrants, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-01to2025-06-30" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,468,308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250630_zqmgzxUN7Rcg" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zvQUToGaAPGb" title="Number of warrants, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250630_zxxH4NlSBGu1" title="Weighted average exercise price, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250630_zZvR0UJDo61c" title="Number of warrants, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-01to2025-06-30" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">837,069</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250630_zCiSDQpCjojl" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-06-30" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zsLqmRuPauL6" title="Warrants outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,751,668</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zEwamcGVBY01" title="Weighted average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250630_zgV9Z5EFy2zg" title="Warrants exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2025-06-30" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,995,263</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zgeMLtj4NIAj" title="Weighted average exercise price, exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.49</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zCEVbE2Ypu6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of June 30, 2025 was approximately $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20250630_zz0TLJTEWeT2" title="Options outstanding vested intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-06-30" id="Fact001065" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.4</ix:nonFraction></span>
million and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20250630_zP6ZPMjgl5v6" title="Options outstanding exercisable intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2025-01-01to2025-06-30" id="Fact001067" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million, respectively, in each case based on the fair value of the Company&#8217;s common stock on June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3p9I5hmQML3" title="Aggregate number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember" id="Fact001069" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">3,235,978</ix:nonFraction></span> Common
Warrants with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zHtH1CeWQp2" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_CommonWarrantsMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, they are exercisable, subject to certain ownership limitations,
immediately upon issuance and have a term of exercise equal to five years. An aggregate of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z6YQFonayyNg" title="Aggregate number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember" id="Fact001073" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">11,576,406</ix:nonFraction></span> Vesting Warrants were issued with
an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zPy6JRbP6R9b" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_VestingWarrantsMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, they are exercisable subject to certain vesting and ownership limitations, and have a
term of exercise equal to five years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have
full ratchet price protection and are subject to other adjustments, as further described in the Certificate of Designation or the Warrants,
as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor price of $<span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zBcTMq3MsIF" title="Floor price per share"><ix:nonFraction name="us-gaap:DerivativeFloorPrice" contextRef="AsOf2025-05-31_custom_GreenshoeRightsMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.454</ix:nonFraction></span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zk2w4UQL8WXe" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_us-gaap_PrivatePlacementMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span>
shares of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zAGNxBhGigk6" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></span>
shares of common stock exercisable immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zlBIbiw8cwJ5" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span>
per share with a fair value of approximately $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_ztFQyDrIsnTf" title="Fair value of warrant"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2025-05-31" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span>
in exchange for the waiver of a variable rate transaction (&#8220;VRT&#8221;). In addition, in May and June 2025, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkeCHpbBmfg9" title="Number of new shares issued"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFBbUCKYyIj1" title="Number of new shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-05-012025-05-31_us-gaap_CommonStockMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-06-012025-06-30_us-gaap_CommonStockMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock and warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA6L0jfQVNMl" title="Number of warrant issued"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsYxWn1lQWze" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_us-gaap_CommonStockMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock with an aggregate fair value of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zW4KDpCWe4Th" title="Number shares issued for service, value"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z36O3KO3ZV2j" title="Number shares issued for service, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-012025-05-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-06-012025-06-30" id="Fact001097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></ix:nonFraction></span></span>
to vendors as compensation for services. The warrants underlying <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMvHrysfUdb" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of common stock consist of warrants underlying <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zw1jvb7eTYbb" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
shares of common stock that are exercisable immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zh0FfPcN2oD2" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span>
per share, and warrants underlying <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zPrzYOKWtdq8" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span>
shares of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember" escape="true" id="Fact001107" name="GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSxQ4PFox24g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zNDak2Z2iooa" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zylrlDxZCov3" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeOneMember" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zuYvvvqyDxh" title="Number of outstanding" style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">476,251</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zghIcncxrhVj" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfU4RWPBx8J7" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKKvqqfA0Joj" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,138</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zzuc7Zx6EXGg" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHdVGYCivtmi" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zBNZitw7tIs5" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zbQUmE4GKwv6" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,235,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zeoCVFtVgzT8" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001127" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkdQtMfLk4F6" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zz0ysIDCUmb5" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrEB11Xg8Dyg" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoP2g8IYBLHg" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zqBrf3XirNg2" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zJF1hkVJEhSl" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember" id="Fact001139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zwbhoc74cPLc" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqZdDvhLf5w5" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z5UfSuUciCKa" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zQMTaL6JPi94" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF6bgnAIVp6f" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYmlIk2k6y5b" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember" format="ixt-sec:duryear" id="Fact001151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.7</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zACP4rkJEKG7" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zvUWzxuujET5" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zwIrLvKs5OB" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmknRphKmfT3" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember" format="ixt-sec:duryear" id="Fact001159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zG83qSeIN0e4" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUJe2w5QLOC8" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5e8u2NRi155" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember" id="Fact001165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zExMoAUjLOak" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember" format="ixt-sec:duryear" id="Fact001167" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.9</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaKdZo99QDYc" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zppRZrBCYBzk" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBXJIl2OnPT1" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zrryqog2Rby" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember" format="ixt-sec:duryear" id="Fact001175" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.0</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYtInJW1Lnq2" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z7j6zJVIJ3x4" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zCKNI3kWO8lf" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zwjwtx0iFxg1" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember" format="ixt-sec:duryear" id="Fact001183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.5</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z6B5pnD06r0d" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z4oI4QSW5qpj" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">102.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z3gz1puzc5t9" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,867</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zqa8Z1DriZgj" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember" format="ixt-sec:duryear" id="Fact001191" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.1</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zpO2RIcwnqZ4" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">102.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zFJVlof6TBW" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z8EfT49bILWf" title="Number of warrants outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zCsUMQtnxai4" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember" format="ixt-sec:duryear" id="Fact001199" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.6</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z4BqBJBXNDX5" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z9G6Qdw0rz31" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zxZ10meisyhf" title="Number of warrants outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,780</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zr9HRA4NQ7O2" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember" format="ixt-sec:duryear" id="Fact001207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.6</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zuA3IsDxnvud" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvJFIU9TLJR4" title="Number of warrants outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-06-30_us-gaap_WarrantMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,995,263</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zqK1AUGxbcI2" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_WarrantsMember" format="ixt-sec:duryear" id="Fact001213" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.3</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsgL3EuScUFa" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_WarrantMember" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zH8srVfQWY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and
stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our
employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards
granted under the Plan is <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zXHJBhMXSGr9" title="Common stock awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,667</ix:nonFraction></span>.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant
under the Plan. As of June 30, 2025, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630_zC2cmFxSpvv4" title="Stock option outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span>
stock options outstanding and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630_zbeK7wTiLC6j" title="Rstricted stock granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-06-30" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,935</ix:nonFraction></span>
shares of restricted stock granted in prior years under the Plan, which left <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zreB7M2SrIU7" title="Available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_custom_OmnibusIncentivePlanMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,132</ix:nonFraction></span>
shares available for grant under the Plan. Only July 24, 2025 shareholders voted to increase the maximum number of shares of common
stock that may be issued pursuant to awards granted under the Plan by <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20250630_zbU6w0Ao5lOg" title="Rstricted stock granted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-01to2025-06-30" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,334</ix:nonFraction></span>. The following table summarizes stock option
transactions for the six months ended June 30, 2025:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001227" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zo9LxrT4uavb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_z5y9KBqzLE5" style="display: none">Schedule of Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250630_zUURxTu1R4j3" title="Number of options outstanding, beginning" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zuPebCPWWmG6" title="Weighted-Average Exercise Price, beginning" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.69</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250630_zMmIK6Rifx81" title="Number of options, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zHZG6IFDTYFk" title="Weighted-Average Exercise Price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250630_zNhmjR7FiBlc" title="Number of options, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_z9oZJEv9WChk" title="Weighted-Average Exercise Price, forfeited/cancelled" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250630_zauh4ESFfEDa" title="Number of options, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zWGtpFYrQJv4" title="Weighted-Average Exercise Price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250630_z4h6eRIePgZ6" title="Number of options outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zbt7vI2z4mDg" title="Weighted-Average Exercise Price, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.69</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250630_zLBTnyA2eoCg" title="Number of options outstanding exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,692</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zn5qNLzwgCQh" title="Weighted-Average Exercise Price,exercisable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">36.85</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z9OhJspF4mn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of June 30, 2025 was
approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630_zBAMadCSyzrl" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:duryear" id="Fact001253" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.75</ix:nonNumeric></span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of June 30, 2025 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250630_zFX8K3ykdbch" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-06-30" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630_zUlVJiX9m8y6" title="Options vested and exercisable intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-06-30" id="Fact001257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span>, respectively, in each case based on the fair value of the Company&#8217;s
common stock on June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the six months ended June 30, 2025 and 2024, was $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250630_zrH3wffxZ8xa" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-06-30" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240630_zSZ70SgSEmZ3" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-06-30" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span>, respectively, and
is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of June
30, 2025, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zot1fKQQGan" title="Stock option, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,692</ix:nonFraction></span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250630_zS9I3J08jJsl" title="Stock option, unvested compensation"><ix:nonFraction name="GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-06-30" id="Fact001265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001267" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z96AsrsqRwN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zI9fjD8kVxV4" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zpYk9IqrLm69" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_RangeOneMember" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zoi5cG4IlAhg" title="Options outstanding" style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-06-30_custom_RangeOneMember" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,428</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMWsSxLQDVLg" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001273" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.3</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4ansmC0W0hj" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-06-30_custom_RangeOneMember" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJXNKmGxXa72" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_RangeTwoMember" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8ojRqMnqIgc" title="Options outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-06-30_custom_RangeTwoMember" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkcTlyi0X7u8" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001281" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.8</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6XQifpXUYjk" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-06-30_custom_RangeTwoMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7hTzr1wd1X5" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_RangeThreeMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zw60N4cokNUi" title="Options outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-06-30_custom_RangeThreeMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdMMyBtv017f" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001289" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.6</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGkicjYnYiK" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-06-30_custom_RangeThreeMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z72dsDauQvu4" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-06-30_custom_RangeFourMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPLmfno1S0Eh" title="Options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-06-30_custom_RangeFourMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,598</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z106bEEQ6gJ2" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001297" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.0</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zOTbkAruaQWl" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-06-30_custom_RangeFourMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630_zGceyO43Ed7" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-06-30" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,692</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zNwNpKTRFaK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001303" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zRwcH9vnzFt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82E_zEtS4yWleeua">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for June 10, 2025, has been
postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not been scheduled. There is
a status conference scheduled for August 19, 2025 before the AAA. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles
naming the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes
(&#8220;Notes&#8221;) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was
seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for
improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF
voluntarily dismissed its complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently
filed a summons and complaint for interpleader against TWF and Z-One, LLC before the Supreme Court of the State of New York County
of New York, asking the Supreme Court to determine if the Company&#8217;s shares of common stock should be registered to TWF or
Z-One LLC, as both of these entities have made conflicting demands for the shares. On February 5, 2024, the Company filed a motion
for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of
Z-One, LLC and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice
and agreed to reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024,
Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing that Z-One, LLC and TWF have settled
their dispute over the entitlement to the Company&#8217;s shares of common stock and there is no remaining dispute before the Court.
On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. On November 14, 2024, the
Court held a hearing on the parties&#8217; motions, at which the Court found that the motion for entry of default was mooted by the
settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February 17, 2025, Z-One, LLC
filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that
Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder, either originally
or by assignment, of a Convertible Note in the principal amount of $<span id="xdx_90F_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z4oV2pdd3nY2" title="Principal amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember" id="Fact001305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>,
that the Company breached the Convertible Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it
damages in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z7lwpXbW28yg" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>.&#160;The
Company intends to seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will
continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2025, Coby Silberfein filed a summons with
notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of
a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zyAE3ocpukJ7" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember" id="Fact001309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.&#160;On July 8, 2025, Justin DiPietro filed
a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages
for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_904_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z5TI4FLoa1b4" title="Damages paid"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember" id="Fact001311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.&#160;On July 9, 2025, Phillip
Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant
seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_907_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z994mWnajMli" title="Damages paid"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-07-092025-07-09_custom_CobySilberfeinMember" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.&#160;The three
summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that the Company breached the convertible
notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are seeking specific performance and damages.
The Company intends to demand that the plaintiffs file complaints and then seek dismissal of the complaints.&#160;The Company believes
that the claims are without merit, and intends to vigorously defend against these claims.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#8217;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use
in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and
allowed for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The
Settlement and Investment Agreement also set Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z4T2TkzC9iMf" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></span>%
of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z8Tjn3xaHaM4" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zersJaECbUn5" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember14126828" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2025 and 2024, the Company recognized research and development expenses of $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znbHdtNB3Dff" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">626,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9MYdmclaWi4" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,000</ix:nonFraction></span>, respectively
and made cash payments amounting to $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zRWPp84O2n5j" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact001325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,000</ix:nonFraction></span> and approximately $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEKl3SMUjXx8" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact001327" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million, respectively to Cytovance. In addition, during the six months
ended June 30, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCtadGfp2tna" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares of common stock exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2XRPsD35Sa" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per
share to settle accounts payable valued at approximately $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2el97SdJg6" title="Fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span>; and during the six months ended June 30, 2024, the Company issued
<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7XLV7yAPkcj" title="Issuance of common stock in settlement of vendor payable, shares"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></span> shares of common stock to settle accounts payable valued at approximately $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zJgiOdJ5R7z" title="Issuance of common stock in settlement of vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember" id="Fact001337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of June 30, 2025, amounted to approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znaoD4J955Zi" title="Stock issued during period, value, issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">310,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2023
Sponsored Research Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zbdtHhXCfvE3" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001341" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $<span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zQp9HhDP5Fad" title="Payments of research and development"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span>
were added bringing the total payments due over the life of the agreement to approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zlwkkGm14Qw7" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001345" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zYG1w6TyPNVa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">431,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zhqFPEv9vlPb" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,000</ix:nonFraction></span>, pursuant to the 2023 Sponsored
Research Agreement, for the six months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately
$<span id="xdx_90D_eus-gaap--UnbilledReceivablesCurrent_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zDCuAOKtFUCl" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">431,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup>
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3dp4KJ2aatg" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, and license maintenance
fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_z3GZvh5j68yb" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaCVDRw5b23" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> per year beginning in year 2021 and each year thereafter. The agreement also
includes 4% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zbd7pNuT90rh" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zGbQNcMrbYyd" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> beginning
in 2022, $<span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zf5G2uYyERf6" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact001363" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in 2025, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zhcDVBExHAri" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember" id="Fact001365" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpJB5wwXQGL1" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001367" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone
payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0LLtoK0ipI3" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001369" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zUNVR4MRrhye" title="Sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001371" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zoJWoJwdn7w1" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001373" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEqAH2gnSqA5" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001375" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative
gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZ5y9iD4Zrl3" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zLjj4h3AfNAf" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJOhnQTyBdij" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z8zCGU12T8s" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z92NnLxxsmk3" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zjsU14Uk98L3" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3WdKZYMWcgd" title="Royalty expense year one"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOne" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT40GpuLv7Zj" title="Royalty expense years two through five"><ix:nonFraction name="GTBP:RoyaltyExpenseYearTwoThroughFive" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001391" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKESBNm0J6Kk" title="Royalty expense year six and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterSix" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001393" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaqKmtkYxFZ8" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001395" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC9PjtiV1NG3" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001397" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zXAY4L0eGXj3" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001399" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRiwWSsZFCH5" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001401" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9zolMcdf4Fa" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001403" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z8wUl3OBYMQk" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zNVnh2gFO2Hj" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>, pursuant to the 2016 Exclusive Patent
License Agreement, for the six months ended June 30, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8ogOGCqIc08" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsCAaaCMn8Fl" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year beginning in year 2022 and each year thereafter. The agreement also includes
<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zDxt4LCKLsH6" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdvZmN6pcEil" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zjyziXdUWq2d" title="Royalty expense year one though four"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOneThoughFour" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdDxgyYhn8Yd" title="Royalty expense year five and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterFive" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001419" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zRhIjtymKXs6" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001421" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zqAdPQXYB629" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001423" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAucye1sF9qc" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001425" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z7tipI69XMK7" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001427" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zST948NdUWc4" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001429" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
six months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRYccYR7t3Nc" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact001431" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the six
months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately $<span id="xdx_903_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRxKtdeu7nFd" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-06-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact001433" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><b>PDPC Advisors Inc., a Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2025, the Company entered into an Advisory
Agreement (the &#8220;Agreement&#8221;) with PDPC Advisors Inc. (&#8220;PDPC&#8221;), to perform certain advisory services. Under the
Agreement cash payments amounting to $<span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zu90pIWGqo83" title="Cash payment"><ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> are to be paid in six equal installments beginning on July 1, 2025 and ending on December
31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC on a pre-funded warrant to purchase <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zixTaOnEyvc8" title="Warrants outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2025-06-30_custom_AdvisoryAgreementMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> shares
of common stock of the Company, which had a fair value of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zMNuYOa3ADJa" title="Stock issuance"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,000</ix:nonFraction></span> at the time of issuance. The Agreement begins on July 1, 2026 and terminates
on June 30, 2026. PDPC is considered a related party as its CEO is an individual who has voting and investment control over an entity
whose beneficial ownership exceeded 5% of the issued and outstanding shares of the Company&#8217;s common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zAnRIH6l3Tnb" title="Contigency minimum required"><ix:nonFraction name="GTBP:ContigencyMinimumRequired" contextRef="AsOf2024-11-21" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#8217; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement,
the Company may be subject to delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001443" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zQm378o3rbs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_822_zhvK5xGCmHLa">Segment Information</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001445" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zABlW2L8AfH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zxXs1bkEkkQd" style="display: none">Schedule of Segment Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zFeVxiSmIG3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zEoob9Bsoco6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zGRoSunlJxNd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zbKmzSCnUx03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_zkUepjTp0BX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,805,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,462,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,561,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_z7vNPeh1kNgk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">632,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">765,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zbqVlsr8oBa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zTDYqOaL1fic" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zDwtSMBk4wQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">734,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,297,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_z8rx2N03qgnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,236,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,021,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0XwqDwv6666" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_custom_SegmentsMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,433,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_SegmentsMember" id="Fact001478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,710,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_custom_SegmentsMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,209,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_SegmentsMember" id="Fact001480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,976,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zN1PMwuDq7V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact001482" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zuQEn7OkIi17" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_826_z4bvuP9xMyX1">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, a Purchaser of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) elected
to exercise their Greenshoe Rights and purchased <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfWHD6Dz2LS7" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">222.22</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock with a stated value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4QcKmhQquai" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">222,222</ix:nonFraction></span>
for a purchase price of $<span id="xdx_90A_ecustom--PreferredStockPurchasePrice_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUZyxu4udV2j" title="Purchase price"><ix:nonFraction name="GTBP:PreferredStockPurchasePrice" contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. As a result of the transaction the conversion price of the Preferred Stock was decreased from $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250727__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrwGwhaW4p7" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-07-27_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001490" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
to $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbFA4VXVKfp" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.7766</ix:nonFraction></span>. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion
of Series L 10% Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
July 1, 2025 through August 10, 2025 the holders of the Company&#8217;s Series L Convertible Preferred Stock have converted <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcIjFuAeFgh5" title="Number of shares converted"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">543,273</ix:nonFraction></span>
shares of Series L Convertible Preferred Stock into <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpWddUlZ3Qxk" title="Number of shares converted"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,507</ix:nonFraction></span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</ix:nonNumeric><p id="xdx_81A_zIGarupRkCj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_006"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; within the meaning of the safe harbor
from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business
strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect
the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified
by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;foresee,&#8221; &#8220;may,&#8221; &#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221;
&#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe
our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn
out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations
for various reasons. You should carefully review all information, including the discussion of risk factors under &#8220;Part I. Item
1A: Risk Factors&#8221; and &#8220;Part II. Item 7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; of the Form 10-K for the year ended December 31, 2024. Any forward-looking statements in the Form 10-Q are made only
as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements
contained in this Form 10-Q to reflect subsequent events or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) fusion protein
immune cell engager technology platforms. Our TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics designed
to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells, or NK cells. Once bound to an NK cell,
our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific
type of cancer cell or virus infected cell, resulting in the targeted cell&#8217;s death. TriKE&#174;s can be designed to target any number
of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific
customization. We believe our TriKE&#174; and Dual Targeting TriKE&#174; platforms that activate endogenous NK cells are potentially safer
than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications. Our preclinical
data suggests that this is explained by the TriKE&#174; dependent CD16 directed IL-15 proliferation of NK cells but little effect endogenous
T cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE&#174; platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies,
solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational
new drug (IND) ready moieties in a timely manner after a specific TriKE&#174; conceptual design. Specific drug candidates can then be
advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKE&#174;s may have
the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr.
Jeffrey Miller, Professor of Medicine, and the Interim Director at the Center. Dr. Miller, who also serves as our Consulting Senior Medical
Director, is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive
rights to the TriKE&#174; platform and are generating additional intellectual property for specific moieties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidate pipeline is summarized in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_001.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was our first TriKE&#174; product candidate and its clinical development was suspended so that we could focus resources on second-generation
TriKEs&#174;. GTB-3550 is a tri-specific killer engager (TriKE) comprised of two single-chain variable fragments (&#8220;scFv&#8221;)
composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We
studied this anti-CD16-IL-15-anti-CD33 TriKE&#174; in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous
leukemia, or AML, and myelodysplastic syndrome, or MDS. The anti-CD33 antibody fragment in GTB-3550 was derived from the M195 humanized
anti-CD33 scFv. We believe the approval of the antibody-drug conjugate gemtuzumab validates the targeting of CD33.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously announced the interim clinical trial results for GTB-3550, which showed significantly reduced CD 33+ bone marrow blast levels
by 33.3%, 61.7%, 63.6%, 50% in Patient 5 (25 &#181;g/kg/day), Patient 7 (50 &#181;g/kg/day), Patient 9 (100 &#181;g/kg/day), and Patient
11 (150 &#181;g/kg/day), respectively. After the end of infusion, GTB-3550 and IL-15 concentrations declined rapidly with overall geometric
mean terminal phase elimination half-life (T1/2) of 2.2 and 2.52 hours, respectively. There was minimal CRS resulting from hyperactivation
of patient&#8217;s T-cell population at doses 5&#8211;150 &#181;g/kg/day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the positive interim clinical trial results, GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKE&#174;, GTB-3650,
that similarly targets CD33 on relapsed/refractory AML and high-risk MDS. A key difference between GTB-3550 and GTB-3650 is the incorporation
of camelid antibody technology instead of a scFv; our preclinical experience showed markedly enhanced potency of TriKEs&#174; comprised
of camelid components. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared
to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the
second-generation, camelid-based TriKE&#174; platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_002.jpg" alt="" style="height: 508.5pt; width: 6in"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Second
Generation TriKE<sup>&#174;</sup>s Utilize Camelid Nanobody Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid
tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred
as nanobodies) are smaller than human immunoglobulin, consisting of two heavy chains instead of two heavy and two light chains. These
nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing
this camelid antibody structure for all of our new TriKE&#174; product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
develop second generation TriKE&#174;s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist
of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of
engaging without the need of a light chain counterpart (see figure below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_003.jpg" alt="" style="height: 175.5pt; width: 354.75pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability
to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation
against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFN&#947; with the single-domain CD16 TriKE&#174; (cam
16-wt15-33; GTB-3650) compared to the original TriKE&#174; (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr.
Felices M et al (2020) in Cancer Immunol Res.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CD33+
HL60 Targets in Killing Assays</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purple line represents the GTB-3650 and the blue line represents GTB-3550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-q_004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3650</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3650
is a TriKE&#174; which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor
on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650. The TriKE&#174; approach provides
a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting,
in an anti-CD33-targeted fashion. We are advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase
in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We advanced GTB-3650 through
requisite preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA)
in December 2023. In late June 2024, the FDA cleared our IND Application for GTB-3650. We started study enrollment targeting patients
with relapsed/refractory AML and high grade MDS on January 21, 2025. This initial study is testing GTB-3650 as monotherapy testing administration
2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy, as agreed on with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black"><b><img src="form10-q_005.jpg" alt="" style="height: 157.5pt; width: 423.75pt"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-5550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-5550
is a B7-H3 targeted TriKE&#174; which targets B7-H3 on the surface of advanced solid tumors (figure above). GTB-5550 is our first dual
camelid TriKE&#174;. B7-H3 is expressed on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies
through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumors, including
head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer
(amongst others). We are advancing GTB-5550 through preclinical studies and initiated a GMP manufacturing campaign in anticipation of
filing an IND. A pre-IND packet was submitted to the FDA in October 2023 with a written response from the FDA in December 2023. The main
question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The initial trial is designed as a basket
trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion),
and is dependent on manufacturing of clinical materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black"><b><img src="form10-q_006.jpg" alt="" style="height: 105pt; width: 6in"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-7550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-7550
TriKE&#174; is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKE&#174; is a
tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv engager against CD19 on malignant
and normal B cells, and a human IL-15 sequence between them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published
data shows that GTB-7550 effectively targets CD19+ malignant cell lines and primary chronic lymphocytic leukemia (CLL). Preliminary data
shows that GTB-7550 can target and eliminate normal B cells, which we are continuing to test in mice. We are currently exploring and
assessing potential manufacturers of GTB-7550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of our financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires
us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure
of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge
of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may
differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we
consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments
and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation
of deferred tax assets. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives
in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging.</i>&#8221; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with
changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of derivative financial instruments is generally limited to warrants issued by us that do not meet the criteria for equity treatment
and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing
model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends.
The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three and Six Months Ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,784,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,421,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Selling, general and
    administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,146,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,002,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(856,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    compensation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Operating Expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,513,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,906,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,393,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(61</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,462,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,561,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,099,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Selling, general and
    administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,976,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,214,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,238,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    compensation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">222,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(215,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(97</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Operating Expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,445,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,997,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,552,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(51</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses decreased by approximately $1.4 and $1.1 million for the three and six months ended June 30, 2025, respectively,
compared to the same prior year periods, primarily due to a decrease in production and scientific research costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses relate to our continued licensing, development and production of our most advanced TriKE&#174; product
candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance
from the FDA with respect to our IND Application in relation to our next generation GTB-3650 camelid nanobody product. Study
enrollment began in early 2025 and we have advanced into the clinic, enrolling patients, and performing tests for data collection
throughout the year. Following our May 2025 financing we have <span style="background-color: white">restarted the final phase of product
development of GTB-5550 and anticipate submission of an IND application for GTB-5550 in fourth quarter of 2025.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling,
General, and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general, and administrative expenses decreased by approximately $856,000 and $2.2 million for the three and six months ended June 30,
2025, compared to the same prior year periods, was primarily due to a significant reduction in legal fees and other cost reduction measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income (Expense)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(64</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Change in fair value
    of warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(114,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(231,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(197</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss)
    on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of
    vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">183,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">678</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Other Income
    (Expense)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">196,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(59</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">247,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(177,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(72</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Change in fair value
    of warrant liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">775,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(763,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain (loss)
    on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Gain on settlement of
    vendor payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">998,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">998,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total Other Income
    (Expense)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,236,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,021,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
Income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income decreased by $67,000 and $177,000 for the three and six months ended June 30, 2025, respectively, compared to the same prior year
periods, due to lower money market fund and short term investment balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
in Fair Value of Warrant Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant liability decreased by approximately $231,000 and $763,000 for the three and six months ended June 30,
2025, respectively, compared to the same prior year periods, resulting from a reduction in our warrant liability primarily due to the
decline in the Company&#8217;s relative stock price at June 30, 2025 as compared to the prior comparable periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
on Settlement of Vendor Payable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$1 million. The Company classified this transaction as other income during the period ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying 24,390 shares of common stock exercisable at $2.24 per share with a fair value of approximately
$44,000 in exchange for the waiver of a variable rate transaction (&#8220;VRT&#8221;). The Company classified this transaction as other
income during the period ended June 30, 2025. The Company also recorded other income of $200,000 in June 2025 due to the extinguishment of
an accrual of consulting fees recorded in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,433,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,710,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,277,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,209,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,976,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,767,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss decreased by approximately $2.3 and $3.8 million for the three and six months ended June 30, 2025, respectively, compared to the
same prior year periods, primarily due to a decrease research and development expenses and legal fees, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that we will continue as a going concern. We do
not have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained
operating losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed
our operations through public and private sales of common stock, the issuance of preferred and common stock, the issuance of
convertible debt instruments, and strategic collaborations. For the six months ended June 30, 2025, we recorded a net loss of
approximately $2.2 million and used cash in operations of approximately $5.2 million. These factors raise substantial doubt about
our ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the
Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s December 31, 2024, financial
statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do
not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if we are unable to continue as a going
concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes we will continue as a going
concern, and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations,
which has raised substantial doubt about our ability to continue as a going concern. While it is very difficult to estimate our future
liquidity requirements we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to
enable us to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed financial statements
are issued. There can be no assurances that we will be able to secure additional financing on acceptable terms. In the event that we
do not secure additional financing, we will be forced to delay, reduce, or eliminate some or all of our discretionary spending, which
could adversely affect our business prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Statements of Cash Flow
    Data:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,216,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,699,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,893,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,493,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,976,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;Net increase (decrease) in cash and cash
    equivalents and restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,277,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,170,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    and restricted cash, beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,044,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,079,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;Cash and cash
    equivalents and restricted cash, end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,321,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,249,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $5.2 for the six months ended June 30, 2025 and was primarily due to a decrease in
accounts payable and accrued expenses of $1.6 million and a net loss of $2.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $ 7.7 million for the six months ended June 30, 2024 and was primarily due to a net
loss of $6.0 million and a decrease in accounts payable and accrued expenses of $1.3 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $12.9 million for the six months ended June 30, 2024, resulted from proceeds
of the sale of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $6.5 million for the six months ended June 30, 2025 and resulted from net proceeds
from issuance of Series L Convertible Preferred Stock and warrants, and net proceeds from the exercise of warrants for cash and inducement
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities approximately $3.0 million for the six months ended June 30, 2024 and resulted from net proceeds
from issuance of common stock and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Capital (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes total current assets, liabilities, and working capital (deficit) for the periods ended June 30, 2025 and December
31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/> 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Increase/(Decrease)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,124,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,232,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,892,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,307,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,902,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,595,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Working capital (deficit)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,817,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,670,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,487,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_007"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f)(1) and is not required to provide information
for this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_008"></span>Item
4. Controls and Procedures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act
of 1934, as amended), as of June 30, 2025. Based on that evaluation, we have concluded that our disclosure controls and procedures were
effective as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by,
or under the supervision of, a company&#8217;s principal executive and principal accounting officers and effected by a company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
    could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations on the Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective
control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a
simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become
inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_010"></span>Item
1. Legal Proceedings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 22, 2024, the Company filed an AAA Arbitration demand against Manu
Ohri, its former Chief Financial Officer.&#160;In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary
duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohri&#8217;s termination
as &#8220;for cause&#8221; under his employment agreement, and that the Company may revoke the separation agreement entered into between
the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s breaches.&#160;In addition to the declaratory judgment, the
Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217; fees and any forum and arbitration fees. On September
3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against him and counterclaims for breach of his employment
agreement and separation agreement. The final hearing date, originally scheduled for June 10, 2025, has been postponed indefinitely in
order to allow the parties to mediate the dispute. At this time, mediation has not been scheduled. There is a status conference scheduled
for August 19, 2025 before the AAA. At this stage in the proceedings the Company is not able to determine the probability of the outcome
of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a complaint
in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the
holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and that the Company did not deliver shares of common stock due on conversion
in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed
a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and
federal courts. TWF voluntarily dismissed its complaint before the California Superior Court of Los Angeles without prejudice. The Company
subsequently filed a Summons and complaint for interpleader against TWF and Z-One, LLC before the Supreme Court of the State of New York
County of New York, asking the Supreme Court to determine if the Company&#8217;s shares of common stock should be registered to TWF or
Z-One, LLC, as both of these entities have made conflicting demands for the shares. On February 5, 2024, the Company filed a motion for
entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One, LLC
and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and agreed to
reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion
for summary judgement seeking dismissal of the action, representing that Z-One, LLC and TWF have settled their dispute over the entitlement
to the Company&#8217;s shares of common stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a
supplemental affidavit in support of its motion for entry of default. On November 14, 2024, the Court held a hearing on the parties&#8217;
motions, at which the Court found that the motion for entry of default was mooted by the settlement agreement between Z-One, LLC and TWF.
The Court ordered that the case be dismissed.&#160;On February 17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of
the State of New York, County of New York.&#160;The Company then filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025,
Z-One, LLC filed a Complaint alleging that it is the holder, either originally or by assignment, of a Convertible Note in the principal
amount of $150,000, that the Company breached the Convertible Note by failing to deliver conversion shares to Z-One, LLC, and that the
Company owes it damages in excess of $500,000.&#160;The Company intends to seek dismissal of the case. The Company believes that the claims
related to the Notes are without merit, and will continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2025, Coby Silberfein filed a summons with notice in the State
of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of a securities purchase
agreement and convertible note in the principal amount of $100,000.&#160;On July 8, 2025, Justin DiPietro filed a summons with notice
in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of a securities
purchase agreement and convertible note in the principal amount of $100,000.&#160;On July 9, 2025, Phillip Werthman Trust filed a summons
with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach
of a securities purchase agreement and convertible note in the principal amount of $100,000.&#160;The three summons with notice are identical
and allege that the plaintiffs are holders of convertible notes and that the Company breached the convertible notes by failing to deliver
shares of common stock due on conversion in in 2021. Plaintiffs are seeking specific performance and damages. The Company intends to demand
that the plaintiffs file complaints and then seek dismissal of the complaints.&#160;The Company believes that the claims are without merit,
and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="b_001"></span>Item
1A. Risk Factors</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes from the risk factors disclosed in Part I, Item 1A &#8220;Risk Factors&#8221; in our Annual Report on Form
10-K for the year ended December&#160;31, 2024&#160;and Part II, Item 1A &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q
for the quarter ended March&#160;31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="b_002"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the second quarter of 2025, the Company issued securities in reliance on the exemption from registration provided by Section 4(a)(2)
of the&#160;Securities Act, in the amounts and for the consideration set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May and June 2025, the Company issued 50,000 shares of common stock and warrants underlying 200,000 shares of common stock with an aggregate
fair value of approximately $718,000 to vendors as compensation for services. The warrants underlying 200,000 shares of common stock
consist of warrants underlying 50,000 shares of common stock that are exercisable immediately upon issuance with a term of five years
from the date of issuance at $2.50 per share, and warrants underlying 150,000 shares of common stock that are pre-funded warrants exercisable
at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, pursuant to the May 2025 Private Placement of Equity Facility, the Company issued pre-funded warrants to purchase an aggregate
of 300,000 shares of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms
and subject to the satisfaction of the conditions set forth in the Purchase Agreement, with a fair market value of $672,000. The pre-funded
warrants may be exercise at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2025, the Company issued warrants underlying 24,390 shares of Common Stock&#160;at an exercise price&#160;equal to $2.46 to investors
in return entering into a Consent and Waiver Agreement dated March 18, 2025, with a fair market value of $44,000. The warrants are exercisable
immediately upon issuance with a term of five years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other issuances of unregistered equity securities during the three months ended June 30, 2025 have previously been disclosed in filings
with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="b_003"></span>Item
3. Defaults Upon Senior Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="b_004"></span>Item
4. Mine Safety Disclosures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="b_005"></span>Item
5<i>.</i> Other Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Amendment to 2023 Sponsored
Research Agreement </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company entered into
the First Amendment to the 2023 Sponsored Research Agreement, effective as of June 18, 2025 (the &#8220;Amendment&#8221;), with the Regents
of the University of Minnesota, which amended the 2023 Sponsored Research Agreement to expire on December 31, 2025. In addition, pursuant
to the Amendment, payments amounting to $216,000 were added bringing the total payments due over the life of the 2023 Sponsored Research
Agreement to approximately $1.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
10b5-1 Trading Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act
of 1934, as amended) <span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20250630_z3ukT50NgE7d" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_908_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20250630_zA3c4SuaLiEl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact001497" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact001498" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>, amended, or <span id="xdx_90A_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20250630_zXVWtpgTosdk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20250630_zLbP3nqxVKCi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact001499" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact001500" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading
arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_011"></span>Item
6. Exhibits</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Herewith</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated
    Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/15/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/ex3-5.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/30/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/1/2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/ex3-1.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000017/exhibitthreeone.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/4/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate
    of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">4.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 12, 2025</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">3.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">4.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Increase to Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 21, 2025</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">3.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/27/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225008387/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Series A Inducement Warrant</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225008387/ex4-2.htm" style="-sec-extract: exhibit">Form
    of Series B Inducement Warrant</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/26/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225010790/ex4-6.htm" style="-sec-extract: exhibit">Form
    of Prefunded Common Stock Purchase Warrant</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/4/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">4.8</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Warrant</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">4.9</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex4-2.htm" style="-sec-extract: exhibit">Form of Vesting Warrant</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">4.2</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein</a></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.2</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex10-3.htm" style="-sec-extract: exhibit">Form of Voting Agreement</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.3</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex10-4.htm" style="-sec-extract: exhibit">Form of Lock-Up Agreement</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.4</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/13/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Securities Purchase Agreement, dated as of May 21, 2025, between the Company and the purchasers identified therein</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/27/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/ex10-2.htm" style="-sec-extract: exhibit">Joinder to Registration Rights Agreement, dated as of May 21, 2025, between the Company and the purchaser identified therein</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.2</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">5/27/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Common Shares Purchase Agreement, dated as of June 10, 2025, between the Company and the investors identified therein</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">10.1</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">6/11/2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">10.8</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-8.htm">First Amendment to the Research Agreement, effective as of June 18, 2025, between the Company and the Regents of the University of Minnesota</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">*</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934,
    as amended.</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934,
    as amended.</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
    2002*</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
    2002*</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the
    liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the
    Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
    BIOPHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 14, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Breen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer and</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 14, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Urban</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>ex10-8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST
AMENDMENT TO THE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESEARCH
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
FIRST AMENDMENT </B>is effective as of the June 18, 2025 (&ldquo;First Amendment&rdquo;) by and between Regents of the University of
Minnesota (the &ldquo;University&rdquo;) and GT Biopharma, Inc. (the &ldquo;Sponsor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,</B>
the parties entered into a Research Agreement dated July 1, 2023 (the &ldquo;Agreement&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,</B>
the parties desire to amend the Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> in consideration of the foregoing premises and the mutual covenants contained herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Expiration Date of the Agreement is December 31, 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Contract Price is now One Million Nine Hundred Forty Thousand Six Hundred Eighty Six dollars
                                            ($1,940,686.00)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following is added to Article 4.2:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsor
shall make a payment of One Hundred Eight Thousand dollars ($108,000) on September 30, 2025. Sponsor shall make a final payment of One
Hundred Eight Thousand dollars ($108,000) on December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
                                            on Other Provisions. Except as expressly provided herein, all terms and conditions of the
                                            Agreement shall remain in full force and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B> authorized representatives of the parties have executed this First Amendment on the date first above written.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGENTS OF THE UNIVERSITY</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GT BIOPHARMA INC.</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF MINNESOTA </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Michael Breen, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 14, 2025</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Michael Breen</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Breen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman of the Board</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Alan Urban, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 15, 2025</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Alan Urban </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Urban</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to 18 U.S.C. &sect; 1350, as created by Section
906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby
certify that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) the Quarterly Report on Form
10-Q of the Company for the fiscal quarter ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section
13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 15, 2025</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Michael Breen</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Breen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman of the Board</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to 18 U.S.C. &sect; 1350, as created by Section
906 of the Sarbanes-Oxley Act of 2002, I, Alan Urbani, Chief Financial Officer and Principal Accounting Officer of GT Biopharma, Inc.
(the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) the Quarterly Report on Form
10-Q of the Company for the fiscal quarter ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section
13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 14, 2025</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Alan Urban </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Urban</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-q_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &Y X0# 2(  A$! Q$!_\0
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M</\ ^!8G_P"0/U%_X6/\//\ H?/!G_A4:'_\G4?\+'^'G_0^>#/_  J-#_\
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MV=2^G.U\O,F-3$RBI*&':=_M8A[2E%_8[Q9]"?\ "Q_AY_T/G@S_ ,*C0_\
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M_"HT/_Y.H_X6/\//^A\\&?\ A4:'_P#)U?/?_# O["W_ $99^R9_XCA\&_\
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M!?V%O^C+/V3/_$</@W_\Q]'_  P+^PM_T99^R9_XCA\&_P#YCZ/]E[XK_P
MPW_RP.;%?R8?_P "Q'_R!]"?\+'^'G_0^>#/_"HT/_Y.H_X6/\//^A\\&?\
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MO<.>NXPE&-&TH1DU)U[KFC"5KQA9VYM].FA]"?\ "Q_AY_T/G@S_ ,*C0_\
MY.H_X6/\//\ H?/!G_A4:'_\G5\]_P## O["W_1EG[)G_B.'P;_^8^C_ (8%
M_86_Z,L_9,_\1P^#?_S'U/\ LO?%?^ 8;_Y8+FQ7\F'_ / L1_\ ('T)_P +
M'^'G_0^>#/\ PJ-#_P#DZC_A8_P\_P"A\\&?^%1H?_R=7SW_ ,,"_L+?]&6?
MLF?^(X?!O_YCZ/\ A@7]A;_HRS]DS_Q'#X-__,?1_LO?%?\ @&&_^6!S8K^3
M#_\ @6(_^0/H3_A8_P //^A\\&?^%1H?_P G4?\ "Q_AY_T/G@S_ ,*C0_\
MY.KY[_X8%_86_P"C+/V3/_$</@W_ /,?1_PP+^PM_P!&6?LF?^(X?!O_ .8^
MC_9>^*_\ PW_ ,L#FQ7\F'_\"Q'_ ,@?0G_"Q_AY_P!#YX,_\*C0_P#Y.H_X
M6/\ #S_H?/!G_A4:'_\ )U?/?_# O["W_1EG[)G_ (CA\&__ )CZ/^&!?V%O
M^C+/V3/_ !'#X-__ #'T?[+WQ7_@&&_^6!S8K^3#_P#@6(_^0/H3_A8_P\_Z
M'SP9_P"%1H?_ ,G4?\+'^'G_ $/G@S_PJ-#_ /DZOGO_ (8%_86_Z,L_9,_\
M1P^#?_S'T?\ # O["W_1EG[)G_B.'P;_ /F/H_V7OBO_  ##?_+ YL5_)A__
M  +$?_('T)_PL?X>?]#YX,_\*C0__DZC_A8_P\_Z'SP9_P"%1H?_ ,G5\]_\
M,"_L+?\ 1EG[)G_B.'P;_P#F/H_X8%_86_Z,L_9,_P#$</@W_P#,?1_LO?%?
M^ 8;_P"6!S8K^3#_ /@6(_\ D#Z#/Q(^'8R3X]\%@ 9)/BG0Q@<G)_T[I@$_
M@:7_ (6/\//^A\\&?^%1H?\ \G5^6?\ P4,_8H_8U\(?L-_M7^)?"W[(W[+_
M (<\1:+\"/B)J&C:]HGP ^$VE:QI.H6^@W+6]]IFI6/A.&\L+VW?$MM=VLT5
MQ;S*DL$D<J(X^R#^P-^PN68_\,6?LF=?^C<?@X2>!R2?!P.3[YXQSUJW#"JG
M&IS8JTIS@E[/#W3A&G)N_M+:^T_!>8>TKW<5'#\RC&37-7VDY+^2_P!D^A/^
M%C_#S_H?/!G_ (5&A_\ R=1_PL?X>?\ 0^>#/_"HT/\ ^3J^>_\ A@7]A;_H
MRS]DS_Q'#X-__,?7PO\ '36?^"/_ .SI\6/BI\%OB;^R3^SO9>//@W^Q'X__
M ."@WCBTTG]D#X8:OIUK^S=\-/%TW@GQ3K6G:I;>#!::EXIM]>MY(K;PE;LV
MIW-J%NP$BDC+1_LO\V*_\ PW_P L'S8G^7#_ /@6)_\ D#];/^%C_#S_ *'S
MP9_X5&A__)U'_"Q_AY_T/G@S_P *C0__ ).K\;? ?Q,_X(I?%#X<_L7?%7X>
M?LV?LQ>+O!'[>WQ!NOA7\ -6TC]DGX83-<>/M,T'Q9KFO^&O&]K)X)BN?!>H
M>&G\#^)]$UY=3B=++7-,DM5,]NZ7A^>/A5^W1_P0/^*?B[X?^%S^R;\/?AII
M'Q>^*6J?!'X1?%CXP?\ !.(> /@1\3_B_H^OW_AF]^'/@_XW:A\(Y_AG=>*$
MUG2M1T_['J'B33HEOK2739KB+5&BL7=L+_-B?_ <-_\ + OB?Y</_P"!8G_Y
M _H9_P"%C_#S_H?/!G_A4:'_ /)U'_"Q_AY_T/G@S_PJ-#_^3J_.']L+X=?\
M$M?V&OV>_''[3WQ[_8Z_9NT_X5?#RZ\&V7B.Y\)_LF?"SQ?XA%UX]\<^&_AU
MX:@TWP[I7@Q]0U*6[\4>+-&M9$ME9X89I)RC+$U7OV;/@U_P3O\ VF_ 5[\0
M?#__  3I\#?":TL?%6K^$I/"O[2G[ ?AS]GOXA3WNBZ=I&J76J6?@;XG?#70
M?$-[X:EM]9@BL_$-M:2:7=7MIJME'<?:M*OHH5;"_P V*_\  ,-_\L#FQ/\
M+A__  +$_P#R!^B'_"Q_AY_T/G@S_P *C0__ ).H_P"%C_#S_H?/!G_A4:'_
M /)U?.C?L'?L'J(V;]C']DE5E94A)_9S^#0$SNI=$A/_  B'[UV16=$CW,Z@
ML@8<U\K_  3\#_\ !,7X]?'/]J_]GSP7^P]^S]9>.?V.O''P^^'WQ1NO$O[+
M?P%T[P[K&N_$KX>6OQ+T"7P+?V6E:G>ZW86_AZZ6/57U32] O+34(9DALKVR
M\N]D/]E_FQ7_ (!AO_E@*6)_EPZ]98G_ .0/TS_X6/\ #S_H?/!G_A4:'_\
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M $/G@S_PJ-#_ /DZC_A8_P //^A\\&?^%1H?_P G5\]_\,"_L+?]&6?LF?\
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M:^*?AR[^,WPXT+P#;_$S3_$WAFQOO^$M;5!H-K)IUMI>J^6ZU_P<)7@\7_\
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M]A+]OKX5>#OC9J7[7.I?'+QQ^SYKW[-O[-ND?#SX,?L]:I\&O#W@;]J[X?\
MQ.\4:+IOQLU'Q?H47CB^T_X=:,UK;:YX\U+2+[SO"D>H6$=QK6L-9R?)%Q_P
M38^-O[57QH_X);0?M!_L?_M6G]G#X$?&W_@H$_[3'A_]N3]MSP'^U;\2&\!_
M%_\ 9A^'NC?"O5M1\?\ ACXZ>+/$NO\ PT\7?$RPNO!=M\,=#U'66T\>&_$4
M_CGP]#X+\5FXUW[T_9&_X+D_"'XC_L>0?M0?ML>$%_8Q\0O\>?CC\!KCX2Z>
MWQ'_ &@O$=KKWP"CCG^(-_-9_#7X5R^*([#PG;1ZG>^-=4?PG_PC?@_3]/\
MM^LZ_!;7".OU#\:_^"R7_!,W]G;4?#NF?&+]KGX>>$[CQA\'/AO^T'X0G@TG
MQWXHTSQ9\%/B[KL_ASX>?$GPQK7@_P )^(-&\0^&?$&IVTKO>:/J%X^BZ1Y7
MB'7XM+T"X@U)P#^2WQG_ ,$E?^"MOBG_ ()^_LD_LW>)?V-K7Q7X]^!G[&'[
M07ACP7XSMOB9^R9XF^,WP;_:+NOVT/B-XX^&'@Z^^)?QH^)WBJR^''PMM?V<
M;#X87OPZ\4_LHV-E\7CXK71?AQXS^)?@GP%H\Q\,?2/[3_\ P2;_ &\/C?\
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M\1^']+UK7]#N+_1=#U:_L_,OBK^V%^S;^VQ^SY\*_BC^RW\5M$^,7P_\*_\
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M;>$/!.NZG\.O"G@+Q/KVD^&O'GB3XDV/A'1?!?B&[71/%%[I.IQSVL7I#_\
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M#;_LQ[XV_P#J^OV?J^WW^Z?P_F*^(-:_Y23?#;_LQ[XV_P#J^OV?JJG\<O\
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MN+'^W='CU'1/[2TS^T/MT'XB?\.8?^"=G_1'/&W_ (D/^T'_ //*H_X<P_\
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MV"ZN+[Q#/I(MM3P_^',/_!.S_HCGC;_Q(?\ :#_^>51_PYA_X)V?]$<\;?\
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MH?\ S9\O\F/ZU7_Z!Z?_ (42_P#F4]U\)?\ !$+QYH?Q,^%7A35OVJM!U/\
M8F^!?_!1K7O^"H/PP^$6G_ ^33/V@K;X\WNJ>*?$?A?X>^)_CW=?$[5O#6N?
M"?P=XM\6ZQK@NQ\(K;QWXHTF_N_"&LZY'9KI>K:3\MZ!_P &W/Q-\4GXO6'[
M2G[=+_&)OBU^QK\:OV3==^*%G\.?B>OQK\2:OX\^.GP[^.G@CXU?$WQ9\5_V
MB_C$OC3Q#HOB+P!86/B3P/X>;X>^!9?"]O9>&?"VFZ#>/JGBN_Z__AS#_P $
M[/\ HCGC;_Q(?]H/_P">51_PYA_X)V?]$<\;?^)#_M!__/*H^J8/_H-Q'_A%
M#_YL%]:K_P#0/3_\*)?_ #*??%M_P3]_:V^)/Q7_ ."=WQG_ &H_VEO@9\0?
M&_[!_P 8/C#XR:?X2_L\^(?A'I/Q'\"_$']GNQ^#.A:3<:%?_%OQWINB>.+/
MQ$->\=>(M<T6+2?"$\.M67AKPQX'\-VF@1W>I?17_!+K]B?6_P#@GE^Q7\-/
MV3]=^(.E_%'4O 'B;XQ>()O&FC>';GPGINHQ_%+XR>//BI!:6V@WNL:[<60T
M>'QFFD2,VISK=364EVBPK.(D_'W_ (<P_P#!.S_HCGC;_P 2'_:#_P#GE4?\
M.8?^"=G_ $1SQM_XD/\ M!__ #RJ/JF#_P"@[$?^$4%^6,T^0_K5?_H'I_\
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M0M7\1Z!'J=QX2NM.\73_ !,^&-WK>D/XRT>&]:_&[]M?V:OV)OB?^SC^V_\
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MBJ_^*_B&ZTWQ+I]E?V7B>;6I0_A'2K>P&FR>0D.I36UC#%+YQ_PYB_X)V?\
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MQ)IT_P 0/#G[/&E_$WQ!:2V[-XAT/5;73]7TWP;_ (<Q_P#!.O\ Z([XU_\
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MPHOQ*\136/ACX8>%FT?P;/HU[K5_K_BZXT:;Q-=:UI]SK$FFV/S=_P .8_\
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M_P 2(_:#_P#GE4?\.8_^"=?_ $1WQK_XD1^T'_\ /*H^J83_ *#<1_X0P_\
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M?MU_'W]E?XSZ.NE>&O'EE8:3X7_9X\(>&?"?BSX)?%#5O 'Q6^'/Q#U[X?\
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M^(=8\.VUJ-*M]:O_ !=X<K?L+_ K]HGX1?L&GQK^TQX;\5^&/B/^U7_P7/\
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MO_HCOC;_ ,2'_:#/_O2OS].]+_PYB_X)V?\ 1'/&W_B0W[0G_P \FG]4P?\
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M8_E\2L5K4PF$<,/?&5THTII-8--RO7J-[XI)6]7J]-"(8JOS5?\ 9Z7\2/\
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M+-\:9=>\9?&KXS:1\ _B-X8_:P^-OQ:NM=MKOPEXA^*GQF\6_'3QWHNK>"O
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M+J[=K]=';V&OE_XG?\G5_L@_]BO^UO\ ^H7\)Z^H*^7_ (G?\G5_L@_]BO\
MM;_^H7\)Z='XY?\ 7C$?^FICDE[NB^.E_P"G:9]04445G+XI>K_0(I<JT6W9
M>?D%%%>3_&OXHK\'OAYJ/C2+P[=>,=<GU[P/X%\$>#+74[?07\8?$;XI>./#
MOPT^'7AJX\0W=KJ%KX:TK5?&GBS0X-?\3W&G:G'X:\/_ -JZ\-*U:334TF_<
M8RG)1BKRDU%+:[>WY.[Z)-A)J,92=E&*O)VO9=[;OLEU=EI<]8_S_G\Z,CUK
MY"\<>._VG_AYH/A_^WI/V;;WQ+\0/B_\(/A?X1N=!T'XNW/AOPR_C[6M2T_Q
M-<>)[34_%ND:OXPCTB"*P/AS5M)O? LFJ3&]FU?PKI*?9[05?^%[?$CP[/\
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M _\ T<[X._\ "2^*7_S 4?\ #S+]@?\ Z.=\'?\ A)?%+_Y@*_B@V+Z?J?\
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M]&W?_?O,_M?_ .'F7[ __1SO@[_PDOBE_P#,!1_P\R_8'_Z.=\'?^$E\4O\
MY@*_B@V+Z?J?\:-B^GZG_&I_X@%PQ_T.<_\ ORO_ .8B_P#B;?CC_HG.%?\
MP'.?_FX_M?\ ^'F7[ __ $<[X._\)+XI?_,!1_P\R_8'_P"CG?!W_A)?%+_Y
M@*_B@V+Z?J?\:-B^GZG_ !H_X@%PQ_T.<_\ ORO_ .8@_P")M^./^B<X5_\
M <Y_^;C^U_\ X>9?L#_]'.^#O_"2^*7_ ,P%'_#S+]@?_HYWP=_X27Q2_P#F
M K^*#8OI^I_QHV+Z?J?\:/\ B 7#'_0YS_[\K_\ F(/^)M^./^B<X5_\!SG_
M .;C^U__ (>9?L#_ /1SO@[_ ,)+XI?_ # 4?\/,OV!_^CG?!W_A)?%+_P"8
M"OXH-B^GZG_&C8OI^I_QH_X@%PQ_T.<_^_*__F(/^)M^./\ HG.%?_ <Y_\
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M1_\ FP_(^BOUP_X<G_ML?\]O@?\ ^'+U/_YBZ/\ AR?^VQ_SV^!__AR]3_\
MF+H_XB'P+_T5F2?^%<O_ )E#_B#?BK_T0/$W_A!'_P";#\CZ*_7#_AR?^VQ_
MSV^!_P#X<O4__F+H_P"')_[;'_/;X'_^'+U/_P"8NC_B(? O_169)_X5R_\
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M7P/X-3PW\(;B]\!Z+XFEN-8N-=\3ZMJ'Q*\1^$]1T:--(BUH^,+J?PS)??\
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M)@\-2G&NWBX*MF52GB)QC7?UV*E6>(<JM.F_@<ESGQXXVH8OC3"\6\%X7-^
M,SXMX8P*R_*\BI9GFF:<=>&?%?$.>8[!+*)X?)<55RW@7 8[)\#C5E\:?"M*
MC@,$\C5+)JF90[+X@_\ !-N+4_%_Q%UOX;:7\%_"NEG5/V#H_@(VIVVOR^)O
MA-X3_98UL7GQ&TJQUX>%]8UG0;SQKI=MIMMH]WHFOWUYXFN[-)_'&IZ=+Y=Z
M_FA_X)M?&W6]9^+>J?$?5_@%X[3XF_"_6/ 6KVFB^(/''PCC\3Z\W[3WACXZ
M>&O&ES#X'^#DOA[X>WF@Z/I%R+33;'PS\1-./C*#/B:#QQI'B?6[JS]S\'?\
M%!/B+K^C?LU^*/%7[,5A\-_!G[2=OX<U3P_\0?%/QGU_4/AQHMCXJNO"6D^'
M/#VL^,O!_P  _$VF^'_B1XOUC7->F\'>&/'?_"#>&]8\.:%IUU+X[L_%6N:E
MX-\*=W^S=^TM\9?%G[+7QU^//QG\%^$1JWPKUO\ :3O-"TCPEXJE-MXBT[X)
MWWC9KCPG>R-X*T]?#JZ7=>%X_"FE>*#%XGO_ !/8,/&&IZ3I%[,?#9XZ>"X(
MS'$QIT*6/M6H8S,*D84<;A<'##TLLJ8^<Z]"MA:25"669PEA.7#5(5\/&.&H
MRJ4Z;P^$^LQ/&/TM^"<AJXK-,?P>UEF9<-<"X3$8S-N'.(^)<3F>8<:4N#*&
M!RO.,KXKS'$/%8;C7PWOQ0X9O@<3@<[CB^(<?@L/BLVQN:YG\WQ?\$WOBSJ?
MCCX1>,?B/X\^%_Q,N/#_ (,^#WAGQM<V,^O_  <N/!NI?"?XP^)OB;::Y\)=
M-^'GP[;1]7-U;:_8RW-M-%\(T\0?$#1+GQOKS,OB74=(MOT _:5^#OB?XU3?
MLZOX<U;0=*B^#_[6/PG^/_B2+79]3MX]1\,> ;+QE:ZOI6@Q:7IFIQR^)+Q_
M$5K_ &5#J(TS2FCAN$N]6LV%NL_R?I/_  46UN:U@T_Q7\"]!\%^.?%_PD^
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M<FJGRI)V<*C4KW>D7;HFW:UG9+Z&IK_=/^<\TZFO]T_A_.N);G5'XH_XH_\
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M_DFC_A>.N?\ 1K7[;?\ XB_XR_\ DFOVZP/0?D*,#T'Y"CZW3_Z!E_X/K?\
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M "C3_P#DC\1?^%XZY_T:U^VW_P"(O^,O_DFC_A>.N?\ 1K7[;?\ XB_XR_\
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M_1K7[;?_ (B_XR_^2:_;K"GH%/Y48'H/R%/ZW3_Z!E_X/K?_ " OJ[_Y^_\
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M9:7=EI^A^(=8L/$WC[61K-WIFGW.K).8[_\ M"XM;2;ZE!^;GYE!^91U(Z$
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M_B+\>/@/XEL_AS\+]7^,O@[]F?6M%\9? MOACX1\(>-=.FL/%OQ7\;^']/\
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M^&GQW\5_#;0-5T_Q+X4URV^('A7Q/XXT;5O!EM'8:Q=FZ\.ZQI.MWON>H?\
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M%X8-_;GQ+\)O'5I8>)[:UUFWCOM7^'_@/4[(Z:+7Q';^)>4^&O\ P3X_9_\
MA'8_"O2O %MXMT+3/A#XN^.OC'PO9_V]97_VNZ^/>C:UX6UC1]>OM0T2YU34
MO#WP^\#ZIIGP^^$VG1WUJ_@OP%X*\"^$1<:EHGAFSM#UJK@KJ7LFFE7=G2ZU
MM4KQEK["22I=%&HU%6@^;!T\1LI_\^[M3>KIZ-Q7+HJB?O:ZM7LKV/8OV3?B
M#XE^*O[+'[-/Q2\;W=O?>,?B5^S]\&O'_BW4+6S@TVTOO$_C+X<^&O$>OW=K
MIUHB6MA;W.JZC=3PV5LBV]K&ZP0JL:*H^A 0>G^>_P#6OB+X+_LC^.O@3:_
M_P '>'/VL/CEXX^$?P8LM%T:U\ _$S2?@BSZCX3\&?"?Q5\+?!7@F/7OA/\
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M_P##+EO_ ,R!_P 1$X^_Z+;BS_Q(LW_^;#])O^'PO_!33_H[KQY_X2GPF_\
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M ,,N6_\ S(/_ (B)Q]_T6W%G_B19O_\ -A^DW_#X7_@II_T=UX\_\)3X3?\
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MOS_DG/P(_P"SZOV$/_6K/A;7W97PG^WY_P DY^!'_9]7["'_ *U9\+:UP_\
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M^,?^Q6\0_P#IINZZFN5\=?\ (D>,?^Q5\0_^FB\HZQ_Q1_,#^*W_ (+#$_\
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M$X?^A6^+G_AWO$G_ ,31_P 0]W_!.'_H5OBY_P"'>\2?_$T?\1]X'_Y\9_\
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MU_>7_P 0]W_!.'_H5OBY_P"'>\2?_$T?\0]W_!.'_H5OBY_X=[Q)_P#$U/\
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M:SXN_P""?FJ6WBO2K%;A+'3?$L%]^UK/%KMA9)=726EGJB75O;+<W"PQH)I
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M(?IZT\QD*KE"$<L$<J0CE I<*Q&&*!U+!2=NY<XR*.6BO^7"77^+B5LN6_\
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MIOPI\)6MOKNDV?B']JS1/$%MIFK0Q1ZA86^O:+HVMPVMQ#%JVD:7?K<6-O\
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M4?\ #??Q*_Z1_?M2_P#AS?V$O_HP*S?[/O?^?&[_ / 2?_XW1_9][_SXW?\
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M_P .;^PE_P#1@4?\-]_$K_I']^U+_P"'-_82_P#HP*S?[/O?^?&[_P# 2?\
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MZ:M3J/K*6CNMFO7729SK.$U[5VY?^?=-:J=)K:]_-:?Y?7@_;Z^)0X_X=_\
M[4N<#_FI_P"PD?\ W\#!^HX/;BE_X;[^)7_2/[]J7_PYO["7_P!&!6$H&!P.
M@[#TI<#T'Y"L>2A_SXC_ .#<1^E0OGK:?O>G_/NG_F;G_#??Q*_Z1_?M2_\
MAS?V$O\ Z,"C_AOOXE?](_OVI?\ PYO["7_T8%8>!Z#\A1@>@_(4^2A_SXC_
M .#<1_\ +1<];_G[_P"4Z?\ F;G_  WW\2O^D?W[4O\ X<W]A+_Z,"C_ (;[
M^)7_ $C^_:E_\.;^PE_]&!6'@>@_(48'H/R%')0_Y\1_\&XC_P"6ASUO^?O_
M )3I_P"9N?\ #??Q*_Z1_?M2_P#AS?V$O_HP*/\ AOOXE?\ 2/[]J7_PYO["
M7_T8%8>!Z#\A1@>@_(4<E#_GQ'_P;B/_ ):'/6_Y^_\ E.G_ )FY_P -]_$K
M_I']^U+_ .'-_82_^C H_P"&^_B5_P!(_OVI?_#F_L)?_1@5AX'H/R%&!Z#\
MA1R4/^?$?_!N(_\ EH<];_G[_P"4Z?\ F;G_  WW\2O^D?W[4O\ X<W]A+_Z
M,"C_ (;[^)7_ $C^_:E_\.;^PE_]&!6'@>@_(48'H/R%')0_Y\1_\&XC_P"6
MASUO^?O_ )3I_P"9N?\ #??Q*_Z1_?M2_P#AS?V$O_HP*/\ AOOXE?\ 2/[]
MJ7_PYO["7_T8%8>!Z#\A1@>@_(4<E#_GQ'_P;B/_ ):'/6_Y^_\ E.G_ )GS
M3\=?VSOB#KW[0_[#.MS?L1?M(:1<>$OB[\:-8LM%O?B'^QA/J/BIY_V5/C5I
M-QINASZ7^U3>Z/976FVFHS^(+V7Q3JOA^QDTK2[^'2[O4]>DTS0[_P"LO^&^
M_B5_TC^_:E_\.=^PE_\ 1@5\A_&;_DX?]AT=A\4_CS@=O^32/C1VKZ? ! R!
MT';VK2=.AR4;T(_!*W[W$:?O:NWO)J]OYFO*^I,:E:]7][]N/_+NG_SZAT]?
M-F[_ ,-]_$K_ *1_?M2_^'-_82_^C H_X;[^)7_2/[]J7_PYO["7_P!&!6'@
M>@_(48'H/R%9\E#_ )\1_P#!N(_^6E<];_G[_P"4Z?\ F;G_  WW\2O^D?W[
M4O\ X<W]A+_Z,"C_ (;[^)7_ $C^_:E_\.;^PE_]&!6'@>@_(48'H/R%')0_
MY\1_\&XC_P"6ASUO^?O_ )3I_P"9N?\ #??Q*_Z1_?M2_P#AS?V$O_HP*/\
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M7EU:Z?:W.H:A=6MAI]HB27=_?7,-E8VL;;(Q)<WER\5O!&7(3?+(B;RJE@S
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M\0?M)Z<;O]G_ /:LN/!NJ+;>,X?B4NCP_M\?LS:+^R_XF\?6DNC?:1\=K?\
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MPM#U36?L@G^$'[-7V?[5_9EI="U^T>3.8/M!C$H@F"%C%)M_'?\ X5O\1?\
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MRA"<95<+]:IXVK4P\:\8^RG6ITYU(0E-TX^T<)0\J^#'P>\"? /X7^#O@_\
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MV_Y.6^'AZ^V!10?[R'^*3_\ *53_ .1?X&T_AG_A_P#;J1]0+T'T'\J6F@C
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M;Q/_ #^?W4O_ )0'U:C_ ,^X_P#D_P#\M/S>_P"'=U]_T?3^VO\ ^##]E/\
M^A2H_P"'=U]_T?3^VO\ ^##]E/\ ^A2K](<@=3CM^/I29'J/S].OY4?6\1_S
M^?W4O_E ?5J/_/N/_D__ ,M/S?\ ^'=U]_T?3^VO_P"##]E/_P"A2H_X=W7W
M_1]/[:__ (,/V4__ *%*OTAR#T-%'UK$_P#/Y_=2_P#E ?5J/_/N/WS_ /EI
M^;W_  [NOO\ H^G]M?\ \&'[*?\ ]"E1_P .[K[_ */I_;7_ /!A^RG_ /0I
M5^D-%'UK$_\ /U_^ TO_ )0'U:C_ ,^X_P#D_P#\M/S>_P"'=U]_T?3^VO\
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M_P#H4J/^'=U]_P!'T_MK_P#@P_93_P#H4J_2&BCZUB?^?S^ZE_\ * ^K4?\
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MT8S5*DY1E4<6FZ5)[.LM]U;2UO(^;?\ AW=??]'T_MK_ /@P_93_ /H4J/\
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M'[*?_P!"E1_P[NOO^CZ?VU__  8?LI__ $*5?27_  U+\'_^@GKO_A-ZK_\
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M:_\ X,/V4_\ Z%*OTAHH^M8G_GZ__ :7_P H#ZM1_P"?<?\ R?\ ^6GYO?\
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M??\ 1]/[:_\ X,/V4_\ Z%*OTAHH^M8G_GZ__ :7_P H#ZM1_P"?<?\ R?\
M^6GYO?\ #NZ^_P"CZ?VU_P#P8?LI_P#T*5'_  [NOO\ H^G]M?\ \&'[*?\
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MD-_I&MZ%K>F3W6F:OI&J6-Q;WFG:EI]U<6=[:3Q7%M-+#(CG<KR;X%Z/\5=
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M?^D5#.K_  I_X5_Z<HGW91116*V^;_-EK9>B_)!1113&%%%% !1110 4444
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M#]<_C32O7GKGL.N<]?3IQQTKX2_X>>?\$\O^CT?V<O\ PZ/AC_Y-H_X>>?\
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M>7_1Z/[.7_AT?#'_ ,FUS+"XI)+ZM7T5OX53S_Z=^9M[6E9?O:6R_P"7D?\
M,^[Z,#T%?"'_  \\_P"">7_1Z/[.7_AT?#'_ ,FT?\///^">7_1Z/[.7_AT?
M#'_R;3^JXK_H&K_^":G_ ,K#VM+_ )^T_P#P9'_,^[B.PP.>>.O8_3([TFP
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M_P#*P]K2_P"?M/\ \&1_S/N^BOA#_AYY_P $\O\ H]']G+_PZ/AC_P"3:/\
MAYY_P3R_Z/1_9R_\.CX8_P#DVCZKBO\ H&K_ /@JI_\ *P]K2_Y^T_\ P9'_
M #/N^N5\=?\ (D>,O^Q5\0_^FB\KXZ_X>>?\$\O^CT?V<O\ PZ/AC_Y-KGO%
M_P#P4R_X)]7WA/Q196O[9G[.L]S>>'-<MK:"/XG>&GDFGGTN[CABC5+PLSR2
M,J(JAF=B$169@"?5<5>/^S5]))_PJG1W_P"?>H>UI?\ /VE_X,C_ )G&_L_?
M"#7OBO\ L*?\$_CHFIZ1IP\/_LD? L77]JF]'G?VM\'OAJ8/(-G:W(_=G3)1
M+YFS'F1[0PW%>Q_X9"\=_P#0S^$O^^]8_P#E37@_[%?_  45_80\&?L;?LD>
M$?%?[7/P!\/^*/"W[,7P"\/>(M!U7XE>'+35-%US1OA1X2T[5M)U*TEO1+:W
M^G7T$]I>6LRB6WN(I(I55T8#Z9_X>=_\$\?^CT/V<?\ PZ'A?_Y-KY;.> <I
MSC-,;F.-RW'U<3B:TG4G3Q.+HQDJ;G2A:G3HN$?<@EH];7>MSSUA<!64*DW!
MSE2H\S6(Y=51I1^%7M:R1SW_  R%X[_Z&?PE_P!]ZQ_\J:/^&0O'?_0S^$O^
M^]8_^5-=#_P\[_X)X_\ 1Z'[./\ X=#PO_\ )M'_  \[_P"">/\ T>A^SC_X
M=#PO_P#)M>9_Q"[A_P#Z%69?^%V._P#E ?4<N[Q_\*6<]_PR%X[_ .AG\)?]
M]ZQ_\J:/^&0O'?\ T,_A+_OO6/\ Y4UT/_#SO_@GC_T>A^SC_P"'0\+_ /R;
M1_P\[_X)X_\ 1Z'[./\ X=#PO_\ )M'_ !"[A_\ Z%69?^%V._\ E ?4<N[Q
M_P#"EG/?\,A>._\ H9_"7_?>L?\ RIH_X9"\=_\ 0S^$O^^]8_\ E370_P##
MSO\ X)X_]'H?LX_^'0\+_P#R;1_P\[_X)X_]'H?LX_\ AT/"_P#\FT?\0NX?
M_P"A5F7_ (78[_Y0'U'+N\?_  I9SW_#(7CO_H9_"7_?>L?_ "IH_P"&0O'?
M_0S^$O\ OO6/_E370_\ #SO_ ()X_P#1Z'[./_AT/"__ ,FT?\/._P#@GC_T
M>A^SC_X=#PO_ /)M'_$+N'_^A5F7_A=CO_E ?4<N[Q_\*6<]_P ,A>._^AG\
M)?\ ?>L?_*FC_AD+QW_T,_A+_OO6/_E370_\/._^">/_ $>A^SC_ .'0\+__
M ";1_P /._\ @GC_ -'H?LX_^'0\+_\ R;1_Q"[A_P#Z%69?^%V._P#E ?4<
MN[Q_\*6<]_PR%X[_ .AG\)?]]ZQ_\J:V_#?[(NLQ:YILWBS7]$O/#T-PLVI6
M.D'4C?:A#$"XL4DN+*TCMX;IPL5U.LOG);-*(-DS)+'-_P /._\ @GC_ -'H
M?LX_^'0\+_\ R;1_P\[_ .">/_1Z'[./'/\ R5'PP/\ V]JZ?ACD%.I"HLHQ
M\G3G&:C5Q6,JTI.,E)*I2G14*D&TN>G)\LXWC*Z;3J."RY-/W'9IV>(<E=.Z
MNG9-72=F^GWR_P#!2>"*U_X)]?M?6\$4<$$/[//Q$A@@AC6*&"&+P[<QQ0Q1
MHJK'%$BJD<:@*B*%4 #%?=0ZM]?Z"OQ2_;__ ."AW["_CW]B3]JCP;X-_:U^
M GB;Q5XD^!_C[1] \/Z/\1_#U_JVL:K>Z)<0V>GZ?96]V\]U=W4Q6*&*)&9W
M89&,L/L*3_@IS_P3TCD=&_;0_9R5D<JP_P"%I>%SAE^4\B^*D9'!4E6&""0<
MU]\\+B5AJ,%AJRY:U;W51J))>QPRC9*DDHV244M$DDM$CHC4I>WJ/VM*SITT
MK5(])5;Z7[-:=+GW917PA_P\\_X)Y?\ 1Z/[.7_AT?#'_P FT?\ #SS_ ()Y
M?]'H_LY?^'1\,?\ R;67U7%?] U?_P %5/\ Y6;>UI?\_:?_ (,C_F?=]%?"
M'_#SS_@GE_T>C^SE_P"'1\,?_)M'_#SS_@GE_P!'H_LY?^'1\,?_ ";1]5Q7
M_0-7_P#!53_Y6'M:7_/VG_X,C_F?=]%?"'_#SS_@GE_T>C^SE_X='PQ_\FT?
M\///^">7_1Z/[.7_ (='PQ_\FT?5<5_T#5__  54_P#E8>UI?\_:?_@R/^9]
MWT5\(?\ #SS_ ()Y?]'H_LY?^'1\,?\ R;1_P\\_X)Y?]'H_LY?^'1\,?_)M
M'U7%?] U?_P54_\ E8>UI?\ /VG_ .#(_P"9]WT5\(?\///^">7_ $>C^SE_
MX='PQ_\ )M'_  \\_P"">7_1Z/[.7_AT?#'_ ,FT?5<5_P! U?\ \%5/_E8>
MUI?\_:?_ (,C_F?=]%?"'_#SS_@GE_T>C^SE_P"'1\,?_)M'_#SS_@GE_P!'
MH_LY?^'1\,?_ ";1]5Q7_0-7_P#!53_Y6'M:7_/VG_X,C_F?=]?"?[?G_).?
M@1_V?5^PA_ZU9\+:9_P\\_X)Y_\ 1Z/[.7_AT?#'_P FU\??MI?\%"/V&_&_
M@3X,6'A/]K/X">(+[2OVR?V,/%>IVVE_$CPY=2V/AOPI^TI\.=?\3:[=!+W%
MOI6@Z)I]]JVJWTNRVL;"TGN;F6.-,UK0PV)C7I2>&KI)R3?LJG6%5K_EWY6]
M?PSK5:7LI_O:>T4E[2-_XE'S['[845\(#_@I[_P3R(S_ ,-H_LY8/_54?#&?
MR^VY_2C_ (>>?\$\O^CT?V<O_#H^&/\ Y-K%87%6_P!VK[O_ )=5.[?_ #[\
MS15:5E^]I[+_ )>1[>I]WT5\(?\ #SS_ ()Y?]'H_LY?^'1\,?\ R;1_P\\_
MX)Y?]'H_LY?^'1\,?_)M/ZKBO^@:O_X*J?\ RL/:TO\ G[3_ /!D?\S[OHKX
M0_X>>?\ !/+_ */1_9R_\.CX8_\ DVC_ (>>?\$\O^CT?V<O_#H^&/\ Y-H^
MJXK_ *!J_P#X*J?_ "L/:TO^?M/_ ,&1_P S[OHKX0_X>>?\$\O^CT?V<O\
MPZ/AC_Y-H_X>>?\ !/+_ */1_9R_\.CX8_\ DVCZKBO^@:O_ ."JG_RL/:TO
M^?M/_P &1_S/N^BOA#_AYY_P3R_Z/1_9R_\ #H^&/_DVC_AYY_P3R_Z/1_9R
M_P##H^&/_DVCZKBO^@:O_P""JG_RL/:TO^?M/_P9'_,^[Z*^$/\ AYY_P3R_
MZ/1_9R_\.CX8_P#DVC_AYY_P3R_Z/1_9R_\ #H^&/_DVCZKBO^@:O_X*J?\
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M(_[(/V1;9C<_LR? CS#<122_ZCX0^!"@0I/%@DS/NSG^'D8(;US_ (336_\
MGGI__@--_P#)U?&9YX@</Y)FV-RS'/,5BL+42JJA@I5J2]JI5Z?+5^LTE*]*
MI3;M3CRMN#5XLX5BZ-)0A)OF5.E>T+ZNE2ZZ7OO<]D_M34_^@EJ'_@;<_P#Q
MVC^U-3_Z"6H?^!MS_P#':\;_ .$TUO\ YYZ?_P" TW_R=1_PFFM_\\]/_P#
M:;_Y.KR?^(J\*?S9M_X;7_\ -H?7L/\ WO\ P ]D_M34_P#H):A_X&W/_P =
MH_M34_\ H):A_P"!MS_\=KQO_A--;_YYZ?\ ^ TW_P G4?\ "::W_P \]/\
M_ :;_P"3J/\ B*O"G\V;?^&U_P#S:'U[#_WO_ #V3^U-3_Z"6H?^!MS_ /':
M/[4U/_H):A_X&W/_ ,=KQO\ X336_P#GGI__ (#3?_)U'_"::U_SST__ ,!I
M_P"E[3_XBKPI_-FVZ_YEKZM+_H-\_P#AE=H^O8?^]_X >R?VIJ?_ $$M0_\
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M2U#_ ,#;G_X[1_:FI_\ 02U#_P #;G_X[5&BB[[O[W_F%EV7W+_(O?VIJ?\
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M&?$-CXATSP'I.BV_B;1H+2:?47BBL[VOUDNOV#OV3[GX/Z%\!HOA1-H_PO\
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M$_9<T>]M+6!5BG\=^+_V=+WPK<WWV[5/*^-'C*[GE.A>![B6TPO#?[6/Q%^
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M1:3=_#F?QKXEU3XR>';2;6_%ND:?J7Q6\ >(?A;X M/!EGXIM?#4>M^!-?\
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M]"G^Q1_X>3X^?_.(H_X4G_P4-_Z%/]BC_P /)\?/_G$5?)#_ *",+_X40_\
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MM,\ESX8MK*XBB\.74DMUHJV-S-),>E_X4G_P4-_Z%/\ 8H_\/)\?/_G$4?\
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MX4G_ ,%#?^A3_8H_\/)\?/\ YQ%9N$&V_K&%U;_YB(?K"XU&HDDZ56Z_N?\
MVYU]%<A_PI/_ (*&_P#0I_L4?^'D^/G_ ,XBC_A2?_!0W_H4_P!BC_P\GQ\_
M^<12Y(?]!&%_\*(?_(#M/_GU5_\  %_\F=?17(?\*3_X*&_]"G^Q1_X>3X^?
M_.(H_P"%)_\ !0W_ *%/]BC_ ,/)\?/_ )Q%')#_ *",+_X40_\ D M/_GU5
M_P# %_\ )G7T5R'_  I/_@H;_P!"G^Q1_P"'D^/G_P XBC_A2?\ P4-_Z%/]
MBC_P\GQ\_P#G$4<D/^@C"_\ A1#_ .0"T_\ GU5_\ 7_ ,F=?17(?\*3_P""
MAO\ T*?[%'_AY/CY_P#.(H_X4G_P4-_Z%/\ 8H_\/)\?/_G$4<D/^@C"_P#A
M1#_Y +3_ .?57_P!?_)G7U\O_LQ_\?G[5'_9Y7QE_P#4>^&]>X_\*4_X*&C/
M_%)_L3_C\9/CWQR.F?@/_G]1\O\ [,OPJ_;FU2^_:@3PUX9_9#G:S_:X^*T7
MB,ZU\5?C;8K;^)Y/#OP]DU&TT4V/P6O6O=#@A-G]DOKT65]-,]RLMDD<4,LN
ML(P]G67M\-M25_;QMK5OK+V?*MMF[WT(DJG-2_=5=)57\&_[N"T]_P#-H^SZ
M*Y#_ (4G_P %#?\ H4_V*/\ P\GQ\_\ G$4?\*3_ ."AO_0I_L4?^'D^/G_S
MB*RY(?\ 01A?_"B'_P @7:?_ #ZJ_P#@"_\ DSKZ*Y#_ (4G_P %#?\ H4_V
M*/\ P\GQ\_\ G$4?\*3_ ."AO_0I_L4?^'D^/G_SB*.2'_01A?\ PHA_\@%I
M_P#/JK_X O\ Y,Z^BN0_X4G_ ,%#?^A3_8H_\/)\?/\ YQ%'_"D_^"AO_0I_
ML4?^'D^/G_SB*.2'_01A?_"B'_R 6G_SZJ_^ +_Y,Z^C ]/\_P"0*Y#_ (4G
M_P %#?\ H4_V*/\ P\GQ\_\ G$4?\*3_ ."AO_0I_L4?^'D^/G_SB*.2'_01
MA?\ PHA_\@%I_P#/JK_X O\ Y,Z^BN0_X4G_ ,%#?^A3_8H_\/)\?/\ YQ%'
M_"D_^"AO_0I_L4?^'D^/G_SB*.2'_01A?_"B'_R 6G_SZJ_^ +_Y,Z^BN0_X
M4G_P4-_Z%/\ 8H_\/)\?/_G$4?\ "D_^"AO_ $*?[%'_ (>3X^?_ #B*.2'_
M $$87_PHA_\ (!:?_/JK_P" +_Y,Z^L;Q)SX<\0C_J :Y_Z:;RLG_A2?_!0W
M_H4_V*/_  \GQ\_^<16-XD^"_P#P4&@\-^(IKOPK^Q8EK'H&LO/)#\8/CS)-
M' -,NO.>*.3X%*DDB1%F1"RJ[*%) .0U&"E%_6,+I)/_ 'B'3_MQZ]E9W&E4
M_P"?57_P#R?]\\Q_91TNPU/]D?\ 9+^W6RW/D?LQ_ +RBTMQ&8Q+\(O!?F8\
MF6+.[RTSN)QMR!FO=_\ A%O#_P#T#4_\";[_ .2J^:OV1?A)^W?JW[)?[+&I
M>%?"_P"Q_-X7O?V;?@3<>&Y_$/Q9^-UAK\V@R?"SPG_8\VMV.F?!74=.LM7F
MT\6\NI6ECJ%_9VU[)-#:WES;QQS/]"_\*3_X*&_]"G^Q1_X>3X^?_.(KS\9D
MF2XO%5\1B<#DM>O4JS]I6Q.'P=6O-QG.*4ZE?"2J2Y(Q44G)J*7*K:HYX4%*
M%.4\-*3=*EJZ,)-I4:2WDV]-C0_X1;P__P! U/\ P)OO_DJC_A%O#_\ T#4_
M\";[_P"2JS_^%)_\%#?^A3_8H_\ #R?'S_YQ%'_"D_\ @H;_ -"G^Q1_X>3X
M^?\ SB*YO]6^'O\ H5\._P#A)EO_ ,Q%?5X?] K_ /!%(T/^$6\/_P#0-3_P
M)OO_ )*H_P"$6\/_ /0-3_P)OO\ Y*K/_P"%)_\ !0W_ *%/]BC_ ,/)\?/_
M )Q%'_"D_P#@H;_T*?[%'_AY/CY_\XBC_5OA[_H5\._^$F6__,0?5X?] K_\
M$4C0_P"$6\/_ /0-3_P)OO\ Y*H_X1;P_P#] U/_  )OO_DJL_\ X4G_ ,%#
M?^A3_8H_\/)\?/\ YQ%'_"D_^"AO_0I_L4?^'D^/G_SB*/\ 5OA[_H5\.OR>
M#RUK[G@F@^KQ_P"@5_\ @BG^AT%EIECIR/'96Z6Z2.KR!6E<NRKM!9Y9)'.!
MG W!5+$JH)8M? Q_G\*Y#_A2?_!0W_H4_P!BC_P\GQ\_^<11_P *3_X*&_\
M0I_L4?\ AY/CY_\ .(KTZ&%PV&I0H8:6 P]"FFJ=&A4HT:4%*7,U"G3I0A&\
MM6U%-O=LT4)15HT:B71*FDOPFCKZ*Y#_ (4G_P %#?\ H4_V*/\ P\GQ\_\
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M1YD7ZONO@Q_P4-N+JYG'A']B=?/N)IMO_"Y/CV=OFR,^TD? @] 0.IYSC (
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M)/\ A2?_  4-_P"A3_8H_P##R?'S_P"<167)#_H(PO\ X40_^0*M4_Y]5?\
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ME3FE[CGZ6$Q5/%P<HQ4)P=IT[IM)_#*+LKQ?5M)IW36U_BC_ (*7@#_@G_\
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M?Q-^-%]KWPTG^)OP[^%VF:AHGP'UWXH_!:?P0?'/B5M*\.^%?#OBR+Q'X<U
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M%>\I->Q4'**6EGSRDOBE;16>TI24I66BDHJ*@]4XI^T<TI-I-6Y5&^R\S]=
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MQO\ ^3ZOV%/^Q(_;"_\ 47^$-?)WPH_9!\8>#?BM\,/C2GPBN-%^*'_#S/\
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MZ%V8_P#A!CO_ )C#V=3_ )]U/_!=3_Y6<517:_\ "M/B5_T3SQO_ .$KKO\
M\@4?\*T^)7_1//&__A*Z[_\ (%']FYE_T+LQ_P#"#'?_ #&'LZG_ #[J?^"Z
MG_RLXJBNU_X5I\2O^B>>-_\ PE==_P#D"C_A6GQ*_P"B>>-__"5UW_Y H_LW
M,O\ H79C_P"$&._^8P]G4_Y]U/\ P74_^5G%45VO_"M/B5_T3SQO_P"$KKO_
M ,@4?\*S^)1_YIYXW'O_ ,(KKO'_ )("G_9N9?\ 0NS#_P (,=_\QC]G4_Y]
MU/\ P74_^5G$L<#/'4<G&!S_ !9(&WU]J_2W]EW1_%NE?#N-_$<SKI6I7+:A
MX1TNXC(N]/T:Y!EDFDD9B4M-6NG?4-/LRI,,$C76\"_%K:_-7P5^ FN^)?%"
MWOCOP[JNB>&-$>&ZN++6].N]-F\07A8O::9##=PQ23:<K1>?J\H!B>'R[!1(
M;V9[7])4C"8 "@!=H51A0!C 4# "@# 7&%' P*_6/#;AK&4*T\^QL:V%BZ=3
M#83#2C5H5*\9R_>UL33J0I5/8P<(K#TJM-*=1O$VC[.BY^UE6%J1E+$3YH73
MA"#YHN:O[TII]$U:":5WS-NUK_$'_!3#_E']^V%_V;]\2/\ TP7-?<0ZM]?Z
M"OAW_@IA_P H_OVPO^S?OB1_Z8+FON(=6^O]!7[5+_=J7_81B/\ TUASTX_[
MQ4_Z]TO_ $NL+1116!T!1110 4444 %%%% !1110 4444 %?"?[?G_).?@1_
MV?5^PA_ZU9\+:^[*^$_V_/\ DG/P(_[/J_80_P#6K/A;6N'_ -XI>LO_ $BH
M9U?X4_\ "O\ TY1/NRBBBL5M\W^;+6R]%^2"BBBF,**** "BBB@ HHHH ***
M* "BBB@#X9_:8_Y.G_X)Q?\ 9=OCE_ZQU\?Z^YJ^&?VF/^3I_P#@G%_V7;XY
M?^L=?'^ON:M:OPX;_KQ4_P#4FH9P^*K_ (U_Z;@%%%%9&@4444 %%%% !111
M0 4444 %%%% #7^Z?P_F*^(-:_Y23?#;_LQ[XV_^KZ_9^K[??[I_#^8KX@UK
M_E)-\-O^S'OC;_ZOK]GZJI_'+_KQ7_*F8U-X?]?:/_I50^X:***DV/AS]OL$
M_"7X1X&?^,X_^"?)X]!^VU\!\G\!R?09)X!K[A!P -K< =O:OSF_X*C:%IGB
M?]F/PQX=UJ*[FTG6OVN_V$=,U&*PU?6O#]\]G??MF? ZUNEM-;\.ZCI&O:3<
M-!(ZQ:AI&IV&HVCD3V=U!<)'*OR,?V1/@)D_\2'XDCIT_:5_:BQR ?\ HM!]
M?\,"NR%&%3#T92J2A>>(LHT^>ZYZ3NW[2%MTK6?>ZV.2525.I)1@I7C3?QJ%
MM*BZTYW_  /W2W?[+?E1N_V6_*OPL_X9$^ O_0"^)/\ XDK^U%_\^>C_ (9$
M^ O_ $ OB3_XDK^U%_\ /GH^JTO^@BI_X(_^[B^L5/\ GTO_  <O_E)^Z>[_
M &6_*C=_LM^5?A9_PR)\!?\ H!?$G_Q)7]J+_P"?/1_PR)\!?^@%\2?_ !)7
M]J+_ .?/1]5I?]!%3_P1_P#=P^L5/^?2_P#!R_\ E)^Z>[_9;\J-W^RWY5^%
MG_#(GP%_Z 7Q)_\ $E?VHO\ Y\]'_#(GP%_Z 7Q)_P#$E?VHO_GST?5:7_01
M4_\ !'_W</K$_P#GVO\ P<O_ )2?NGN_V6_*C=_LM^5?A9_PR)\!?^@%\2?_
M !)7]J+_ .?/1_PR)\!?^@%\2?\ Q)7]J+_Y\]'U6E_T$5/_  1_]W#ZQ4_Y
M]+_P<O\ Y2?NGN_V6_*C=_LM^5?A9_PR)\!?^@%\2?\ Q)7]J+_Y\]'_  R)
M\!?^@%\2?_$E?VHO_GST?5:7_014_P#!'_W</K%3_GTO_!R_^4G[I[O]EORI
M&8D<!NH/(].>W>OPM_X9$^ O_0"^)/\ XDK^U%_\^>D/[(OP% )_L'XD]O\
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M_P#0"^)/_B2O[47_ ,^>C_AD3X"_] +XD_\ B2O[47_SYZ/JM+_H(J?^"/\
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MT,#T?\A1@>C_ )"OPO\ ^&1/@+_T OB3_P")*_M1?_/GH_X9$^ O_0"^)/\
MXDK^U%_\^>L_JM+_ )_S_P#!'_WP7[>?_/I?^#O_ +B?NA@>C_D*,#T?\A7X
M7_\ #(GP%_Z 7Q)_\25_:B_^?/1_PR)\!?\ H!?$G_Q)7]J+_P"?/1]5I?\
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M8J?\^E_X.7_RD_=/=_LM^5&[_9;\J_"S_AD3X"_] +XD_P#B2O[47_SYZ/\
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M,B? 7_H!?$G_ ,25_:B_^?/1_P ,B? 7_H!?$G_Q)7]J+_Y\]'U6E_T$5/\
MP1_]W#ZQ4_Y]+_P<O_E)^Z>[_9;\J-W^RWY5^%G_  R)\!?^@%\2?_$E?VHO
M_GST?\,B? 7_ * 7Q)_\25_:B_\ GST?5:7_ $$5/_!'_P!W#ZQ4_P"?2_\
M!R_^4G[I[O\ 9;\J-W^RWY5^%G_#(GP%_P"@%\2?_$E?VHO_ )\]'_#(GP%_
MZ 7Q)_\ $E?VHO\ Y\]'U6E_T$5/_!'_ -W#ZQ4_Y]+_ ,'+_P"4G[I[O]EO
MRHW?[+?E7X6?\,B? 7_H!?$G_P 25_:B_P#GST?\,B? 7_H!?$G_ ,25_:B_
M^?/1]5I?]!%3_P $?_=P^L5/^?2_\'+_ .4G[I[O]EORHW?[+?E7X6?\,B?
M7_H!?$G_ ,25_:B_^?/1_P ,B? 7_H!?$G_Q)7]J+_Y\]'U6E_T$5/\ P1_]
MW#ZQ4_Y]+_P<O_E)]W_M,!C^U-_P3C8*<+\=OCEDXX!/['7Q_P!H)]6P<#J<
M'T-?<F[U5OP&?UK^:#XM?LN_!.P^.W[&^E6VB^/UL_$'Q*^-=GJJ3?M!?M'7
MD\MOIW[+OQ=UJT6RU"]^+EQJ.BRKJ-C:23W6AW6FW5[:I+I=]-<Z5=7=E/\
M1G_#(OP%(!_L'XD\@=/VE?VHAV]/^%T'^9^M:U,-2<,/^_J>[2FK^PWO6J2_
MY_\ 1HF.(GS5?W2^./\ R]7_ #Z@_P#GS_7IH?NGN_V6_*C=_LM^5?A9_P ,
MB? 7_H!?$G_Q)7]J+_Y\]'_#(GP%_P"@%\2?_$E?VHO_ )\]9?5:7_014_\
M!'_W<KZQ4_Y]+_P<O_E)^Z>[_9;\J-W^RWY5^%G_  R)\!?^@%\2?_$E?VHO
M_GST?\,B? 7_ * 7Q)_\25_:B_\ GST?5:7_ $$5/_!'_P!W#ZQ4_P"?2_\
M!R_^4G[I[O\ 9;\J-W^RWY5^%G_#(GP%_P"@%\2?_$E?VHO_ )\]'_#(GP%_
MZ 7Q)_\ $E?VHO\ Y\]'U6E_T$5/_!'_ -W#ZQ4_Y]+_ ,'+_P"4G[I[O]EO
MRHW?[+?E7X6?\,B? 7_H!?$G_P 25_:B_P#GST?\,B? 7_H!?$G_ ,25_:B_
M^?/1]5I?]!%3_P $?_=P^L5/^?2_\'+_ .4G[I[O]EORHW?[+?E7X6?\,B?
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M:UE>Z50KU[I2H25VO>Y96BG-1UC&[2LN;3F\]$V?K?\  +]HWP'^T7\/=?\
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M83GR<JN$:TI-+DWDXW3=ERW<D[I.ZBKW5XMRC%/F;2_0NOE_XG?\G5_L@_\
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M4;M6W4W?6UU[CVOU[!S1;LFF[-Z6V7SWU6G9I]K^LT445!05C>)./#GB$_\
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M_@G_ (?_ &ZD?4*]!]!_*EI%Z#Z#^5+6!04444 %%%% !1110 4444 %%%%
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M83#9I@,/B<-3Q"S=911Q>?SQ'"F30SK,<!C,[/T-_P"$.UO_ )Z:3_X&7O\
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M?X66_@/P?X<\6^(=.:S\/:G\4=0\!W'GM)!?V\4,!OG@B_;Z_9&E^,?_  H
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M?UAJSC'7E;MR\R^%M)<UGK?=ZJZ[7Z36?VM_@YHD.@^.;[XF>&;+X17OP?\
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M'/$(]?#^N#_RDWE5'XX?XE^H+_/\F?*7[/Q _9'_ &.A_P!6R? []?A%\/\
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M1VUQ8W=]%-LLRSI0Q]7#\.+#5,%3P<,+26']M/%8S,,QHK-<3"M1I4*LL)+
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MC_AA?]A[_HRW]D7_ ,1G^"?_ ,P]'^K?_44__!:_^2#_ %YI?]"RI_X5T_\
MYG.]^TVW_/W:?^!=M_C1]JMO^?RT_P# NW_^*K@O^&%_V'O^C+?V1?\ Q&?X
M)_\ S#T?\,+_ +#W_1EO[(O_ (C/\$__ )AZ/]6_^HI_^"U_\D'^O-+_ *%E
M3_PKI_\ S.=[]JMO^?RT_P# NW_^*H^U6W_/Y:?^!=O_ /%5P7_#"_[#W_1E
MO[(O_B,_P3_^8>C_ (87_8>_Z,M_9%_\1G^"?_S#T?ZM_P#44_\ P6O_ )(/
M]>:7_0LJ?^%=/_YG.]^U6W_/Y:?^!=O_ /%4AN;8@C[7:'/_ $]V_'?^\/\
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M\BZ[6&^-:5)^S>6U)647=8JG%>_&%1*WU=[*HEYM-G>_:;;_ )^[3_P+MO\
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M"RI_X5T__F<[W[5;?\_EI_X%V_\ \51]JMO^?RT_\"[?_P"*K@O^&%_V'O\
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M2N.:223RRI=:/_:Z>_7_ )ASO?M5M_S^6G_@7;__ !5'VJV_Y_+3_P "[?\
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MA3PQXM\0ZUXGMO%&J7'U8/V%_P!A\=/V+?V1?_$9_@EV_P"Y&I/^&%_V'O\
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M*22RNHDE9+ZW3T2Z?[N_S9WOVJV_Y_+3_P "[?\ ^*H^U6W_ #^6G_@7;_\
MQ5<%_P ,+_L/?]&6_LB_^(S_  3_ /F'H_X87_8>_P"C+?V1?_$9_@G_ /,/
M4_ZM_P#44_\ P6O_ )(?^O-+_H65/_"NG_\ ,YWOVJV_Y_+3_P "[?\ ^*K'
M\1W5M_PCGB/_ $JTX\/:X<_:[?MI-YSQ(#SGVQ[5S7_#"_[#W_1EO[(O_B,_
MP3_^8>L?Q#^PW^Q'!X>\0SP?L9?LDPSPZ!K4T,T7[-?P6BFAFBTR[DBFAE3P
M0KQ2Q2*LD4D;*\;JKJ0R@AKARVOUK;57I[6Z_$'^O-+_ *%E1?\ <W3_ /F<
MY#]D6XMU_9(_91!NK967]F3]GX,K7-NK!A\(_!ZLK OE64Y!5@&!'*@XQ]"?
M:K;_ )_+3_P+M_\ XJOD+]DS]C#]C7Q%^RE^RSXA\0_LA_LL:]K^O_LU? ;7
M->UW6_V=_@]JVM:YK6K_  H\(:AJNLZSJNH>#;B_U35M5O[FXO=1U*^N)[V^
MO)YKFYGEFD=V^@/^&%_V'O\ HRW]D7_Q&?X)_P#S#TY\/>TG*?UJW/*<[>S6
MG/.<K7YM;<R2V_4/]=J5-NF\MJ2=.U._UJG&_LTJ=[?5^KIM[]5Z+O?M5M_S
M^6G_ (%V_P#\51]JMO\ G\M/_ NW_P#BJX+_ (87_8>_Z,M_9%_\1G^"?_S#
MT?\ #"_[#W_1EO[(O_B,_P $_P#YAZG_ %;_ .HI_P#@M?\ R0?Z\TO^A94_
M\*Z?_P SG>_:K;_G\M/_  +M_P#XJC[5;?\ /Y:?^!=O_P#%5P7_  PO^P]_
MT9;^R+_XC/\ !/\ ^8>C_AA?]A[_ *,M_9%_\1G^"?\ \P]'^K?_ %%/_P %
MK_Y(/]>:7_0LJ?\ A73_ /F<[W[5;?\ /Y:?^!=O_P#%4?:K;_G\M/\ P+M_
M_BJX+_AA?]A[_HRW]D7_ ,1G^"?_ ,P]'_#"_P"P]_T9;^R+_P"(S_!/_P"8
M>C_5O_J*?_@M?_)!_KS2_P"A94_\*Z?_ ,SG>_:K;_G\M/\ P+M__BJ/M5M_
MS^6G_@7;_P#Q5<%_PPO^P]_T9;^R+_XC/\$__F'H_P"&%_V'O^C+?V1?_$9_
M@G_\P]'^K?\ U%/_ ,%K_P"2#_7FE_T+*G_A73_^9SO?M5M_S^6G_@7;_P#Q
M5'VJV_Y_+3_P+M__ (JN"_X87_8>_P"C+?V1?_$9_@G_ /,/1_PPO^P]_P!&
M6_LB_P#B,_P3_P#F'H_U;_ZBG_X+7_R0?Z\TO^A94_\ "NG_ /,YWOVJV_Y_
M+3_P+M__ (JC[5;?\_EI_P"!=O\ _%5P7_#"_P"P]_T9;^R+_P"(S_!/_P"8
M>C_AA?\ 8>_Z,M_9%_\ $9_@G_\ ,/1_JW_U%/\ \%K_ .2#_7FE_P!"RI_X
M5T__ )G/$?VZ9[=_V,OVHU6YMG=O@AX\552YA=V)TF4*%16W$DG  !)/'6OK
MG4[FU&I:CB\M,?;KOK=6X/\ KW']\^GL?;O7PE^V]^QM^QYX5_8Z_:;\2^%O
MV2?V7O#/B30O@OXYU/0_$/A[]GOX0Z)KNC:G::2\EKJ.DZOIG@ZUU#3;^V?Y
M[>\LKB&XA?YHY%(S7U;J'["O[#B:AJ")^Q9^R(J)>W2*J_LS?!,!569P% _X
M0?   P .F*I\/MQC2^L[2G4O[/5W4(6OS^2Z=!_Z[4TE4_LZ=I-TU'ZU"Z]G
M&-2]_86_Y>I*T;Z.^ROV7VJV_P"?RT_\"[?_ .*H^U6W_/Y:?^!=O_\ %5P7
M_#"_[#W_ $9;^R+_ .(S_!/_ .8>C_AA?]A[_HRW]D7_ ,1G^"?_ ,P]3_JW
M_P!13_\ !:_^2%_KS2_Z%E3_ ,*Z?_S.=[]JMO\ G\M/_ NW_P#BJ/M5M_S^
M6G_@7;__ !5<%_PPO^P]_P!&6_LB_P#B,_P3_P#F'H_X87_8>_Z,M_9%_P#$
M9_@G_P#,/1_JW_U%/_P6O_D@_P!>:7_0LJ?^%=/_ .9SO?M5M_S^6G_@7;__
M !5'VJV_Y_+3_P "[?\ ^*K@O^&%_P!A[_HRW]D7_P 1G^"?_P P]'_#"_[#
MW_1EO[(O_B,_P3_^8>C_ %;_ .HI_P#@M?\ R0?Z\TO^A94_\*Z?_P SG>_:
MK;_G\M/_  +M_P#XJC[5;?\ /Y:?^!=O_P#%5P7_  PO^P]_T9;^R+_XC/\
M!/\ ^8>C_AA?]A[_ *,M_9%_\1G^"?\ \P]'^K?_ %%/_P %K_Y(/]>:7_0L
MJ?\ A73_ /F<[W[5;?\ /Y:?^!=O_P#%4?:K;_G\M/\ P+M__BJX+_AA?]A[
M_HRW]D7_ ,1G^"?_ ,P]'_#"_P"P]_T9;^R+_P"(S_!/_P"8>C_5O_J*?_@M
M?_)!_KS2_P"A94_\*Z?_ ,SG>_:K;_G\M/\ P+M__BJ/M5M_S^6G_@7;_P#Q
M5<%_PPO^P]_T9;^R+_XC/\$__F'H_P"&%_V'O^C+?V1?_$9_@G_\P]'^K?\
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MS_!/_P"8>C_AA?\ 8>_Z,M_9%_\ $9_@G_\ ,/2_U;_ZBG_X+7_R0?Z\TO\
MH65/_"NG_P#,YWOVJV_Y_+3_ ,"[?_XJC[5;?\_EI_X%V_\ \57!?\,+_L/?
M]&6_LB_^(S_!/_YAZ/\ AA?]A[_HRW]D7_Q&?X)__,/1_JW_ -13_P#!:_\
MD@_UYI?]"RI_X5T__F<[W[5;?\_EI_X%V_\ \51]JMO^?RT_\"[?_P"*K@O^
M&%_V'O\ HRW]D7_Q&?X)_P#S#T?\,+_L/?\ 1EO[(O\ XC/\$_\ YAZ/]6_^
MHI_^"U_\D'^O-+_H65/_  KI_P#S.=[]JMO^?RT_\"[?_P"*H^U6W_/Y:?\
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MXNZO^T1\'_A^VM/\;?"/CGQEX[\9?!7X,^$[./X%Z7X4T;P_\1?C-\<_AO\
M#<^-O#=DOC[Q#JDWA?PAX0\2>,/$5SX$\;:GXXU*_;2[+4KOQQ9V&DZGI^M:
MUC\0_B?X0^+'Q,^"7C+QE!XS@M?V>HOCQX ^*7A_X.ZIJ'C?PU$?&6N_#W6/
M#/B_X5^ )=9MOB9J<>I6FF>)_AV/ 6B>'M:\66UMXM\%WOA2_OM L]?UN'42
M>J:]5TM>^][6\KWNK.S9K[%M7C*#TDTDY-M1E",K>XD^64XJW->7-%QNKGU[
M_/TZG\OQHK\_/!W[0'BC5?@7\5?B=XP^+>M:3\._"OQF\3>'O 7QS\+?LQ^*
M_&'Q!UGX6^"_#.CKXXO?B1\ ?"^A^*]7^&?B+P1\7;'XJ_#[Q!JOC;P#X*&E
MZ%X TR_\7>"/!VL>);75+GZF^ 7B3X@^,?@E\*?%OQ4LO#MA\0O$_@?1M>\3
MP^$IK&;PW/<:G$;K3=5TK^R_$?C'2[6+7M"ETK7I],TGQAXOTC1[W4[O2-)\
M6>)--L+76KZE--I6:ND]4UO=VU2U[K=75TKV"I1E33;:?+/D=KZOE4O=>S23
MM*VTM#UVBBBJ,1K?P_[P_K7R1^S+J&FZ0O[8>K:S=)8Z1I/[9GQYU;5KZ1D2
M.RTK2_"'PTO]2NY&<A5CMK.WFG=F(15C)=E49'UNW\/^\/ZU^?W@SX<:A\9/
M@Y_P4:^#VE>+7\ ZA\6OV@_VL/A?;^.8]%E\22^$#\0OA9X&\(3>(X- @U[P
MM-K%UI%MK$U[:6,?B30VENH8<:G:E1(,YWO&V^MOQ]?.VF]C>ERN-12=HMTN
M9VO:/MX7T]-/F>P_#_\ :2LK[X!?L]?%;XGZ#JVA>.OCW\-_!_C?2OA3\-?!
MWC_XH^+I=3\2^!;'X@ZIHGAOP;X/T#Q%XUU.R\&Z!?P_\)3KMQI4&CZ',+>/
M5KZPN-8T2SO=W3?VJO@-K?@_6/'^A>._[<\&:+IGP*U:X\0Z5X9\6W5E>6O[
M2UKX6OO@A%HZ#0TNM:U+QU8>./!E[#HVFVT^KZ)!XKT$^(['27U&!&\8^)/[
M'OB'XKWGPK\0>-?%_P"SSK_B'X1^%?B9\-?#V@^(?V3M>\6_!.Z^&OQ+A^$5
MQ)87_P )?%?[4.M:D?'7AC6?@WX=ET/QDOQ(;PW/X:U/7?">N?#75HKQ-7BU
M;_\ 9%U6\^(&NZO;_%VUTKX5>)?VG_@3^U%KWPOT[X4:=!K&L:O\ _ 'P<\%
M^$OAI>>/XO'$6D0?#"QU+X$_#GQKH&D:#\,=!U7P_K6DR:?<ZQXCT.86$6?/
M6NWR>[;2-O>O9NU[VM[MG=Z2G'HI&CCA6M9R4N><I--N/*ZC2A%<NDDFN6^D
MK26C23U?#/[7G@(>+OCMH/Q!\0^'_#MC\-/B1\1],\/OHVD^)M8GTKX2?"/P
M_P"$_#'C+XB?%?5-*.O:5X8&K_M#V'QH^&'P[2Z@\,S^/[[P99^#? FA>,_&
M6B^)[E^C_P"&PO@6MQ8:5/JGQ"L_%NI_$75_A+9_#B\^!OQMM/BM)\1=&^%F
MG?&VX\+-\+9_A^OCZ.\N?A3K.C>-[&[D\/+I4^BZM:2R:A!-'?0V7S_!_P $
M\[&W^'/Q>^',?Q<5]/\ CUK'A+XL?%8W?PNM+W2?%G[4?@?]H.V^/>G?'*Z\
M/R>/4#Z%XLBTSPW\+?BK\*+G5+F#QEX$\#^#9- \<^ =?L-<U7Q)['X3_9;G
M\(ZQX-\3Z)XC^%O@W7? OPN_:0\'>'K'X1_ "W^&/@.P^(/[0FN_"S4!\7%\
M'CXH^*=0NM9\'Z+\*M.\/WFGZMXNU/6_')\0>(-1U+QSHL<UMIL(G63:M=6=
MFXZWTLTE)Z<UVHMW4+>]S*Q4HX.S:E-NZLE+E5N6-[WISN^;VBNG:T8NSY]*
M+?MT?LYZ[\/O$WCGP9\2)7TFR_9_\=?M#>&?&'B'X2?&>'P3KO@3P*NAZ9XD
M\0:&TOA#P_>?$1_ 7BOQCX,\._$+X?> ]1N/B'I6O:['X,?3]/\ %27MKIOH
M=Y^TC\-_"OBS1/A?XNU[4]1^(O\ PF'@+X0^+;_P+\+?BKK7PTT+XU^.=#TK
M5]*\":CXZLO#VO\ A/PEJ^KV^JV.N6GA?Q#XRNM>\*>%-9\/:GXUETVRU;3-
M3U+PKQ'^PG8:IX+\'^"M$^)%MI.G_#;]FG]G/]F[X?P:S\.7\2:+8Z/\$OC+
MX#^+GCC4?%&BV?Q#\*W/B70?CY:?"CX9^ ?&_@_3=;\)7FD>'_#M[>V?C34K
MW5H(M$[+3?V5/$%E\2_"'B6Y^,,.H?#7P1^U/\:/VL=*^&S?# 6_B'6?'/QI
M\)_&/1[K2_&7Q/\ ^%BW":]IOP[\2_&35M<^&DUG\/M!;2?#>B:%X-\1VWB:
MZTG0/%F@OFJ\WPZ72OOHWV3MHNO?1V0N7!V:C4FK*32:>K;M%<R@ND:;:Y%;
MFFFVHJ3^TX;*]N$\R"SNITW%0\-O-(A88RH9$(+*3@C.>AQ@BO)/C/\ $Q/A
M)X"U/Q1!HEUXL\5WFI:)X)^&_@&PE%OJOQ$^*_CC5K;PO\// 5A.R2+I_P#;
MOB6_M!KNNW$3Z=X.\)VGB/QOKYM_#OA?6+NVI>-/V?/V?_B7K,OB7XE? /X'
M?$;Q+/96VFS>(_B!\'OAQXV\0RZ;9(ZV6G2ZWXH\,ZKJ<EC9++*EG9R736]J
MDDBPQ(';/*^/?V<?!WQ3^(7@37_B)#H7BCX8_"WP?J6F_#SX)W?A*WB\*Z%\
M1]:F32+SXL75]'JYM;[5M!^&\#?#7X<Z%9>&='@\":%XK^)\R:QKB>.X=.\+
M:/VGO:1[1:;OZR[?+SMK8PI^R4H.?/9-2E%*.K5FHQ?2[TO+1;M/8^;?%_[<
MGB/P;^SU^R?\:+[X?:!J&L_%O7])E_:!T"QU77%T[X.?#GX>^'?$FI_M<>/O
M#KO:?VGK4/P+U'POJMO9:?K:V_\ :=HD:7;M>S0";+\<_M[>(+37?VIY?AA\
M.O#_ (P^''P"_9^'BKP#X\U/5]4C3XW?'_Q'\5M>^"O@#PIX9M=*5D_X4]K/
MQ3\)>-?AK#XS23^V/&'BWP/XGU+P=')X&C\.>+/%'L7P^_8R\(^"K[1].U'6
M=,\4_"[PSX8_;7\#^&?A'/X(BTKPSIW@K]M3XZ^&OB]XB\+WDZ^*=4AU+2/
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MA@>@_(48'H/R%'^HO!__ $3V7_?C/_G@'_$4>/\ _HJ<U_\  L)_\[C]S_\
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M %JS6UV[<V$M=JS?_(MZI);]%V1^Y_\ Q$!_M<?]$:_9=_\ "9^-'_S\J/\
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M_P#GY5^&&!Z#\A1@>@_(4?ZB\'_]$]E_WXS_ .> ?\11X_\ ^BIS7_P+"?\
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ML_&?_P"?C^?J>3S1_P 1 ?[7'_1&OV7?_"9^-'_S\J_## ]!^0HP/0?D*?\
MJ+P?_P!$]E_WXS_YO%_Q%'C_ /Z*K-?_  +"?_.X_<__ (B _P!KC_HC7[+O
M_A,_&C_Y^5'_ !$!_M<?]$:_9=_\)GXT?_/RK\,,#T'Y"C ]!^0H_P!1>#_^
MB>R_[\9_\\ _XBCQ_P#]%3FO_@6$_P#G<?N?_P 1 ?[7'_1&OV7?_"9^-'_S
M\J/^(@/]KC_HC7[+O_A,_&C_ .?E7X88'H/R%&!Z#\A1_J+P?_T3V7_?C/\
MYX!_Q%'C_P#Z*G-?_ L)_P#.X_<__B(#_:X_Z(U^R[_X3/QH_P#GY4?\1 ?[
M7'_1&OV7?_"9^-'_ ,_*OPPP/0?D*,#T'Y"C_47@_P#Z)[+_ +\9_P#/ /\
MB*/'_P#T5.:_^!83_P"=Q^Y__$0'^UQ_T1K]EW_PF?C1_P#/RH_XB _VN/\
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M?CM_P42^.'[.UWX1\*_$KX:?LT:;\3/$7P?USXY/X+/QB^*,(U'0AJGA[0?
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MTSPG#\5/$>A?M3?M:VOQY^-/B/X:ZW\1OVH9O&'PDO/C+K.D?"72]<T7P/\
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M@>(?%_A_5_$7AB]_X5/:>!?%?P3OY+'0/BG<6'VF.@__ %?IVKQC0O@#\-]
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M$-US_P /3\;?_G@5]+_Q%KAS_H"SG_PFPG_S<?&_\0$XL_Z&7#__ (49A_\
M,)_$KN/I_P"A?_$T;CZ?^A?_ !-?VU?\.:O^"=/_ $0W7/\ P]/QM_\ G@4?
M\.:O^"=/_1#=<_\ #T_&W_YX%'_$6N'/^@+.?_";"?\ S<'_ ! 3BS_H9</_
M /A1F'_S"?Q*[CZ?^A?_ !-&X^G_ *%_\37]M7_#FK_@G3_T0W7/_#T_&W_Y
MX%'_  YJ_P""=/\ T0W7/_#T_&W_ .>!1_Q%KAS_ * LY_\ ";"?_-P?\0$X
ML_Z&7#__ (49A_\ ,)_$KN/I_P"A?_$T;CZ?^A?_ !-?VU?\.:O^"=/_ $0W
M7/\ P]/QM_\ G@4?\.:O^"=/_1#=<_\ #T_&W_YX%'_$6N'/^@+.?_";"?\
MS<'_ ! 3BS_H9</_ /A1F'_S"?Q*[CZ?^A?_ !-&X^G_ *%_\37]M7_#FK_@
MG3_T0W7/_#T_&W_YX%'_  YJ_P""=/\ T0W7/_#T_&W_ .>!1_Q%KAS_ * L
MY_\ ";"?_-P?\0$XL_Z&7#__ (49A_\ ,)_$KN/I_P"A?_$T;CZ?^A?_ !-?
MVU?\.:O^"=/_ $0W7/\ P]/QM_\ G@4?\.:O^"=/_1#=<_\ #T_&W_YX%'_$
M6N'/^@+.?_";"?\ S<'_ ! 3BS_H9</_ /A1F'_S"?Q*[CZ?^A>_^S[=J,GT
M_P#0O_B:_KC_ &N?^"5'["OPJ_9;_:!^)G@3X/:OH_C3P)\*?%_BCPMJT_Q9
M^+NK1:=K>DZ:]Q87<NEZMXWO-+U!(9@K-:ZA:7-K, 5FA=>*^D;[_@C-_P $
MYH;Z]AC^!>N+'#=W$4:_\+J^-[$1QRNJ L_Q"9F(4 %F))ZDDY)7_$6^'+V^
MI9S>S?\ NV$V32_Z#O/;MJ4_ +BU14_[2X>LY2BO]HS&]XQC)W7U"UN6<7>[
MO>UKIG\1>X^G_H7_ ,31N/I_Z%_\37]M7_#FK_@G3_T0W7/_  ]/QM_^>!1_
MPYJ_X)T_]$-US_P]/QM_^>!3_P"(M<.?] 6<_P#A-A/_ )N)_P"("<6?]#+A
M_P#\*,P_^83^)7<?3_T+_P")HW'T_P#0O_B:_MJ_X<U?\$Z?^B&ZY_X>GXV_
M_/ H_P"'-7_!.G_HANN?^'I^-O\ \\"C_B+7#G_0%G/_ (383_YN#_B G%G_
M $,N'_\ PHS#_P"83^)7<?3_ -"_^)HW'T_]"_\ B:_MJ_X<U?\ !.G_ *(;
MKG_AZ?C;_P#/ H_X<U?\$Z?^B&ZY_P"'I^-O_P \"C_B+7#G_0%G/_A-A/\
MYN#_ (@)Q9_T,N'_ /PHS#_YA/XE=Q]/_0O_ (FC<?3_ -"_^)K^VK_AS5_P
M3I_Z(;KG_AZ?C;_\\"C_ (<U?\$Z?^B&ZY_X>GXV_P#SP*/^(M<.?] 6<_\
MA-A/_FX/^("<6?\ 0RX?_P#"C,/_ )A/XE=Q]/\ T+_XFC<?3_T+_P")K^VK
M_AS5_P $Z?\ HANN?^'I^-O_ ,\"C_AS5_P3I_Z(;KG_ (>GXV__ #P*/^(M
M<.?] 6<_^$V$_P#FX/\ B G%G_0RX?\ _"C,/_F$_B5W'T_]"_\ B:-Q]/\
MT+_XFO[:O^'-7_!.G_HANN?^'I^-O_SP*/\ AS5_P3I_Z(;KG_AZ?C;_ //
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MI?\ AS5_P3I_Z(;KG_AZ?C;_ // I_\ $6N'/^@/.?\ PFPG5)_]!W9HG_B
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M>HV$.HZAIFE7=IILL%K;?>__  JCP!_T+>G_ /?B/_XBC_A5'@#_ *%O3_\
MOQ'_ /$5>(\.<CQ<N?$T8UG[+V*YJ,(1A2=2-6<*-.C6H4L.JLHQ5=X:EAYX
MFG'V6)GB:3G3J<.2?27\4>'*-.AD?$>9Y=3IXW^T7*GB*&)Q%?&1P<\!0JX[
M&YGE.<YAF<,!A:DH93A<VS'-<!DE14\3D.79'BZ-#$T/D;5/A#^R=XK\8-XD
M^(W[1FN_$[P]I.@_$WPO\./A7XN^*/@>'X9_"#P]\7/">I> /%^E_#_2O"GA
MGPSX@:.'P%J]_P""_"MQXR\3>+KGPGH,[#29(]36/4H^K_9X\&_LN?LY1>(;
MGP]\?#X_\3^)M&\!>$M1\;_%+XB^#]<\30>!/A5H+^&_AMX TE?#FB^$M TG
MPKX1TN>\,$5EH4>K:YJ>H7FL>*-5UO46MI[3Z/\ ^%4^ /\ H6]./U@C_HHI
M/^%4^ /^A;T\?]L(_P"J&JI>'F34<13Q=.%L51G4G3KNFIUXSJPC3<G4J8FK
MS>SIPC3P\9PG'!TKT<%'"4I2I2C,/I)>)F:9'BN&<=G^/J\.XVA@,-B<CISP
M>#RNI0RVO4Q6&IK!9?D>74:*J8RH\?F4\/\ 5JV?9C&GF7$N(XES"E3QE.P/
MCE\&!U^*_P /N?\ J:](] /^?D>G;BG#XX_!EF55^*OP_9F. H\5:1N))
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M ,N#_4?(^V-_\*__ +B?D[_PL']JK_I';^T-_P"'G_8E_P#HFJ/^%@_M5?\
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M)OFDL9=I+_>ND8QBO^7/2,8KY(_)W_A8/[57_2.W]H;_ ,//^Q+_ /1-4?\
M"P?VJO\ I';^T-_X>?\ 8E_^B:K]8J*?^L^9?\^\'_X)J?\ RX7^H^1]L;_X
M5_\ W$_)W_A8/[57_2.W]H;_ ,//^Q+_ /1-4?\ "P?VJO\ I';^T-_X>?\
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MW5S\G?\ A8/[57_2.W]H;_P\_P"Q+_\ 1-4?\+!_:J_Z1V_M#?\ AY_V)?\
MZ)JOUBHI_P"L^9?\^\'_ .":G_RX7^H^1]L;_P"%?_W$_)W_ (6#^U5_TCM_
M:&_\//\ L2__ $35'_"P?VJO^D=O[0W_ (>?]B7_ .B:K]8J*/\ 6?,O^?>#
M_P#!-3_Y<'^H^1]L;_X5_P#W$_)W_A8/[57_ $CM_:&_\//^Q+_]$U1_PL']
MJK_I';^T-_X>?]B7_P"B:K]8J*/]9\R_Y]X/_P $U/\ Y<'^H^1]L;_X5_\
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MY_V)?_HFJ/\ A8/[57_2.W]H;_P\_P"Q+_\ 1-5^L5%'^L^9?\^\'_X)J?\
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MQ$8M1E*AF%*M%-Q4DG*E&HD[.]FT^JNM3\G?^%@_M5?]([?VAO\ P\_[$O\
M]$U1_P +!_:J_P"D=O[0W_AY_P!B7_Z)JOUBHK/_ %GS+_GW@_\ P34_^7&W
M^H^1]L;_ .%?_P!Q/R=_X6#^U5_TCM_:&_\ #S_L2_\ T35'_"P?VJO^D=O[
M0W_AY_V)?_HFJ_6*BC_6?,O^?>#_ /!-3_Y<'^H^1]L;_P"%?_W$_)W_ (6#
M^U5_TCM_:&_\//\ L2__ $35'_"P?VJO^D=O[0W_ (>?]B7_ .B:K]8J*/\
M6?,O^?>#_P#!-3_Y<'^H^1]L;_X5_P#W$_)W_A8/[57_ $CM_:&_\//^Q+_]
M$U1_PL']JK_I';^T-_X>?]B7_P"B:K]8J*/]9\R_Y]X/_P $U/\ Y<'^H^1]
ML;_X5_\ W$_#/XB6W[87C#XK_LV>/=._X)]_'2VTOX,>./B;XG\16EY\:?V+
MQ?ZG9^-O@1\1?A9IMOHJP_M)36\EU;:WXPL+^]%]<642Z9;7;P/<70BM9?:O
M^%@_M5=_^"=W[0^>^?C/^Q+G/<<?M->ON?K7ZQ$ ]0#]:*7^LV8IM^SP=W:_
M[FITO;_E]I:[_I%/@G)6HQ:QK4$U'_:E>SES:OV.MFW;U/R=_P"%@_M5?]([
M?VAO_#S_ +$O_P!$U1_PL']JK_I';^T-_P"'G_8E_P#HFJ_6*BG_ *SYE_S[
MP?\ X)J?_+B?]1\C[8W_ ,*__N)^3O\ PL']JK_I';^T-_X>?]B7_P"B:H_X
M6#^U5_TCM_:&_P##S_L2_P#T35?K%11_K/F7_/O!_P#@FI_\N#_4?(^V-_\
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M#KWBGX!7_GZIXPO9G3X6ZKXDU2/PQI\DCZ;!HHTSPQ=6EUX9T'0M)TU_C?\
MX)A_L'?$:(1>-/V;O!WB GQQ\:/B*]Q>:KXPBOIO%7[1.I2:U\:YKK4K3Q+;
MZA=Z+\1-7==4UWPE<W,WA$:C!9WMCH=I<6-G)!K&KE2G?ZIB&E*,DY3NKJ2;
M4Z:JQ4XN,5>/,GS-IMQ5GDZ6.<.5UJ2<HRC+EBE;F4M8RE3DXR7,TG9Z1CHI
M2;C^6_[./_!53XMZ+X6O(_'6F_$K]J#XQ^.HO^"7'PE^%7PZ5O@9\+?">J_&
M_P#:N_8BTKX^^.-7MO%VB^"?"=QX1\*:U-HOCCQWXQO/%J^,UTG6XK?P[\./
M#>@>'KJST6TH?#7_ (+/^+_@Q\!+GX@?M(^$];^+7B!?VD?VPSX^\/Z5X@^&
M.D_%;X'_ +/?PM_:WOO@AX2B3X?_  Q\-W>@^-K;P#;ZA!X3N_'>NZWX0\!:
M_?>#M4MKCXS^(O&6J:5:ZU^L.H?\$TOV'=6\)Z_X(U+]GGPQ>>&_$DGP+NM0
MMI=<\:_VA:ZC^S/X$LOAE\"M:\/:\OB==?\ "/B'X<> M/MO"^C>(_"FJ:-K
MMSIK78U?4-1GO[^:YXW5?^"1W_!.;6_#6G^$-0_99\%+X:TO3_&.CV6D:?KG
MCW2+9=$\=^/?^%I>(="N&TGQ;937N@K\1"_C#P[H=[+<:3X,UR6>\\&V>@O/
M-YC6(RUMN>%JVDX7Y(1C)*"V@XUH\BE)W=DY2:O)NS37L<:N7DKT[QC+67.U
MS3DG>47'WW&*:BW-*-](I6/B"?\ X*\?&'X6>*_VR[?XV?L]Z)J^C_#7]N[P
MC^Q1^S-IOPU\77USJ/B[QGXL^&^D>/[#2_B(]KX<\5:S;6-KX(M]7^+/B#QQ
MX;\,:K?VFGZW9_##P_\ ##7_ !=X;N=0\1>\?!O_ (*SV'Q=^-O[-7P<U+]F
MKXE_ QOV@? D_B4ZY^T=J@^#DZ^+M-\0?$_PEK?PR^$NB^(_#7E?&OQ?X=UG
MX7S:QK&D6FM>"]?E^'?C#P;X\T+P_KECJ-]8:;];^._^"?'[''Q*\2_%WQAX
MU^!/AG6_$_QVU?X>>)?B=K9U7Q9IM[K7C#X465KIOP[\>Z2^D^(;!?!7Q%\*
MZ=96=AIWQ$\#)X<\;M9VMO;76OW$,,<:V_#W[!/[)WA?QK\-?B'I7PBMIO%?
MP@@L%^'%YKWC'XA>*].\,ZKIEEXDTVQ\8Q^'/%'BW6?#6I?$>VL/%_B6RC^*
M&L:1J'Q$^RZO=0/XF:/RECSE5R^46_JM:$W!I.,Y)1DJ$(P?(ZLH-*O%S;=I
M2C.4OB2B6J>,C-6KTW!.-U*-Y./MIR<7)4U)?NI1BDKV<5=V;D?85(<97..O
M?Z&EIK9XP,^HX'TQGW^E<#.W^OQ/\Q+]M;G]M']L7'(_X:O_ &C^G/\ S67Q
MIZ>^:^9\'T/Y&OZ6OVB/^#?G]N7XL?M"?'SXK>&?&W[+]IX;^*/QP^+GQ)\.
MVNN_$3XH6FMVV@^//B#XA\5Z-;ZS:6'P3U2PM=6@T[5K:+4;>QU&_M(+Q)H;
M:^O($CN)/'O^(;K_ (* ?]#]^R3_ .',^+?_ ,X.O[PRGQ)X%HY3E5&KQ9DU
M.K1RO+*-6G+$8A2I5:678"E5IR2P$DI4ZE*<)6DUS1E9VL?Y9<0^"WBIB^(,
M^Q6&X%SZMAL5G><XG#UH4<#RU:&(S;-*]"K'FS2,N6I1K4JD>:,9<LXWBG='
MX#8/H?R-&#Z'\C7[\_\ $-U_P4 _Z'[]DG_PYGQ;_P#G!T?\0W7_  4 _P"A
M^_9)_P##F?%O_P"<'7?_ ,1-X!_Z*_)/_"C$?_.\\C_B!WBU_P!$!G__ ()P
M'_SV/P&P1V8>XR/U'2OM?_@G]^V;\2_V'?VC?"WQ8\!V6K^*]$UJ:S\&?$KX
M8:7YEQ)\4?!NKW]O&WA[3K(+()/&EC>-#J?P]O8@MU:^)D@TV1KG0M=\0Z7J
MGZ1C_@VZ_;_!R?'O[))^GQ*^++$'U ;X"*/S/'6OTQ_X)=_\$,_&/[+OQTF^
M/W[5^K?"7QWK_@*"UF^"'A;X=ZQXG\4:'I7BZY\Y;WXA^*9/%G@KP2G]N>%K
M98K?P)I]M8ZO:V.J7]WXKDGM/$&A>&;FT\#BGQ+\/*G#N<4JN;99Q!&M@:U&
M.38:IB)U,QJ5H2ITJ"G+!THT%&LZ=6IBN>,\)"E]8I-UJ=*,OK>!/!3Q>PW%
MW#^*I9#F_"L\+F>&Q,L_Q4,)&AEE'#SC5KUY1I9A6EB'.A&M0A@^2<,9*O\
M5:RCAZU>I3_I*TF\.H:?9Z@;2\L/MUI:W@LM1@^RZC:"Z@2?[+J%KN?[->VW
MF&&ZM_,D\F=)(M[;<UI5%$& .X8Z8R0>.>N">?4\9ZX'02U_$&FMDTKNR;<F
ME=V3D]9-*RYGK*W,_>E)+_36*:C%-\S22<K*/,[*\N574>:2E+E3:C?E3:BF
MRBBB@H0G [>V?7!Z>]?S>_%#]MK]NQ?^"G_QI_9_^"/BOQ/XY\)?"S]I_P#8
MG\ 6/P T_P#9:N?&?P\E^ ?QH^$G@7Q;^T3\0OB-^TMX=\-VD?P>U/X>1:OK
M?C#PA<>-/'<$NNW8CT'2O"GBNS7[)9_TAUY/X.^!_P +/ 'Q'^,'Q<\'^$;;
M0_B+\>]1\$ZK\7?$\%_J]Q<>--0^'7A6W\#^#+F\LKW4;K2]/;0O"MI;Z1"F
MC6.FQW,,:W%]'=WF;@[T*M.BZTJE"-=SH^SA&:BX1FY_$[IOX)2^%7NHVE&]
MUC6ISJ>S4*LJ24^:<H\W,XJ+LERM+>WQ.W=27NO\5(O^"YVI3_"GX0_$>+]B
M+XGW%_\ M$ZO\8(O@'X6TWXBZ+XGN_B1X>_9WO/$EA\;_$B)X)\(^)_$WAR+
M0]4T_P *>&/ ^E:YX.@U#QMXI\9))?KX0^'^@ZI\0ZU_C[_P54^*OQ$_9S_;
M>\8?LG? 7XI>!=*_9O\ V5/&OC+Q+^T?\2;WX9>%?$7P/^/>J_LBVW[3'@/P
M;/\ LZ>.K?Q3XA\5:OX.MO%W@/PWX_'B/1(M&T/QUJ=WHPT+Q;H&BZWJL'Z,
MZK_P3O\ V,]9^$OPS^"%Y\#M&A^'?P9UKQ3XB^$UGIGB3QSH?BCX=:QXYU'7
M=4\:W7A#XC:)XIT_XCZ$GBVZ\2ZVGB6TL/%D-EK=C?-I6HV]SI<-M9P9OC#_
M ()L_L0^._$GB;Q;XE_9Z\+7>O\ C3X4S_!+QE?V&L^,= 7Q=\-IOAO=?"!-
M&\3V7A_Q+I=AX@U.P^%][<^ =&\7:O:W?C+0?"SC2=%\06%K'$B="JY;=26%
MJP2G.44W*I%Q]K3=.+INK%ZT5.+O-VJ3;:Y+*&#IXQW7MX6<%&W+RR4O9S4I
M1FH.UJCC*-X7<8V^)WE^=WA#_@IK\5?!7Q"\8> [GP+\1/VG/&OC;]J_X#_L
MR_#CP7)K_P $_A;I_A;Q%XX_X)M^%OVM-6OO#^N6O@[PS'>>%]6\2:=X@N=>
M/Q UK5==T2Y\0:@_AB[NM)T70/!-YQ&@?\%J]#U36M+^/\OA'XV?\*Q\1?L&
M?"OXH:%^S)9)\%YVG^/_ ,2/VZO$G['>D:+8^--2TO0?%)U_4/B+:V7A>ZU_
M6?B+I_POM/ ,,/C!O VF^)Q>B?\ 7[3OV'_V6-*\:Z7\1+#X0Z5;>,]&^*_A
MCXXZ9KJZ[XN>>T^*W@WX'G]G#PSXP6VE\126$EWI/P3)\ PV,UK)I$MC_P 3
M&YTZ?7,:M7!:=_P3-_83TOPOJ/@J#]F[P1>>$M6^#US\ M0\.:W=^)_$6D77
MPEN?BQKOQT_X122R\0:_J4(:T^+_ (EUCX@Z5X@15\4:+XBGMKK2-:L4TW3(
MK.W7RR3N\)7UY>9QE%+EO34DH\_+%I1J./)%2O)+VFTA*EC%"RKPNK.-TWJE
M4LW)KF=^:-^9M:-\JU3^:/BQ_P %4=<_9[\3?!/P9\>_V:)?!GBWQO=_#./X
MS^$O"OQQ\(?$_P 3? ?3?C/\>=5^ OPQ\5:G9>$?#4VG:KX+UK5K72O$=WXD
M\7ZQ\++*ZT_5;SPSX"'Q!^('AOQ!X1LO(;7]LO\ :5L?^"3G_!0?]I^Y^(-O
MJOQS^ OQ-_X*,Z)\,?%FI>$_ T5CH&E? 7X_?%3P7\*]+N/#^G>'=+\,:O:>
M%_#7AO1]):[US2K[4=9CLS?^([_5=2FNKV;[9N?^"5W[ ]Z_A*:^_9UT2_N_
M!%AX:T[0=0OO&?Q,O=5:+P;\3-2^,/A.[U_5KKQM+J7B_6/#OQ%UK7/$&C:_
MXNN]<US3TU[7M%M]1CT#6]5TJ[]SD_9!_9RG^"7Q5_9QF^&&G-\%/C=JOQ7U
MSXI> _[9\3"Q\6ZM\<?$VM^,?BK>W6IKK@U^PD\7^)?$6L:K=IH^JZ?#837K
MQ:/'IUM'#!''ML!"--PP]2<E5H5*KFDE*-*M*=2$(NI4Y8SI<D'%2DI-)OWE
M+FKV>*<IN56"CR58TU&Z:G.G",92:A"]I)RNDK/X>G+^)GP2_P""F/[9'PST
MN]F^)7PH^)W[8G@SXP?M+?L^_L\_L>_$#Q%\((?V'O'_ ,3_ !K\5/V=?C#\
M7?B?87GA;XF:!X0T;4_ ?PI\:_##2_ UE\2%\*>%=%UBQ\1ZYKFFZQXN/A=K
M.\^IM-_X+&^%;7Q4=3^(/[./Q+\$?L\:EX]_:9^#?A+X_P 'B_P%XJ/B'XR_
ML@^ OB+X[^-GAJ?X8:7J%MXMT?PD$^#7Q;T'X=^-Y)KN3Q;JWA.RDU?PSX0T
MSQ%8W\7ZA>,O@)\(_B!'\'(O&'@RUUM/V??'V@?%'X.K/J.LV_\ PA/CWPMX
M0\3^ ]!\161LM2MFU"YT_P )>,O$VBI;:X=3T^:#5II[FSGO(K:X@\9TO_@G
MY^QAH_QE\7?'^R_9Q^&W_"UO'+^.;CQ+XBO=*FU33[[4OBAI!T#XH:[;^#]3
MO+SP3I'B7XG:$\VB_$CQ1HOAS3O$/CW2+F[TWQ9J>KV=W=0S2ZV FY2J8.<7
M).RI2:2M)*&TZ=.#4(QDY>QG'G<X^R:?,B%+%0BHQQ"ERV7-4@Y-KE5[\UYR
M_><RY?:.\5!\R>A^/N@_\%>/CQ#^T39>-?B)\$O%O@#X&_$#]E/]@SQI\-?V
M=]3\:?"#7M2N=3_;1_;6U3X&^%/V@)OB)X.\/:SXBLKA_ ?B3PU'XC^%.LZN
MMKI.K^"]8T_2]/SJ5GXZUOZWD_X*QZIXE^(-[\$/@]^RCXQ^*WQXNOVH?VP/
MV?O"7@:W^*W@'P7X>U?PG^Q9/\.XOBE\6M=\>>+X-/M/#46J2?%'PI:>$_!%
MKHWB+4]0U"ZGBN]7L+"SO-4M_=M(_P""2?\ P3LT#PIXV\#Z/^R[X.M/"OQ#
M\%^&?A[XNTD^(/']Q'J?@_P5XZM_B5X*TB"YNO%\U[HS>"?&MEIVL^#-2T.Y
MTW5?":Z3HNF>'[[3M'T;2]/M-J]_X):_L"W_ ()L?AY-^S3X.C\+:5\2?&'Q
M<TB&RUCQIIFN:+\0/B'I>FZ)\0-;T/Q?IOBBT\7Z-:>.]'T;2=-\9^'=,UVT
M\->*;.QMX-<T>^1"#<JN6S2_V:K%J$()1C:+48RO*:]MS2EK3C/WHNIR2E>-
ME$F-/&1;_>TVG)R=W)R2E[-.,6Z=DO=<H>ZXP;<;23;7"_\ !/[]K?\ :)_:
M:\;_ +<^E?&GX2>#O GAC]G+]JGQ?\#?A[JG@WQ4NN:A=6WA/PGX-U?4/!OB
M/2F%Q+JGB;2;77M-\3WGCJQO=.T'7'\;1>%-+\+Z=-X*OM5USY1_91_; _:@
M^)?[+DW_  57^,?[0WPDTC]G/Q-X6^)_BKP]^QCH_@CX?^#]!\'Z;I7B[7?A
M]\/?#'B3]J_QGXR37+CXG)KFBZ<OC*>YT&PT>X\5ZOJO@K0? @OX=&1OUV^'
MW[-OP3^%/Q.^+_QB^'7P_P!-\'_$3X]7?AO4?BWKND7^M16WC/5/".E?V)H6
MKW?AV34YO#&G:Q'I@CM=1U?1=&TW4M>$%M+KUWJ4]M;21?,&J?\ !)O_ ()T
MZOXJ^)'C.[_9-^&:Z]\6[3Q';>/FL!XATC1]6G\77%A=^)-;T_PQI.O67AGP
MQXKU>]TK3[^Z\9>%=(T3Q9]OM8K^+6H[P-,8]O@Y2JIT)4X5/J[BXT857",8
M6Q%)*I5?)*M47M/:QE=))+D;:5JEB5&'[U3G#VM[R<%)RFW2E)PII3]G3Y8<
MCBHZ/5M'QK9_\%J;[Q#I_P /]$\#?L=_$#Q=\8O%7Q%_; ^$?B7X8S_$C0O
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MDX./KVH _GS^&_\ P5*_:X67X=_&?XJ_"/\ 9RU']D[XE_\ !0;Q1^P%#/\
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M/3/V@/VV[GX/_L"ZU^U[#\.M8T+QWJW@+PN/AI\'_B7;+HVMZI\:/BGK&E>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !3-A))XZGCVSG&>HY_+)(ZG+Z*35[>5_P 5;U^YH"'RO9?R_P#K4>5[
M+^7_ -:IJ*7)'M^(?-_>_P#,A\KV7\O_ *U'E>R_E_\ 6J:BCDCV_$/F_O?^
M9$(^O3GOU]!C''^3TJ0#  ] !2T4U%+;K_7]=/( HHHI@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-q_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *F D # 2(  A$! Q$!_\0
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M$V%WJXFGWFR2PCLD@29T)168E7((W*00,'.<5H3^)M.MG99FFCQ&9/FB89
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MAT[0X!-KFKRR0V\2I]HQ(PC<*WR%U'7!;BM%M&M)-+M;)#*D5L%\ATD(=,#
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M3[B_2@#C-GQ,_P">_A3_ +]W'^-'E_$W_GY\)_\ ?FX_^*KM** .+\KXF?\
M/UX4_P"_%Q_\51Y7Q+_Y^_"G_@/<?_%5VE% '%^1\2_^?[PL/^W:?_XNE^S_
M !)_Z"'AC_P%G_\ BZ[.B@#C?LWQ(_Z"7AG_ ,!)O_BZ/LOQ&_Z"GAO_ ,!)
MO_BZ[*B@#COLGQ$[ZMX=_P# .7_XNE^Q_$/OK'A_\+*7_P"+KL** /.]$OO'
MVM'40FJ:%%]BO9+0YLI#N*8^;[_?-:OV#X@'_F.:&/I8/_\ %T> _O\ B;_L
M.7'_ ++77T <A_9_C[_H/:+_ ."]_P#XNG?V=X[_ .AAT@?]PYO_ (Y76T4
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M@$=#7FGQ*L-<O+*]G_LZ"[TNVLLVZ_:"K+,?O2%-IW$#A>>,D]<5Z+9-,]C
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M-X4S ==H<A,].2:]3KE9 #\4X1@8_L9__1RT =51110 4444 %%%% !1110
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M8]6T:+=Y=]9)N.YMLBC)]36?X@U;3I]&ECBOK=Y&DB 59 2?WB]J .BKE_\
MFJA]M%'_ *.-=17+K_R523VT1?\ T>U '44444 %%%% !1110 4444 %%%%
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MKXDU!O#6M:M-$!>6I?&G%?FMMHX5R.6)&&)'&#Q0!L_VGJ'_ $ ;S_O]#_\
M%T?VGJ'_ $ ;S_O]#_\ %UA3>(;K1!%'+J,6L7%WY7DQQQA"A<,=Q*@_(<?+
MP6]SVHCQQJ#71FCM=\+)N2U.W>"5C(&X9S@N3QDGMF@#J9=8O887E?0KP(BE
MF(EAZ#_@=:5M.MS:Q7" A)4#J#UP1FLR'4DU?PH]_'MVS6TAPK9 (!!&<#N#
MVJWI'_(%L/\ KWC_ /010!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%_Z ^G_ /@,G^%'_"/Z+_T!]/\ _ 9/\*TJ* ,W_A']%_Z ^G_^ R?X4O\
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M;2V<CK@=*XK6/B9XGL_ FF:M#/;"[N+QX9"8 05 )&!7*#XU^.%_Y:6#_6W
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MJP/!&#7MOA;1=-L=!TZWD"QW&TR2+C# GGFL#XB:+87BQRI$%G0?(X&,^QH
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MVKU"QT&6\N?M+3'@G>/49KR+P3ITEUXIA*L5^S_,Q'Y5]"Z4ICM -I /7UH
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MTYK4HHH XCXL_P#)/[S_ *ZQ?^ABOGSM7T'\6?\ DG]Y_P!=8O\ T,5\_P
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MEEU.8EB#SY:<8_$USLV%B)'YU[8^K_"JZAM[>32I&2!=D*;&X!/0?-ZTD_\
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M^H[US7P=_P"1?U[_ 'Q_Z#73>#DE.K7920*@ACW+MSNY?OVK'DN^;L>#BO\
MD:4/21W%%%%,]T**** "BBB@ HHHH **** $)"C)( ]Z 0PR""/45Q/Q3B2?
MPS8P2#=%-JUG'(N<;E:501^(-9VH:=8>"O&^@-H2"TCU 7,=Y:B4B)T2(NKD
M$D+M8#YO0T >D45Y3I'COQ#?ZU8V"7%G=-J=K<-"Z6,L4,4J)N4)(Y'FKV)
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MWGSN#AC9UIJ6D4[6]-4SE%8^;&0!R>XS6K'"DNF75T;LH]J56&'/7)YXK."
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M$8^6N1^!AG,NK[#'Y>(=^X'=_'T[5[&&5\NKOSC^IQU(WQ$)>3/::***\<[
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M5ELO-F52M3I+WV<5<1Q\811\P!X]Z6&.,"Y^1<;5/3_:K0OM/=9/, 8Q9W9
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M^VQ &FGQ$>V6/?WXKB/"5T(M=AMVC#*K>9@=>.U>@_%Q);?3;:$#,;W')/\
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M*\2]62]N'DMG.)$QD*/;TQ_*JNJVXTBXD-U)',\Y/[N,[CL)^9C[],>]/N-
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M>X\+R:?.))!\GD/UP!VJLEQ<Q207,#F.6+)#8Z<5[&$AB/8-UFG/6SZ6Z?\
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MNYK>YCN?,8PG!8#H#[5[7I\P^SDDY)/Z5Y#C'E33U_(V:TN>>_%VS1O#K2(
MS*_)]Z\^^&6B/=^(I-2=#Y-L-JMC^-O_ *U>C_$Y;671#<3O(H@<LH!X/L1W
MJC\(;JVN](O;-0%EB.]EQR30U'E33U!VMH>E&,LL+8Q@<@5D^*UEGT"\V1X2
M.$DY[UMVL;21)()!]S-<3XX\2:I8N--L]/>>V> FXE,3,#D\ ,.F.]71HSK2
MY8;_ '!&-V>6?#:QEU#XBP;$)6)7=CC@8.*^E&B+.G;!Y&:^=O"4NO0:CJ*Z
M%N6Y5R\@C52Q7VS7M'@C5]1U304DU2"5;I79&>5=I?!ZX[5I+#-4?:J2MM;J
M5R:7(?%EHEY9SP,A;S05Q^%?.NCV(;7?LKC:(V;\,5]#>(_$%GHZ)-<6MQ<A
MYA$%@7/7_/XU\^RW\5EK=W>1HWE^:^Q#UY)X-8.G)04VM&3;2Y[@)M>D\#V<
M'AK"W:#?*5(#,G/"YX)Z4FKZMJ&E> 6N];91J*1$2<8R3TSCOTS4'P[\56MY
MX;,@66)8TV$OC@CT/?K7G_Q.\6+J\::=:3EX0VZ4^N.@JG5O3]GRKUZCYM+&
M%\/--_MGQ?:&7.(Y/./US7TE:* '; [X8CH*^>OAG+]@\00W4P*P2 HK]@1Z
M^@KW6TU6%K*:-)0S(N?SZ5DR3F]?\:Z-%->::JW#2P;@\I V%@,D#O7@UW=-
M?W]Q=''[QB1]*]>^(-UI-IX>FD00-?7 V%D4;F'N:\;A&V$9ZUM5=-M>S5M-
M=;ZC=NA[S\#L'PQJFY=R^=R,XS\M=FEU8+!&O]CVP1>4#SQ C//<Y[9KB_@:
M<^%M4S@#SCRW3[M=)I=F+Z5TO(=)F0A<&.Y9F+;.,Y/.<C\#CM6(C5&H6R2"
M,:5 '\L,!Y\7W&)P<YZ$YJ2*\CO)&>'2(II!C+1W$1/!R.A]:H:I DQ1@VGB
M5K8H@61N"AR^.P4+5#1'&G1R3VJ6,-NCHTLL&XL\?<;<9QU.1[9/!H [&QOF
MNVG22W>"2%PK*S!NH!!R#[U<K-TXYU'4R.\J?^@"M*@ HHHH **** "BBB@
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M?WL\ MM8O-.1ELKI8XY\,4;UQUK4@\2+'HETUY>+<7LB[4C*8*GW]O>O;I/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#N,29R.AS[9/YT >DT5R7AGPEJ^AZD]U?^+]3U:(QE!;W(4("2/F^O'ZUUM
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M16!90J#</2O0^U !1110 45S/BGPQJ>O3V\NG^*-1T81*5=+4*5D]SGO7/\
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M YP?:N,^)EEI]MK8UC7M!,VEJB#[;8ZD8+CY<Y#1[AY@&3@@Y -=SIK:7>^
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M[?ZB;#Q)?:=IVJ.7O[.)%82,5"L48\IN P:[.UMHK.TAM8%VPPHL:+Z*!@4
M345S7C?5=6T;1$O-*%L-MQ$L\DV251I%7Y5Z$G=W/'O7)ZQX\UK2]5U65)+.
M2TB>[MX;0QX>)H8E<2,V<D$D\8'!% 'HFL//'H]X]K9+?3K$QCM6( E;'"DG
MCFN ^"\X@\!7]Q=HEH$U.Z>5"PVPX()&>F!_2K]EXWGT;PQK-_KSG4O[)NQ
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MTTZUMFF:=HHE0RMU?  W'ZT 6:**\W\3:MKNF>)M=6+4F,::"]U:P1Q<0L)
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MY%1(8RQR0>BCK]!7'? *-HOANT; ADOYE(88((V]1VKT#7X#=:!?P"TDO#)
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M2?XUEZKJOQ=TJ\TVV9-"N#?3^2'@MI66+_:<YX'O0!ZY17F_E?&#_GZ\+_\
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M:OJNE6L9TG2'U&9@[N Q 5$7)' )+'HH[F@";Q1<ZE:>&[VXTE%:]C4%<X)
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MHHY0.6 '&3T)'7 K<H *HZQJ]EH.ES:EJ,IBM(=OF/M)VY(4<#W(JZS!1EB
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-q_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J =D# 2(  A$! Q$!_\0
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M.N:=/;V%Q'/F+4'V6S;#\YP3Z<<*>OI6@X)1@.I!KS-/ ^JPZ!HJ6US>1ZC
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M4J*:"& (((/(([TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ASQ+'9&+3M1D"([B."1SQN/13]>U8>M20>%;[R+ZY6.-P6C9L_,OL/6O/\
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M:9X<?2;R5[75+H6DLS3-:,D97)&,;MN[' [UOT %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'C?QF_Y"^E?]<7_]"%><S?ZH?2O1OC-_R%]*_P"N+_\
MH0KSF;_5#Z5XN)_BL_1<F_W&/I^K/7M M_%K>$+)[2^L4M#; HCQDL%QT)QU
MKQ^V_2O7] D\8CPC9BTATPV7V8;"[-OVX[\XS7D%MTJ\1\,=_F893?VU2_+O
MTMY[G8_"_P#Y'R#_ *XR?^@U[T*\%^%__(^0?]<9/_0:]Z'2NS"?PSY_/_\
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MA]*]&^,W_(7TK_KB_P#Z$*\YF_U0^E>+B?XK/T7)O]QCZ?JSZ"\*?\D]T_\
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M #XP_E1_8&E?\^,/Y5I44 9O]@:5_P ^,/Y4?V!I7_/C#^5:5% &;_8&E?\
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M(4[F(+$CC/6K\?ANPBL+.Q7SO)M+K[7'E^=^\OR>XRQXK:HH **** "BBB@
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M!%;U% %'3M-L])MVM[*'RHVD:1@7+$LQR2223DFKU%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6(?#&C?:I;AK)7>0N65G8IEQAR$
M)V@D$Y(&3D^M;=% &=IFCV6DI(ME&R>8079Y&D9L# !9B3@#@#/%4YO"6B7$
M,<4EE\L:[4V2.A W[QR"#PW(]*W:* ,)/"FCI$(TM74B4S>:L\@E+D;23)NW
M'@D8)Z5I6%A:Z98PV5I"(K>%=L<8)(4>G-6Z* "BBB@ HHHH **** (Y(DFB
M:*10R.I5E/0@]17.V>D7'AK1X++1]US(UUF1[ENJG/4@'  "J..@%=-10!S5
MEH;WFF:E)?22QW6KP!+E5 'ED)L^7(]/6I-9\,1:QIMO8M=-'%"NPAHDD#C&
M,X8'##'##!%=#5:[NH[*V>YFW^6@R0B%V/T5023]* ,*V\'6EK)=-'<W)^T0
M2P'<02!)MR<XY(VCK6)+X.OWO8M.B>6'1TN//8^:C!OW94D#;N#$G./N]_:M
MZ7Q-'>Z1?3Z$HN[JU0[HYU>$(V#][<N>,=.M8U[XEUF.+2KK)MK&33X[J\NE
ML6G168C(R&&T 9/<X[4 :8\&6R7T<\5TZ)MA$J&*-C(8P IW%<KD  XZX[59
MUCPW_:D\\L6HW%D;FW^S7(A53YB#./O [2-S<CUJ#6_$Z:/KNGVDC!H[V%_)
MC09DFEW(%53G'1B>>*RAKVOQ07VLR7%J]A:ZBUJ]EY!#B,2!,B0-RPSGI@T
M7YO ]O-;M92:A='3AYC0VWRXB=P06#8R<;F(!X&:T7\.6[W<\YGFW32V\I&1
M@&'[H''?O3-+\3P:IK$VF""2&>.,RKN=&W(&VDD*25.<<'!YK?H XRV\ 6MO
M?V]V;ZX=K>7S$'EH"W[P/\[8RQR,9)Z5L6?ARWLI-/=)Y6-EY^S=CYO-;)SQ
MV[5MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!#/"L]O) ^=DB%&QUP1BL.Y\)VEQ;PV_P!J
MO4MDMTM9(8YL+-$O17&/J"1@D'%=%10!CZGX=T[575[J-LK;O;IM;&P,5.5]
M&!12#VQ5*+P;91SEY+S4)X&N#<M:RS#RFE)SN( !//."<9[5TM% '/Z/X4L=
K$NUN+::Y<I"T$:2.NU$+!B  !DY'4Y/O70444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-q_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #O I8# 2(  A$! Q$!_\0
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MTZ_MM2M&RJW%K,LJ$]QN4XK2'2@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M*!+$V[*2'[NTEAEL@=ZV[+Q!?7-QJ]Z+_4+#Q#/9:I<Z[:2SNR6 A -FV",
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MR;V>"-V;#$L@RQ4\$^N*>94.T;E;=R#GKCT]:2/<9<EL\84>WKZTP!+.!(#
ML:"-\AD"C:<]01[U"=&T\WL%[]B@^UPH88KCRQO13V![#BK('W< @YX)!Y]<
MU&TOE<9!SDJ <\>XZ_E0!#<:59W=]!<S6D4UW;DO#/+&&,6>NT]13;?2K*PD
MNW@M;>%KIM]P4CQYI/!+?WC5CS2L(8L0>ZA3DGT ZTIF /\ ?&=ORC=_+^M
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M\7Z?X"\+:GXBU=Y$TS3K=KFX:)"[+&HRQP.3@5\L?\$J5W?LMRC_ *F/4O\
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M%?0\NEVT\D$DEM#)) <Q.\2EHSZJ?X?PI[V:3%?-C27;G&Y0>2"#CZ@D?0T
M?+^F^*?%?Q%M_B##?^*;O1X]0\.1:GIUE:6QBGLXV!8E6ZEL#:?3-<YJ^H7%
MKKOPT\0R:J=6UVUT_3K>+PO=0R^=<L[_ #S)(."V.N1CUQ7V =-@-R+@01"<
M1^4)?+&_9G.W/I[4UM(MFDAE%O")H05BD\H;HU/4*>H_"@#YH^/WBB35-.TW
M4#9ZGX<\96TL<EAI5U,?-E3S0'-N(\H\Y'12>F<U)X<U^/3?C'XNOO#5[<WD
M3:/>W%U#.TC/#>1,2/M(8849X3'4 ]:^EIM-@N)())K>&:6!B\3RQAFC;^\"
M>A]Q2)IEM#/--%;Q1R3C]ZZQ@-)_O''S?C0!\=:]J5HVCZ>?$FHW5RC^$H-7
MT47%Y+;PW5](SRW.V5!@RJ2H5?3'%;=[X8T_5O'NE^*)K'4K34+SP3-J<XGG
MD_=W0C55+#@;\#/3J37TGI/@'1=%T:#2+>PADT^WD>:"*YC$HB=F+$KNSCEC
M],ULFQB(7>BNP79N= 25]/I0!\6_LT^)]9\.^(EFTZTE\4_;=%$MWIV@W1E6
M.Y$N#)=M,0(YB#PH.< \5-\1O$4]CXU\0S^"[R\EDO--D358YGF:2SD$Z>:]
MPH'RQHA(3;SSQD5]<S0:-X/L[R]\BQTBTQY]U.L:0Q\=7<@#\S7+6/Q7^'-_
MJ/D6OBC0)+_5,1KY5S"9+GL%X/S_ $.:I1E)72V+C"<ES16B/EFZNEF\-^'[
MDZS$L/A^>ZET[2V6>6TUZ7> ODR<$,1D!>2,YQBMFSU6\GO=9NQ>:A9>)GL-
M4NO$%M([@6:Q@/9,<\##X5<<L,U]>C2;!([:!K&U6.!A)!&85Q$W/S*,8!Z\
MCUK-\2>%]'\0Z5?6VJ0QI:W2K]K8@1F95.0'?NHQT)J+-Z(A+6ZW*2^(UE^&
MEMJNIRQ6$MSIN]_M#A%#M'T)/O7DW["5W#+^S3X=C2:-Y(IKK<%<$KF9B/YY
MKQ+]LKXOVGQ^\-WWPM^%VF:AXQU+3[B&ZU"_T92;6W6%LF,2#AF[8!KR3]C7
M]F7XC?$70M9U>S\7ZM\/='=U%L;9=RWA&0QQG@ ^G>O>A@XK".=67+JCZ.E@
M*?U!U:T^5W6A^H%]K-AIT/G7M_:VL9. \TRQKGZD]:X7Q/\ M'_#/P?'<R:O
MXWT6T%NVQ\7B.RMZ84D_I7A>E_\ !.'PE/)!)XE\8>*?$8 )>&YU!_*:4]7"
MYXY[5W?A?]A+X*^$?LDZ>#K;4;VV<L+N^9I7=CW;)P:\]PPT&_>;/.=/!4V^
M:;?HK'R3^V=^VE;>.O%&E:%X&NM/U[PSILUMJ@U! Q_TN-V8)R!D=,U]T_LP
M?$_4/C!\$_#/BS5H(K;4;^!FFC@SL!5V7C/TKYC_ &S?V6_AWH]OX8US2]$&
MEW5[K5CI-S%9?NXC!))AOE'\1SU%?8GPL^'FC_"GP/I?A;08GATK3X]D"R/O
M8 DL<GOR37;BYX9X6G&DG<]'&SP;P5*-"+OYG7*.I]:=35.<TZO%/G HHHH
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MA&<FF=&'A2K2<:E[+L?5.B:U8^(=*M=2TRZBO=/N8Q+#<0-N213W!KFOB?\
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M%#!%YC[3(G&0W.?3BOI_X/\ @C5_A]X-AT?7/%NH^-=121W?5M4QYS@GA<
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M;VEK&(8HHU 55    '3I76_]EIZ?'+\$>FVL)1M]N7X(\!_;D&?A-X?SP?\
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M@GX;:5+\1_B',YB33K $V]JV,AII1P![9K@)&^.7[9_F['G^#7PJF<+AT/\
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M6UK+TV(IQ2G+0[1>:=35%.KX@ZF%%%%,04444 %%%% !1110 AYHV\8[4M%
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M*KS7M(\J4$E'>^RMZ>A+HP34DMCW6/#L,>F!SD8J9  .3FHX@00I&3US5D#
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M_6OIV.W"], 9]*_2.).*L-B,:ZN6486:7O./O+3^]I]R.6E0E&/O2/CCP_\
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M)Z#^T8?_ (JC_A:?@X'!\6:&#Z?VC#G_ -"H ZJBN6_X6GX-QG_A+=#(Z?\
M(1A_^*H/Q3\&@9/BW0@.O.HP_P#Q5,#J:*Y4_%3P8H&?%NAC/0G4(N?_ !ZC
M_A:O@L9'_"7:%D#./[1A_P#BJ .JHKE1\5?!FW/_  EVA$>HU&'_ .*I5^*7
M@UP-OBW0SGI_Q,8N?_'J .IHKE1\4_!I.W_A+M"W9QC^T8>O_?5+_P +2\&D
M\>+-$_\ !A%_\50!U-%<JOQ4\&'_ )F[0O\ P8P\?^/4H^*7@TG \6:&?^XC
M%_\ %4 =317++\4_!C D>+=#('4C483_ .S4G_"TO!P8@^+=#!]/[1B_^*H
MZJBN5_X6GX-Y_P"*NT(D=?\ B8P\?7YN*#\5/!F_;_PENA[O[O\ :,.?_0J
M.JHKE1\5/!I&1XMT,CVU&+MU_BH_X6KX,S@^+M"SC/\ R$8>G_?5 '545RW_
M  M/P;_T-NA_^#&'_P"*I#\5/!@(_P"*NT+GI_Q,8>?_ !Z@#JJ*Y9OBGX-7
MKXMT,9.!G48?_BJ0_%3P8#@^+M"!]]1A_P#BJ .JHKEC\4O!P)!\6:&#C./[
M1BZ?]]4G_"T_!H./^$MT/)Z#^T8>?_'J .JHKEC\4O!JYSXMT/CG_D(P]/\
MOJM;1O$FE^(;8W&EZE9ZG IVM+9SK*H/IE2: -.BD[TM !1110 U_NFE*]<<
M9H(R,4M 'GWQV^'M]\5/A!XK\(Z;J;Z1?:M8M;0WJ,5,;<$9(YVG!4X[$U\T
M?LO?LL^,/ 'Q;T_Q5K'A'P?\.M/TG3)]-EM/"!<_VV[[<2S@\87;D#U-?:VP
M5'Y7 )Z]_?VI <1X=^"'@OP?XWU3Q=H/A^TT;7M4C\J^N+)?*6Y'7<Z#Y2V>
M^,UW"$1J !D =13U&!Z5&S$/C'7O3 #/@D!3@#DU\<?\%66#_LOQD=M>L/\
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MZKX>_#3PQ\,?#\.B>%=%M=%TR$8$-I&$W'NS$<L3ZFNE\C#E@<$G-<VGQ/\
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MBOJSX!Z_>^+?@YX$UO5;AKS5;[1;:YN;@KM\R1XP68@>Y--:JXF['R9\*O\
M@D=\+]!\*&U\=R7?B77/M$D@O[&[DMX_*S\B;,]0*23_ ()%_#(_%R#5XIKC
M_A !IS0R: ]Q(;@W1/RS";/"X[5]\A0!TI-H].:!GP+:?\$C/AI'\69]6GGN
M9/ 1L!%%H!N9?M"W.1F7S<XVXS\N*Y:7_@C[H<'A'QK;P>(U/B&^NQ+X=O7\
MPQV$(8'RY5S^\)7(S7Z0'('OZTTC<.12A5J49J<)-275:":3T9^;FN?\$>=-
MN(_$!TGQJ]C+<QVO]F"2.1EM77;]H9\.-P?YMH[<5R^B?\$G=7\/_'_1H]9U
M67Q7\*I_->[:.\>WN+<A/W:L,DMEL<CM7V)^U'XT\21^+OAE\./#&N7'A6X\
M9:A/#<ZU9QI)/;0Q0F0B,/QDD#GTJ_\ LH?%_P 0?%/]G^+Q#K40U7Q'IUS>
MZ;</:J(_M\EM(R!E'0%PJ^P)-;SKUJS=2<VV_-A:VB/.3_P2M_9_,N]M$U;!
M.2O]J2[2?SSS6%XZ_P""3_P>U7PGJEIX6M[W1/$$L!6QU&ZO))X[>3J&9,@D
M#TS7<?LA?%OXD?$GXE?&.P^(UO#I=SHNHVT=GHEO(LJ:?"\98)O4#>2 "2>]
M?4:KZ_>]:B,ZE)^[)H3U=CXH\(?\$H/@KIOA?2K3Q)9:CK&O16L:WU_#J$L:
M7$P WR*F?E!.>*PO _\ P2-^&FE^,O%5YXFDNM8\.W<L;:)I\-W+'+8QC.\.
M^?GSD?E7WPBC)XIVT>E9ZMW91^=NF_\ !'WP9#8>/8KS6))Y]1D8^&Y5:0#2
ME.<>:,CS2.*@L?\ @CYX4MW^'OGZZUPFFF3_ (2H$RK_ &N"/D\GYOW6T^N>
MM?HQM'I1@8Z4:@?EW+_P1F0WDT@\?0BW62[986MY"WEN#]F5CNY*':2>^*G^
M"_\ P2;L-)^*FLV'Q%M)-;\&PZ5"EGJ-I?-$UQ>Y'F-L'*C&<"OTV).6.0,8
MP!Z^E?*OP,^,'Q,\:?M;>._#GC.Q3P[H=EHL5UI6AQ-YA$9E*K/(_9V /RCB
MF!G'_@E+^SVW30=6'L=5EKB/B5_P2*^&>L7/AL^#9+KP_%;7RRZJMU=23F\M
ML<Q(<_(V?XJ^]H,%,\@GJ#VJ0@'K0!\7ZQ_P2A^!%SI5W#IVE:K97[0/'!<M
MJ4C[)"/E<C/.#CCVKC/"W_!(CX=Z=\)&TG7+R;4O'S02J->@GEC@$K,3&1%D
M\*-N?7%?H'@4;1Z4 ?G/J/\ P1[\*2_"#3=(M-=>#XAQS1O>>(F:4P3H&)D5
M8=WRY4@ ]B*BU7_@CSX6GU'QG+I_B%[6RO=/AB\.QR&5FTRZ 7S)I3N_>AB#
M@#&-U?H[M'I2%1CID>E 'Y=>(/\ @C*+C7M+N=(\<Q6VEV]O%]MLI(9&DNI5
M'[QD?=\@8^N<9KK/V;_^"57@U_ UV?BUH%[_ ,)(NI7"P_8]48(;0-^Z)V]\
M>O->Q_MJ_&#XG_#(^$+?P?8IIWAJZUO3[?5_$CNK3!99PHM8HSUW _,^>!TK
MAOC?\?OB#I'Q ^)GB?1/$LFF:%\,M4T>Q_X1M($>WU1+J14G:=S\P(63Y-O0
M@41U&SK#_P $I?V>F^;^P=5P?[NJR_XUQ47_  2*^&:?%FYU62>Y;P&U@(8M
M!6XE$ZW/>7SMW3VQ7WA87 O+."<#Y9HU<#TR,_UJSM'I0(^!OBO_ ,$B_AAK
M_A/[)X#DN_#&N_:(V^WW]U)<IY0;YUV\<D=Z?\3O^"1WPPUWP0]EX)EN?#?B
MC?$1JMW<2SQJHQYG[O/\0]Z^]MHYXZT8'I0!^?FH?\$A_AY+XX\*7MM>S0^&
M+*R\K7--::4RZA<8_P!;&^?W8SVYKE+7_@C=HR20&X\7>:JZ]+<R(HD&[2BJ
MA+7.[_6 @G?[XQ7Z52X"GH,]_>O,?VA_&7C'P-\+=7U/P)H<6O\ B81,((KB
M810VXV$M,Y[A0I.._ H _.+XJ_\ !'7Q/I/A>XO_  9XJMM8UB&XF=--E62(
MRPEQY2"0L1E5SGCFOU"^&6A7/ACX<>%])O8UBO+#2[>WGC0[@KK&H8 ]^0:^
M-M,^,GQ%\?\ PN_9Y\,0>,IM#UWQU:ZC?ZMXFM[='F M5W+'&#\H#,RCZ+7.
MVG[2/Q.^+V@Z;9Z?XK?POJ?AOP7?^*;Z\M+5)/[4O+6?RTC=3]V)E#$XZDT7
MUL.VES]%@1@=O:BN(^#?CN;XB_"?PEXIN8A%<:OIL%W+&G 5V0%L#TSG%%2X
MZDW1W5%%%4,*3%+10!Y7^T-\$X_C=X4TRPAU:3P_K>D:G#J^DZK%$)3;746=
MI*'AE()!'O7">%_V6+CPSX,MO#*>,[B>#4]2O-2\6R&S0?V\;F-DDCX/[A1D
M$8R?E%?1K#./:F+"$S@<DY- 'SS\ OV4V^#GC%=?U/Q;<^*[C3M)_P"$=T1)
MK58%L-.\SS!&<$^8^0 6..!79_ +X)I\$-(\267]KG5_[9UNYU@LT7E^69FS
ML'/.*]45, #L/6D$0W%L'<>,T / #"G4@I: "FG[XI3P*JW5]#91RS3S1P01
M#=)+*P14'N32 P_B+X+TWXD^"M<\*ZNCOINK6DEI.(CAMK#&0?4=:\%\"_LE
M>(?!=IXDOU^)-S=^-KS2[30-+\0#3HXQINGV[;HX1$&P[D%MSGKQ7T!H/C7P
M]XMDF71]=TS5VA.'6QNTF*?4*3BMCY2NY.>PI)6'?2QY/K/P-?6?CAX!^(]S
MKS277A?1[K2Y+4P@?:3-LW2DYXY4\>]>MQKSC'([TP*$8LN,8QUZ4Y6'7H<=
M>HIB)AS2U#O)/J#Z=J4.3S_#ZBF!)FEJ 2]\;A^N?2FRW4<$;RRNL448+/([
M *H]SVH G89%>4_%SX)I\3_'?PT\0-J[:<W@[4WU-;=8@_VK,9382?NXS7IL
M=ZES DL+K+$Z[D=6!5QVP103O^^,'IGU_P * )H3NR3C/?';VJ3-4;J^ATR(
MS7,T-M"N,M*P103T&3QS52/Q5I+ZY_8ZZI9G5S$)QI_GK]H\L_Q[,YV^^,4
M;5)FH!(Q8$J0#V'-*9&!QD9/3^M $]%0^;QD]/3TJE?:_8:9]D6\O8+66\E$
M%O'/(J--(>B*">3["@"AX]\,+XV\$^(?#WG_ &5=6L)[$SA=WE^8A3=COC-?
M/>J_L;32?#_X;Z5X?\=W.@>)O!6CRZ#'K:6*3"YM98_+F5H6(QG'!SP1FOIY
MBK$9QD<]>:Q=8\9^'O#VIP6>J:]INF7MQ@0V]W=)%))G@;0Q!.?:D!G_  B^
M'6E_"+X<>'O!FB^9_9FBVJVD1F.7;&2S,?4L6)^M=>O%8FO^+=#\(0)-K6LZ
M?H\,A(1]0N4A#GJ<;B,G%3V/B/3-6G>"PU.TNIXXTF>**56=8WY1BH.0&['O
M0]1+8UE[TB_=%-1^.GY4X-S2L-#J0BEHJ@/G_5?V5=+\2^(OC+>:SJ\UUI?Q
M'LH+&:T2()]B6.(H&5L_,2<,/I7%V?["_P#:?A+Q'!XJ\<W.O^*]1BT^"QUU
M;)(18)98-J!&"0Q!&6)/S9-?5[0AAR#]*18 KE\L2?4T6'<\K^ _P2E^#]AX
MCN]4UM_$_BOQ+?-JFLZMY"VZ33E0H"1KD(H4  9[5ZO'TH"X[Y]*55"]*!#J
M*** "BBB@ HHHH *:X&WFG4ASCB@#YM^.W[(4?Q>\<7^NV7BZZ\-6NO:?%I/
MB6Q@MEF.I6D4F]%5B<QMU4L,\&M3XB?LUWOQ&T;7-&O/&$MKI6_3[GPU;PVJ
MD:%/: ;'!)_>ABH)!QWKWMHMS!NA]J/+')P2<YYH#S/G[PO^RZ=#^#_Q#\+7
MOBB75O$WCQ[FZUGQ#);+$6N)HPFY(0<*JJ  N:]8^%O@D?#?X=^&O"OVHWPT
M:PAL1=% GF[%"YVCIG%=085)Z$9'(I5C"D=>.E $E%(*6@!G%!(P:<>E9&O>
M*=(\,6WVG6=6L='MCPLM]<)"I/L6(S19 >;_ !X^!]Q\6)O#>L:)XA;PKXP\
M,7C7NDZL+9;F-&9"CQR1M@,I!-9GPI_9]O/@[8^!]&\/^+KE/#VBQW3ZI8R6
MJDZQ<SL6:9WS\F&8D*.V*]=T[4;36K>.]L+RWO;60?)/;2K(A]P0<'-74 P>
MV?4\FDM%8'J>7_#+X(1_#KXH_$SQHNK/?GQK=V]T;5H0@M?*C\O:"/O9ZY->
MJ+AF;';BH5"Q [<\C.#W/K4B.0<' .>U5>X(F&,<4M1^82>,8I YX]#WI 29
MHS4!FR. >G(':HKG4K>QC62ZGCM8V<1JT[A S'H!GJ3V% %IE'+8R:\JTKX*
M#2OVCM>^*)U9I6U/18-(_LSRL",1N6W[O?/2O4C(0.>&Y'_UZB7#L0<>I0_S
MH GC;)/I4E4GU&WMYE@FFBCG=2Z0M( [ =2!UP*@T7Q'IGB.T-UI.I6FJ6P<
MQF:SG65 X."N5)&0>U+<#4HJ$LR^C>U()"1T;D^E,">D)ZU$TA4'L>,9JC;Z
M[8W6J76GPWUM-?VJH\]K'(K21*V=K.H.5S@XSUP: /.?VA_@D/CQX*TKP\=6
M;1ELM;LM7\Y(O,\PV\GF;,=L]*\]^)O[&5O\1/B%K&L0^+;O2?"_B2ZLKWQ+
MX?2U63^T9+1@\.R4G,0W!=V <XKZ2?& #P#P6!QQ6-I7C/P]KNJ7&FZ;K^G7
M^HVRDRVEM=))+& <'<H)(YXY% =#=MT6.-$10B*H"@= .U35SLWCGP_;:R=&
MDUW34UA5W'3S=)]HQC/^KSGISTK4T[6+/6+*.\T^[@O;.092>WD$B/\ 1AQ0
M)%ZBF1ECG<0?I3Z!B8S61XHT5=?\-ZOI7F& 7]K+;&0#)3>A7..^,YK8II 8
M'(X/% 'RO<?L77%G\,?AAHFA>.)='\6^ 5N(].U\6:S+)%< K,CPDX.01@]B
MHJEK/[",%OH.A67A+QO=^'+VWT2;PSK%X;19CJFG3R"292"1Y<A8<,.@.*^L
M6@SMY(P<X'?VI3 K9SWH\P\C$\'^$['P3X4TCP_I:F'3],M8[2 /UV(H _E1
M6Z(Q@#J!ZT4:BLA]%%% PHHHH **** "BBB@ HHHH 1NE?#'[?U_K/Q$^,7P
M;^"=MJ]QHOA[Q==O+JL]G(4EFCCZQY'."!^M?<YZ5\S_ +8W[,&N?'!/"OBG
MP-K$.@_$3P?=?:]*N[@?NY1_%$_H#Z^YJ7N@.6\._P#!._P?\)/BGX3\8_#/
MQ#J/@@::S#4[#SVFCU.+'(8,>#ZURQ_:C^._QFE\<>*_@_X=\.CX?>$;Z:Q
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M_L:_$OX.^)=:T/PM\*_AS\0_#=]JSZA8>)O$S*+JQBD;)B=#\SE<G&*0'?\
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?$0 1W[U)44?0\8XJ3UJ5L4+1113 **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-q_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_005.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 D # 2(  A$! Q$!_\0
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M_AG/_AB?]GS_ (03_A6G_"M?^$E_X5;X'_X6S_9?]F_\(_\ VU_PM3_A%?\
MA,_^$_W_ /%1?\)E_P )+_PE?_"4?Z;Y^_FH_#G_  2A_9Y\)_$?]CSXS:9X
M[_:+;XJ?L2_#H?!CX5>-]4^,&JZAXE\5_"K^W)-=D^'/Q6N&\/[O'OALQM)X
M;,+QP!O"0,+22;$G4 XY_P#@M'^R'%^QEX@_;!O(OB/:Q^&?C$?V:-:_9_/A
MJ5OV@K']J3^V_P"P_P#AGY_ OGB4^/\ =_Q4PA$X4>!L>,C^X!2L?7/^"O\
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M*SH_CT#Q(9%\%>-$\*^+"JHS6QC0,GVGX1_X(_\ [(FCQ?M%2_$Z'XR_M/\
MB7]J7X<Z7\'/C#\0/VG?BIKWQ1\<7WPNT*1-8TKX>:#K>/#(\.^&O^$B$7B<
MP^&DB)\7 7!N T(\GSC1O^")/[,NG>._V:_B%XI^,_[:?Q5U;]DCQQX:^(GP
M%TGXM?M+>*/'/ASP1JOAX1MHFB)I.OZ%LU/1H6MEBDF)/BTP[+7[<(Y'1@#H
M_$?_  6#^#'_  E7QOTOX,?LZ_M>_M0^$OV8/%OB;P3\=_BU^S_\(-+\2_#/
MP)XH\#NC>/=#T?6->\6^$?$OQ$\2^$-H3Q=X;^%/A/QK)!NPCO\ .9^>U#_@
MK'X!\>_'#_@EGHW[/?B'P;X]^"'_  44L?CYJVB^*]2\.^,V\3^5\)M'T C2
MO#AMD3P_X=\2^&_$&LZMX:\<P^*BQBDC6*$'9YDO5^-_^".'[,/B'QI\9_%/
M@3XF_M9_LX:9^T1K&I>*?CO\-/V:?VB_&?PA^%GQ/\6>('D'C/QEK'@G1%>#
M1/$/C'8!XV\0>$6\*R^+4*+<EVE4OZIIO_!+?]D30/&7[$7C+P/X2USX?)_P
M3\M/BGIG[.G@WP/XCN=)\%Z>/BUHFAZ#XZ;QOHK;I/'$D\>A*^9[J-Q</(Y)
M9510#\_/VF_^"^?@GPE^S)^U!^T3^R?^SA^T?\<_ ?P'?Q9X8T;]HO\ X5AO
M_97U_P")_@K7H-"UG29->'BJU^(DOP[A7B3XG>'O!DO@Q99 [7Z,LAE][\;_
M /!2?XH_"'XE?\$L[[XB_#WP#%^S[_P4=\/^!? >H>*O#UYK1\6?![]ISQ[\
M-](\=^!O#Y$TB^'=?^&_B]Y;KPS9NTD7BV.:,2Q;[:/R9<KQI_P06_8Q\7>$
M/BY\*=+\=?M<_#C]GWXV^(M6\9>,_P!F;X9_M'^,O!OP C\4>(M7'B#6=8T'
MP&(YHM##^) /$C^&$F/@<3*#'X+=T 3T_P",?_!-R?XN_&7_ ()WP7WQ%T[3
M_P!DK_@G;=>&OB#X&^%3Z+K6L_$[XD?&+P%X5'@/X5:SXU\=3>)#X=3PSX.T
M5QXG+Q>%$\6>)_%K31/+#:2#(!^NB]!]!_*EID?W1]%_] 6GT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 5Y'5 '(' /'8<G^?\ G@U^
M?O\ P4+UFXF^"'ACX41W-U;V7[1GQ=\$_!KQ'>6RB-O^$$U@ZUXT\?:+A/OI
MXR^'O@GQ!\-R6)RWB5"0"!7W??WUAIUG-?:A<6]C86UN9KBZN;A+.QM8EZO(
M[E$C7))9G( XQR<'^?;]L_\ X*2? _\ :)M;C]FO]@_PA\1OV^/VEO OQ \#
M>*;&\_9JT:/Q#\(?A'XE\#Z];Z]$OQ._:,UHP?";PY#XL\/1:]X4&SQ+XJED
M37=<CDC1X"K=F6U\'ALVRGZZKI55)WM;EBU=/6WQ).[M=Q]$>)Q'AL=B^'\X
MPF3/_A7=*2@NTGL_2UUT3OWU6'^V+\5/C[\-XO@3X;_9E\*^&_$?C_XG_$;4
M_!ECX?U;1]&U+3#X8T+X9Z]X\(SX@^)'PD\,Z 0-#+'=XP7_ (HOIX*)^6N5
M_9 ^/OQB^-WQ&_:(TKXG3^ -.T?X<^._%'@KPWX>\)_\(=_:=AJG@76O[!UW
M_B=_\+(\7?$WQ!]?%GP?\''KT&:^N/!'C#PK\3M T_QCH=D?M&EWNJ6=YI7B
M#2!IWB;X:^/-"_XD6N^#-<T0_P#(O?$3PI_R+!')SP#@#.UH_@GP/H.O:QXC
MT/P=X2T3Q1XH_P"1D\0Z3X;T;3?$NNX_Z#FN?\S!GWY'48K^EUA<7+$K%X3-
M;QDOA=I12:=TO);*Z=[W5XM7_P PWF6#PF3YQDN-R>V>K[WKU\_T7<ZBN+MK
MV7P1^T=^S%\2=,'V>^U'QWJGP-\2A0"=?\!?%/P7X@U\:*!R?^*5^(V@>!_$
MZ@G!'_"3^M=FIR/)@]P<'W../\_S-<W\&-(F^.7[2WA2^T,C4?AE^RMJFJ^*
M/%_BVU!DTK7/CEKG@W7/ &C?#C1M9VK'X@'@WPWXBUWQ7XWBR'\)>,=<\+QJ
MQ8X3#C?$X7#<.YI];MRRC))-:\SBN1KSZ))WE=I[6/?\',NS?%>(_",LG:48
M)RFWLHQUFV]K**;;V25WH?LK1117\QG^G 4444 %%%% !1110 4WAQWZ_B#3
MJ* ,R]O+#3;4WM]>6NGV=LHW7%S=QV%BH()&Z1W$8''RAC@]%W5R_P#PGW@K
M[5]@_P"$T\)_;_\ A(?^$4^Q_P#"4:3]M_X27K_87E>9G_A).W_"/;/.SQY>
MWBL/XP?"SPG\:?A_J_PV\;_;CX8\07WAN[O%TR^.FZ@)?#^O:/XBT9DF\MRK
M+K^C::2I3+ ;"5&:^+S_ ,$T?@,?&[>/UUOXH#6/^$UTKQ(+1O%&C#3QHVA^
M,3X]7P>8?^$9&="'B4"9M=\P>.Q8X\&?\)P/!I%D0#Z4_:JTS4+W]GKXP7FC
M>*O&?A37/#G@'Q9XGTG7_A_XA_X1KQ+9:CX?T'6=7TD1:RQ)2+S%C#QG(8D,
M=P*FO&/@O^S['XN^#WPG\5ZW\>?VGY=9\3_#GP'XCU>Z_P"%[^+_ /3=3USP
MCH>L:J2H*GRW9F9 ,8#N!@D@\;^WI^QQ^R=\4OA?\;OC-\7?A1X1\3_$#2_@
MKXOM=+\6^(]7U?3V5M$\':^VAQJ\&NVT($;N5!=&ED4%F+.'>OL+]G;_ )-]
M^!'_ &1_X8?^H7H- '#?\,L:9_T73]J/_P /QXN_^+H_X98TS_HNG[4?_A^/
M%W_Q=?4=% 'RY_PRQIG_ $73]J/_ ,/QXN_^+H_X98TS_HNG[4?_ (?CQ=_\
M77U'10!\MC]EG2V'_)=/VHR/?X[^+O\ XNH3^R[I'?XZ_M1G_NO/C#^K"OJ0
M'Y.#U;M]*X#XC7LNG^"_%M]!-)#/:^%/$-W;7 (.QH])D=7'&0RR!64$ @\C
MI5*+NOG^"U+H4OK.(6&?5Q7?5RC'NNLEL>+?\,P:/C)^./[3Y&S.1\=_%^"G
M?'S'Y<]><4]/V6](=5V_'/\ :AP<L!_PO7Q;MXSGC?P>.N.<8]Z\=_X)M_%+
MQ%\6_P!C[X5>+_%NNZAXB\4R6OBC1=;UC5+L7NH:AJ.BZUJL#22N,;F"J%'.
M[8BKD*HK[P$QAAW<YCM&<\G.6<@?CS^AZUCEU;Z[A(8J+=ZCNE==%IW6[7X]
M#U.)\@QO"'$N=<,Y@DLWX;XDQ'"]9K93P]1PG9.[Y6H\T>9.5FM7U^>?^&6-
M,_Z+I^U'_P"'X\7?_%T?\,L:9_T73]J/_P /QXN_^+KZCHK0\@^7/^&6-,_Z
M+I^U'_X?CQ=_\71_PRQIG_1=/VH__#\>+O\ XNOJ.B@#Y<_X98TS_HNG[4?_
M (?CQ=_\71_PRQIG_1=/VH__  _'B[_XNOJ.B@#Y<_X98TS_ *+I^U'_ .'X
M\7?_ !='_#+&F?\ 1=/VH_\ P_'B[_XNOJ.B@#Y<_P"&6-,_Z+I^U'_X?CQ=
M_P#%T?\ #+&F?]%T_:C_ /#\>+O_ (NOJ.B@#Y<_X98TS_HNG[4?_A^/%W_Q
M='_#+&F?]%T_:C_\/QXN_P#BZ^HZ* /E$_LNZ0)5!^.7[3H(Z _';QB.O]U=
MW [<'K[\T']EG23O4?&_]I[/\6?COXQQQ_>^89Z_YS7'_%+XE7EK^TY\#_">
MC>)L:=-;>._^$J\/VFL1AFN8]!B?0CK&CH2QV.UP\+2!'1\$+@*6^B?B1X]T
M3X:^"O$'C?Q%<36NAZ-9I>W\L%M)=LD>T%V"1*68[BJ[25 )R2.,^IB,HQ>&
M>5))N6>P4X1LTVG.<$E>V[@]FM&G?J?#Y?QUE.+?%B3BH\!U73K3;5HVI*HY
M72;T32U4MFK7T/,!^ROI8_YKG^U%GV^._BX?^ST']EK2QP?CK^U'_P"'W\7?
M_%5]%Z-JMOK.FV6IV1W6^H6JW5MGNKJ&![#^( _C6BYVDGKR?ZUYO*V[+U/M
M*4O;QO9?TK^7<^9/^&6-,_Z+I^U'_P"'X\7?_%T?\,L:9_T73]J/_P /QXN_
M^+KZCHJ30^7/^&6-,_Z+I^U'_P"'X\7?_%T?\,L:9_T73]J/_P /QXN_^+KZ
MCHH ^7/^&6-,_P"BZ?M1_P#A^/%W_P 71_PRQIG_ $73]J/_ ,/QXN_^+KZC
MHH _._X?:7X@^&G[<C_#"+XG_%7QAX'UC]E+4OB%=:!\2O'6M>--/L/%6D?&
M+P_X=36M*76G;^QY/[%G>/:K%&$@8$E=[?HA7PU<?\I*-._[,>U;_P!7]H%?
M<M "  # I:** "BBB@ HHHH **** "BBB@ HHHH **** "N?U;Q!H>AHK:SK
M.CZ2".#J>L0:<#GH1YSH#GU'U%?)/[7?["_P>_;5TOPAI7Q:\4?';P]:>";[
M4[[2!\$_CO\ $[X)"^EUB-(Y?[>D^'7B/PW_ &VF%0JLTC.&+*9&!4+\>V7_
M  0._P""6?F"Y\;?LY:E\8+M;46GVKX[?&CXU_%XE0005/Q!^(OB<H^1P<'&
M. >P!^@_CW]KC]E/X4V!OOB?^TW\!/ %B1_Q]^,/B]X%\-J#UX.M>(HR?QZ>
ME?)WB;_@LU_P2F\*1W%U?_\ !0K]E/4OLHQ=V'A#XP^$/'.I@@8+#1/ <_BG
MQ"<?]< 1[UL>!?\ @C]_P2\^&4L-UX&_8%_97TZ[@Y%W>_![P?XD<'OEM?MK
MHL^>2Q7'M7U3X4_99_9F\#L9O!G[.GP*\'S3=6\+_"#X<^'B1UY?1?#L1/!S
MN9V!XR1Q0!^;8_X. ?\ @EA>:C;Z!X5^//C[XC>(+H 66D?#G]F#]JWQIJ5[
M_NIH/P2E7C.#R1GH.Y\=T;_@M#\0OVR9/$/@S_@E1^Q9\6/VA_$6A^)=6\%>
M-_C9^T5I\O[.'[+?PC\3:'(D&LZ;XRUG7C-\3O'/B*T$Z)=?#7P?X,3Q@GFK
M<2>1$&"=W^V5^TS\6OVG?C?J?_!+G_@G[XJO/!7Q M](TZ]_;9_:K\-6P;2O
MV+_@[X@P(O!W@J58B7_:F^*.@,Z^!/#0%O\ \(98,OC>ZV/$LUO^GO[-'[-O
MPB_9"^!_@CX"_ OPS:>%?ASX#TT6>GVCJMYJVN:C.1_;7B_QCK07SO$/BOQ/
MK4DOB'Q=XEG(FN;R61VBBA"J@!^75M_P2;^*7[5%Q9>)?^"LO[5WC']JB 2K
M>Q?LJ?!6/6O@#^Q=X=!#J-'U;P5H6NR_$7XQ-" 'B\1_%;Q?<-G -OLP'_8;
MX7?"+X9_!3P5I'PZ^$'P\\%_"[P)H%K]ET;P9\/_  UI'@[POIR8 "P:-H,,
M%O$2,!BJDL#ER[$,OIU% 'PM\:?V,?!OQ-\2W'Q0\">)_$WP-^,UY;:;9:KX
M^\"2:?J6G>.M.T:1I-&T;XI^"?$,%QX=\>VB.\BI(Z6OBJ"-8;>V\7V]NL2'
MP<?LP_MF:=/<6\7C']F3Q%; $V>L:QX<^+OAS4KX  G^V]"\/>*7\.'M_JU/
M/O7ZNCY1GY?;'4_C_P#6([<<5 Z*W4'/L?P]0*]O+>*^(,LA]3PF:-0TER-7
M:Y=5I?OLD]+*R5E;\^XC\,.!N*\3]=SK)H3FM.9-POYNUU?Y:W/S T7]B/XP
M^-G:#X]?'C2],\)$.EU\/OV<O#.M?#D:[8X&Q->^*7B#Q-XJ^);8)^9?"4_@
MHD#8'!.Y?T(\#^ _!OPO\(Z)X$\!>%]'\*^$/#EHMCHGA[0K1;#2]-L%X2*&
M%, <C+'.]CU8G!'<KYAR2RL!UZ' 'UY__7TI_88(^A'3UP2,?K^9KCS3.<VS
M647CLTE4Y7=*ZLG;>S:2>^K3:N[6/8X:X1X<X3PCP7#.40R.G:S4$]5YN[?1
M?\.34445P'U(4444 %%%% !1110 4444 %%%% 'R'^V]J_PRT?\ 94^.$_Q4
MN/"-OX>N?AGX\L[ ^-3HQTK_ (263P9KQT((-=_=_P!M_*/(W$R@+(!\I;/J
M7[.W_)OOP(_[(_\ ##_U"]!K@_VP/%5OX3_9A^.=[<:/XLUU+CX5>/M(6V\%
M>&]5\4:I&^K^#=>A75I-%T.1[AM'C;)EFZ(P9&8N<UWG[.W_ ";[\"/^R/\
MPP_]0O0: /:J*** "BBB@"H/N?\  $_]%J/Y\5X[\9I1:_"[XEW7_/OX \>L
M.,X_XDNI <_C7L _U /<1H?Q^6O ?VDY_LWP'^,UT!_JOAOXZ/;.3I!7V[,3
M^8I5WRX>IVLX_>IK]3OR3#_6^(<APO\ /Q5PJO\ P+B?"+OW?],_/;_@B7?B
M7]CBPT:>4&X\-^-O$@O#GJVLRMXAYST^76U/_ :_8AL^8&':,C\N!^?>OQ7_
M ."-#+IW@3XS>%QS!:>)? VLCGOKGPS\/1M^NAL!R.#GUQ^U1'&[IE#G\6
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MKX:N/^4E&G?]F/:M_P"K^T"ON6@ HHHH **** "BBB@ HHHH **** "BBB@
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M)G.<\)?V#DCBO]:O:-\4\70C?W*5%Q4*=[I2<4G-*\M3^D/=G((S_N\_R/\
M6F_)_M?I7XQZ'K?Q$\(B#_A"/BU\2/#<%NIT^TTNYUD^-/#E@IS@#1_'Q\6.
MN,DJ58%6R00<&O?O"G[7OCKPXMG;?%WPC;>(]&C*$^-OA7:ZR^JV@0JH&O\
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MU/J?I"X>-#CO+,2K?ON#.$&VMKPHUJ%K^7L[=-;EJBBBOI#\/"BBB@ HHHH
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MQ-@^,?\ ;&E> ]+^)WC'Q#X(^"GC+XD?#3X:>!->UDZ#H7C3XJ>./#_/P_\
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M2/V7_$WQ'^&?BS]K+QCXD^!N@Z9X%\:#7OBO_8?PL\0>(_\ A61_X1/PX/\
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MZ!X#\=:UH>N>(/#?A$^(/#OA/Q'KFA^%S_Q1_']O]:V/!_[6G[-GCSQ1X?\
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M:=%5HSX-\90H_BOP7*[>5*\;*L?Y@_"7XVS^-M>\0?"OXC>!];^"?[1'@/\
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M=^Q-X^\0_&?]CVQMO%O@[QEK']M_'?\ 9%\0:R--\->.R.=<\:_ X$%?A_\
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M,_BSSQ;)X:_:)\#F\NO^H7KC)X?(/3C&O]?3MGFOZ%;>/:A]$BS]<RL".GH
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MK.E>)=+M]5T.^%SI]U_TY_V8;#5/^@+KFA_\R_XB&/\ D5JT*_G(^?"BBB@
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MN/%5GJVH:2-*_P"$.UTZOOCT/_2!*8@<;0(P5EW@?NZ[?]G;_DWWX$?]D?\
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M7Q\^&=I9^(?#_P ;M*^T_P!JZ#XE\,:AXB^;_B6V'AG1.6UDK@8^7'.2<Y!
MQDXX+(\ES_!9KD&;J,%GL%]7E2M+V?%2C&%":4M%S1YZ3W3BTFGSQ:^:SOBW
MB_P^SCA'Q!X-7-'(.,;<:1?PRX/NGQBI*ZNE*TUU4HQDMF?T&1A<$@CCCCG'
MO_GWJ0$$<<CI7.Z3>17^FVEY$?.BN+:QN8V'4JX217 [G!![#@]JV$ERAR,>
MH'UQ_P#K'TK^1VK.WIKZ_P##G^NN'K_6<*L4DK-7Z=;?YKR+=%-_C_X#_6H?
M-'FX[8Q[X_\ U]OUQ4G0?$5Q_P I*-._[,>U;_U?V@5]RU\-3_\ *273?^S'
MM4_]7YH-?<M !1110 4444 %%%% 'BG_  I'X._\++_X7'_PK3P+_P +=^R?
M9?\ A97_  CNC_\ "=?V=_9G]B_9/^$B\K_A(/+_ +"_T/R/.V?9_P!SC%:/
MQ*^#GPL^,&BVOA_XK_#SP5\1] L[V/5;72/&WAS1O$NFV.HQ[RNI);:U%+$C
MH#@O'&LA &25 "^J?)_M?I1\G^U^E<WL,/V7GMK_ .2F'U:C_)OOM_E_6G8S
M--TS3]%L+'3-+L;;3]/TZU%I9V=J-MC9V*;=J(,(NW:@VCKU).,L=FBBNDW"
MBBB@ HHHH **** "BBB@"KM8HI/53Q[]3ZX^G7TSV'X:_P#!3C_@B?\ #3_@
MHC\4O 7QG3XQ>+O@7\1O#7AMO ?BO4_"OAW1/$NF^.O!/]N_VUHD&L:/KYDC
MCUSPU)-JCV/B(SM*PN1$(D6!(T_<I6B,9PQVC&3CD=??U/X^_-0K)&?E$O&<
M88$_3KD''M_A7/BL)0Q>&EA,6N:#M=6:LT[IWLTMVNE[L]3(N(\YX4S:GG60
MYK4R3.*:?)5IM7LU9W5TFMG9IJZB]UK_ #J?";_@V=_X)\^"6M9_BEJ'QV^/
M][;</_PL+XD2>'?#]V<< Z!\/(?"D:D'J3+TZ>M?J=\&/^"=/[#'[/%O'%\(
M/V3O@5X,N+1=UGJUK\/-"U3Q&G^[K^NP:]XB;KAMUUQSP:^X?)"@\9X/WFV_
MH ,C_P"OUJNY*GY7MT^O./Q(/]/UK'#9;@,'I@\LA'UY4_QE-_UMM;OSOC;C
M/B.SS[B[BG.]_P"+B9M6?E'EB]EJT_)K5.W#$(1Y74'GTZ8_S_CS5FBBNX^<
M"BBB@ HHHH **** "BBB@ HHHH **** "ODKX\_&KXE_"GQ+\*-.\ _!;Q-\
M6-(\?^(UTCQ-JN@17JGPM&VK>&-%S-)%$\.C8AUS5_$33>(I!"8/#WB) WFQ
M^8/K6B@#\T_VZOVQ?V9OA9\//C?\&_B;X].G?$?5O@IXONM(\(KX$^(GB5+I
MM;\'Z\NB$/X>\*^*O#[F1T^<,QPP_>*&4;>G^!/[8O[,&D? WX,Z7JOQL\#:
M?J&F?"KX86%[:75^0UEJ7_"%:%\K?)QRW W$ DG(R0?T%K,_L?3?^@?8?^ D
M= 'RS<?MP?LC:79W-[JO[17POTO3[,?Z5?:SXFCTW3[1L<F35]9\J$]P#O'K
MM7)-4YOV[OV0+:XN()?VC?A1;SV>H:-IMY;W'B6V5K/4=?+'0M)96V[=:U[S
M&$4>YI6PP$3D*TG<?M'_  4^!OQM^#'C#X8_'GP]HVH?"/Q4?#/_  E^FWMU
M)H$5Z^A>+]!\0:!]HU;1I(IT3_A)=&T-A'#)&Q*(IE16*'Y@\4?M@?LR#QIX
MI^%5OX+N[CXG/\2I/ %X-3^%^E+IX^)_@?7/ 6@^ ]:UJ;67@.NJ->\<^!QX
M&\2_O?+<AA<>%-BR,'.>T1?MV_L=32VUO%^T?\)+N:\NM4T.UME\5Z3NO-7T
M-A_;6B(#LSX@C4D'0-PN24&V'YOEKZG^WG^QUINGW&IS_M$_"][<.]G&UKXF
MAOCJ&JA9B-%T<HA.MZZ?D4>'( ]SEP3"@5R=G]FSPK\0KOP!;ZM^T%\._A=H
M7Q&LOB)X\UO16\(^&=(LWETS6=7N%T3QC.A0R:%X_P#%'AYX7\:>1*MQ)/F-
MF50XD]HTOX9> ]$M[:WTOP1X3T^*W\3ZGXUMX(?#ND)'8>*-;U275]8UZ-5C
M('B&YGU;5)&UV!EEC>X<EF!"2@'XQ?M?_P#!2+X+?$#P%K?PG^"OQ(T4KXNT
M34]%\=?$O44USPYIOPSL"=(4:+YDOAYC_P +#\417!C\%>'%5)KI]TDIC0B$
M_$NC_M<?L[^ GMO"%SXE\$_#6>TM-*L]!\+^(?&?A'P[JCZ6  ,CQ$WA)5P%
M  50 !P*_IR_X0?PE=C4/M'AGP],VN76GW^MK<:'H\@U?4M(6%]*U/5I(HE$
MYMO[,A6W,D9VE55 O(KY#^,?_!-?]A[]H[Q%\9O%_P ;OV>/A_\ $;Q+\>/A
M_P"%/AK\2/$7B2SNKO4;_P ->!5UI?!O]B.]VB>"-?\ #,?B&[-EXG\(KX;\
M3K*D$HN@UO%M]+#5.$;RQ.,X0GG_ +JA**XMJPC*/,Y*+<8.,WS6=G+5I.VB
MOS_V]XLT,JR7)^&_$6GP#E%.M/$<4OA+A&CB)<7SE"5+GXF?%TZWLHJCS0BJ
M*C:$YP4I.<W+\ _!_P 9_ $VJ7\'A7]I/X77/B"ZL_MO_"/>'OB3HOC;[?JG
M_8#\/_R],UVWAG]J/6/A5\7=2^-&C>,?AQ->/X:?X8:UX=U2ZU35=+U$2:QH
M6N:-H>OZQHL4L&B:_(LCKX,CEBDC=?$+94]:_2OX$_LQ?\$N_@/^T=\)?@=\
M&?V=]!\"?&;]EK2_$VC_  W\4V'AW5(M:TH:]\,QK7B'1-?^(,]T_B#XC2/\
M/_BJQD;Q=/XH,:^(659%F4$_JB_@7P8PU1+SPKX8NH-4U?3]?U>.72-.D^WZ
MOHPT.72-3U*(VZ"?5K=M"\/FWN)O,DCBT;1!&8HK6)%^_P \\0<-Q0^;B/@W
MA*<XM."IP;;DM;*3:CS1T;WLVN\6_P 9X.\)>(_#2+7 7BYQGPY12Q#J\)3J
M?ZW<&<74^*K3E4XPX1XLE)MOEC4BZ->E.*@I\\7&-ORKO?\ @L-\&+2:>TG^
M'_B-?$MG8:=<:OIMUXCT<:?8QLX==7:;/VG_ (1I, #Q,GA9$/=0 @75T#_@
ML7^S3J>MP:?K5CXH\+1#3VU:ZN-9LOMVHV.F.<MK9TGP^L\@\-X)V^)-C1'[
MI4#YE_4?5O ?@K7AK5MJWAKPWJ<7B/2(O#?B!+O0M)OWUKPVZ2(=$U<26["Y
MT:578?996:)6VX0$\V4\&^%%:(Q>&_#2K_PC\OA;9'X>THJ_AL9(T(N8]R^'
MH^O]@AA;* "(<D5\O0S3@])K_5"HKQ=FN*ZTFN:+V_=R6VUTXWW3BV?19EP[
MXC8RSP'B+2R7WJ>BX0HS_A22J_%-?\E+:]11<7"S5.478^%KG_@JW^P?;V_V
MU_C[H+VJ65EJ]U.GASQCMM='=LKK<F[PP@7P^1D'Q"";8$CYL*F,>3_@K!^Q
MK-XAN-,TGXD'Q%HMK:#[7XP\/^'_ !AXC\-KJGF;3HAG\/\ AVY1=<*8?8BD
MA?D'S?*/OW_A _!4J30?\(EX2,%QI6GZ)<6XT?2BLFCZ0V=)TAT:W*-I%MA_
M)LW0Q("%0(JA4^ X?BQ^QU^PJ/B=\+= \*^)_",,'Q-U'XM^.+'2] UKQ!I]
MSX^_:&D^('Q:\8>+-,UK6C,LJO%X*\;^(;Y4G2*+[,L5M$4D+1^70K92M<9E
M4Y.S7*ZMEKKS74&[K2R>EKZ72;^CS'+N+<5'_8>+H9)[T6K<)1J-K2Z;]J[)
MK6]N;2RE&[O\M^+?^"J_P]G\9^%]?\#7TB> O"[:A:^+=/\ $>B:WIWB3QS'
MK/F:%H"Z"A\/Y _>MXE8JR.\*QQLQ"U\Y?&[]MB[^,/C/1M1O/&UE\(/AWI5
MC%9VEU9+KE_K]AIOC*.-=775(M$T&?[-KL9C!BA5RL; R!FE=W/[?_!>7XX:
MSJ?Q6E^,FB^%M*\-P>+M-7X1W6D:9INEWU_X2_LB"2X;Q!'!XF\5J;F/7 Y@
M!=&7>[!7087Z!-AIHQ)]BL/)V $"2T6# XSY;#C/7H#G)R*^_P @X]RGA]0Q
MF#X X:GGM/#SH1JU\17KM.7,U4E&K^ZJ5USMQK3HOEBE3]GR7B?@7&OT=>(N
M/\+]0XI\<>-UP_G7%E/BOBKA.CAN%.%[T8*/)A83P\*M6C2@Z:?LI5.3G7.[
MSNU^!.C?M _L6PR_#K5;'XN^$]2_X1K2=3\->$-6M;/QEJ6F#3-J*=:&N?\
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M.\EZK[[M^9)11161TA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-q_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ D # 2(  A$! Q$!_\0
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M::NFVLLEF)T:X>)ERXR05(/1<<Y^E96F3^(V\/:N99+EKP(AMV:,Y5R/F !
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MG@8J6P0"23 '08JI!+O7.1S6AI_+R^P% %K:54D+DU-\K#!Q49) JI>WL=E
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M_KNW]*QM?TS5+S5K*XT^XEBC6)HI2DNW;ET).".3M##/:MFQ_P"7G_KNU6Z
M.'.G>,%6Z0WCR!Y,*1*H(7<<%?\ @. 0<=Z;!HGBK9*9+^:.:10[.DXPTFQ%
MP!C@9#>W-=UBB@#BI=,\7K=XAU%C H81$NI.,M]_(Y."N/3%6]-TG6H-;M9[
MRZGN+>)77+3 \LB9R,#(WAL>F:ZJB@"KJ/\ R#;C_<->>7W*DXZ=*]"U/_D&
M7/\ US->?SJ67B@"A']SC@UEWJ3O(#&>0>1GK6B_[HD=0:>#&V#@9Q4RCS*Q
M=.;A)270SK*.6/[W!)^N*NS 8ZU)A%Y(Y%1OF0X&,=J:5E8)S<Y.3ZB6R[=S
M8[UJ::PWS>X%453:N*N:>?G?MP*9!<?UQSTZUS'BI)'M%*'@$\"NF8<G/3TJ
MK- DRE&4%".010!Y?%-#%%(DL!>0]#6UX62478;G;@UN3>&K)Y-Q#J#V%:-M
M8P642I"N!ZGD_C41@HMON;5*SJ1C%I:$@!(/H.U(Y&,8Y%2'_.*BD.:LQ-:W
M;_0XN/X>:8P R!^M-M6S:( >U*1QSS_2@#S_ ,3I+]N=CG&<UCRSI,8EA@\M
M@>37I5YIT-ZF)DR>Q'45FP^'+..7>V6([5#@FU+L;0K2A"4%;4;H ==.P_)S
MD5K*&/+#!]Z5$6(;5  'M2DXYS5F(D9 N8O3=5^4!L@],UF(?WZ?[U:+?,.M
M %+4-S6<H3&XJ>M>:3MY-]F>(R)R"*]2=0<@ ?XUDWNAVUT2[*5;N<=:F4>9
M6-*<W3DIKH<-8%I=0W0KMCW<+Z5Z#&6\M-H)) R15:RT:ULQNC09]:OCA0.
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M *YC^= '44444 %<EXV\5W/AN."&TTR>\FO%=8WC) 1ACJ0#C@D_A76UX_\
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MHG=0",+U4YXX^M '=Z?')%IUO'+())$B4,X8L&..N3R?J:9JU_\ V7H][?\
MEF7[- \VP=6V@G'Z4:3:?8-)M;3RDB\F)4V(Y8+@=B>35ME5U*L 5(P0>A%
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ME<BREQG.#V]<UT0Y%(  , 8'M2T %%%% !1110 4444 %%%% !1110!4L?\
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MH_L#33_R[#_OH_XT >>FW3(.T9^E/*[17??\(_IG_/L/^^C_ (TG_".Z6?\
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J(:'J$(BN;+>@8, )77G\#4FC>%](T"::73;4PO, LA,KOD#I]XF@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>gtbp-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOG+bP9z5Z86ekhvWBxbXlajyEi6tqlJSl05T/28TMG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:GTBP="http://gtbiopharma.com/20250630" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20250630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" id="StatementsOfStockholdersEquityDeficitAndMezzanineEquity">
          <link:definition>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" id="OrganizationAndGoingConcernAnalysis">
          <link:definition>999013 - Disclosure - Organization and Going Concern Analysis</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" id="AccountsPayableAndRelatedParty">
          <link:definition>999015 - Disclosure - Accounts Payable and Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>999016 - Disclosure - Warrant Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
          <link:definition>999017 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" id="CommonStockWarrantsAndOptions">
          <link:definition>999018 - Disclosure - Common Stock Warrants and Options</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999019 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999020 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999021 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" id="AccountsPayableAndRelatedPartyTables">
          <link:definition>999024 - Disclosure - Accounts Payable and Related Party (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>999025 - Disclosure - Warrant Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
          <link:definition>999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" id="CommonStockWarrantsAndOptionsTables">
          <link:definition>999027 - Disclosure - Common Stock Warrants and Options (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999028 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" id="OrganizationAndGoingConcernAnalysisDetailsNarrative">
          <link:definition>999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
          <link:definition>999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
          <link:definition>999032 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" id="ScheduleOfAccountsPayableToRelatedPartyDetails">
          <link:definition>999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" id="AccountsPayableAndRelatedPartyDetailsNarrative">
          <link:definition>999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" id="ScheduleOfWarrantLiabilityAssumptionsDetails">
          <link:definition>999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" id="ScheduleOfWarrantLiabilityTransactionsDetails">
          <link:definition>999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>999037 - Disclosure - Warrant Liability (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" id="ScheduleOfFairValuesAndAllocationOfNetProceedsDetails">
          <link:definition>999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
          <link:definition>999039 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999040 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>999042 - Disclosure - Schedule of Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" id="ScheduleOfOptionsOutstandingAndOptionsExercisableDetails">
          <link:definition>999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" id="CommonStockWarrantsAndOptionsDetailsNarrative">
          <link:definition>999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999045 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" id="ScheduleOfSegmentInformationDetails">
          <link:definition>999046 - Disclosure - Schedule of Segment Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999047 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="GTBP_SeriesLPreferredStockMember" name="SeriesLPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficersEmployeesAndDirectorsMember" name="OfficersEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MezzanineEquityMember" name="MezzanineEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesLConvertiblePreferredStockMember" name="SeriesLConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CytovanceBiologicsIncMember" name="CytovanceBiologicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UniversityOfMinnesotaMember" name="UniversityOfMinnesotaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LegalServicesFirmMember" name="LegalServicesFirmMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OtherAccountsPayableMember" name="OtherAccountsPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" name="TwoThousandTwentyThreeCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" name="TwoThousandTwentyThreePlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeWarrantsMember" name="TwoThousandTwentyThreeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InducementWarrantsMember" name="InducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesAInducementWarrantsMember" name="SeriesAInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesBInducementWarrantsMember" name="SeriesBInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" name="SeriesLTenPercentConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GreenshoeRightsMember" name="GreenshoeRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_VestingWarrantsMember" name="VestingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OmnibusIncentivePlanMember" name="OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeEightMember" name="RangeEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeNineMember" name="RangeNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTenMember" name="RangeTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeElevenMember" name="RangeElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwelveMember" name="RangeTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThirteenMember" name="RangeThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ZOneLLCMember" name="ZOneLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CobySilberfeinMember" name="CobySilberfeinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" name="TwoThousandTwentyThreeSponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" name="TwoThousandSeventeenThroughTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyTwoMember" name="TwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFiveMember" name="TwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" name="TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdvisoryAgreementMember" name="AdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SegmentsMember" name="SegmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" name="SeriesL10PercentageConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" name="StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" name="StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" name="StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" name="StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" name="StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" name="StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfWarrantsForVrtWaiver" name="IssuanceOfWarrantsForVrtWaiver" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GainOnSettlementOfDebt" name="GainOnSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" name="FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" name="FairValueOfPrefundedWarrantsIssuedForElocFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" name="FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DividendOnSeriesLConvertiblePreferredStock" name="DividendOnSeriesLConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" name="DisclosureCommonStockWarrantsAndOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockWarrantsAndOptionsTextBlock" name="CommonStockWarrantsAndOptionsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MezzanineEquityPolicyTextBlock" name="MezzanineEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" name="ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" name="RepaymentsOfPrefundedWarrantsAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfWarrant" name="ExtinguishmentOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" name="ConvertiblePreferredStockAndWarrantsFairValuePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" name="ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" name="WeightedAverageVolumePriceOfCommonStockPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AggregateStatedValue" name="AggregateStatedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiableOfLiquidatedDamagePercentageDescription" name="LiableOfLiquidatedDamagePercentageDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockSharesOutstandingPercentage" name="CommonStockSharesOutstandingPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOne" name="RoyaltyExpenseYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearTwoThroughFive" name="RoyaltyExpenseYearTwoThroughFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterSix" name="RoyaltyExpenseYearAfterSix" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOneThoughFour" name="RoyaltyExpenseYearOneThoughFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterFive" name="RoyaltyExpenseYearAfterFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ContigencyMinimumRequired" name="ContigencyMinimumRequired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreferredStockPurchasePrice" name="PreferredStockPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfWarrantsIssuedForVrtWaiver" name="FairValueOfWarrantsIssuedForVrtWaiver" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>gtbp-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="loc_GTBPIssuanceOfWarrantsForVrtWaiver" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIssuanceOfWarrantsForVrtWaiver" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="loc_GTBPGainOnSettlementOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPGainOnSettlementOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999032 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999037 - Disclosure - Warrant Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999040 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999046 - Disclosure - Schedule of Segment Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999047 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>gtbp-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapRestrictedCashCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapDeferredOfferingCosts_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDividendsPayableCurrent_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_GTBPWarrantLiabilityCurrent_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_50" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPMezzanineEquityMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_70" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999032 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999037 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPMezzanineEquityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPAggregateStatedValue_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_250" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice_250" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_250" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage_250" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock_250" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_250" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_250" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_250" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999040 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeElevenMember" xlink:label="loc_GTBPRangeElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeElevenMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwelveMember" xlink:label="loc_GTBPRangeTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwelveMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThirteenMember" xlink:label="loc_GTBPRangeThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThirteenMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_290" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PrefundedWarrantsMember" xlink:label="loc_GTBPPrefundedWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_190" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ZOneLLCMember" xlink:label="loc_GTBPZOneLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPZOneLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CobySilberfeinMember" xlink:label="loc_GTBPCobySilberfeinMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPCobySilberfeinMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AdvisoryAgreementMember" xlink:label="loc_GTBPAdvisoryAgreementMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPAdvisoryAgreementMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_390" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour_390" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive_390" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt_390" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_390" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_390" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired_390" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999046 - Disclosure - Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999047 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>gtbp-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="GTBP_SeriesLPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLPreferredStockMember" xlink:to="GTBP_SeriesLPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLPreferredStockMember_lbl" xml:lang="en-US">Series L Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityMember" xlink:label="GTBP_MezzanineEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityMember" xlink:to="GTBP_MezzanineEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MezzanineEquityMember_lbl" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="GTBP_CytovanceBiologicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CytovanceBiologicsIncMember_lbl" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="GTBP_UniversityOfMinnesotaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UniversityOfMinnesotaMember_lbl" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LegalServicesFirmMember" xlink:label="GTBP_LegalServicesFirmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LegalServicesFirmMember_lbl" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OtherAccountsPayableMember" xlink:label="GTBP_OtherAccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OtherAccountsPayableMember_lbl" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PurchaseAgreementMember" xlink:label="GTBP_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_InducementWarrantsMember" xlink:label="GTBP_InducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InducementWarrantsMember_lbl" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="GTBP_SeriesAInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesAInducementWarrantsMember_lbl" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="GTBP_SeriesBInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesBInducementWarrantsMember_lbl" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="GTBP_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GreenshoeRightsMember" xlink:label="GTBP_GreenshoeRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GreenshoeRightsMember_lbl" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonWarrantsMember" xlink:label="GTBP_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_VestingWarrantsMember" xlink:label="GTBP_VestingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_VestingWarrantsMember_lbl" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantsMember" xlink:label="GTBP_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PrefundedWarrantsMember" xlink:label="GTBP_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantsMember" xlink:to="GTBP_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="GTBP_OmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeOneMember" xlink:label="GTBP_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeOneMember_lbl" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwoMember" xlink:label="GTBP_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwoMember_lbl" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThreeMember" xlink:label="GTBP_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThreeMember_lbl" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFourMember" xlink:label="GTBP_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFourMember_lbl" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFiveMember" xlink:label="GTBP_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFiveMember_lbl" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSixMember" xlink:label="GTBP_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSixMember_lbl" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSevenMember" xlink:label="GTBP_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSevenMember_lbl" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeEightMember" xlink:label="GTBP_RangeEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeEightMember_lbl" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeNineMember" xlink:label="GTBP_RangeNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeNineMember_lbl" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTenMember" xlink:label="GTBP_RangeTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTenMember_lbl" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeElevenMember" xlink:label="GTBP_RangeElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeElevenMember" xlink:to="GTBP_RangeElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeElevenMember_lbl" xml:lang="en-US">Range of Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwelveMember" xlink:label="GTBP_RangeTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwelveMember" xlink:to="GTBP_RangeTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwelveMember_lbl" xml:lang="en-US">Range of Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThirteenMember" xlink:label="GTBP_RangeThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThirteenMember" xlink:to="GTBP_RangeThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThirteenMember_lbl" xml:lang="en-US">Range of Exercise Price Thirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ZOneLLCMember" xlink:label="GTBP_ZOneLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ZOneLLCMember" xlink:to="GTBP_ZOneLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ZOneLLCMember_lbl" xml:lang="en-US">Z One L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CobySilberfeinMember" xlink:label="GTBP_CobySilberfeinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CobySilberfeinMember" xlink:to="GTBP_CobySilberfeinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CobySilberfeinMember_lbl" xml:lang="en-US">Coby Silberfein [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Exclusive Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="GTBP_TwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="GTBP_TwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="GTBP_TwoThousandTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentySevenMember_lbl" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AdvisoryAgreementMember" xlink:label="GTBP_AdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdvisoryAgreementMember" xlink:to="GTBP_AdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AdvisoryAgreementMember_lbl" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SegmentsMember" xlink:label="GTBP_SegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SegmentsMember_lbl" xml:lang="en-US">Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Dividend payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="GTBP_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_lbl" xml:lang="en-US">Mezzanine Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series L - 6,301 and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 250,000,000 shares authorized, 3,272,995 and 2,234,328 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative (including $4,000 and $120,000 from stock compensation for the three months ended June 30, 2025 and 2024, respectively, and $7,000 and $222,000 for the six months ended June 30, 2025 and 2024, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividends on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Loss attributable to common stockholders&#8217;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xml:lang="en-US">Mezzanine equity balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Series L convertible preferred stock and warrants issued for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Series L convertible preferred stock and warrants issued for cash, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series L convertible preferred stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series L convertible preferred stock into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xml:lang="en-US">Issuance and exercise of prefunded warrants for ELOC fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xml:lang="en-US">Issuance and exercise of prefunded warrants for ELOC fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock and warrants for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock and warrants for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of warrants for VRT waiver</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividend on Series L convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of prefunded warrants in settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_lbl" xml:lang="en-US">Issuance of common stock and warrants for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_lbl" xml:lang="en-US">Issuance of common stock and warrants for cash, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CFO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CFO, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of common stock in settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of common stock in settlement of vendor payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_3_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xml:lang="en-US">Mezzanine equity balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_lbl" xml:lang="en-US">Issuance of warrants for VRT waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="GTBP_GainOnSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GainOnSettlementOfDebt" xlink:to="GTBP_GainOnSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_GainOnSettlementOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) Decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">(Increase) in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sale of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants and issuance of inducement warrants for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series L convertible preferred stock and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase in Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" xlink:label="GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" xlink:to="GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction_lbl" xml:lang="en-US">Fair value of vested warrants issued in Series L conv. preferred stock transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:to="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_lbl" xml:lang="en-US">Fair value of prefunded warrants issued for ELOC fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Fair value of common stock and warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" xlink:label="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable_lbl" xml:lang="en-US">Fair value of prefunded warrant or common stock to settle vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DividendOnSeriesLConvertiblePreferredStock" xlink:label="GTBP_DividendOnSeriesLConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DividendOnSeriesLConvertiblePreferredStock" xlink:to="GTBP_DividendOnSeriesLConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DividendOnSeriesLConvertiblePreferredStock_lbl" xml:lang="en-US">Dividend on Series L convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of Series L convertible preferred stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Going Concern Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="GTBP_WarrantLiabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xml:lang="en-US">Common Stock Warrants And Options</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xml:lang="en-US">Common Stock Warrants and Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityPolicyTextBlock" xlink:label="GTBP_MezzanineEquityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityPolicyTextBlock" xlink:to="GTBP_MezzanineEquityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_MezzanineEquityPolicyTextBlock_lbl" xml:lang="en-US">Mezzanine Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable to Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:to="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xml:lang="en-US">Schedule of fair values and allocation of net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding and Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Accounts payable interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Invoices, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payments in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Payments in common stock, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_2_lbl" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_2_lbl" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Prior year unpaid fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Liability Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_WarrantLiabilityCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="GTBP_ExtinguishmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfWarrant_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_WarrantLiabilityCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility amount utilized in the value calculation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_lbl" xml:lang="en-US">Convertible preferred stock and warrants fair value percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_lbl" xml:lang="en-US">Convertible preferred stock and warrants net proceeds percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Warrants to purcahse</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xml:lang="en-US">Weighted average volume price of common stock percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Placement agents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xml:lang="en-US">Issuance of warrants, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Equity issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AggregateStatedValue" xlink:label="GTBP_AggregateStatedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AggregateStatedValue_lbl" xml:lang="en-US">Aggregate stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Issuance of shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Percentage of dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Aggregate number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Aggregate number of shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="us-gaap_DerivativeFloorPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFloorPrice" xlink:to="us-gaap_DerivativeFloorPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFloorPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xml:lang="en-US">Liable of liquidated damage percentage, description</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="GTBP_CommonStockSharesOutstandingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_lbl" xml:lang="en-US">Common stock shares outstanding percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xml:lang="en-US">Dividends to holders unpaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of warrants, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Warrants weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants outstanding, weighted average remaining contractual life (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xml:lang="en-US">Schedule Of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-Average Exercise Price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options outstanding exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price,exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Range of excercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding vested intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options outstanding exercisable intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFloorPrice" xlink:to="us-gaap_DerivativeFloorPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFloorPrice_2_lbl" xml:lang="en-US">Floor price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of new shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3_lbl" xml:lang="en-US">Number shares issued for service, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Common stock awards granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Stock option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Rstricted stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Rstricted stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options vested and exercisable intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Stock option, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock option, unvested compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Damages paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Damages sought value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Aggregate research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Payments of research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US">Unbilled and unaccrued amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Proceeds from upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">License maintenance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">Royalty fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">One-time sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cumulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="GTBP_RoyaltyExpenseYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOne_lbl" xml:lang="en-US">Royalty expense year one</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xml:lang="en-US">Royalty expense years two through five</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="GTBP_RoyaltyExpenseYearAfterSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_lbl" xml:lang="en-US">Royalty expense year six and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xml:lang="en-US">Royalty expense year one though four</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="GTBP_RoyaltyExpenseYearAfterFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_lbl" xml:lang="en-US">Royalty expense year five and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="us-gaap_RepaymentsOfOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ContigencyMinimumRequired" xlink:label="GTBP_ContigencyMinimumRequired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ContigencyMinimumRequired_lbl" xml:lang="en-US">Contigency minimum required</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceCommissions_lbl" xml:lang="en-US">Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="GTBP_PreferredStockPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreferredStockPurchasePrice" xlink:to="GTBP_PreferredStockPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PreferredStockPurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityCurrent_doc" xml:lang="en-US">Warrant liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLPreferredStockMember" xlink:to="GTBP_SeriesLPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLPreferredStockMember_doc" xml:lang="en-US">Series L Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_doc" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xml:lang="en-US">Stock issued during period value issuance and exercise of prefunded warrants for eloc fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_doc" xml:lang="en-US">Stock issued during period value common shares to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_doc" xml:lang="en-US">Stock issued during period shares common shares to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_doc" xml:lang="en-US">Stock issued during period share issuance of common stock and warrants for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_doc" xml:lang="en-US">Stock issued during period value issuance of common stock and warrants for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during year for</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_doc" xml:lang="en-US">Issuance of warrants for vrt waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xml:lang="en-US">Decrease in operating lease right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:to="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_doc" xml:lang="en-US">Fair value of prefunded warrants issued for eloc fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfWarrantsIssuedForVrtWaiver" xlink:label="GTBP_FairValueOfWarrantsIssuedForVrtWaiver" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfWarrantsIssuedForVrtWaiver" xlink:to="GTBP_FairValueOfWarrantsIssuedForVrtWaiver_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfWarrantsIssuedForVrtWaiver_doc" xml:lang="en-US">Fair value of warrants issued for vrt waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable_doc" xml:lang="en-US">Fair value of prefunded warrant or common stock to settle vendor payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xml:lang="en-US">Stock issued during period shares issuance and exercise of prefunded warrants for eloc fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CytovanceBiologicsIncMember_doc" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityPolicyTextBlock" xlink:to="GTBP_MezzanineEquityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MezzanineEquityPolicyTextBlock_doc" xml:lang="en-US">Mezzanine Equity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UniversityOfMinnesotaMember_doc" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyTwoMember_doc" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LegalServicesFirmMember_doc" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFiveMember_doc" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OtherAccountsPayableMember_doc" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentySevenMember_doc" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOne_doc" xml:lang="en-US">Royalty expense year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xml:lang="en-US">Royalty expense year two through five.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_doc" xml:lang="en-US">Royalty expense year after six.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xml:lang="en-US">Schedule of Accounts Payable and Related Party [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xml:lang="en-US">Repayments of prefunded warrants at fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xml:lang="en-US">Royalty expense year one though four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_doc" xml:lang="en-US">Royalty expense year five and thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ContigencyMinimumRequired_doc" xml:lang="en-US">Contigency minimum required.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SegmentsMember_doc" xml:lang="en-US">Segments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityTextBlock_doc" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfWarrant_doc" xml:lang="en-US">Extinguishment of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xml:lang="en-US">Weighted average volume price of common stock percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AggregateStatedValue_doc" xml:lang="en-US">Aggregate stated value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GreenshoeRightsMember_doc" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_VestingWarrantsMember_doc" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xml:lang="en-US">Liable of liquidated damage percentage, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_doc" xml:lang="en-US">Common stock shares outstanding percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_doc" xml:lang="en-US">Convertible preferred stock and warrants fair value percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_doc" xml:lang="en-US">Convertible preferred stock and warrants net proceeds percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xml:lang="en-US">Common Stock Warrants and Options [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantsMember" xlink:to="GTBP_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PrefundedWarrantsMember_doc" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsMember_doc" xml:lang="en-US">custom:WarrantsMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of Warrants Oustanding and Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeOneMember_doc" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwoMember_doc" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThreeMember_doc" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFourMember_doc" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFiveMember_doc" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSixMember_doc" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSevenMember_doc" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeEightMember_doc" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeNineMember_doc" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTenMember_doc" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeElevenMember" xlink:to="GTBP_RangeElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeElevenMember_doc" xml:lang="en-US">Range of Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwelveMember" xlink:to="GTBP_RangeTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwelveMember_doc" xml:lang="en-US">Range of Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThirteenMember" xlink:to="GTBP_RangeThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThirteenMember_doc" xml:lang="en-US">Range of Exercise Price Thirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OmnibusIncentivePlanMember_doc" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InducementWarrantsMember_doc" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesAInducementWarrantsMember_doc" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesBInducementWarrantsMember_doc" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options non vested in period fair value 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityMember" xlink:to="GTBP_MezzanineEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MezzanineEquityMember_doc" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreferredStockPurchasePrice" xlink:to="GTBP_PreferredStockPurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreferredStockPurchasePrice_doc" xml:lang="en-US">Preferred stock purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdvisoryAgreementMember" xlink:to="GTBP_AdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdvisoryAgreementMember_doc" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_3_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_3_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_3_lbl" xml:lang="en-US">Issuance of warrants for vrt waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GainOnSettlementOfDebt" xlink:to="GTBP_GainOnSettlementOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GainOnSettlementOfDebt_2_lbl" xml:lang="en-US">GainOnSettlementOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseRightofuseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_2_lbl" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityTextBlock_3_lbl" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityPolicyTextBlock" xlink:to="GTBP_MezzanineEquityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MezzanineEquityPolicyTextBlock_3_lbl" xml:lang="en-US">Mezzanine Equity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_4_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_2_lbl" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>gtbp-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_GTBPMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="loc_GTBPIssuanceOfWarrantsForVrtWaiver" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPIssuanceOfWarrantsForVrtWaiver" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="loc_GTBPGainOnSettlementOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPGainOnSettlementOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" xlink:label="loc_GTBPFairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:label="loc_GTBPFairValueOfPrefundedWarrantsIssuedForElocFee" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfPrefundedWarrantsIssuedForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" xlink:label="loc_GTBPFairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DividendOnSeriesLConvertiblePreferredStock" xlink:label="loc_GTBPDividendOnSeriesLConvertiblePreferredStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPDividendOnSeriesLConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="loc_GTBPWarrantLiabilityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="loc_us-gaapCapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="loc_GTBPWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityPolicyTextBlock" xlink:label="loc_GTBPMezzanineEquityPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPMezzanineEquityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="loc_us-gaapScheduleOfConversionsOfStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfConversionsOfStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999032 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="loc_GTBPExtinguishmentOfWarrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPExtinguishmentOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999037 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999039 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPAggregateStatedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999040 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeElevenMember" xlink:label="loc_GTBPRangeElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwelveMember" xlink:label="loc_GTBPRangeTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThirteenMember" xlink:label="loc_GTBPRangeThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999042 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PrefundedWarrantsMember" xlink:label="loc_GTBPPrefundedWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ZOneLLCMember" xlink:label="loc_GTBPZOneLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPZOneLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CobySilberfeinMember" xlink:label="loc_GTBPCobySilberfeinMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPCobySilberfeinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_AdvisoryAgreementMember" xlink:label="loc_GTBPAdvisoryAgreementMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999046 - Disclosure - Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999047 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250630.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Montgomery Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,557,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,228,000<span></span>
</td>
<td class="nump">$ 3,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,043,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL ASSETS</a></td>
<td class="nump">7,124,000<span></span>
</td>
<td class="nump">4,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,374,000<span></span>
</td>
<td class="nump">3,853,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">608,000<span></span>
</td>
<td class="nump">1,797,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,307,000<span></span>
</td>
<td class="nump">5,902,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 250,000,000 shares authorized, 3,272,995 and 2,234,328 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">700,378,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(697,521,000)<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">2,861,000<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</a></td>
<td class="nump">7,124,000<span></span>
</td>
<td class="nump">4,232,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Mezzanine Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series L - 6,301 and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">$ 1,956,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,272,995<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,272,995<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, shares issued</a></td>
<td class="nump">6,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, shares outstanding</a></td>
<td class="nump">6,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">1,784,000<span></span>
</td>
<td class="nump">1,462,000<span></span>
</td>
<td class="nump">2,561,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including $4,000 and $120,000 from stock compensation for the three months ended June 30, 2025 and 2024, respectively, and $7,000 and $222,000 for the six months ended June 30, 2025 and 2024, respectively)</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="nump">2,122,000<span></span>
</td>
<td class="nump">1,983,000<span></span>
</td>
<td class="nump">4,436,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(1,513,000)<span></span>
</td>
<td class="num">(3,906,000)<span></span>
</td>
<td class="num">(3,445,000)<span></span>
</td>
<td class="num">(6,997,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">247,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(114,000)<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">775,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">998,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), Net</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="nump">1,236,000<span></span>
</td>
<td class="nump">1,021,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(1,433,000)<span></span>
</td>
<td class="num">(3,710,000)<span></span>
</td>
<td class="num">(2,209,000)<span></span>
</td>
<td class="num">(5,976,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividends on preferred stock</a></td>
<td class="num">(85,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss attributable to common stockholders&#8217;</a></td>
<td class="num">$ (1,518,000)<span></span>
</td>
<td class="num">$ (3,710,000)<span></span>
</td>
<td class="num">$ (2,294,000)<span></span>
</td>
<td class="num">$ (5,976,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.17)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.17)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">2,771,765<span></span>
</td>
<td class="nump">1,711,955<span></span>
</td>
<td class="nump">2,559,604<span></span>
</td>
<td class="nump">1,546,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">2,771,765<span></span>
</td>
<td class="nump">1,711,955<span></span>
</td>
<td class="nump">2,559,604<span></span>
</td>
<td class="nump">1,546,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series L Preferred Stock [Member]</div></th>
<th class="th">
<div>Mezzanine Equity [Member] </div>
<div>Series L Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 689,539,000<span></span>
</td>
<td class="num">$ (682,065,000)<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">1,380,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,976,000)<span></span>
</td>
<td class="num">(5,976,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrants in settlement of vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">2,975,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,546,000<span></span>
</td>
<td class="num">(688,041,000)<span></span>
</td>
<td class="nump">5,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,234,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">689,641,000<span></span>
</td>
<td class="num">(684,331,000)<span></span>
</td>
<td class="nump">5,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">1,380,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,710,000)<span></span>
</td>
<td class="num">(3,710,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">2,975,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,546,000<span></span>
</td>
<td class="num">(688,041,000)<span></span>
</td>
<td class="nump">5,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,234,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,051,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (96,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock and warrants for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of warrants for VRT waiver</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on Series L convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,209,000)<span></span>
</td>
<td class="num">(2,209,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrants in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">700,378,000<span></span>
</td>
<td class="num">(697,521,000)<span></span>
</td>
<td class="nump">2,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">3,272,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,956,000<span></span>
</td>
<td class="nump">$ 1,956,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">695,019,000<span></span>
</td>
<td class="num">(696,003,000)<span></span>
</td>
<td class="num">(980,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">2,536,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">436,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">436,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (96,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock and warrants for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of warrants for VRT waiver</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on Series L convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,433,000)<span></span>
</td>
<td class="num">(1,433,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 700,378,000<span></span>
</td>
<td class="num">$ (697,521,000)<span></span>
</td>
<td class="nump">$ 2,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">3,272,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,956,000<span></span>
</td>
<td class="nump">$ 1,956,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share issuance of common stock and warrants for cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance and exercise of prefunded warrants for eloc fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance and exercise of prefunded warrants for eloc fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and warrants for cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of prefunded warrant to settle vendor payable, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,433,000)<span></span>
</td>
<td class="num">$ (3,710,000)<span></span>
</td>
<td class="num">$ (2,209,000)<span></span>
</td>
<td class="num">$ (5,976,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IssuanceOfWarrantsForVrtWaiver', window );">Issuance of warrants for VRT waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">114,000<span></span>
</td>
<td class="num">(117,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="num">(775,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(998,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GainOnSettlementOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) Decrease in prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,623,000)<span></span>
</td>
<td class="num">(1,231,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">(Increase) in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,216,000)<span></span>
</td>
<td class="num">(7,699,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sale of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants and issuance of inducement warrants for cash, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series L convertible preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,441,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,493,000<span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase in Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,000<span></span>
</td>
<td class="nump">8,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,044,000<span></span>
</td>
<td class="nump">1,079,000<span></span>
</td>
<td class="nump">$ 1,079,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">$ 5,321,000<span></span>
</td>
<td class="nump">$ 9,249,000<span></span>
</td>
<td class="nump">5,321,000<span></span>
</td>
<td class="nump">9,249,000<span></span>
</td>
<td class="nump">$ 4,044,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction', window );">Fair value of vested warrants issued in Series L conv. preferred stock transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee', window );">Fair value of prefunded warrants issued for ELOC fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock and warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable', window );">Fair value of prefunded warrant or common stock to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DividendOnSeriesLConvertiblePreferredStock', window );">Dividend on Series L convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Series L convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DividendOnSeriesLConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DividendOnSeriesLConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of prefunded warrant or common stock to settle vendor payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of prefunded warrants issued for eloc fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GainOnSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GainOnSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfWarrantsForVrtWaiver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants for vrt waiver</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfWarrantsForVrtWaiver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,433,000)<span></span>
</td>
<td class="num">$ (3,710,000)<span></span>
</td>
<td class="num">$ (2,209,000)<span></span>
</td>
<td class="num">$ (5,976,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Going Concern Analysis</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zLEV62EVlkn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_z9TKPvbm3UX3">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The
Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future.
Historically, the Company has financed its operations through public and private sales of common stock, the issuance of preferred
and common stock, the issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30,
2025, the Company recorded a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zpENKaWznPqb" title="Net loss">2.2</span>
million and used cash in operations of approximately $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zlO6G3zoUVT3" title="Net cash used in operating activities">5.2</span>
million. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of
the date that the financial statements are issued. In addition, the Company&#8217;s independent registered public accounting firm,
in its report on the Company&#8217;s December 31, 2024, financial statements, raised substantial doubt about the Company&#8217;s
ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zbhqx6OdlYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_824_z2ZMo578HY9a">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1yDj5UG7pt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zR6OwY5RDU07">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--UseOfEstimates_zhEdzgSn4ROd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z7BcxPB2Ntg2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4SjGrr2hpN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zC5etwP6Mndk">Cash
Equivalents</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At June 30, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_zlw5dHhPhBak" title="Cash equivalents">4.9</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zTHlkxQTmVR6" title="Cash equivalents">3.8</span> million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zuLfr8H4lvzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zpLohf8KFOt1">Restricted
Cash</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The
Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the
same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zrw9QSB92Pmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z9tYdQmnwDFj">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses.&#160;As of June 30, 2025, there was $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250630_z39qRWhw9aui" title="Deferred offering costs">0.8</span>&#160;million of deferred offering costs on the consolidated balance
sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBNOjN3ZtlO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zNr1pr6PKkog">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_900_ecustom--WarrantLiabilityCurrent_iI_c20250630_zeY6Pis1mQQg" title="Warrant liability">240,000</span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_z95d9INiBjZ6" title="Warrant liability">252,000</span> at June 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zzjREssO3MYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z0SMOmeygsmk">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--MezzanineEquityPolicyTextBlock_zhhC9ZWZiqCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfB9zpdQRTsf">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z5VdWMBCHuWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zdDJNBitkyR">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVFnZfwbYQCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B5_zSKXQcRn5Ve">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z79HEwK8goC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zTcM4jjU8cec">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z8nUnOa1arL9" style="display: none">Schedule of Anti-dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible
    preferred stock <b><sup id="xdx_F4E_zNIpjxvAfxFj">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,084,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,751,669</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,133,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,960,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,260,027</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share">2.043</span> per share, as of June 30, 2025</span></td>
</tr></table>

<p id="xdx_8AB_zHlsfpWsJME3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z68Myz1d8pI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ztAeaEzQPvtf">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20250630_zxroiafA4Vy7" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2yEebsh9Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zp5MBuogswXa">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztoQDRMqA6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zabjQIR5FpHc">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_854_zSphDe2DYUz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Related Party</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFyidnjsY8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82F_zeNVb29eQlfi">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLoADPOTcSZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z5xdaPWmqwL6" style="display: none">Schedule of Accounts Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250630_zqT9xxd4ApCb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zAQeoUhxNx27" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, <br/>
    2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zn3m6wkeYMui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to Cytovance, a related party <b><sup id="xdx_F42_zWvCot73Bpz4">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zlF7tyJeMuH7" title="Accounts payable interest rate">44</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zn43xrZCRtr1" title="Accounts payable interest rate">31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zNbhlRSfuPb5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University
    of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">432,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zD4p7hdqONKa" title="Accounts payable interest rate">31</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">712,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zx9a0O4DQCL3" title="Accounts payable interest rate">18</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z3qTuviRILM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zYBl9cG3c2xf" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zi6GWXtUKJge" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zRjY8xRkQrs5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zMdk2AEfa6f1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">344,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zcWnGQ4VuzWb" title="Accounts payable interest rate">25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNUhi0cHgKul" title="Accounts payable interest rate">12</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zyUoH1ArR81a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,374,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630_zzldxFzUBNx7" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,853,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zfUyh2Qpl2Hg" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F02_zzW27guC4jY5">1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zS1vfydUx7A3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td></tr></table>

<p id="xdx_8AA_zIHPIENRySpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zfPzkRmitlG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B7_z2szJcyXcmNk">Schedule of Accounts Payable to Related Party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250101__20250630_zeZOS0OUYWXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240630_z5rRWGsXn3Nc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zbQUuhGvsRSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,515,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9GeCP6JTmU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">626,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">778,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTM2XvgnEZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(364,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,641,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zH6PoVGKIThl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in common stock,
    at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(810,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIcmYJ9ZRH57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments
    in pre-funded warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(847,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zBF3iIgEViI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">842,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zIhslV6GwNO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and June 2024, the Company issued an aggregate of <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB8ZdmFhN50d" title="Issuance of prefunded warrant to settle vendor payable, shares">127,597</span> shares of common stock with a fair value of approximately $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20240101__20240630_zXo5H3a32y47" title="Issuance of prefunded warrant to settle vendor payable">810,000</span> to
Cytovance as partial payment of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjDXuHDRqfm2" title="Issuance of pre-funded warrants">326,251</span> shares of common stock exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7vYly99QAUd" title="Exercise price">0.0001</span> per share
with a fair value of approximately $<span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zzVzGpSsxzn3" title="Payments in pre-funded warrants, at fair value">847,000</span> to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpLm4km7m4O5" title="Prior year unpaid fees">1</span> million. The Company classified this transaction as other income during the period ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_808_ecustom--WarrantLiabilityTextBlock_zOlz8YeTr0Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_82E_zyauPDLekUS2">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate
of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zovNsnTgRgDk" title="Warrants to purchase">216,667</span> shares of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zWtWlFYy0kL1" title="Warrants to purchase">13,000</span> shares of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_z4lKmWtLNMLg" title="Volatility amount utilized in the value calculation percentage">100</span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zsyEGhgEAUGl" title="Warrant  fair value">5.8</span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zvN0uJtHZ0Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zj5GFkPO6bY1" style="display: none">Schedule of Warrant Liability Assumptions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zMRaoSHMbGci" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zOEchUvwyMma" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zR4NEA7W5L54" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zUghOTnWsWWi" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z7DEEYXKYyrh" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">111</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zUiUML0kgpkj" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____z8DPmaUwmuz6" title="Expected life (in years)">2.5</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zXBAlpEzUHif" title="Expected life (in years)">3.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zP2IqcNqlPej" title="Expected life (in years)">3.0</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zb5TRxpqlamj" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zHDWhiBMoW8l" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zVd24N3s9O86" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zSBeyTu8ftGi" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">240,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zx5PEV1dsO5b" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0B_zMY6SPzd685c"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zPSDqIoGOGi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zbMpmvqZUpyf" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_zM3f9fFjxWu3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0F_z7vjk12pZ6Sa"><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_z4fCAsr4Xz53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F00_z6cW6eqbfiDa">4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_zfI28UCMF0N6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<p id="xdx_8A6_zGCiIYluZunb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLe24w7itmB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zQqix48w7G1l" style="display: none">Schedule of Warrant Liability Transactions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20250630_zhVN18dsfG8j" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20240630_zPEwsW5r4H1e" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zH5wLvB2rDkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,052,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_z94fK3t2S4zf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at
    fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zn1u4FH4ak8b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(775,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zcihmlUBCKf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zd0T0KijeE01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zcMXOpmsNzE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9LePaa2nNHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_827_zspFBQN2pBwk">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of June 30, 2025 was <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_zmTL5pJtTJIf" title="Common stock, shares authorized">250,000,000</span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250630_zpHuDjFmZ4fc" title="Common stock, par value">0.001</span> per share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250630_zEVcGcYZERth" title="Preferred stock, shares authorized">15,000,000</span>
shares of preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630_zmtZZfO8SmW3" title="Preferred stock, par value">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Equity Facility</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#8220;Purchase
Agreement&#8221;) with investors (collectively, the &#8220;Investors&#8221;) relating to a committed equity facility (the
&#8220;Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to
the Investors up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF7eF2GrWFK8" title="Warrants to purcahse">20</span>
million of its common stock subject to certain conditions and limitations set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the
Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market
conditions, the trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of
such shares of common stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and
prices at, which the shares of common stock are sold to the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be <span id="xdx_90C_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7ddTMl6SBce" title="Weighted average volume price of common stock percentage">93</span>% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to
purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCv1LOuVrsOd" title="Warrants to purcahse">300,000</span>
shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zZ30HP9Ugi3i" title="Proceeds from private placement">686,000</span> before deducting placement agent fees and other offering expenses
of $<span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zge4LiRJJlec" title="Other offering expenses">70,000</span> in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zW0ZQlglhOAi" title="Issuance of warrants, exercisable">302,069</span> shares of the Company&#8217;s common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zectYv7kG3tj" title="Share price">4.35</span> per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zep4Qz0Hgg6j" title="Share price">2.27</span> per share in exchange for the Company&#8217;s agreement to issue the holders new warrants
(the &#8220;Inducement Warrants&#8221;) exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zYlSb9FEM1fi" title="Issuance of warrants">604,138</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zb96CDLdLc7" title="Issuance of warrants">302,069</span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zGQqpzO5dZt" title="Exercise price">2.02</span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zD47LyZzbrhe" title="Warrant term">five years</span> from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zczLTEjo14Ef" title="Issuance of warrants">302,069</span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zXylTgIAvtB7" title="Exercise price">2.02</span> per share exercisable immediately
upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zbzA4hNPEAXd" title="Warrant term">eighteen months</span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_z1OESNPFBh17" title="Placement agents">21,145</span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zRlrlaV0737g" title="Exercise price">2.8375</span> per share exercisable immediately upon issuance with a term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zcTUxLso45Nd" title="Warrant term">five years</span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250630_zD6aQk1WrWEl" title="Equity issuance cost">1.1</span> million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Series L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, and as amended on May 21, 2025, the Company entered into a securities purchase agreement (the &#8220;Securities
Purchase Agreement&#8221;) with the purchasers identified therein (collectively, the &#8220;Purchasers&#8221;) providing for the
issuance and sale to the Purchasers of (i) <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zarCk86s68qi" title="Issuance of shares">6,611.11</span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Series L Convertible Preferred Stock&#8221;),
(ii) warrants to purchase up to a number of shares of common stock of the Company equal to 100% of the shares of the Company&#8217;s
common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock (the &#8220;Common Warrants&#8221;), and
(iii) warrants to purchase up to a number of shares of Company&#8217;s common stock equal to the number of Greenshoe Conversion
Shares (as defined in the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the
&#8220;Vesting Warrants&#8221; and together with the Common Warrants, the &#8220;Warrants&#8221;), with an aggregate stated value of
$<span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zIctUc4ICvI9" title="Aggregate stated value">6,611,111</span>,
for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zys4wTWv0qE" title="Issuance of shares, value">5,950,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an
aggregate stated value of up to $<span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_z1KC69dSYb51" title="Aggregate stated value">24,018,349</span>
(the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zKTNo8NprII9" title="Issuance of shares, value">21,616,514</span>,
subject to adjustments, as further described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its
respective Greenshoe Rights for an amount of Series L Convertible Preferred Stock equal to the ratio of such Purchaser&#8217;s
original subscription amount to the original aggregate subscription amount of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
filed with the Secretary of State of the State of Delaware a Certificate of Increase (the &#8220;Certificate of Increase&#8221;) increasing
the shares of Series L 10% Convertible Preferred Stock as designated in the Certificate of Designations from <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zjqBiuyFCbG9" title="Issuance of shares">28,056</span> shares to <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zl6BkDZuGUL4" title="Issuance of shares">30,630</span>
shares. The Certificate of Designation creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms
and conditions on which shares of such preferred stock would convert into shares of our common stock, as well as its liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be
converted at any time at the option of the Purchasers into shares of the Company&#8217;s common stock at an initial conversion price
of $<span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zCMTE1mMQBi5" title="Conversion price per share">2.043</span>,
subject to certain conditions, as further described in the Certificate of Designation. In addition, the holders of the Series L
Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value
per share) of <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztSReXVKfFRb" title="Percentage of dividend">10</span>%
per annum until May 11, 2026, increasing to <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z4PBmYYRKa2l" title="Percentage of dividend">12</span>%
per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date of
issuance of the Series L Convertible Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in
cash, shares of the Company&#8217;s common stock (subject to the Company&#8217;s satisfaction of the conditions set forth in the
Certificate of Designation), or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right
to require the Company to redeem the Preferred Shares at a premium, in accordance with and subject to certain conditions as further
described in the Certificate of Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#8217;s common stock equal to 100% of the Conversion Shares (as defined in the Securities Purchase Agreement) underlying
the Preferred Shares issued to such Purchaser and (ii) a Vesting Warrant (the exercisability of which shall vest ratably from time
to time in proportion to the Purchaser&#8217;s (or its permitted assigns&#8217;) exercise of such Purchaser&#8217;s Greenshoe Rights
pursuant to Section 2.4 of the Purchase Agreement), each to purchase up to a number of shares of the Company&#8217;s common stock
equal to the number of Greenshoe Conversion Shares (as defined in the Securities Purchase Agreement) applicable to such Purchaser,
in accordance with the Securities Purchase Agreement. An aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zeKMbz6a5lf7" title="Aggregate number of shares issued">3,235,978</span>
Common Warrants were issued with an initial exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z0aleKWOeapf" title="Exercise price per share">2.043</span>
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zaimnRnnO2he" title="Warrants term">five
years</span>. An aggregate of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zYMPm5YBwpI1" title="Aggregate number of shares vested">11,576,406</span>
Vesting Warrants were issued with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zZ9QsUoJyeJd" title="Exercise price per share">2.043</span>
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $<span id="xdx_90C_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zy4EIPDm1CFb" title="Floor price">0.454</span> per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration
statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the
Series L Convertible Preferred Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement
within 30 days after the initial closing and after each closing of the exercise of a Greenshoe Right in accordance with the
Securities Purchase Agreement, to become effective no later than 90 days after filing. If these deadlines are not met, <span id="xdx_90C_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8uPmJVJoJf" title="Liable of liquidated damage percentage, description">the
Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the Securities
Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_908_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc70S6wPsKbb" title="Common stock shares outstanding percentage">19.99</span>% of the number of shares of the Company&#8217;s common stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). In connection with the required Shareholder Approval, all of the Company&#8217;s officers and directors (each a &#8220;Voting
Agreement Party&#8221;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval. Shareholder Approval was obtained on July 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zfxeuClwKSj3" title="Dividends to holders unpaid">85,000</span> were declared and unpaid as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, there were <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqQixzlzdl4d" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAc1AjdiuT45" title="Preferred stock, shares outstanding">96,230</span></span> shares of series C preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9yvFiItTky4" title="Preferred stock, par value">0.01</span> per share (the &#8220;Series C Preferred Stock&#8221;)
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4vBEy8ioKVe" title="Preferred stock, shares outstanding">96,230</span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mezzanine
Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Series L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May 12, 2025 private placement of Series L Convertible Preferred Stock and Warrants produced net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfWHUntL7L5j" title="Proceeds from issuance of Series L convertible preferred stock and warrants, net">5,441,000</span>,
which was allocated to mezzanine equity and additional paid in capital based on the relative fair value of the Series L Convertible
Preferred Stock and Warrants at issuance, respectively. Series L Convertible Preferred Stock is classified as mezzanine equity as it is
conditionally redeemable upon the occurrence of certain events that are not solely within the control of the Company, and upon such
event, the Series L Convertible Preferred Stock would become redeemable at the option of the holders, while Warrants are classified
as additional paid in capital. The relative fair values and allocation of net proceeds is below:</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfConversionsOfStockTextBlock_z4eXOwBTwrta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ztAV5Hmk04k2" style="display: none">Schedule of fair values and allocation of net proceeds</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250512__20250512_zoK18SsbtBfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relative
    Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZUKKfTWedoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series L Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,688,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDixMPeB8Pji" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">37.7</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdz5utsYe719" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,089,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ivnyYMac1a" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">62.3</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zBTmFcgTcKBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,777,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512_zE7CVK7xIZxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49F_20250512__20250512_zYihwjyeE2e3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation
                                                                                                                                                                          of Net Proceeds</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zxyeobCFgYGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Mezzanine equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,025,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zORHzGTl2Fi" style="text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">37.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zUZLCKFpD2x6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,389,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zEkicuT39JCl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">62.3</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_z5DFcgIRmWW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,411,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512_zjp40NXazyE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A7_znFb3FxML5fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Series L Convertible Preferred Stock is converted into common stock it is reclassified from mezzanine equity to additional paid in capital
based on a pro-rata basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockWarrantsAndOptionsTextBlock', window );">Common Stock Warrants and Options</a></td>
<td class="text"><p id="xdx_80A_ecustom--CommonStockWarrantsAndOptionsTextBlock_zyfxNdUrAs64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_zwzcaLLtxo4d">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFRRZXXlycMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the six months ended June 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zud5tta1Phy6" style="display: none">Schedule of Warrant Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_z37492ouCh32" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,120,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zOovBpyVmDqc" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">18.85</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zc0TWRY0dmE8" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif">16,468,308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250630_zqmgzxUN7Rcg" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zvQUToGaAPGb" style="text-align: right" title="Number of warrants, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250630_zxxH4NlSBGu1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250630_zZvR0UJDo61c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"><span style="font-family: Times New Roman, Times, Serif">(837,069</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250630_zCiSDQpCjojl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">2.11</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zsLqmRuPauL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">16,751,668</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zEwamcGVBY01" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">3.07</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250630_zgV9Z5EFy2zg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">4,995,263</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zgeMLtj4NIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">5.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zCEVbE2Ypu6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of June 30, 2025 was approximately $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20250630_zz0TLJTEWeT2" title="Options outstanding vested intrinsic value">25.4</span>
million and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20250630_zP6ZPMjgl5v6" title="Options outstanding exercisable intrinsic value">7.4</span> million, respectively, in each case based on the fair value of the Company&#8217;s common stock on June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3p9I5hmQML3" title="Aggregate number of shares issued">3,235,978</span> Common
Warrants with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zHtH1CeWQp2" title="Exercise price per share">2.043</span> per share, they are exercisable, subject to certain ownership limitations,
immediately upon issuance and have a term of exercise equal to five years. An aggregate of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z6YQFonayyNg" title="Aggregate number of shares vested">11,576,406</span> Vesting Warrants were issued with
an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zPy6JRbP6R9b" title="Exercise price per share">2.043</span> per share, they are exercisable subject to certain vesting and ownership limitations, and have a
term of exercise equal to five years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have
full ratchet price protection and are subject to other adjustments, as further described in the Certificate of Designation or the Warrants,
as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor price of $<span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zBcTMq3MsIF" title="Floor price per share">0.454</span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zk2w4UQL8WXe" title="Issuance of pre-funded warrants">300,000</span>
shares of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zAGNxBhGigk6" title="Number of warrant issued">24,390</span>
shares of common stock exercisable immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zlBIbiw8cwJ5" title="Exercise price per share">2.46</span>
per share with a fair value of approximately $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_ztFQyDrIsnTf" title="Fair value of warrant">44,000</span>
in exchange for the waiver of a variable rate transaction (&#8220;VRT&#8221;). In addition, in May and June 2025, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkeCHpbBmfg9" title="Number of new shares issued"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFBbUCKYyIj1" title="Number of new shares issued">50,000</span></span>
shares of common stock and warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA6L0jfQVNMl" title="Number of warrant issued"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsYxWn1lQWze" title="Number of warrant issued">200,000</span></span>
shares of common stock with an aggregate fair value of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zW4KDpCWe4Th" title="Number shares issued for service, value"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z36O3KO3ZV2j" title="Number shares issued for service, value">718,000</span></span>
to vendors as compensation for services. The warrants underlying <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMvHrysfUdb" title="Number of warrant issued">200,000</span> shares of common stock consist of warrants underlying <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zw1jvb7eTYbb" title="Number of warrant issued">50,000</span>
shares of common stock that are exercisable immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zh0FfPcN2oD2" title="Exercise price per share">2.50</span>
per share, and warrants underlying <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zPrzYOKWtdq8" title="Issuance of pre-funded warrants">150,000</span>
shares of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSxQ4PFox24g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zNDak2Z2iooa" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zylrlDxZCov3" title="Range of exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zuYvvvqyDxh" style="width: 20%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif">476,251</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zghIcncxrhVj" title="Warrants weighted average exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfU4RWPBx8J7" title="Range of exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKKvqqfA0Joj" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">369,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zzuc7Zx6EXGg" title="Warrants outstanding, weighted average remaining contractual life (years)">2.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHdVGYCivtmi" title="Warrants weighted average exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zBNZitw7tIs5" title="Range of exercise price">2.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zbQUmE4GKwv6" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">3,235,979</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zeoCVFtVgzT8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkdQtMfLk4F6" title="Warrants weighted average exercise price">2.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zz0ysIDCUmb5" title="Range of exercise price">2.46</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrEB11Xg8Dyg" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">24,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoP2g8IYBLHg" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zqBrf3XirNg2" title="Warrants weighted average exercise price">2.46</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zJF1hkVJEhSl" title="Range of exercise price">2.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zwbhoc74cPLc" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqZdDvhLf5w5" title="Warrants outstanding, weighted average remaining contractual life (years)">2.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z5UfSuUciCKa" title="Warrants weighted average exercise price">2.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zQMTaL6JPi94" title="Range of exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF6bgnAIVp6f" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">21,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYmlIk2k6y5b" title="Warrants outstanding, weighted average remaining contractual life (years)">4.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zACP4rkJEKG7" title="Warrants weighted average exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zvUWzxuujET5" title="Range of exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zwIrLvKs5OB" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">437,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmknRphKmfT3" title="Warrants outstanding, weighted average remaining contractual life (years)">3.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zG83qSeIN0e4" title="Warrants weighted average exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUJe2w5QLOC8" title="Range of exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5e8u2NRi155" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">88,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zExMoAUjLOak" title="Warrants outstanding, weighted average remaining contractual life (years)">3.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaKdZo99QDYc" title="Warrants weighted average exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zppRZrBCYBzk" title="Range of exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBXJIl2OnPT1" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">216,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zrryqog2Rby" title="Warrants outstanding, weighted average remaining contractual life (years)">3.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYtInJW1Lnq2" title="Warrants weighted average exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z7j6zJVIJ3x4" title="Range of exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zCKNI3kWO8lf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zwjwtx0iFxg1" title="Warrants outstanding, weighted average remaining contractual life (years)">2.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z6B5pnD06r0d" title="Warrants weighted average exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z4oI4QSW5qpj" title="Range of exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z3gz1puzc5t9" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zqa8Z1DriZgj" title="Warrants outstanding, weighted average remaining contractual life (years)">0.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zpO2RIcwnqZ4" title="Warrants weighted average exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zFJVlof6TBW" title="Range of exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z8EfT49bILWf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">52,316</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zCsUMQtnxai4" title="Warrants outstanding, weighted average remaining contractual life (years)">0.6</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z4BqBJBXNDX5" title="Warrants weighted average exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z9G6Qdw0rz31" title="Range of exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zxZ10meisyhf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">7,780</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zr9HRA4NQ7O2" title="Warrants outstanding, weighted average remaining contractual life (years)">0.6</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zuA3IsDxnvud" title="Warrants weighted average exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvJFIU9TLJR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">4,995,263</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zqK1AUGxbcI2" title="Warrants outstanding, weighted average remaining contractual life (years)">4.3</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsgL3EuScUFa" title="Warrants weighted average exercise price">3.07</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zH8srVfQWY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and
stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our
employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards
granted under the Plan is <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zXHJBhMXSGr9" title="Common stock awards granted">166,667</span>.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant
under the Plan. As of June 30, 2025, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630_zC2cmFxSpvv4" title="Stock option outstanding">124,600</span>
stock options outstanding and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630_zbeK7wTiLC6j" title="Rstricted stock granted">25,935</span>
shares of restricted stock granted in prior years under the Plan, which left <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zreB7M2SrIU7" title="Available for grant">16,132</span>
shares available for grant under the Plan. Only July 24, 2025 shareholders voted to increase the maximum number of shares of common
stock that may be issued pursuant to awards granted under the Plan by <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20250630_zbU6w0Ao5lOg" title="Rstricted stock granted">583,334</span>. The following table summarizes stock option
transactions for the six months ended June 30, 2025:</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zo9LxrT4uavb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_z5y9KBqzLE5" style="display: none">Schedule of Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250630_zUURxTu1R4j3" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zuPebCPWWmG6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250630_zMmIK6Rifx81" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zHZG6IFDTYFk" style="text-align: right" title="Weighted-Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250630_zNhmjR7FiBlc" style="text-align: right" title="Number of options, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_z9oZJEv9WChk" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250630_zauh4ESFfEDa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zWGtpFYrQJv4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250630_z4h6eRIePgZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zbt7vI2z4mDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250630_zLBTnyA2eoCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"><span style="font-family: Times New Roman, Times, Serif">109,692</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zn5qNLzwgCQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"><span style="font-family: Times New Roman, Times, Serif">36.85</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_z9OhJspF4mn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of June 30, 2025 was
approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630_zBAMadCSyzrl" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term">7.75</span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of June 30, 2025 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250630_zFX8K3ykdbch" title="Options outstanding intrinsic value">34,000</span> and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630_zUlVJiX9m8y6" title="Options vested and exercisable intrinsic value">12,000</span>, respectively, in each case based on the fair value of the Company&#8217;s
common stock on June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the six months ended June 30, 2025 and 2024, was $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250630_zrH3wffxZ8xa" title="Fair value of vested stock options">7,000</span> and $<span id="xdx_90F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240630_zSZ70SgSEmZ3" title="Fair value of vested stock options">222,000</span>, respectively, and
is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of June
30, 2025, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zot1fKQQGan" title="Stock option, exercisable">109,692</span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250630_zS9I3J08jJsl" title="Stock option, unvested compensation">26,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z96AsrsqRwN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zI9fjD8kVxV4" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zpYk9IqrLm69" title="Range of excercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zoi5cG4IlAhg" style="width: 20%; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">8,428</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMWsSxLQDVLg" title="Options outstanding, weighted average remaining contractual life (years)">9.3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4ansmC0W0hj" title="Options outstanding, weighted average exercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJXNKmGxXa72" title="Range of excercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8ojRqMnqIgc" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">16,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkcTlyi0X7u8" title="Options outstanding, weighted average remaining contractual life (years)">7.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6XQifpXUYjk" title="Options outstanding, weighted average exercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7hTzr1wd1X5" title="Range of excercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zw60N4cokNUi" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdMMyBtv017f" title="Options outstanding, weighted average remaining contractual life (years)">7.6</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGkicjYnYiK" title="Options outstanding, weighted average exercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z72dsDauQvu4" title="Range of excercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPLmfno1S0Eh" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">34,598</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z106bEEQ6gJ2" title="Options outstanding, weighted average remaining contractual life (years)">7.0</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zOTbkAruaQWl" title="Options outstanding, weighted average exercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630_zGceyO43Ed7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">109,692</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_zNwNpKTRFaK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockWarrantsAndOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants and Options [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockWarrantsAndOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zRwcH9vnzFt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82E_zEtS4yWleeua">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for June 10, 2025, has been
postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not been scheduled. There is
a status conference scheduled for August 19, 2025 before the AAA. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles
naming the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes
(&#8220;Notes&#8221;) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was
seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for
improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF
voluntarily dismissed its complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently
filed a summons and complaint for interpleader against TWF and Z-One, LLC before the Supreme Court of the State of New York County
of New York, asking the Supreme Court to determine if the Company&#8217;s shares of common stock should be registered to TWF or
Z-One LLC, as both of these entities have made conflicting demands for the shares. On February 5, 2024, the Company filed a motion
for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of
Z-One, LLC and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice
and agreed to reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024,
Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing that Z-One, LLC and TWF have settled
their dispute over the entitlement to the Company&#8217;s shares of common stock and there is no remaining dispute before the Court.
On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. On November 14, 2024, the
Court held a hearing on the parties&#8217; motions, at which the Court found that the motion for entry of default was mooted by the
settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February 17, 2025, Z-One, LLC
filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that
Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder, either originally
or by assignment, of a Convertible Note in the principal amount of $<span id="xdx_90F_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z4oV2pdd3nY2" title="Principal amount">150,000</span>,
that the Company breached the Convertible Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it
damages in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z7lwpXbW28yg" title="Damages sought value">500,000</span>.&#160;The
Company intends to seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will
continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2025, Coby Silberfein filed a summons with
notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of
a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zyAE3ocpukJ7" title="Damages sought value">100,000</span>.&#160;On July 8, 2025, Justin DiPietro filed
a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages
for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_904_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z5TI4FLoa1b4" title="Damages paid">100,000</span>.&#160;On July 9, 2025, Phillip
Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant
seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_907_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z994mWnajMli" title="Damages paid">100,000</span>.&#160;The three
summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that the Company breached the convertible
notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are seeking specific performance and damages.
The Company intends to demand that the plaintiffs file complaints and then seek dismissal of the complaints.&#160;The Company believes
that the claims are without merit, and intends to vigorously defend against these claims.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#8217;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use
in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and
allowed for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The
Settlement and Investment Agreement also set Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z4T2TkzC9iMf" title="Equity method investment, ownership percentage">4.9</span>%
of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z8Tjn3xaHaM4" title="Equity method investment, ownership percentage">9.9</span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zersJaECbUn5" title="Equity method investment, ownership percentage">5</span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2025 and 2024, the Company recognized research and development expenses of $<span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znbHdtNB3Dff" title="Research and development expenses">626,000</span> and $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9MYdmclaWi4" title="Research and development expenses">778,000</span>, respectively
and made cash payments amounting to $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zRWPp84O2n5j" title="Cash payments">364,000</span> and approximately $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEKl3SMUjXx8" title="Cash payments">2.6</span> million, respectively to Cytovance. In addition, during the six months
ended June 30, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCtadGfp2tna" title="Issuance of pre-funded warrants">326,251</span> shares of common stock exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2XRPsD35Sa" title="Exercise price">0.0001</span> per
share to settle accounts payable valued at approximately $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2el97SdJg6" title="Fair value">847,000</span>; and during the six months ended June 30, 2024, the Company issued
<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7XLV7yAPkcj" title="Issuance of common stock in settlement of vendor payable, shares">127,597</span> shares of common stock to settle accounts payable valued at approximately $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zJgiOdJ5R7z" title="Issuance of common stock in settlement of vendor payable">810,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of June 30, 2025, amounted to approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znaoD4J955Zi" title="Stock issued during period, value, issued for services">310,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2023
Sponsored Research Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zbdtHhXCfvE3" title="Aggregate research and development expense">1.7</span> million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $<span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zQp9HhDP5Fad" title="Payments of research and development">216,000</span>
were added bringing the total payments due over the life of the agreement to approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zlwkkGm14Qw7" title="Aggregate research and development expense">1.9</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zYG1w6TyPNVa" title="Research and development expense">431,000</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zhqFPEv9vlPb" title="Research and development expense">862,000</span>, pursuant to the 2023 Sponsored
Research Agreement, for the six months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately
$<span id="xdx_90D_eus-gaap--UnbilledReceivablesCurrent_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zDCuAOKtFUCl" title="Unbilled and unaccrued amounts">431,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup>
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3dp4KJ2aatg" title="Proceeds from upfront amount">200,000</span>, and license maintenance
fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_z3GZvh5j68yb" title="License maintenance fees">200,000</span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaCVDRw5b23" title="License maintenance fees">100,000</span> per year beginning in year 2021 and each year thereafter. The agreement also
includes 4% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zbd7pNuT90rh" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zGbQNcMrbYyd" title="Annual royalty payments">250,000</span> beginning
in 2022, $<span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zf5G2uYyERf6" title="Annual royalty payments">2</span> million beginning in 2025, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zhcDVBExHAri" title="Annual royalty payments">5</span> million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpJB5wwXQGL1" title="Performance milestone payments">3.1</span> million, and one-time sales milestone
payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0LLtoK0ipI3" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zUNVR4MRrhye" title="Sales">250</span> million in cumulative gross sales, and $<span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zoJWoJwdn7w1" title="Sales revenue">5</span> million upon reaching $<span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEqAH2gnSqA5" title="Cumulative gross sales">500</span> million in cumulative
gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZ5y9iD4Zrl3" title="Proceeds from upfront amount">145,000</span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zLjj4h3AfNAf" title="License maintenance fees">50,000</span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJOhnQTyBdij" title="License maintenance fees">100,000</span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z8zCGU12T8s" title="Royalty fee percentage">1</span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z92NnLxxsmk3" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zjsU14Uk98L3" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3WdKZYMWcgd" title="Royalty expense year one">250,000</span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT40GpuLv7Zj" title="Royalty expense years two through five">2</span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKESBNm0J6Kk" title="Royalty expense year six and thereafter">5</span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaqKmtkYxFZ8" title="Performance milestone payments">3.1</span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC9PjtiV1NG3" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zXAY4L0eGXj3" title="Gross sales">250</span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRiwWSsZFCH5" title="Sales revenue">5</span> million upon reaching $<span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9zolMcdf4Fa" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z8wUl3OBYMQk" title="Research and development expense">0</span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zNVnh2gFO2Hj" title="Research and development expense">150,000</span>, pursuant to the 2016 Exclusive Patent
License Agreement, for the six months ended June 30, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8ogOGCqIc08" title="Upfront license fee">20,000</span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsCAaaCMn8Fl" title="License maintenance fees">5,000</span> per year beginning in year 2022 and each year thereafter. The agreement also includes
<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zDxt4LCKLsH6" title="Royalty fee percentage">2.5</span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdvZmN6pcEil" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zjyziXdUWq2d" title="Royalty expense year one though four">250,000</span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdDxgyYhn8Yd" title="Royalty expense year five and thereafter">2</span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zRhIjtymKXs6" title="Performance milestone payments">3.1</span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zqAdPQXYB629" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAucye1sF9qc" title="Gross sales">250</span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z7tipI69XMK7" title="Sales revenue">5</span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zST948NdUWc4" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
six months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRYccYR7t3Nc" title="Annual royalty payments">2.1</span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the six
months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately $<span id="xdx_903_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRxKtdeu7nFd" title="Unbilled and unaccrued amounts">1.9</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><b>PDPC Advisors Inc., a Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2025, the Company entered into an Advisory
Agreement (the &#8220;Agreement&#8221;) with PDPC Advisors Inc. (&#8220;PDPC&#8221;), to perform certain advisory services. Under the
Agreement cash payments amounting to $<span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zu90pIWGqo83" title="Cash payment">100,000</span> are to be paid in six equal installments beginning on July 1, 2025 and ending on December
31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC on a pre-funded warrant to purchase <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zixTaOnEyvc8" title="Warrants outstanding">150,000</span> shares
of common stock of the Company, which had a fair value of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zMNuYOa3ADJa" title="Stock issuance">537,000</span> at the time of issuance. The Agreement begins on July 1, 2026 and terminates
on June 30, 2026. PDPC is considered a related party as its CEO is an individual who has voting and investment control over an entity
whose beneficial ownership exceeded 5% of the issued and outstanding shares of the Company&#8217;s common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zAnRIH6l3Tnb" title="Contigency minimum required">2,500,000</span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#8217; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement,
the Company may be subject to delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zQm378o3rbs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_822_zhvK5xGCmHLa">Segment Information</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zABlW2L8AfH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zxXs1bkEkkQd" style="display: none">Schedule of Segment Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zFeVxiSmIG3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zEoob9Bsoco6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zGRoSunlJxNd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zbKmzSCnUx03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_zkUepjTp0BX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,805,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,462,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,561,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_z7vNPeh1kNgk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">351,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">287,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">632,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">765,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zbqVlsr8oBa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">121,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">152,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zTDYqOaL1fic" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">222,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zDwtSMBk4wQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">734,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,619,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,223,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,297,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_z8rx2N03qgnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(80,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(197,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,236,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,021,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0XwqDwv6666" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,433,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,710,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,209,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,976,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zN1PMwuDq7V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zuQEn7OkIi17" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_826_z4bvuP9xMyX1">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, a Purchaser of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) elected
to exercise their Greenshoe Rights and purchased <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfWHD6Dz2LS7" title="Shares issued">222.22</span> shares of the Company&#8217;s Preferred Stock with a stated value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4QcKmhQquai" title="Shares issued value">222,222</span>
for a purchase price of $<span id="xdx_90A_ecustom--PreferredStockPurchasePrice_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUZyxu4udV2j" title="Purchase price">200,000</span>. As a result of the transaction the conversion price of the Preferred Stock was decreased from $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250727__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrwGwhaW4p7" title="Exercise price">2.043</span>
to $<span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbFA4VXVKfp" title="Exercise price">1.7766</span>. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion
of Series L 10% Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
July 1, 2025 through August 10, 2025 the holders of the Company&#8217;s Series L Convertible Preferred Stock have converted <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcIjFuAeFgh5" title="Number of shares converted">543,273</span>
shares of Series L Convertible Preferred Stock into <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpWddUlZ3Qxk" title="Number of shares converted">284,507</span>
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1yDj5UG7pt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zR6OwY5RDU07">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_zhEdzgSn4ROd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z7BcxPB2Ntg2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4SjGrr2hpN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zC5etwP6Mndk">Cash
Equivalents</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At June 30, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_zlw5dHhPhBak" title="Cash equivalents">4.9</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zTHlkxQTmVR6" title="Cash equivalents">3.8</span> million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zuLfr8H4lvzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zpLohf8KFOt1">Restricted
Cash</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The
Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the
same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zrw9QSB92Pmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z9tYdQmnwDFj">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses.&#160;As of June 30, 2025, there was $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250630_z39qRWhw9aui" title="Deferred offering costs">0.8</span>&#160;million of deferred offering costs on the consolidated balance
sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBNOjN3ZtlO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zNr1pr6PKkog">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_900_ecustom--WarrantLiabilityCurrent_iI_c20250630_zeY6Pis1mQQg" title="Warrant liability">240,000</span> and $<span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_z95d9INiBjZ6" title="Warrant liability">252,000</span> at June 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zzjREssO3MYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z0SMOmeygsmk">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_MezzanineEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><p id="xdx_84B_ecustom--MezzanineEquityPolicyTextBlock_zhhC9ZWZiqCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zfB9zpdQRTsf">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z5VdWMBCHuWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zdDJNBitkyR">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVFnZfwbYQCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8B5_zSKXQcRn5Ve">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z79HEwK8goC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zTcM4jjU8cec">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z8nUnOa1arL9" style="display: none">Schedule of Anti-dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible
    preferred stock <b><sup id="xdx_F4E_zNIpjxvAfxFj">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,084,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,751,669</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,133,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,960,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,260,027</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share">2.043</span> per share, as of June 30, 2025</span></td>
</tr></table>

<p id="xdx_8AB_zHlsfpWsJME3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z68Myz1d8pI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ztAeaEzQPvtf">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20250630_zxroiafA4Vy7" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;), a related party, and the University
of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2yEebsh9Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zp5MBuogswXa">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztoQDRMqA6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zabjQIR5FpHc">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_MezzanineEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_MezzanineEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z8nUnOa1arL9" style="display: none">Schedule of Anti-dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible
    preferred stock <b><sup id="xdx_F4E_zNIpjxvAfxFj">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,084,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,265</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,751,669</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,133,762</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total anti-dilutive
    securities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,960,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,260,027</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share">2.043</span> per share, as of June 30, 2025</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLoADPOTcSZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z5xdaPWmqwL6" style="display: none">Schedule of Accounts Payable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250630_zqT9xxd4ApCb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231_zAQeoUhxNx27" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, <br/>
    2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zn3m6wkeYMui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable to Cytovance, a related party <b><sup id="xdx_F42_zWvCot73Bpz4">1</sup></b></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zlF7tyJeMuH7" title="Accounts payable interest rate">44</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zn43xrZCRtr1" title="Accounts payable interest rate">31</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zNbhlRSfuPb5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable to University
    of Minnesota</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">432,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zD4p7hdqONKa" title="Accounts payable interest rate">31</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">712,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zx9a0O4DQCL3" title="Accounts payable interest rate">18</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z3qTuviRILM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Legal services firm</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zYBl9cG3c2xf" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zi6GWXtUKJge" title="Accounts payable interest rate">39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zRjY8xRkQrs5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,505,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zMdk2AEfa6f1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">344,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zcWnGQ4VuzWb" title="Accounts payable interest rate">25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNUhi0cHgKul" title="Accounts payable interest rate">12</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zyUoH1ArR81a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,374,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630_zzldxFzUBNx7" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,853,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zfUyh2Qpl2Hg" title="Accounts payable interest rate">100</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F02_zzW27guC4jY5">1</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zS1vfydUx7A3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td></tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock', window );">Schedule of Accounts Payable to Related Party</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zfPzkRmitlG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B7_z2szJcyXcmNk">Schedule of Accounts Payable to Related Party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20250101__20250630_zeZOS0OUYWXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20240630_z5rRWGsXn3Nc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zbQUuhGvsRSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,183,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,515,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9GeCP6JTmU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Invoices, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">626,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">778,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTM2XvgnEZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(364,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,641,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zH6PoVGKIThl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments in common stock,
    at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(810,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIcmYJ9ZRH57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Payments
    in pre-funded warrants, at fair value</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(847,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zBF3iIgEViI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">842,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Payable and Related Party [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Warrant Liability Transactions</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLe24w7itmB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zQqix48w7G1l" style="display: none">Schedule of Warrant Liability Transactions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20250630_zhVN18dsfG8j" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20240630_zPEwsW5r4H1e" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ending</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zH5wLvB2rDkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,052,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_z94fK3t2S4zf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of warrants at
    fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zn1u4FH4ak8b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(775,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zcihmlUBCKf7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Extinguishment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zd0T0KijeE01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Warrant Liability Assumptions</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zvN0uJtHZ0Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zj5GFkPO6bY1" style="display: none">Schedule of Warrant Liability Assumptions</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023
    Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zMRaoSHMbGci" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zOEchUvwyMma" style="width: 16%; text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zR4NEA7W5L54" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">3.68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zUghOTnWsWWi" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z7DEEYXKYyrh" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">111</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zUiUML0kgpkj" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____z8DPmaUwmuz6" title="Expected life (in years)">2.5</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zXBAlpEzUHif" title="Expected life (in years)">3.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zP2IqcNqlPej" title="Expected life (in years)">3.0</span>
                                            &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zb5TRxpqlamj" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zHDWhiBMoW8l" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0886">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zVd24N3s9O86" style="text-align: right" title="Warrants measurement input"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0888">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Fair value of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zSBeyTu8ftGi" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">240,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zx5PEV1dsO5b" style="text-align: right" title="Fair value of warrants"><span style="font-family: Times New Roman, Times, Serif">252,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0B_zMY6SPzd685c"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zPSDqIoGOGi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zbMpmvqZUpyf" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_zM3f9fFjxWu3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0F_z7vjk12pZ6Sa"><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_z4fCAsr4Xz53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup id="xdx_F00_z6cW6eqbfiDa">4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_zfI28UCMF0N6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfConversionsOfStockTextBlock', window );">Schedule of fair values and allocation of net proceeds</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfConversionsOfStockTextBlock_z4eXOwBTwrta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ztAV5Hmk04k2" style="display: none">Schedule of fair values and allocation of net proceeds</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20250512__20250512_zoK18SsbtBfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relative
    Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZUKKfTWedoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series L Convertible Preferred
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,688,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDixMPeB8Pji" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">37.7</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdz5utsYe719" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,089,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ivnyYMac1a" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">62.3</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zBTmFcgTcKBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,777,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512_zE7CVK7xIZxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants fair value percentage"><span style="font-family: Times New Roman, Times, Serif">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49F_20250512__20250512_zYihwjyeE2e3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation
                                                                                                                                                                          of Net Proceeds</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p></td><td style="padding-bottom: 1pt; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zxyeobCFgYGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Mezzanine equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,025,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zORHzGTl2Fi" style="text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">37.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zUZLCKFpD2x6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,389,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zEkicuT39JCl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">62.3</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_z5DFcgIRmWW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,411,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512_zjp40NXazyE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"><span style="font-family: Times New Roman, Times, Serif">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfConversionsOfStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfConversionsOfStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFRRZXXlycMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the six months ended June 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zud5tta1Phy6" style="display: none">Schedule of Warrant Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_z37492ouCh32" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,120,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zOovBpyVmDqc" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">18.85</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zc0TWRY0dmE8" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif">16,468,308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250630_zqmgzxUN7Rcg" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zvQUToGaAPGb" style="text-align: right" title="Number of warrants, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250630_zxxH4NlSBGu1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250630_zZvR0UJDo61c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"><span style="font-family: Times New Roman, Times, Serif">(837,069</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250630_zCiSDQpCjojl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">2.11</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zsLqmRuPauL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">16,751,668</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zEwamcGVBY01" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">3.07</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250630_zgV9Z5EFy2zg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">4,995,263</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zgeMLtj4NIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">5.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zo9LxrT4uavb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_z5y9KBqzLE5" style="display: none">Schedule of Options Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at December 31, 2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250630_zUURxTu1R4j3" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zuPebCPWWmG6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250630_zMmIK6Rifx81" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zHZG6IFDTYFk" style="text-align: right" title="Weighted-Average Exercise Price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1235">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250630_zNhmjR7FiBlc" style="text-align: right" title="Number of options, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_z9oZJEv9WChk" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250630_zauh4ESFfEDa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zWGtpFYrQJv4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250630_z4h6eRIePgZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">124,600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zbt7vI2z4mDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"><span style="font-family: Times New Roman, Times, Serif">32.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250630_zLBTnyA2eoCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"><span style="font-family: Times New Roman, Times, Serif">109,692</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zn5qNLzwgCQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"><span style="font-family: Times New Roman, Times, Serif">36.85</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Options Outstanding and Options Exercisable</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z96AsrsqRwN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zI9fjD8kVxV4" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Options Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zpYk9IqrLm69" title="Range of excercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zoi5cG4IlAhg" style="width: 20%; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">8,428</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMWsSxLQDVLg" title="Options outstanding, weighted average remaining contractual life (years)">9.3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4ansmC0W0hj" title="Options outstanding, weighted average exercise price">2.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJXNKmGxXa72" title="Range of excercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8ojRqMnqIgc" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">16,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkcTlyi0X7u8" title="Options outstanding, weighted average remaining contractual life (years)">7.8</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6XQifpXUYjk" title="Options outstanding, weighted average exercise price">10.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7hTzr1wd1X5" title="Range of excercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zw60N4cokNUi" style="text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdMMyBtv017f" title="Options outstanding, weighted average remaining contractual life (years)">7.6</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGkicjYnYiK" title="Options outstanding, weighted average exercise price">25.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z72dsDauQvu4" title="Range of excercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPLmfno1S0Eh" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">34,598</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z106bEEQ6gJ2" title="Options outstanding, weighted average remaining contractual life (years)">7.0</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zOTbkAruaQWl" title="Options outstanding, weighted average exercise price">74.40</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630_zGceyO43Ed7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif">109,692</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSxQ4PFox24g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of June 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zNDak2Z2iooa" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding and Exercisable as of June 30, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining
                                            Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zylrlDxZCov3" title="Range of exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zuYvvvqyDxh" style="width: 20%; text-align: right" title="Number of outstanding"><span style="font-family: Times New Roman, Times, Serif">476,251</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zghIcncxrhVj" title="Warrants weighted average exercise price">0.0001</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfU4RWPBx8J7" title="Range of exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKKvqqfA0Joj" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">369,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zzuc7Zx6EXGg" title="Warrants outstanding, weighted average remaining contractual life (years)">2.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHdVGYCivtmi" title="Warrants weighted average exercise price">2.02</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zBNZitw7tIs5" title="Range of exercise price">2.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zbQUmE4GKwv6" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">3,235,979</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zeoCVFtVgzT8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkdQtMfLk4F6" title="Warrants weighted average exercise price">2.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zz0ysIDCUmb5" title="Range of exercise price">2.46</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrEB11Xg8Dyg" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">24,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoP2g8IYBLHg" title="Warrants outstanding, weighted average remaining contractual life (years)">4.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zqBrf3XirNg2" title="Warrants weighted average exercise price">2.46</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zJF1hkVJEhSl" title="Range of exercise price">2.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zwbhoc74cPLc" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqZdDvhLf5w5" title="Warrants outstanding, weighted average remaining contractual life (years)">2.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z5UfSuUciCKa" title="Warrants weighted average exercise price">2.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zQMTaL6JPi94" title="Range of exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF6bgnAIVp6f" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">21,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYmlIk2k6y5b" title="Warrants outstanding, weighted average remaining contractual life (years)">4.7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zACP4rkJEKG7" title="Warrants weighted average exercise price">2.8375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zvUWzxuujET5" title="Range of exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zwIrLvKs5OB" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">437,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmknRphKmfT3" title="Warrants outstanding, weighted average remaining contractual life (years)">3.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zG83qSeIN0e4" title="Warrants weighted average exercise price">4.35</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUJe2w5QLOC8" title="Range of exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5e8u2NRi155" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">88,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zExMoAUjLOak" title="Warrants outstanding, weighted average remaining contractual life (years)">3.9</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaKdZo99QDYc" title="Warrants weighted average exercise price">5.4375</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zppRZrBCYBzk" title="Range of exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBXJIl2OnPT1" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">216,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zrryqog2Rby" title="Warrants outstanding, weighted average remaining contractual life (years)">3.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYtInJW1Lnq2" title="Warrants weighted average exercise price">30.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z7j6zJVIJ3x4" title="Range of exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zCKNI3kWO8lf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zwjwtx0iFxg1" title="Warrants outstanding, weighted average remaining contractual life (years)">2.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z6B5pnD06r0d" title="Warrants weighted average exercise price">37.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z4oI4QSW5qpj" title="Range of exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z3gz1puzc5t9" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">1,867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zqa8Z1DriZgj" title="Warrants outstanding, weighted average remaining contractual life (years)">0.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zpO2RIcwnqZ4" title="Warrants weighted average exercise price">102.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zFJVlof6TBW" title="Range of exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z8EfT49bILWf" style="text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">52,316</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zCsUMQtnxai4" title="Warrants outstanding, weighted average remaining contractual life (years)">0.6</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z4BqBJBXNDX5" title="Warrants weighted average exercise price">165.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z9G6Qdw0rz31" title="Range of exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zxZ10meisyhf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">7,780</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zr9HRA4NQ7O2" title="Warrants outstanding, weighted average remaining contractual life (years)">0.6</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zuA3IsDxnvud" title="Warrants weighted average exercise price">206.25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvJFIU9TLJR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"><span style="font-family: Times New Roman, Times, Serif">4,995,263</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zqK1AUGxbcI2" title="Warrants outstanding, weighted average remaining contractual life (years)">4.3</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsgL3EuScUFa" title="Warrants weighted average exercise price">3.07</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Oustanding and Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zABlW2L8AfH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zxXs1bkEkkQd" style="display: none">Schedule of Segment Information</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zFeVxiSmIG3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zEoob9Bsoco6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zGRoSunlJxNd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zbKmzSCnUx03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_zkUepjTp0BX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,805,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,462,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,561,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_z7vNPeh1kNgk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Salaries</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">351,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">287,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">632,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">765,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zbqVlsr8oBa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">121,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">152,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zTDYqOaL1fic" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">222,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_zDwtSMBk4wQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">734,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,619,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,223,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,297,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_z8rx2N03qgnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(80,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(197,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,236,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,021,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0XwqDwv6666" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,433,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,710,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,209,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,976,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 1,433,000<span></span>
</td>
<td class="nump">$ 3,710,000<span></span>
</td>
<td class="nump">$ 2,209,000<span></span>
</td>
<td class="nump">$ 5,976,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,216,000<span></span>
</td>
<td class="nump">$ 7,699,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,960,651<span></span>
</td>
<td class="nump">1,260,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember', window );">Series L Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,084,382<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">124,600<span></span>
</td>
<td class="nump">126,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,751,669<span></span>
</td>
<td class="nump">1,133,762<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share">2.043</span> per share, as of June 30, 2025</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 277,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,374,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,853,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 598,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 842,000<span></span>
</td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">44.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember', window );">University of Minnesota [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 432,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,505,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember', window );">Other Accounts Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Invoices, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">626,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">778,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(364,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,641,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments in common stock, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(810,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="num">$ (847,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(847,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 598,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 842,000<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
                                            7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">326,251<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Prior year unpaid fees</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of prefunded warrant to settle vendor payable, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="num">$ (117,000)<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="num">$ (775,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on rates
established by the Federal Reserve Bank</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Determined by the
remaining contractual life of the derivative instrument</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Based on no dividends
paid or expected to be paid</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="num">(775,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfWarrant', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 277,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember', window );">2023 Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">216,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember', window );">2023 Placement Agents Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility amount utilized in the value calculation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of fair values and allocation of net proceeds (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="nump">$ 9,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="nump">$ 5,411,000<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="nump">$ 6,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="nump">$ 3,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="nump">$ 3,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember', window );">Mezzanine Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="nump">$ 2,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and warrants fair value percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and warrants net proceeds percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>May 22, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 11, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Issuance of warrants, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series L convertible preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember', window );">Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember', window );">Series L Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">Dividends to holders unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series L convertible preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares issued</a></td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="nump">11,576,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember', window );">Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember', window );">Series A Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember', window );">Series B Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember', window );">Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price</a></td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage', window );">Weighted average volume price of common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LiableOfLiquidatedDamagePercentageDescription', window );">Liable of liquidated damage percentage, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the Securities
Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockSharesOutstandingPercentage', window );">Common stock shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series L 10% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,611.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,611,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series L 10% Convertible Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,576,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,018,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,616,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AggregateStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate stated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AggregateStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiableOfLiquidatedDamagePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liable of liquidated damage percentage, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiableOfLiquidatedDamagePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average volume price of common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WeightedAverageVolumePriceOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted | shares</a></td>
<td class="nump">16,468,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of warrants, forfeited/cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited/cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised | shares</a></td>
<td class="num">(837,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, ending balance | shares</a></td>
<td class="nump">16,751,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable, ending balance | shares</a></td>
<td class="nump">4,995,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending balance | $ / shares</a></td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">16,751,668<span></span>
</td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">476,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">369,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">3,235,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">437,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">88,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 102.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 102.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">52,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range of Exercise Price Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">7,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">4,995,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning | $ / shares</a></td>
<td class="nump">$ 32.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, forfeited/cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeited/cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending | $ / shares</a></td>
<td class="nump">$ 32.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options outstanding exercisable | shares</a></td>
<td class="nump">109,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price,exercisable, ending | $ / shares</a></td>
<td class="nump">$ 36.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Outstanding and Options Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">109,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">8,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">16,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">34,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding vested intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options outstanding exercisable intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number shares issued for service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Rstricted stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Rstricted stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock option, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1', window );">Stock option, unvested compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember', window );">Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price per share</a></td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number shares issued for service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember', window );">Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares issued</a></td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="nump">11,576,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options non vested in period fair value 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2025</div></th>
<th class="th"><div>Jul. 08, 2025</div></th>
<th class="th"><div>Jun. 18, 2025</div></th>
<th class="th"><div>Feb. 17, 2025</div></th>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>May 13, 2024</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Jul. 18, 2016</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
<th class="th"><div>Aug. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="num">$ (117,000)<span></span>
</td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="num">$ (775,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">$ 1,784,000<span></span>
</td>
<td class="nump">1,462,000<span></span>
</td>
<td class="nump">2,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ContigencyMinimumRequired', window );">Contigency minimum required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember', window );">2023 Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Aggregate research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments of research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="nump">862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Proceeds from upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOne', window );">Royalty expense year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearTwoThroughFive', window );">Royalty expense years two through five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterSix', window );">Royalty expense year six and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | 2017 through 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOneThoughFour', window );">Royalty expense year one though four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterFive', window );">Royalty expense year five and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember', window );">2024 GTB-3650 Clinical Trial Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember', window );">Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,000<span></span>
</td>
<td class="nump">778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364,000<span></span>
</td>
<td class="nump">$ 2,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 626,000<span></span>
</td>
<td class="nump">$ 778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=GTBP_ZOneLLCMember', window );">Z One L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=GTBP_CobySilberfeinMember', window );">Coby Silberfein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ContigencyMinimumRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contigency minimum required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ContigencyMinimumRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year after six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOneThoughFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one though four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOneThoughFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearTwoThroughFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year two through five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearTwoThroughFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=GTBP_ZOneLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=GTBP_ZOneLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=GTBP_CobySilberfeinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=GTBP_CobySilberfeinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="nump">1,236,000<span></span>
</td>
<td class="nump">1,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,433,000)<span></span>
</td>
<td class="num">(3,710,000)<span></span>
</td>
<td class="num">(2,209,000)<span></span>
</td>
<td class="num">(5,976,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember', window );">Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">1,805,000<span></span>
</td>
<td class="nump">1,462,000<span></span>
</td>
<td class="nump">2,561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">632,000<span></span>
</td>
<td class="nump">765,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Insurance</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">734,000<span></span>
</td>
<td class="nump">1,619,000<span></span>
</td>
<td class="nump">1,223,000<span></span>
</td>
<td class="nump">3,297,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(197,000)<span></span>
</td>
<td class="num">(1,236,000)<span></span>
</td>
<td class="num">(1,021,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 1,433,000<span></span>
</td>
<td class="nump">$ 3,710,000<span></span>
</td>
<td class="nump">$ 2,209,000<span></span>
</td>
<td class="nump">$ 5,976,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 28, 2025</div></th>
<th class="th"><div>Aug. 10, 2025</div></th>
<th class="th"><div>Jul. 27, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272,995<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">222.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="nump">$ 222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PreferredStockPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="nump">$ 1.7766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PreferredStockPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PreferredStockPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Organization and Going Concern Analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</Role>
      <ShortName>Organization and Going Concern Analysis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Accounts Payable and Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</Role>
      <ShortName>Accounts Payable and Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Common Stock Warrants and Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</Role>
      <ShortName>Common Stock Warrants and Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Accounts Payable and Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</Role>
      <ShortName>Accounts Payable and Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiability</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Common Stock Warrants and Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</Role>
      <ShortName>Common Stock Warrants and Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SegmentInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative</Role>
      <ShortName>Organization and Going Concern Analysis (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails</Role>
      <ShortName>Schedule of Accounts Payable to Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative</Role>
      <ShortName>Accounts Payable and Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Warrant Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>Warrant Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiabilityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails</Role>
      <ShortName>Schedule of fair values and allocation of net proceeds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails</Role>
      <ShortName>Schedule of Options Outstanding and Options Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative</Role>
      <ShortName>Common Stock Warrants and Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails</Role>
      <ShortName>Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>gtbp-20250630.xsd</File>
    <File>gtbp-20250630_cal.xml</File>
    <File>gtbp-20250630_def.xml</File>
    <File>gtbp-20250630_lab.xml</File>
    <File>gtbp-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
    <File>form10-q_002.jpg</File>
    <File>form10-q_003.jpg</File>
    <File>form10-q_004.jpg</File>
    <File>form10-q_005.jpg</File>
    <File>form10-q_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="685">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gtbp-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 212,
   "keyCustom": 54,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 49,
   "hidden": {
    "total": 149,
    "http://fasb.org/us-gaap/2025": 111,
    "http://gtbiopharma.com/20250630": 34,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 221,
   "entityCount": 1,
   "segmentCount": 73,
   "elementCount": 532,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 685,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "shortName": "Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
     "longName": "00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)",
     "shortName": "Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:IssuanceOfWarrantsForVrtWaiver",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis",
     "longName": "999013 - Disclosure - Organization and Going Concern Analysis",
     "shortName": "Organization and Going Concern Analysis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty",
     "longName": "999015 - Disclosure - Accounts Payable and Related Party",
     "shortName": "Accounts Payable and Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://gtbiopharma.com/role/WarrantLiability",
     "longName": "999016 - Disclosure - Warrant Liability",
     "shortName": "Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficit",
     "longName": "999017 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions",
     "longName": "999018 - Disclosure - Common Stock Warrants and Options",
     "shortName": "Common Stock Warrants and Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "longName": "999019 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://gtbiopharma.com/role/SegmentInformation",
     "longName": "999020 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://gtbiopharma.com/role/SubsequentEvents",
     "longName": "999021 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999022 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables",
     "longName": "999024 - Disclosure - Accounts Payable and Related Party (Tables)",
     "shortName": "Accounts Payable and Related Party (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityTables",
     "longName": "999025 - Disclosure - Warrant Liability (Tables)",
     "shortName": "Warrant Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficitTables",
     "longName": "999026 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
     "longName": "999027 - Disclosure - Common Stock Warrants and Options (Tables)",
     "shortName": "Common Stock Warrants and Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://gtbiopharma.com/role/SegmentInformationTables",
     "longName": "999028 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
     "longName": "999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)",
     "shortName": "Organization and Going Concern Analysis (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "longName": "999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "longName": "999032 - Disclosure - Schedule of Accounts Payable (Details)",
     "shortName": "Schedule of Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails",
     "longName": "999033 - Disclosure - Schedule of Accounts Payable to Related Party (Details)",
     "shortName": "Schedule of Accounts Payable to Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CytovanceBiologicsIncMember",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
     "longName": "999034 - Disclosure - Accounts Payable and Related Party (Details Narrative)",
     "shortName": "Accounts Payable and Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-012025-03-31_custom_LegalServicesFirmMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
     "longName": "999035 - Disclosure - Schedule of Warrant Liability Assumptions (Details)",
     "shortName": "Schedule of Warrant Liability Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
     "longName": "999036 - Disclosure - Schedule of Warrant Liability Transactions (Details)",
     "shortName": "Schedule of Warrant Liability Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "GTBP:WarrantLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "999037 - Disclosure - Warrant Liability (Details Narrative)",
     "shortName": "Warrant Liability (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
     "longName": "999038 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)",
     "shortName": "Schedule of fair values and allocation of net proceeds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-05-122025-05-12",
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-122025-05-12",
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
     "longName": "999039 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-262025-02-26",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999040 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999041 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_custom_WarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "999042 - Disclosure - Schedule of Options Activity (Details)",
     "shortName": "Schedule of Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
     "longName": "999043 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)",
     "shortName": "Schedule of Options Outstanding and Options Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
     "longName": "999044 - Disclosure - Common Stock Warrants and Options (Details Narrative)",
     "shortName": "Common Stock Warrants and Options (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999045 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-21",
      "name": "GTBP:ContigencyMinimumRequired",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
     "longName": "999046 - Disclosure - Schedule of Segment Information (Details)",
     "shortName": "Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30_custom_SegmentsMember",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999047 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockConvertibleConversionPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Related Party",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46",
      "r48",
      "r823"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "verboseLabel": "Total accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r637"
     ]
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableInterestBearingInterestRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable interest rate",
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r44"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r425",
      "r426",
      "r427",
      "r428",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r425",
      "r426",
      "r427",
      "r428",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r637",
      "r890"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r767",
      "r768",
      "r769",
      "r770",
      "r837",
      "r893"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r795"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AdvisoryAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "AdvisoryAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreement [Member]",
        "documentation": "Advisory Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AggregateStatedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "AggregateStatedValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate stated value",
        "documentation": "Aggregate stated value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r717"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r685",
      "r695",
      "r720"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r713",
      "r721",
      "r725",
      "r733"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangement, expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r353",
      "r355"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r109",
      "r122",
      "r123",
      "r124",
      "r210",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r410",
      "r412",
      "r441",
      "r637",
      "r789",
      "r790",
      "r847"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r623",
      "r626",
      "r830",
      "r832",
      "r833"
     ]
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r105",
      "r593"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents and Restricted Cash at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents and Restricted Cash at End of Period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r65",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase in Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r857"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CashPaidDuringYearFor": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CashPaidDuringYearFor",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:",
        "documentation": "Cash paid during year for"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r107",
      "r108",
      "r122",
      "r124",
      "r147",
      "r148",
      "r151",
      "r153",
      "r159",
      "r160",
      "r210",
      "r239",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r276",
      "r279",
      "r280",
      "r284",
      "r287",
      "r294",
      "r441",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r545",
      "r563",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r741",
      "r762",
      "r764",
      "r771"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r159",
      "r269",
      "r279",
      "r280",
      "r282",
      "r284",
      "r287",
      "r292",
      "r294",
      "r418",
      "r500",
      "r501",
      "r502",
      "r503",
      "r621",
      "r741",
      "r760",
      "r762"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125",
      "r295"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase",
        "verboseLabel": "Placement agents",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of pre-funded warrants",
        "verboseLabel": "Number of warrant issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of pre-funded warrants",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "GTBP_CobySilberfeinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CobySilberfeinMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coby Silberfein [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r231",
      "r232",
      "r588",
      "r780",
      "r785"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r767",
      "r768",
      "r770",
      "r837",
      "r889",
      "r893"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r526"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Number of shares converted",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r526",
      "r543",
      "r893",
      "r894"
     ]
    },
    "GTBP_CommonStockSharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CommonStockSharesOutstandingPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding percentage",
        "documentation": "Common stock shares outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.001, 250,000,000 shares authorized, 3,272,995 and 2,234,328 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r267",
      "r275",
      "r469",
      "r637"
     ]
    },
    "GTBP_CommonStockWarrantsAndOptionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CommonStockWarrantsAndOptionsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants and Options",
        "documentation": "Common Stock Warrants and Options [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r80"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440"
     ]
    },
    "GTBP_ContigencyMinimumRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ContigencyMinimumRequired",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contigency minimum required",
        "documentation": "Contigency minimum required."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of Series L convertible preferred stock into common stock",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ConvertiblePreferredStockAndWarrantsFairValuePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock and warrants fair value percentage",
        "documentation": "Convertible preferred stock and warrants fair value percentage"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ConvertiblePreferredStockAndWarrantsNetProceedsPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock and warrants net proceeds percentage",
        "documentation": "Convertible preferred stock and warrants net proceeds percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License maintenance fees",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CummulativeGrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CummulativeGrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative gross sales",
        "documentation": "Cummulative gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CytovanceBiologicsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "CytovanceBiologicsIncMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cytovance Biologics Inc [Member]",
        "documentation": "Cytovance Biologics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r84",
      "r85",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r636",
      "r760",
      "r761",
      "r763",
      "r766",
      "r781",
      "r782",
      "r783",
      "r843",
      "r844",
      "r856"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r636",
      "r760",
      "r761",
      "r763",
      "r766",
      "r781",
      "r782",
      "r783",
      "r843",
      "r844",
      "r856"
     ]
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain on short-term investments",
        "label": "Debt Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r752",
      "r753"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ]
    },
    "us-gaap_DerivativeFloorPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFloorPrice",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "verboseLabel": "Floor price per share",
        "documentation": "Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "DisclosureCommonStockWarrantsAndOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants And Options",
        "verboseLabel": "Schedule Of Warrant Activity",
        "terseLabel": "Schedule Of Options Activity"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "verboseLabel": "Schedule Of Warrant Liability Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DividendOnSeriesLConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "DividendOnSeriesLConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend on Series L convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend on Series L convertible preferred stock",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r73"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r666",
      "r678"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r115",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r144",
      "r147",
      "r151",
      "r152",
      "r153",
      "r156",
      "r265",
      "r352",
      "r368",
      "r408",
      "r431",
      "r432",
      "r464",
      "r476",
      "r599"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r115",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r147",
      "r151",
      "r152",
      "r153",
      "r156",
      "r265",
      "r352",
      "r368",
      "r408",
      "r431",
      "r432",
      "r464",
      "r476",
      "r599"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r155"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r98",
      "r99",
      "r100",
      "r112",
      "r113",
      "r114",
      "r128",
      "r129",
      "r130",
      "r132",
      "r139",
      "r141",
      "r143",
      "r158",
      "r211",
      "r212",
      "r224",
      "r264",
      "r296",
      "r352",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r407",
      "r408",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r475",
      "r493",
      "r494",
      "r495",
      "r505",
      "r563"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r364",
      "r441",
      "r742",
      "r743",
      "r744",
      "r825",
      "r826",
      "r827",
      "r828"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment, ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r441"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r717"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r714"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ExtinguishmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ExtinguishmentOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment",
        "documentation": "Extinguishment of warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value of warrants",
        "terseLabel": "Fair value",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r631"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "GTBP_FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of prefunded warrant or common stock to settle vendor payable",
        "documentation": "Fair value of prefunded warrant or common stock to settle vendor payable"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "FairValueOfPrefundedWarrantsIssuedForElocFee",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of prefunded warrants issued for ELOC fee",
        "documentation": "Fair value of prefunded warrants issued for eloc fee"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested warrants issued in Series L conv. preferred stock transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "GTBP_GainOnSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "GainOnSettlementOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on extinguishment of debt",
        "label": "GainOnSettlementOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of vendor payable",
        "negatedLabel": "Gain on settlement of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ]
    },
    "GTBP_GreenshoeRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "GreenshoeRightsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greenshoe Rights [Member]",
        "documentation": "Greenshoe Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_GrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "GrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross sales",
        "documentation": "Gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r444",
      "r490",
      "r492",
      "r548",
      "r591",
      "r592",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r635",
      "r829",
      "r831",
      "r860"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r414",
      "r415",
      "r416",
      "r417",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r444",
      "r490",
      "r492",
      "r548",
      "r591",
      "r592",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630",
      "r635",
      "r829",
      "r831",
      "r860"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r118",
      "r360",
      "r361"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) in operating lease right-of-use assets",
        "documentation": "Decrease in operating lease right-of-use assets.",
        "label": "IncreaseDecreaseInOperatingLeaseRightofuseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) Decrease in prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r713",
      "r721",
      "r725",
      "r733"
     ]
    },
    "GTBP_InducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "InducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Warrants [Member]",
        "documentation": "Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r736"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r736"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r736"
     ]
    },
    "us-gaap_InsuranceCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceCommissions",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants at fair value",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "GTBP_IssuanceOfWarrantsForVrtWaiver": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "IssuanceOfWarrantsForVrtWaiver",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of warrants for VRT waiver",
        "documentation": "Issuance of warrants for vrt waiver",
        "label": "Issuance of warrants for vrt waiver"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LegalServicesFirmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "LegalServicesFirmMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Services Firm [Member]",
        "documentation": "Legal Services Firm [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS\u2019 (EQUITY) DEFICIT",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r86",
      "r472",
      "r637",
      "r640",
      "r641",
      "r760",
      "r765",
      "r778",
      "r842"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r104",
      "r122",
      "r123",
      "r124",
      "r210",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r411",
      "r412",
      "r413",
      "r441",
      "r637",
      "r789",
      "r847",
      "r848"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LiableOfLiquidatedDamagePercentageDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "LiableOfLiquidatedDamagePercentageDescription",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liable of liquidated damage percentage, description",
        "documentation": "Liable of liquidated damage percentage, description."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r233",
      "r234",
      "r235",
      "r238",
      "r357",
      "r615",
      "r787",
      "r788"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r233",
      "r234",
      "r235",
      "r238",
      "r357",
      "r615",
      "r787",
      "r788"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Damages paid",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Damages sought value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on short-term investments",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r234",
      "r235",
      "r236",
      "r237",
      "r322",
      "r346",
      "r347",
      "r348",
      "r357",
      "r435",
      "r462",
      "r489",
      "r491",
      "r498",
      "r518",
      "r519",
      "r569",
      "r571",
      "r574",
      "r575",
      "r576",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633",
      "r634",
      "r638",
      "r791",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r631",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r433",
      "r434",
      "r435",
      "r623",
      "r625",
      "r626",
      "r631"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r623",
      "r625",
      "r626",
      "r631"
     ]
    },
    "GTBP_MezzanineEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "MezzanineEquityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity [Member]",
        "documentation": "Mezzanine Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_MezzanineEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "MezzanineEquityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mezzanine Equity",
        "documentation": "Mezzanine Equity [Policy Text Block]",
        "label": "Mezzanine Equity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r234",
      "r235",
      "r236",
      "r237",
      "r322",
      "r346",
      "r347",
      "r348",
      "r357",
      "r435",
      "r462",
      "r489",
      "r491",
      "r498",
      "r518",
      "r519",
      "r569",
      "r571",
      "r574",
      "r575",
      "r576",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633",
      "r638",
      "r791",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r67",
      "r88",
      "r100",
      "r102",
      "r110",
      "r111",
      "r114",
      "r122",
      "r123",
      "r124",
      "r127",
      "r131",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143",
      "r149",
      "r210",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r265",
      "r268",
      "r271",
      "r277",
      "r352",
      "r368",
      "r408",
      "r432",
      "r441",
      "r474",
      "r544",
      "r561",
      "r562",
      "r595",
      "r597",
      "r598",
      "r650",
      "r789"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss attributable to common stockholders\u2019",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r116",
      "r135",
      "r136",
      "r137",
      "r138",
      "r144",
      "r145",
      "r150",
      "r153",
      "r268",
      "r271",
      "r277",
      "r408"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering expenses",
        "documentation": "Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r892"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense), Net",
        "verboseLabel": "Other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OfficersEmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "OfficersEmployeesAndDirectorsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers, Employees and Directors [Member]",
        "documentation": "Officers, Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "OmnibusIncentivePlanMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Omnibus Incentive Plan [Member]",
        "documentation": "2022 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r595",
      "r598",
      "r601",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Going Concern Analysis",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r745",
      "r759"
     ]
    },
    "GTBP_OtherAccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "OtherAccountsPayableMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Member]",
        "documentation": "Other Accounts Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r627"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r684",
      "r694",
      "r719"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r722"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r722"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year unpaid fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale of investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments in common stock, at fair value",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends to holders unpaid",
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issuance cost",
        "verboseLabel": "Stock issuance",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of research and development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "GTBP_PerformanceMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "PerformanceMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance milestone payments",
        "documentation": "Performance milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of dividend",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r570",
      "r572",
      "r573",
      "r577"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on preferred stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r646",
      "r647",
      "r648",
      "r649",
      "r889",
      "r893"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r279"
     ]
    },
    "GTBP_PreferredStockPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "PreferredStockPurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Preferred stock purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r526"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r279"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Number of shares converted",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r526",
      "r543",
      "r893",
      "r894"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r267",
      "r274",
      "r468",
      "r637"
     ]
    },
    "GTBP_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series L convertible preferred stock and warrants, net",
        "verboseLabel": "Total",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants, net",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r500"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invoices, net",
        "verboseLabel": "Research and development expenses",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ProceedsFromUpfrontAmount",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from upfront amount",
        "documentation": "Received upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants and issuance of inducement warrants for cash, net",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "GTBP_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r234",
      "r235",
      "r236",
      "r237",
      "r300",
      "r322",
      "r346",
      "r347",
      "r348",
      "r351",
      "r357",
      "r435",
      "r460",
      "r461",
      "r462",
      "r489",
      "r491",
      "r498",
      "r518",
      "r519",
      "r569",
      "r571",
      "r574",
      "r575",
      "r576",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633",
      "r634",
      "r638",
      "r644",
      "r784",
      "r791",
      "r839",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "GTBP_RangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeEightMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Eight [Member]",
        "documentation": "Range of Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeElevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Eleven [Member]",
        "documentation": "Range of Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Five [Member]",
        "documentation": "Range of Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeFourMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Four [Member]",
        "documentation": "Range of Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "auth_ref": [
      "r164",
      "r234",
      "r235",
      "r236",
      "r237",
      "r300",
      "r322",
      "r346",
      "r347",
      "r348",
      "r351",
      "r357",
      "r435",
      "r460",
      "r461",
      "r462",
      "r489",
      "r491",
      "r498",
      "r518",
      "r519",
      "r569",
      "r571",
      "r574",
      "r575",
      "r576",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633",
      "r634",
      "r638",
      "r644",
      "r784",
      "r791",
      "r839",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "GTBP_RangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeNineMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Nine [Member]",
        "documentation": "Range of Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeOneMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price One [Member]",
        "documentation": "Range of Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeSevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Seven [Member]",
        "documentation": "Range of Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeSixMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Six [Member]",
        "documentation": "Range of Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeTenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Ten [Member]",
        "documentation": "Range of Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeThirteenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Thirteen [Member]",
        "documentation": "Range of Exercise Price Thirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Three [Member]",
        "documentation": "Range of Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeTwelveMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Twelve [Member]",
        "documentation": "Range of Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Two [Member]",
        "documentation": "Range of Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r714"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r127",
      "r206",
      "r301",
      "r318",
      "r455",
      "r456",
      "r467",
      "r473",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r542",
      "r568",
      "r891"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r127",
      "r206",
      "r301",
      "r318",
      "r455",
      "r456",
      "r467",
      "r473",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r542",
      "r568",
      "r846",
      "r891"
     ]
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfOtherDebt",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment",
        "documentation": "Amount of cash outflow for the payment of debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "GTBP_RepaymentsOfPrefundedWarrantsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RepaymentsOfPrefundedWarrantsAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments in pre-funded warrants, at fair value",
        "negatedLabel": "Payments in pre-funded warrants, at fair value",
        "documentation": "Repayments of prefunded warrants at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments in cash",
        "label": "Cash payments",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r591",
      "r595",
      "r596",
      "r607",
      "r855"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r680",
      "r690",
      "r715"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r681",
      "r691",
      "r716"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r688",
      "r698",
      "r723"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r758"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r73",
      "r471",
      "r496",
      "r497",
      "r504",
      "r527",
      "r637"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r128",
      "r129",
      "r130",
      "r132",
      "r139",
      "r141",
      "r143",
      "r211",
      "r212",
      "r224",
      "r264",
      "r352",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r407",
      "r408",
      "r419",
      "r421",
      "r422",
      "r424",
      "r430",
      "r452",
      "r453",
      "r493",
      "r495",
      "r505",
      "r893"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r157",
      "r170",
      "r171",
      "r192",
      "r198",
      "r202",
      "r204",
      "r205",
      "r297",
      "r298",
      "r299",
      "r463",
      "r595",
      "r598"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual royalty payments",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "GTBP_RoyaltyExpenseYearAfterFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyExpenseYearAfterFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year five and thereafter",
        "documentation": "Royalty expense year five and thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearAfterSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyExpenseYearAfterSix",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year six and thereafter",
        "documentation": "Royalty expense year after six."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyExpenseYearOne",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one",
        "documentation": "Royalty expense year one."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOneThoughFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyExpenseYearOneThoughFour",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one though four",
        "documentation": "Royalty expense year one though four."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearTwoThroughFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyExpenseYearTwoThroughFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense years two through five",
        "documentation": "Royalty expense year two through five."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "RoyaltyFeePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty fee percentage",
        "documentation": "Royalty fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time sales milestone payments",
        "documentation": "Sales milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SalesRevenue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales revenue",
        "documentation": "Sales revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable to Related Party",
        "documentation": "Schedule of Accounts Payable and Related Party [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r623",
      "r626",
      "r830",
      "r832",
      "r833"
     ]
    },
    "us-gaap_ScheduleOfConversionsOfStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfConversionsOfStockTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair values and allocation of net proceeds",
        "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r38",
      "r39",
      "r40",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Transactions",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r364",
      "r441",
      "r742",
      "r743",
      "r744",
      "r825",
      "r826",
      "r827",
      "r828"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding and Options Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r71",
      "r72",
      "r73",
      "r106",
      "r107",
      "r108",
      "r159",
      "r279",
      "r280",
      "r282",
      "r284",
      "r287",
      "r292",
      "r294",
      "r418",
      "r500",
      "r501",
      "r502",
      "r503",
      "r621",
      "r741",
      "r760",
      "r762"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule of Warrants Oustanding and Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r157",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r205",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r229",
      "r230",
      "r402",
      "r405",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r604",
      "r607",
      "r608",
      "r614",
      "r639",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r157",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r181",
      "r183",
      "r184",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r205",
      "r602",
      "r605",
      "r606",
      "r607",
      "r609",
      "r611",
      "r612"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r201",
      "r204",
      "r603",
      "r604",
      "r610"
     ]
    },
    "GTBP_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SegmentsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Member]",
        "documentation": "Segments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative (including $4,000 and $120,000 from stock compensation for the three months ended June 30, 2025 and 2024, respectively, and $7,000 and $222,000 for the six months ended June 30, 2025 and 2024, respectively)",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r594",
      "r595",
      "r596",
      "r598",
      "r754"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624"
     ]
    },
    "GTBP_SeriesAInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesAInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Inducement Warrants [Member]",
        "documentation": "Series A Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesBInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesBInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Inducement Warrants [Member]",
        "documentation": "Series B Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r748",
      "r792",
      "r793"
     ]
    },
    "GTBP_SeriesL10PercentageConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesL10PercentageConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series L 10% Convertible Preferred Stock [Member]",
        "documentation": "Series L 10% Convertible Preferred Stock [Member]",
        "label": "Series L 10% Convertible Preferred Stock [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesLConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L Convertible Preferred Stock [Member]",
        "documentation": "Series L Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesLPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L Preferred Stock [Member]",
        "documentation": "Series L Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLTenPercentConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SeriesLTenPercentConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L 10% Convertible Preferred Stock [Member]",
        "documentation": "Series L 10% Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rstricted stock granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility amount utilized in the value calculation percentage",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "label": "Number of warrants outstanding",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Share based compensation arrangement by share based payment award non options exercised weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited/cancelled",
        "documentation": "Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Warrants weighted average exercise price",
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding exercisable",
        "verboseLabel": "Stock option, exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price,exercisable, ending",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding exercisable intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, forfeited/cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Common stock awards granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate number of shares issued",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding vested intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning",
        "periodEndLabel": "Number of options outstanding, ending",
        "label": "Stock option outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Exercise Price, beginning",
        "periodEndLabel": "Weighted-Average Exercise Price, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price",
        "verboseLabel": "Range of excercise price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested and exercisable intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, unvested compensation",
        "documentation": "Share based compensation arrangement by share based payment award options non vested in period fair value 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding intrinsic value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate number of shares vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r101",
      "r157",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r205",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r226",
      "r229",
      "r230",
      "r402",
      "r405",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r604",
      "r607",
      "r608",
      "r614",
      "r639",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r107",
      "r108",
      "r122",
      "r124",
      "r147",
      "r148",
      "r151",
      "r153",
      "r159",
      "r160",
      "r210",
      "r239",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r276",
      "r279",
      "r280",
      "r284",
      "r287",
      "r294",
      "r441",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r545",
      "r563",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r741",
      "r762",
      "r764",
      "r771"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r98",
      "r99",
      "r100",
      "r112",
      "r113",
      "r114",
      "r128",
      "r129",
      "r130",
      "r132",
      "r139",
      "r141",
      "r143",
      "r158",
      "r211",
      "r212",
      "r224",
      "r264",
      "r296",
      "r352",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r407",
      "r408",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r475",
      "r493",
      "r494",
      "r495",
      "r505",
      "r563"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r158",
      "r266",
      "r267",
      "r269",
      "r272",
      "r453",
      "r463",
      "r499",
      "r506",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r597",
      "r598",
      "r645",
      "r891"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r158",
      "r206",
      "r266",
      "r267",
      "r269",
      "r272",
      "r453",
      "r463",
      "r499",
      "r506",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r597",
      "r598",
      "r645",
      "r891"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r683",
      "r693",
      "r718"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common stock and warrants issued for services",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for cash, net, shares",
        "documentation": "Stock issued during period share issuance of common stock and warrants for cash"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vendor payable, shares",
        "verboseLabel": "Issuance of prefunded warrant to settle vendor payable, shares",
        "documentation": "Stock issued during period shares common shares to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series L convertible preferred stock into common stock, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33",
      "r51",
      "r54",
      "r73",
      "r258"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L convertible preferred stock and warrants issued for cash, net, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33",
      "r50",
      "r51",
      "r73"
     ]
    },
    "GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net, shares",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, shares."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and exercise of prefunded warrants for ELOC fee, shares",
        "documentation": "Stock issued during period shares issuance and exercise of prefunded warrants for eloc fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of new shares issued",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r500",
      "r563",
      "r579"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancellation of common stock previously issued to prior CFO, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r331"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vendor payable",
        "documentation": "Stock issued during period value common shares to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series L convertible preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r73"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L convertible preferred stock and warrants issued for cash, net",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r73"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, value."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and exercise of prefunded warrants for ELOC fee",
        "documentation": "Stock issued during period value issuance and exercise of prefunded warrants for eloc fee"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for cash, net",
        "documentation": "Stock issued during period value issuance of common stock and warrants for cash"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of prefunded warrants in settlement of vendor payable",
        "verboseLabel": "Issuance of prefunded warrant to settle vendor payable",
        "documentation": "Issuance of prefunded warrant to settle vendor payable, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for services",
        "verboseLabel": "Warrants to purcahse",
        "terseLabel": "Number shares issued for service, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73",
      "r505",
      "r563",
      "r579",
      "r651"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants for VRT waiver",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Rstricted stock granted",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r73"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancellation of common stock previously issued to prior CFO",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r68",
      "r528",
      "r543",
      "r564",
      "r565",
      "r637",
      "r652",
      "r760",
      "r764",
      "r765",
      "r778",
      "r842",
      "r893"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r278",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296",
      "r418",
      "r429",
      "r566",
      "r567",
      "r583"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r458"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r459"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series L - 6,301 and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "periodStartLabel": "Mezzanine equity balance",
        "periodEndLabel": "Mezzanine equity balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r266",
      "r267",
      "r269",
      "r273",
      "r354",
      "r356",
      "r470"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r269"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r269"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock, shares outstanding",
        "periodStartLabel": "Mezzanine equity balance, shares",
        "periodEndLabel": "Mezzanine equity balance, shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r269"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r845"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Exclusive License Agreement [Member]",
        "documentation": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandSeventeenThroughTwoThousandTwentyMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 through 2020 [Member]",
        "documentation": "2017 through 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Exclusive Patent License Agreement [Member]",
        "documentation": "2016 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2025 [Member]",
        "documentation": "Beginning in 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 GTB-3650 Clinical Trial Agreement [Member]",
        "documentation": "2024 GTB-3650 Clinical Trial Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2027 [Member]",
        "documentation": "Beginning in 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyThreeCommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Common Warrants [Member]",
        "documentation": "2023 Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyThreePlacementAgentsWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Placement Agents Warrants [Member]",
        "documentation": "2023 Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyThreeSponsoredResearchAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Sponsored Research Agreement [Member]",
        "documentation": "2023 Sponsored Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Warrants [Member]",
        "documentation": "2023 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "TwoThousandTwentyTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2022 [Member]",
        "documentation": "Beginning in 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled and unaccrued amounts",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "GTBP_UniversityOfMinnesotaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "UniversityOfMinnesotaMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Minnesota [Member]",
        "documentation": "University of Minnesota [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront license fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r161",
      "r162",
      "r163",
      "r164",
      "r465",
      "r466",
      "r600"
     ]
    },
    "GTBP_VestingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "VestingWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Warrants [Member]",
        "documentation": "Vesting Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Warrant liability current."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Policy Text Block]",
        "label": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Text Block]",
        "label": "Warrant Liability [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r646",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant fair value",
        "verboseLabel": "Fair value of warrant",
        "terseLabel": "Warrants outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (in years)",
        "verboseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840"
     ]
    },
    "GTBP_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "WarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "custom:WarrantsMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r153"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r153"
     ]
    },
    "GTBP_WeightedAverageVolumePriceOfCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "WeightedAverageVolumePriceOfCommonStockPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average volume price of common stock percentage",
        "documentation": "Weighted average volume price of common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "GTBP_ZOneLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250630",
     "localname": "ZOneLLCMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Z One L L C [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001493152-25-011971-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-011971-xbrl.zip
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MU0U[)#^))?_[1+)@H8R!%8+="AL>8 QQ/$XKSV4<(J%Q*Z%'QK[* N@$_BI
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M$J&-@$$6)8D&)9QPERE.E0W+<D:L.!%&Y RK2@SQ;2Q($,4'XT7P9L7FNZA
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MV!\N[.S-G$)W .4RA%>!,CH)\Z5 +!2D;=GDSP6_(Q:6=PN.A[D^Q[TC*8^
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M[)+J339<;D^[ =>47JKXMD'.)0?N=O<:]*/ICOL5-?W8^M]02P,$%     @
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MB9XI$8Y%]=XNAQH:$^T028GC,F$\F;,L<283S#KN1(SL1-O/$?I(4Y(K%O$
MMPS3,;C!Z5QN32 1@;"6FSF)Q/Q.8-Z23HM[(8S!E(H(A^8@@4":((LAEF X
M+$&\L]E$!A-F,_JW&C\31A1*: &QM$KP4"9CY PWP0)M*@)O(.E-89H.L4P
M DX9S<MNV"/Y22P%;Q/)@D4R 58(=BML5 %CB..Q*3V7282$QIV$'ID$*@NA
M$_@K :$*[$JCYBP%? CY%!%*K:!=H,H^F!K1$TI27"6)3$$ >-8 G9_.>GL"
M;B<L4GIF%V W8BRM,QP3<;J9VPTKJR7,VH4Q:];N8?LD<,)7YE<>>\@  G*D
M!&TM$\#I2$D[H51%^QTC[U+NI>M0VD!IFR&U448V6N7828T.1(C;EAT *J$
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M<\F!N]V].OV:.?]Y,_T*^D]02P,$%     @ )( .6WQNWF(0!   XQ$   H
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MW^=,4M%$6UA@FDA*7<!E(N-ZK6,9[RNI=A1"F,AB'?+,9Q'<E,: Y#N M[E
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MP'\EZ8%ZIGY)4[ZUT2]W_@)02P,$%     @ )( .6^4OR1<(!   :A    H
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M\?7?\YHBZT#6LUU(\SG%6__Z]UP'4_V3.7L_P;L^68_\^E_9+'4E DGX3'6
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MB C?4$SL.67(HG4MG#MP]=,^RZ($ER35@/)QAN0,(,"8Q%<1XE?0VMR,ZTO
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M^P:!)_DG!X(U#Y19?EK"P3F#P,/RWCBMJPOD-E!Y^/,)G]NURT'Q95BL(;F
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M4#'3E5=.YL&EJ$C*4.31,1_I!D<'CD(PT(&GUC%'MP :&D)3?@6:CIZX_2T
M=]QX#4;>7#F2I6&++;GT8!X=G\,4""[2A0M;;(GB8M4YV<$!.D\SQ3)3)OC
M"Q]'BHOLX,6B!N$>:(!3^5$5+G/@%4C*Q&3T%+F*)Q!UNP<27+R%-ESW9UT5
M.K4<CVP6Z-NN_A(3?L(,##Y5&8/%<8 W"F\:4^M%$P&$0^(XJU,AOY@*P94F
MF0ID*NPW%?(1ID+^ %.AD(5_+SXY4Z'[IG1'BJ%QLM!]@S3/S-1!9P*AH*A
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MX/O_PD4=F#D;Y*NM%%%\H/^A1IQ&#40)>GF<)-GEC1K\^\40D>L'/;X^L"^
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M1^<B-[3#"#%FR&X]8%=>/<!>&8\5V3M:UU5N?XCM3O7MFY1DL?U> 3E$P5:
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MV@!/Y/;Z!#R8@H>89>]9#J[AD=7SEZK"LZ'I:(^ UE4\<BIF7?HEIP$![2
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MDM6N]E7AV=!TM%- ZRH>*1:S.OV2TX" ]A$ 6>/01::::4W01^T>O!BB)NK
MKG6SPK?W@%>&LOG$WEQAU=;SV^UD(*>GF=,5)ZK4*PI"6VVW-=T)J)@#42SB
M"? Q!#Z10V3W@NSPPDUT9 KA(8? 4XCDG[$3W4XGZD!64'(5+X7H6X=(HAMC
MU 94. 6R<0@[T>&N<+RC0(7H6XZ(,L$7D<2*?,]R\(T$W0&]*?/*&-PHFM:;
M/W__WIQ<5IF6$"5>$T^5S!?*N<IZ$[QNL@];((GF,"1(H8<0XGVA/X#[BBH
M=?&Z2PFR$KV4TA1)%&*-9NT$>)AQ)#4!7'A_. 80P2<O^,#FK'^&FV#EQ+%"
ME,0[%7Q@)>%_RAW!"L&*A17__;<$*R>.%9\ZFC7W)X'*K$)I[^.]F0R3JX2)
ML"2-Z<W:&P+G],%Y1Q@PQ"Y:@EB"6&+1$\'C+GBW*"A+NS;3W6C%-%(DR##-
MZJ?;$QN]^3/STK[_5?@A7??CKVAS>,)\+.R%R$M.0NV6,M1W0P84F\M0B,"
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M/AKK:VY@G)7Z>66WO0 \/KUWA5;\$CQ]A71E[1)6.6#;%!!R$_=W7-S?&W)
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M+EK[]X6[FX[A_36-[TG"%ZX)LI7M<5/%[2R['_K7>@K_XJ""!0G__0O;[G,
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M,>/0T</ADB1.27$E<?:O7QED5D[;(_[^=329E5S%$?VI\-.JBA,!50Z?I6^
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MM! O<C#L*9VS2]<YF3I?:?-3JO[ ZT0XC!9U2>L-YW5,*7'T*$H!CYF?-_)
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M=V;GT6GU#=)I<]':V=VE4;\<F"<!JVFCM5<&4JS-W6,L"F Z50L5H9QL.@5
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MKY2U-CHE'LVSJ1%^QR3F7CWJ\0S@ IG5K-')PCRKD([49_,T$!PWT9$:NZ&
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MV H 7KJD EZBIB()#8B%U0;9'J[<X28&KJ>NR)LS!QPT,*CH-UKHWN)" BM
M+\(TAO ^]QO^]!&6KO5BH 5T#?H&J56!8TX!70D,::1V9"#\NO*BN==VK7A;
M'5U;9ZU6H-0Y8 >X&7!_D0$QG=IYGFVC.4<&(])\ICKFE(JUQFXCL>_<$][S
ME V$#I;53KEXX''6S&<7D@K?0,F4:S(R=1L%21ETG!O+RJF8+\^(W/UV@33:
M)BS9Z(#O37@2K"D9GM&V#?C79R*O);>!\8=!QGGZG'8MF?;8G[D8-I#IIP-\
M.6D3D\=/?(X\-2!*A@9* UB\?^Q#NA)VQ$.L_?&,[(3GH?%)OT8HTC0T9/*.
M-#3(E5*$9LO0'+='!P<*^:C>(<D5/D7.4I1G?&[<L>_&_I:4*E&A1 $%26&C
M6*9]J5MO;P6+=@MS+8YIJY@V@E3GQU417B-[:K;?!;\^,LP;Q:U(NNHD)C1B
MH;CG25A-K7SNO"C.OC8ZNWTJ>2K".QP^<#B.CJ9J5I3OK!M-0_[V<;\C&:$I
MFQ+*@EBIX^S!D+:8&YRD7DD==$YR._!U34+J($XQ.2J,5 )=G#JZ H[L4GA[
M7>"\RULX[V7">9>W<-X;!S^]3*1I-@]Q/ZJ4MEC?N=L)38N+RO "C790N1]5
M^D>)[5/!MO]P.CZS;O<_0PA@/UZC__FNOKQJK[)6]E/I/J&P!O5HI6G*Y+.X
M;02<O:7NI=D6FD^RZMR5*U/W$O"U9FO2"MY,4IZ*6"'LZ[]3EART.4#B+S;<
M?/9-!.XEYYTLABK2J!;$6'2(>)MJ<BZ<16WR_2@P W:/N:.0)BSPPT0J!J?P
MR@Q@YETK)EGJ4HFY,1X>J2?VW?.XG$S,WG9FN_ZD#>5,!8O7NQ9WB\D#=P))
MU4F [@EUYX8>.%981<I6? ;8^M&KT8^8Q+,<C3C!.L;K#<?R,M^$JG=HSIOV
M$"E#%3] RX.\\4E>N(:@M% 8.Y)+=W.:/OX+C75I)(7A0A=BG#@-J_@M=5AY
MN'<XKJO&V0]EV3IL>>)_/LB(J>(_*N:36-T=NN>%8VB4$8LH.QA$52Q\?R :
M$X;C(45,NN%& $VWM$?'<"7ILB,-J\&\Y12,B<D54H0@3.>"" >W41U@H!=S
MS#B#$)-<:BN4Q@!J4I"B0>0Y)J;)N(Z#,9=P>)'FT .+2#XBS3*\E#+MS[6U
M<0CK@B[%#>ZH'7("HYZB^_&+UIB<QYXAF?(N#PZH'!<,FGH8H9@(;)&%1.P>
M2(=N;ZE!D8T4U#E[B!?*ZZNDJ[K"T0*PK6>XG0*UG0(U8S58$"052QJ&M)YA
MD2O%LED<W0F*@E32&FU%D>-G=X;2!^R#&!]W,0BG9P^2\LK9LP<)*8.';_>Z
M?5X[KSP%#!JV%5(^$@39\,XHJ+ZC\'I$#WDEOG VTZV?F4YDUCQTXNXC9M'<
M.85*H5P6TM(*!8[F-#%5*&F:T998.K+OBG8VD)26P#%8+$FC!458Z4RK2WG2
MR.,FGXG=C!5KDQ.$XVB92Z5ER0Z43/B@U!K8+-E2:%9D"O'DUA ^$3['>?@=
M<!1CAA#BUR\F0Y)0'!+:=^":1H%"<9;$<S/"8<NKX!<X8N441YXU ^X?-0A9
MK6!@R;&0?\RP*F F6U,"9QP:U<PA,21>-3458ZZ8^EF,BMA+0_(';H*,-OIG
M(OTSM2YO<D2O8L%Z,!=BXBR"(+L(0K1;\;;=4V1'\U@7:U!=B70'+]O3D'DQ
M">$*QGHC!%"<Y?O@@BD_KT9[=R,@BD_KKGG"ZC*D%.I[![]?[>:/RK?^<['\
M+'I[ ?<"]!*\#*Y+^?2O>RIXS]FI('SW,R7;9CW+'4R<_<-+CFU\Y:=GZNJ8
MJ&/?)+X;_>HGS#JEI.MH'NL3RTVE)>GFOK\)ZP;3<?Z;R(-&"EUR"UC\*\].
MTTNR"<1NS._MWF;A%/&WI(?1):!RH_H[QC1X-<Z$^JW5LO<ZO6@"-3%G&[.W
M7 _VALDQLJ$CI&(2V$PXZ9ACC5GBLN[Y32XUXSW%7DJ^]O>"=QWO2+FG$/*!
M-F'A?O5C=/$KIAI2%\!$I"<!PB-:B>6ORZZY07-@!XY)BSA5@R430H9PX/._
M>[DY%;_NS\XZ=P^*;#Q]2A?HH#& Q+NFX>@R:@W#_(<WNZW/8K%<$$OU@EBI
M?)D4^DR55%&5Q)1PS'OJZ98@601+S<<*#K8J\:_EB(OP6X1\MYXJ$=U75B/O
M).I[@9=. 3=8D)Z7Y"8*69.G$VYBJ5"MU]/<Q*1S7_U5OR,:]H(P=3%8V9\0
M6PC0#YHI;OHU4NKO8*WYD@,S!^K+Q;6R5[]^4B/(YM.C+L&(0* %X&WXF748
MS'7@R^+AF5+?R<T&I=IN[6V9^:_I-D)YR39"?%=Z%$_*)6OYM>+8UJ-2$QIS
MF 8//=56)NV!?(TO/V3_MO[!'#[!,E7#+.MX%Y:!FU@/47!$D,P]/+=:*-8;
MLQ@#L4[QJN[^P]&\;S4<O8W5,)M4K:E#??QX(;4%*6]CX>W9?@4&1!96SVG6
M0U7<3<1Y6C7/9[ >JGE:#Z][=_VC=O>N?;8G+24PX!X8#4D+I/TD>HCB;F4A
MZ75GV)*6\<(6?=><DI*\EI<-![CEC0V$Y*6\!QLA+"+$N><4-PJU6FT1:X <
M\]O9 Q^#SGVCH+("H^#UL+;_XZSV<O+KI;,2I;YJ5EV^7H^PYTQM#VG3FHJ[
M:\2H,4K<[1\,%F=YF9/\V.+CY99C4[[>ZZO%?,.F,R>?O94L.7Z[8#H9+]5O
MI<W_S/P,^5%LAOQ1[8V>QLJAJ)3RS9#[FZK.OZOX1&33*_4@E[$9_S$ZL$F;
MO_:*4EHS>3IO3$9I2UL//GN#TY@Y'!#AB27E_#] .<$*KSLV$G"T0 WS3*4%
M7K\#C8&Y,:Z7L6*T]H^ZC\>]I<0.<C3)+B*UKQ%>6J;(6)4'N#I/?JG5X;&T
M%G$;LB8+)[QZL8 ( S-X]<N^O(TF/-_[;LSF?8,)XM+0TE+Y"3+KZN;;Z_&=
M)A[-D<,/%77'^/!KY*#'GG#^C)@31. L6?O5!MOW\E6Q4W)(3:_YX%I2Y1-]
MGW8>N+1[_^M\_^QH<""^5//+U$^:,/FF%IN)#17;S.::9O.7H]_=C%XJD4?D
MR]P-8*5":9O,7U^2]RV'\EM9#HN)XL-GM>W<E1JG^UK^=L3;2X*5V!ES"(32
M3(A/[R;E?[B %?):.3AJ=T]N^@\/]6V&_]UD/M<I;;A4NR$B .:N]:\4RD)J
M2_@VH;\&9+WJD,+KTZ!<O/PIO8X/&RM2Y&N;U%] ET>8-*=B_O5/ZP/_^(G]
MZ%"50%=]L_;[53]JE8Y>+LXK'7G#NN2QK""$K(QX<SNW2A?M:!=0&2Z>@%.O
M/_A,T\HV@ L!-.B?W;D+X2%?")V!<^9\D V"SC(!LT$&UR4%03@/0$1"4;)C
M2K:$H"*JM<9@YDG]PS%,D#?(1:GV*6%.2F T-QNFG !Q46S&#I1)^?[OUW'G
MY5*^-YM6M;PH\^9\$9>&K7!5 N8I"%\CB,EUL?[[=?3:EL[/[1>C+'_ZE\VG
MH13NXZ" 5F.;]J[SHT&:Y7PO]*"Y\$&O"'-LV4>=.U,WDI%K;@.S86C,!BD^
M.F Z"<WF(!;-9L9G_GX]NKGY]?.G-FY?:&NON\GF.'?N<W#2J3>*RU)?>"!.
MNX>#-V50/R' 2 HOB0.%#4TS1M8_&TVQ87FX5_K]ZL@5VY:$Z]ZXF@7BAY$%
MWT3XK6#IP#*++;/-U]A"]&1"<ZFN#>K.K?I"EG=!F>]PDOG6"( G$(K<'/I:
M&3#0LDGETAV(]R8[_Q!'_$ >#1S8!,(F%8!O<=(;R69OA+2V)F)\=CR"%:*E
M;>\JM-I#-J2<K/$:_)5UPKC+RON+@G+E0.NA8:N2S1\H;9*@Y4L"L5S*'Q"_
MJ!;T+G'*PAX&\["F0 &G"WVNP'CAO;'_$3;'L0E>FGQIZ#3T0CW1$]T"!YE,
M>0S,FZ#6P&_U-C!((SR^\K54*S=$P]GOE40ODQ%W>06^I8 W1@8VMR0-DW1O
MA$/D.?LK.+K8@1WE'4'<P9J"8#"BO-A4*:$@B,5"64P<>;S%%%MH8__)! RR
M.$D%2<@U%)F=Z*H4HDU2>?+*&.X-QC_Z!W_:/D^Z5J=$G\8K['$(@H]8W^O"
MGB3 OKJ#G(%#YYN6%IR3)=1WZY6UX]!%S($I0%Q^=<X"2SY&9:+([[.'86^Y
MRIR=7;*L:!?O'FX>BW+_L.[)"B\($!C?T*4/6F'7P1+U]+&[F:Q)A) <F&]>
MGB<#JH5RM5XH%>O;;J!E87'DH#X8B:3JX$2F^M/OOK[<7]9NVMWL"GCU'):7
MJLUP5G.RVGP3ZH(J5]PMEM>#T9;K=>>J<8\,LZ. 8I?_;J,EJ&GO5?M6EZM]
MV3DZ0(E-73Y\&:@F>:CU6[VD58)JO  9?K^_,XZEYO5Q*U4K=R8O:CGR(_C%
M'4MI[Z@O.SU5EA5X.!REJ+ZT3 T8MH%G7A<%T3_TK4[+!70R!SF=2([S:;F7
MEV_E2^UV[]@1LFNY=:/8BK 6%+L2'RSOD+Q+)U'ED!+;_D -9LM4+-[)3U,D
MOX8WQ?O3 Z,JM%,5B<NF\INT@WU>N0=XZ.]W'L.T,E\LR#5*ZZ5:H5C-'*M=
M=B_8ERW_+E?Q>M0VGZ+=5V\/O@_VGXPG+;NB?5N.7J[#F>D\Y^3L^:([89=3
M$-:%M=_,#\VK@2PI$3Q/^=I':V:KK#Q1?)@LQ*SS/_T;YUIRSJM3$L4*O>1H
M&FHMVMK>/'D<+[3FBY,%0M*UBE"H5C.'I+==JDME[)1L<[Y1[LS9YA3&/AQ)
M_?;QC[W'X@QA@'7F\77(0,>S^4RC)V)MD])N,3/FU9LP^1(#(;F;)(RHW0'@
M6Y,D4\ ]/_&5Y-7CA?Q63P(BBPBJ[H_&K\KAT5A\[4Y:((&[_!#2*>WLLDND
MZF)5:^5"HU$IB-6Y47&V=L>J[(Z]901$D-C2[8Y))E8NSNVG\N5)\VGF6,B'
M8>ZLYSL#HR]>_%;9+<\=\5RIZ9$-6T/X_;I_^*-U*#X.G*JZ]OVYR^A=7_JB
M[WH*)W6[IM*5; 7!,$Q5M]0VFV=C='A)TWQ<G%"$2)?#?QPJ%I$0\/N0V6;A
M8R*-R/!+:3 PC1>@:5O1QOQ_POV\C6(N57N3;L*)NT,RY89(/[VB5X/R[[5X
M=WYZ=_B@W/GU]NQ!H0-@^XV<V=+"&M/V,H.DR1J W:EX*#[5"<1M$#9)LH8#
M6M1PZT@+$S=;S/%F75EKG>ATU!@!E(M<<O"&(Y[U=?77]<535ZL,JZEW'23H
M%5]XEBW.%XBO9HUII=%!+9D,>$8&!1ZTTT#!-GM@]0*"Y"A2N\>W8<>\!Y.#
M^ 6!45H@,_ W>&:2/B;U [6O5ABI!WX(R96<D77>"H)#>6EKCJS\&X1FN@;#
MXBL\Z(^C@$D%#ZA\Y<G5@^8F\$S$JI758=94%)O=9!L#LEOO%^X7JL3LG@D%
M(1NV01RJ2G(H M87:Y2DCXX*02F$$*[8 7[E[\8#>'_3E%IJVX6ZPD.^-/ X
MA4KP6W^[7\,_^9:,:\;\]V\X]Y@;,!7I>:>E (O!LP?D H.G7HTY=7H<DY/$
M@M0R"+TPN$Q</UUB@(HVE1'6?M'7CHE0F#9G&T1474AC:MV X3]$:^H:>(Y(
M>!1FF9#)4%]Z\9* ^.-5,E,3_L[[QAH\-*I:#W-4K<=TF"=3.L>F85F_!P/1
M=14K)5>1DI]FF>! C^(\C%?( )C]!['OL^-@V#WA!U$H)O? 7 CGTJ!Q4NGU
MOU^<ESR=WO1.3?=*<RSB-;&C7;86CSG-9 3&DN#_Y$YM2#LT]I&XXXAH_*SA
M;3$FE%0JB*5*H5%+3&'Q#!K+H^"1:O>09E5XE"IID: !WD&JV1]+ 2'OVONC
MA^TDA ,:8=J<FZ2^V=^$?>7A^\#W" [#>QD 31&"FD9(<VTJR;8/$LCTVZ_-
M%TJ,UOHGAA+]0RB@\!KS\%,X,&0YK2>P Q$YL0TR4 )+T!CIBFGUU &OJ7W5
MIM6R!4[M]Q59I;ZA,X!35!GN,)&1/6D(/X" -_M(11Y=@9H&,H.G=\#4Y,>*
M9%J[?'.*T#R("LW6=#9O);#Y#^(3TN0RR#YR:ILA-:N/WX\,71J/+[M9I"9U
M?C-)S9R/\PW$9BUK:"Y.; I"H5*K%LK%:B+?X#;1R_0%)P*U,9V/0I2;38B6
MWUB(LOU$2>QZ7#V]:5U7;QJM]16CL6N/D$,>!6P+R-$X,3ID)(32,5ZD!@0G
MET5P4M!;-$)EE !V3[+)OZ3!0 ,/#=?A8A$&9,(N?T?-UCX+_TS0-K@Z/;(.
MKN-H&F]*=KM'X+;)_9N&K=#[)O%%,[19^":<C"2C,4\R:@6"9NB8Y/>R8K5-
MM45"<M1X1C.[ VNE<O] L< 5(*?!,[Q$=U$%C@8DV<8\155 ;QE5$+%D6!2#
MXOYZ:R"8OX:NLV633^*SO;.%5Q^;"@B_GJ'PE!)AW7Q',V 5R4PL!ICX0"$N
M!=S-$7XKE+EQ?+J*Y=<I@U%<GO662%?H\NQ>^^[B3^G".CGR6/8HL/#,_!JW
M@RSL&+NL"#LNWL)8W"U7DJ.9WB;YSP%B]$F P&^:"GAU%C5/X-^HQ'@+\;0M
M#'\Q4&CUE3(C^90%S*E)9@C)\\M["&'-L>B852X1Q7<VSYWR#0_DIFH$]GO2
M+Q^8RD['(:"/7CH$GCUPS'9/(D21;H(>35/8@:@_\GTLGSLM2P63V1S?2AX6
M;F3X$=N?MSV7RY_%4?G^^WG]X:?BL;D[Z /7&[._N11T8!NIS.].$(I?;X3]
MYRO9\KS:8C%M> C'=!L<0BCT+!$,>3APA3;X$1F@HC8 *W-H4/V(WU"IB A2
M T'JC7\L<77P[ZBAB9C@ B*'?!%>9W78D;,@.:R$PM!;O*40<00ZB"G!:_>M
M3: _<HA41<>1;!_XH!707*#QD<AMX"9>ZL"2PEZ8H]NJ;X\2M8LJ_8.*L-4N
M^D3G/*D5(Y"\*\4;-K4Q6F!1H5.96^B\-H\O7_9ZQVKWN9K<\Y8QLK:(H A+
M@OIBI5)BN5!JS"P(0IG!Q* %C81Y 8M$*QO^YK.8G9X[S<FS>]7V3EKJJ-X>
MG5;6SRV+W/#B-3+B;CG1$0]8>NS"P@G)*24+0N!R D,GZ"Z3F<D^^CX^,$\L
M_:[CV]BA]S*&FG;X:>^<X8SG'L)=+J=J4DS[OH NTKN*!U@_DH 3B-"08+NF
M2MC()/ZF;Q7SGS']*Q:__KBY(S\)7[_L\B>Z-WV%I)11'*)6(AEAW%PA3C!&
M[ZP4#/XA0Y^0SQTX)AP:#=93R@'13/[D.5G%*9&\*7,H P-*/"M,V?\V:.WU
M.]U&C%3503=$4Q:1S33GW4PU5!61RV:.]EKW^V>/XY,G(>-FTB.)F;:3'!LL
M"C'FY<2R(YRP6,_/,C=4]3:$91V9-[28J5Q)LI23*@[3+6A]V69*+G3<K)X7
MGSK??UQ>:%E,G5DCL;&+SXT)K<>7!UW0OC^\*F]JIV4ET,9B%MQR-C +AS46
M0RT0$YW1N5C,S;_ZL8>9[)G#Z>J$E"#17Q\9)C@K0S#QXE7DZT/Y[&"P_Z"4
M[WI18@RI F(<6/11!:_&;G95E[JV:@1CN7I5.KLJ_?HA/LVQMGD$??SJLBFP
M",W-;;"M8.%A1159>%;].K'PFE"?BT]L@Q\JNFR WT4".'Y.,GBQ%HV09%%.
M;RS?#R^&W\RQU;F74T#,EBS?9Q*/BQD@R>*1YLT2Q" )U%EV$(XG[4[WEV]P
MN$D73$N3&%PT53H2GH:MFG+WV'J[BPVF81(6&KI=H;B8]DXT+U-U',E+1A.D
MRP_$3"6215+LBU)/KWC4N6Y?BL;!&M<K92.I/ (^E62B"F3:L_HC4W,U]SKE
MRV7)AFOS]?'J[,&6_]27FJQQ]Y'?92X(Z[R@@(C+>$3ZR]<TVQ'7B3^BG?CK
M,0\T8 DP@HC20>*,4*$8'OSK#_/TI(KC:BH"J>E=V!WYGX3YH,5 ,^V<3_S=
MFZ7F*<JEMR_?R]='QHM8[BZE<W$E-.%NB@LU_L4T]$45\#L=,KKW^_7R0'H6
M?XFJ84@S#!FU^*M(ZV2 [%8R>)0UFE"H4LFQC2RS2!O8KL.^:=)96?C5F<>3
MQHP/6]V,NV5C+*[;B#9AHB/KS>?ID46F<$"<3-G :6[I%#\+.*1W\OG*RP4O
M-'X@^@UF],C&L_X'9Y^V_@V(/7X3]NDZ/9NX=C8?,;3P-Y23ZSRW<E/9D(:'
M-I$X XIA2Z+OF41=H)R9E(4WPWGS"/M&Z4LJ#OR;:</[\"2,;6!'QKG:4?C/
MCQB@_++EC2UOO!_>"(UOSOJ?M3!C5C+;>=G#5<-O$XMY#QY-*8V,;Z6G4=ZF
M8_<,$RA%OL<(/$DDTE[0:TWRL7 ('1"_XWXP4$SRTSGVNB5BZ,[4OQB)Y?W.
M8^E[X\G%A]]*?G6E*VX$<:R9VL'+KWUCZ.,8D,^$.O=(.F<^]()\CCP->VA:
M7-C];7CKD?CPXI"\Q=TB/&E*<<!V?/-286DGNNR7CI0?!;;<0!'@/ Z'PS_C
M@Y>)BBD0 48PA;]L>;[64/WS"Q=A073=6A74>.91)%N1DO_&\AV9'F.K7O[=
MW%[G>[!!RV\SU^$=J*%N[Z2MMU_,WH^G25CW43HT] :,@%A ?2Q>GK3>MND2
M9D6L2E0N4Y1,'_NT=6?)K^Y&ABM$.O?EFX?KO9?Z:>U#N+/>UB,B(Q?P('%&
M@;$=!IW)2<T%=/Q#.*D!QCX[&_[YTVD63XV)WIE@Q7V<N[IU43,(C,6Z4$O5
M1D$H91X[MQ44;VM9E/*00).DB@!I=SUINM'LI2P#6<@[Q*+Y+=N/[\44>77:
MM5\OU<.?QS%CJD*#,B><&],]'\+K;II6(VE:TD?RQ9-$BY=-)XF'@#C8L93V
M/[)CXKLC<J/Q*2\9N QZ0C.F,3'^96O$K+%LJF\#*',*G&_RC^/'?75H]]4/
M&D!),&[$7""IU\L;6FY]P'L0),UM^"2C".F9BA>%W;O\I=JCFGUB53Y& ,7?
M?$1HY-$46DS$>]U:'XN$4(ZV(91YF+OU_;Y_6#X^&PU3$!6W090%A,9BS<?N
M\)/,\S6WXF+=4S3;0$H.<DLQ]G\<V3^ZKW?U#0JE!(5$IF"*6%OS8$IY&TS9
M+/E4W 93YA8ZS_)W^Z)S_EP^JG[4<$JBF;-XM?3:^4;;(I18"3)]V.,VBD)^
M=60XII?Z*8ZMDX/]^W[K8P11_+V'Y40IC\!K,I+ZUNA8)(92W\90YF!M\W!/
M$'YVZP?C[C:$LH!MD2@R%L0V3AVOL944ZV5<3&_8W(9/%A=9QK78K9\\[IU_
MVZ!"E*!\R!0\*56VP9.M=,JY2FX;/)E/Y/S9,SNEGZIYV14_:.PDT;Y9?([H
MVKE$VUJ4#''8;10EDQ!1AUX ]O1(Z#W_.#WLW6H?(XKB[3TB,O*(MB;#DV^M
MCT6B*-5M%&4.UAZU>D:[5FY?G[>W491%K(P$D5%>YI",K:18+^,B%Q&TC:),
M$5E_?LD'P]YYIS*J;% 4)2 ?,D51RJ4UCZ)L^WDV3#K5ME&4>45.Y;YSZ]RW
MU?TSZ:-&49+LFSSP#=;,)=H6H,3*C^FE_MO0"?G5K?KB"H[O%W?2>?7T6FV4
M/T3DQ-MZ1$KD$6NMEVJ5M9(3&VYR^*&37% (/D3H),#:1]565V^>_!A4.]O(
MR0*619+(6'!VK%  VV0;.-D,TT+<!DZ6+[ >^]K)L_A<'5=:FQ,W"4B'3&&3
MBK#F89/R;FT;-MDDV;0-F\PK<)K[UV7S^?3P[+CV0:,F";9-)0]$@[5SA[;%
M)]-$R72\R6T$A?*-,E1T5XP,[Q]>7QSGZ?#N8_3P!#8?$1N+QUK+NZ7U$AH;
M;G]LL6079.[1B7D^/+,J5WO;(,HBAD:BS%@,3K9<JA4:I<P33[:RXFT-C%RF
M+FWC*-.$5O]9OQGTSOJ=N](&15*"(B);+&7=(65+VQ*4S9)/1]M8RMQ"Y[A>
M^G.KG%P6E?)'C:8D&3G5Q=$-ULXQVA:AS F8OPVAD%\=XFI<V7%_JHBCRO?S
MJ_WZAPBA!#8?D12+1UXKN^5UB[QNN.'A!U'*VR#*/.Q=4>J.>'FCD@CA-HHR
MMX&1+#860Y.MUPOU;1?/^S$QMD&4'(36X<N%T;Q_.K^2GC<GB!*2$)F"*-5U
MAY+=!E$V3#XUMD&4N86.=";_,AJ-[P>/[0\:1$FV<18'-UA#UVA;E+(M2LE)
MD%RJ_HCTP>#FE[FW_[CW^OPA BK^WL-"H[9XY+6$(]'72F9LN GBAU-R20=_
MB'!*D+?W?IZ>:.*5?GTG;*,I"U@:B3)C06!9H5JH5E-PU[:B8K/,BVTT97&9
M99KC/T97O&F--R>6$I0/F4(IM74'EBWM%K>AE$T23H?;4,J\$N?1/M%/'X1S
M_<]'!99-M&\6!SM8/Y]H6XZRQ419:*"77\A6>ZJ^GOXX.2V]? Q,E+OXHK7:
MXO'64FW=H),VW.38MO,LQ-G[9Y<GI>>'J[JVA419Q+)(D!CUQ;!DA=(62W9S
M+(MMW&0% FOT-+)?BNK12U?8G+C)W8QM//7U1Y*M;,,FFR2;A&W89$Z!4]VK
M#/2#8M4LRA\T:I)DVRR.;;!^WM"V^&0[CB>O*C8MV M8-D[*WV\?*G\&3Q\B
MA!+<?41N+!YL%8KBND5;-]P$\<,HE6T892X&+W5?A8'SVJ[8C6TD99%JUV3!
ML1B^K%"H5VO;6,IF6!FU;2QE)5+KCU3_)1R8ZJ_NT^:$4\(B(E-$I;'N(+/%
M76$;4=DD"5791E3F%SN#*_'FI#W2__SZJ,@HR69.8W' @S7TC[;5*%MPE(4B
MLB-%\Z=['9W^T(Q.]6[OX4,$4X*;CPB+Q8.P0K6R;L)BPZV/+3K*HOQ=/^S<
ME1NMD_.';5G*0JF;9,&Q&,IL12R4A&U'SX98&<(VFK(2L;5OW5]\M_4728UQ
M:]8UFA*6$=FB*>L.,UO<K6ZC*9LDH0ZVT93YQ4YY[\_>Z=[/RX.?,>/5/T0T
M)='.$8N+PQVLH8.TW#*5@23C?>W09_S#"P/[*[\J*3/UY:N?9+@-P5 FZZFF
MK?A!W,9Q];L\*IJO)>%C1&%"^X^(F1SF@Q6KN^*L4$SKQJJYOBHJEUJ&"03@
MO6Y/ ]F&+^4M0U/E%>Q[.W]Y<:GQ\DLH]A75&O=F#NW,<O_;T$^:M%H,'+=6
MJ-4S=R5]* FU;IM=KN4TO11X&U;*1VB:C6\WS?+E]]I5#'3#V@:6(A(H2VA)
M+*X[^.[,H:5UDPE; 9B; *QNHU:+2#6G63JQ#E[TH?-A6ZO2C+3%T28VQ:5<
M0G%0=!?B;N4M15',ZQ<51HN^?^7;7WUL@+R6EPVGI2G;\,"D3O ^P_[HS>\^
M/3JY;]R=G]Z4<_'1D^_AG;OI;"&_0^<;%O/"8A AY4*C42F(U=*\_OB[EPSK
MN.'EFJ7['\HO?_US)C3OCU]:[9/U=HXS>L#"NH-_E'=+BWG Z\"!6Y&3J\AI
M;I GG&3U6-WSTJ%SV[X_DMZE.YK%&,D!TV.WF-)ENS[RP?4Y_[8EL$K_Y;@)
MF3;PZ+O>%'^_?JM;YH_.]X?':N=3< W@(1?!NDU=P5>^+YE=%3:"'RV&]]:&
MZX:+F'=W7WGR64M]5>A2)K8[P-T-%EQSGNO[;^M?X(2^H7,DDL0S(O_OWZU_
M\UUT^*"?0$*IG?&ZG_32%WVB<TV06AH/PD'DP23@42Y)^IA7+.0&U>J!H,/?
MDP]<]76UY5C\B8Z4J@X5'H-^_&?\P/_YWW51+'[%7Y ?A:]?=OF['OO(2+)X
M:3 PC2$\KS4&8\SD]PP0;#R(,L["N^\9&OB+%OW2P#$'AD7J1VSW&:K%VP;?
M18G%DV_@=WF#4@S^";[4[DGX+7AZFY 5_6"!?A)-'E[UUBZA8(7#@6_"%SBE
M/]",L8+'):NFTK8-TZ)??%;&*$TM1[-1 ] 5]J47M>_T>=WSABTB]_"GX+MA
M_9(-GQ[S+06V8#EP +!0R\%MP*OI*CBR+?B3@U'5T)YC1L@M;M,S/CLF*NU$
MOP;Z,*CZ%(ME9I##3R%%2KYX-QY$ KJ,*#R:P'6[BO3GM].]WL7/VV/3A\+8
M#QX.W3W/=K\T+SYVN['E0.).L4PM>/*3;\$G;S.B.!=KIQ"J."$E46_N<DA[
M/J5%*9W2CS8FCHP$:]4TA? 8KJFCJ,1NH6?.:#%"<$BH4A<,?B!7>#!PR5!2
M-52,^ 1Z45SX.[M\DZSEU-$5OE0LH*RH%/#/I@+6$OS/4MS227O(CX#Y=N#K
MOMCN'[W<#H9#/X)%=0V5'*'8U9+I;Z:0482L%H0\$<N%:G+I*I7 GBP-' FA
MG:6(H*DN:8QPBD8+7EO*66UTIY[O5P-@6O!$M8V43G>U;.$RXT;2JA!M(^G^
MQ<6"@\"0C5)B_H?S!0K\7^SI@=Y$_P9$ (F&1,1&@1_UU':/&.<3U%+-)01.
M^.6JP[*0KE Z,DQRNF&F7TAGP<MK%^*M>7)?\TBJ.2D$EQ=Q3M]IECQC5ETE
M+C;-2Z@6A)(XC:AB% @?52!7NC8&_0'_ W**Z ^JXYA-R \-)$&PEL!Z,Q4T
M\>Q,)A@W@PG&)YA@8*VF=M'A&T[(0P\<$R0FY?(?DN8H-QXSD4^1ZSTV#<M*
M$&;WU5&Q:52TJ^["PFR>5<TIF;)&"HKA.,&G?ROU4J%4*B?:.L3.[AB:9HQ0
M$Q'WG+></OA(X,-8?%!I<38<C$4?8!%*PPNTU!<>R,#N6;P"MRJ';91_PMY:
MUNAN^"@4JRT-L,W#=)3(P4P6,+7!G7(TA3'W9(F%7TUA-6$K0] K=[CK.UC)
MG@9__!0*1C3J04)<^.&_7XW&^8MY5W:D86O1R,;R?.L0,];W*K]?*^/&V=Z?
MU_/#BK=J6;4&F@3O@BM5/OWK'@Z*!G8&O'L(82J@5(:&,PM&$<+%?\.GVNZ_
MYSR;'520__"28QM?>98@;0.!2P,+-NO^])4?J;+=^X>O%__RODGBM/2KGS*5
M2*3#I"P8:IH2=R8/HH%27(XF?^575G\&IXB__;^?JIG+Q6.6F^M9W:HO9'D7
M5!0=>J*(RJ%9RF\FEOHV]3=K15Q+IB/Q4PI9Y[IMK[+B37;^(8[8S9GP+&GR
M-B>]D6SV%C)<7!L9[F4FUD96;Z\J8;5N(I2LD61#U^C6EMNPS0S':O&OQ4D]
M' :T^0.E36((?$D@=DLYX539&L1%EC"]LH*]1?AKI>6<S>5&KF\36\-?[^]O
M7NX<X:;\5(JIQ(R)W!;XE@*.@QZLR70/K?K71A1?SA0V+^\(X@XVH(=\\*6&
MS1,H?R4T^0Z8[3\KY[/T&J(4[G.NE=;^]<-#_[CJ5P2QA^VPI_'NXZC.>9?\
M-W/)42Q7EA:'8BF)N]7&VO'E$MM7:.2(5<W,N^1C&CU^3Y!4OLRH+Z\P(E$N
M7/1/SJHW:N>E+B1KY8(7M8\[E7P*,-D7L9AX1WW9Z:FRK,##X61$]:5E:L!T
M)3S"NBB(_AG&<LL6 2T3N4U'"PJ0FS43O:6JJ41:_/;KN'IR='#W>/2<74>M
M!656UH(R5P.EE8L</W*+>?[VBGS>)Y/E:0>R0W,PJZ[+AR\#U21/\,6\>DFX
M2U;C&>RRUW^ZJ1VI>UH[3=AW)B_G;=FKMA;L]6YH,I>)1%EI<CY5T#!^G1X.
M&P_[O1E4P=K1;6,MZ'8E-GW> 5OW;J-J(27R^5$ V_:G%^]0)S-8,.&=9S+/
M24ZO?'A[U#D\D-*T@]LM)+\-F%E&WBL+&7EOW6!>/@H5'^7I?;C4O:#6>3BV
M!T>/YO?30*GU5*VS(?R0U7G>,,R4V2& %^V934@NA0KSUJ9]=[VP1/+L_(E)
M/ATF<W:Y5U5N3I3K[J]JUN23\A[10!;OXR@O!K@Y8T)J'=O/WQ'#IB2P]MXB
M@97"P2V[-CP17\O]@^X,NOEC\/"\??01SEY\FOU,2:TW[95?-CY;#@8&,RQ)
M.??6P%BY@7'H'W\2,MGK^=Z=/FZ*BK'?S696!"_U?8JEB6.;00 M6.M2;!2J
MC<1VKK40/Q^'55=4&Q,@M]GP=5[URI_+\]=1=_][+[-!$>#>]VU<9#S6[+Q=
MR:%BIKI;3T& 70/NG@V(Y_#W:^.J=VH-CLI]O9HO$,\6'X8N^JZG<+- Y8'6
MEC0M/B" 0 +!/PX5RV;8%"%3;1)+ M%C.((>\P)4;BO:9$?N!,QJ:SKSMF9F
MWB0H/"$1SO!UKWDAR?NWXU=3\^$G\.T[Y/78I^PMD9?\-6+;L17XW("ND_8J
M%R;2"52D9KPJ&Y8\ YIAN-\U$W)A)1ZY<+67\NG?VFZMD@!02&$,=ODCQT2T
MAKYA*@2RA)>Z75/I I7Q*CQ.U2TXFR&V3:<0=T;:YA)HFP_3]G^BQ'V8(W'_
M("MSX_Q'DFJ2GG AGGJ/?M;/2N-GN=7VE7Q< #=R5)G4ZQ(V,5\#>V7N!O92
MN5!,#L:1ZY^XS"5)JA/W!MAUAD%P[K4?I^K/1K\^KD[<8X(<7O&5)F]E!B,I
M:P1FXB(%,>TB"XB*,E"P71SXLX!0*(K4[O%MV M/Q3.<!PJ/#I"B+RT">&HD
M=U3[:G$AL";X(20,=C?,/(BS:> (E9>VYLC*O__]7SL[_)&J:/(__#5(ZJ_P
MH#^.HK?Q =6O/+E?L"WYG1WF;<GJ,&L6D+7%V\: [-;[A?N%*G$'9^KFG]Z0
M+Q2Q(W\2Q3 Y' ;KBS6;TSHZ0Z_[%#I&]P"_\@AJ\P_?-*66VO[*7P(STD.^
M-/ XA6KP6W^[7\,_^;:V:VC_]V\X]Y@;,!7I>:>E $O!LP?D H.G7HTY=7H<
M'N$&R-&GED'HA<%EXOKI$@-4M*F,L/:+1N/>-FPP",-BRT-41-0<IAUD4AV3
M 5.%Z!'L^R@0RV9"_1T$U%]3QEV1 H4[HPGLB>^5M&M)!=V^+PU46-MT+),;
MH&W54FT%]CD$IYH:!3=*V^CJY(GQIHWYK33J=%Y^U5_\<IVCT#FPK8>@T::I
MP15M:4Y#)VN <$(_UF:W<X[>Z*++WD67Z47?_JH5;[NWA_U?I7=RT64/9;X<
M=\W5K+&BB6L6Q9GL((1N52W$Y$)!32#B+-"LQ-OO*CIX9QKUC.0^.&B6C:6M
M0\3+QK- "Y,Z7.TVM9%0P#BZY,@$I1+V+>/'\%[ +R(G3:63PDID@[B3G(\[
M&27$/,MU8Y,: 3O;L(7.V??OQY(>BS49<M?7.)-071 7+CV3$&8TBA":% S2
M$8Z-_3$4*G&)2.H;CL[ X::XT4($F7X!;^72T&=SI&\;)Z738OWIU-(2*"-V
MF]/!Y)>SB?GT2W5N1UJLILF==^(6Y0HN5YT=7&[>^7U)X'/"+.!S"[_\]VNC
MVK1,Z\_-Z+*R]M%^QF)<*$@8$_V#4XE&ORG@H?7/1A-]2/36]TJ_7T\:G:>#
M^O./EQ_E64#ZKB)15O?W >VVOOA]C9SP^V(P=E:' [7L(OMUPS$2)@)";X<;
MB *2K#"&[./DR0;B'*63^2R] -YQYRLK\Q_*\M_6OT2WD8UG_0^" H:&HO";
ML$]7H6_BVAER6&CA;R@<UQG1;5/9D#K&FTB< ;MH2Z+OF43=:H>9E(4';KIY
MA.V5<\RTX4#M!W].AG8^DJ&=6][8\L;[X8T0L&G6_ZR%&;,2U--EPQ.&WR86
M\P;QB\2KIP-,98JJ3<;4[@<#Q20_G:M]U4YL&ON=Q^OC@GKA83SD5U>ZX@[@
M&3P^-T[^F.?]JC\TCGP&W5WEI9UEVFIZ$B6?<TL+DD_.Y GO,A+,G:]S(UC=
M+>X*PHS#5K=HI;DV3Y67Q:[N0*B R<_"06ECCU?*LH9::1^73[1FKYM6)QK%
M0<U?A*Y.&"3?2I8)76G2H+;8J+=ZH2S6UPX9]3W+@,C&<@?WG;D<?$Z2GB3E
MC*7V8F+_PQO)HXL'Z_;E_/O!C_-4>92Y8X(TMWPF+0-?9NB<F,[WF;HI:AF[
M*59^[9_^;>R6$AHLM@+G/?@@$[,[5T9TH:_LN4CJ>Y*&V(3"VE@^9?A6?[_X
M4.P]S2AI7."K&1R9-3G\A0V<^3!P-L7=60)&QJI$Y3)%R71$G'<4SK@;&:Z$
M./UY>=8_?ODIU<3W%L[P=AGA[\61<(3B;B4%Y6HJ\6[ABQ? K7]G<8H +]:-
MIYL_%_J?DVX[4YSBX\8FDEA[08R9:J%:K68-3FP9^FTU]D1$\^T]SK4(- 0$
MRG/[3ANKQ9\UI[Z&@88 $V<*-. 0FS4---1VZ[,%&K;"XVV%QP26W)HXKVMC
MBU1_?E<[@Y_WCT_/V\A!1O.C/E]CVGI[%LNMC7@/LD3X4*&#GJEXX<5:[^[5
M%$:R\+/R[H('_CXC3)Y#>+"R;DR^X0;#+.B3[RU\$.3'4;5X66X;SY?WZC:
MD*[!$]E[ONB@R]J58EJK\):IUTMS[V]#"-.%BGQQ,=ZSAT6AUEG'($*0D;.%
M$1IK'$:H;L,(FR1 BMLPPC3Q<?RLMI\>]4?U;!M'R&R%-!8'U%X_)V,%TSG>
M>K[?<LN=ID_5>T>!AB/#,;TX@RA;!Y+S?>B4WUN<P=]F1 (L'DNLE7?+LTJ
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M0NJ #T5R15R6W0 A8M+)]G?D/;"EZ HH25*[/=+!%>NI UY#R%!6*F_ST7!
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M5TM8V?U?B#]OKJV#4N76O__#F?#XY]I?KC106GS&87$7E$8R&8"#SQ%2H-U
M&')%2!,*/ ?BE! "*1M'')]I"N8@0!U'DFJ2>J2FC X>B09XQ[5J4^%"5+1&
M[58^[58]8L %9JN(3]W*D@R%TMP68;U<2S,4OE(;.DY-Q#C(Y3@UP47OO?%;
M<:^!@)B?D(]1)_P:P15D2H[[1-30G^\,&N'_ 2\US&M*:JNV.6H_SW_4QLWK
MY_93K)*(-OH'^ICAKT.R=)=-"DRF)E'3\=W>]3^+'<^2K)C28J//!+%6J#1J
MLZJ:/ 3.WE3"(WR[=G1WVE6OY-/*3>UU8;*;A]RR'<JRJ&WN5M>ZD%Z=OF%!
MRHV,K#8M3,,G>Q*AF+>+= TD3/(O+,?JZ"UP:U@4W=$)A!K\RZUBX6D$EN9K
M]GL$P>W*)"T"!##%K^XC:")NM9B/(XL(2V.% =J9J-1,BG([N7(:^: -S%-D
M36C^: I?T5\?&:9;Q[9J8T>7C(/R::-2^>5WJ]Q244*]/*;\">R17*#2MN#^
M,7BF4X>;S'(,RS*4YNX>+*U4G&R(Y%AF6>Z]KI(>&XI3=:'JNF(9MK3>-;C+
M.&OZOWC"*SAUQ'+C;@<@40P4@UXHW2NCV<"JXHU4G2X^8JQG%2D-M;S[\O./
MX;(G_/*-TG4+B/&?/G_Q0?[B/^,?66WQ5&IP"X\+O-+IT(@CPP5T80%112LO
M ]4%D@K\M;++7[M)!1M>37KPINC5<B@JG9(X.23]*_#$9IM !LHG.DGK8&^E
M%0Y:5\0B,^3)3][SL<?GJM,T"2PL/CJL5N]&QEW/<"S8X=T(_CJ^PRY'[[2\
MU;EGY6K<EFQ_Z_W<[PP/2Y[&;7;A4UWLQ)V609X>UY[[4)),^,H.%N.[/[DZ
M=[[MA]5Q.6O(*BTB+NPF>Y,L(LYAS(KT;KK0;F0(L(L;%\9B'CCFP+ F_XJ(
M66Y]?49> N[T(&Q&AOG,><SH<C+[!;P"Y,L3/+UKX  )L('[(.;_X3\+7SQD
MMSC#^<Y4SP[_"Y] *5<KHY2#G[UV@VB; ]K9&)*4-.[XXCK2]0 L#*^QOO*?
MQ2^)#P8/L"^UC6=55VRPLWAC8*M]]96:Z[#LG@,/M5B?*%;V! 9 4!G!X$01
M6YU579B&0WO0)1EVK5H,UYL&GSZ7OJ2V,R0M%*QA)"UZI_1L67,ONJMDG 9>
M,QD;\0^'YXREH.Y23RX/0,K")QD>MT2N/N%=B)AHFZ2G(@S$%]L3LL#5D"HB
M55:FT%WZ#;*#X673Z;I'0@#O]2XM_&<@X>A=J!0D$QTI%9'UAXJ.[2B?3WY\
M<2D;_ZWJ'<=B_AJY6>P1 %40?D7X=O$A?,O0',34QF>CAV$;NB)I_/^<7/^_
M O;$M!U;TA5\Q?_<?O]_7SBJ36P:>KP^BQ <MAYC>;!?U4L:Z[RZ*PR6L&VZ
M0 *P%*;&R.6P=5^>D295?F ,'.:)(@HMTJ&CV9Q+OQZU)!SU$L@YV()!I8E!
M</N.#II4=>)@G,_HE1GT.EJ*]_LO!)(2SMDAG$N;[=UMD)N?]G(05(CLPF0V
MW3RG]OOH)I,6<^4%05@O0)F $02:AF#BPD$BOF_"PP\NFW\CD 103EO%H0VT
M5]:B[.BA0GH2DPY5\+I9-/ 6=8M($L0.WH9U5EA#*]2#,1VT]_@T8Y% ?;KM
M2$!MQ"PD> H'2IN-;? LPU">.F/M22E8^,2^<F<P6\<S=>(M)#?/*+AP->2G
M9=N"WP>-;[V#Z\J1)/OPE.YFR2"">$DQM8)IQMTGA5NJ.T+=_RE7TV_NE)4H
MI-;$<2.$W07:0=&!RM--71$7PR>EZ>9@AC#?8>[NR,I)4!L]/Q_WA?+W46T#
MW)'ETF36U%:Z.Y+8*N*Z(ULEM>*I@<%Y+(QP$9K&LNAH.3*Q)=DDFR(#*EEE
MP)30_I+X^_%8&%7OQM>7/Z3,%;(+<?5LH?M<^';N)&$9#(Z9ZZMGN_#D1/&2
M+KSWY^CZ<-@8:M>M-[SPQ-1O+A<^=QJG7A73*Z 'CHFI=:^S-&S5<I-6;<&?
M09&U>218GKG5!6^3A\XI#>V.7:4S9E-"@2Y=<;%T%><M+3%?S:46X]VSK=Z
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MMN4)Z4D?]VJ7?LF+A;'.GY[*O5*S<]GLK")EY)+%H@0R<R"K-G=M_92P9WK
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M?,MTM9<_])[8/;H2OSVM.=+;[%<[?R5#>K@O#N$M!H^"F\"C6!#G;<.DYCL
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M\OVD8XF+?+H1%7Z?/C,]?$C.:W; *C4#D($:W1:X#D@6UXF&.@M13#AA#RR
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M:W&9W:5U8-"Z#ZR*IY?R(IFR>0=^)?N$3.GA<IVI3N'SUA18:X\N"7@!/:H
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M@QG&.9OVEZ'#7EQ@)47](C.)Y9IAZ'0<G*CGA'H$["4T.<\!!N"3OU!J17&
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MB58X!3:4N6;3',A\)CD/8MD,:S#%1.++&D61<0F8Z#<4#2&Y:Q]T"P%8"N!
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MW;#UW+D%;MI#J)?)L^&=UC8&T@S.V,XS$1VN+YY=O6<Z7_J$6#9&7,FD&9U
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MF_'>W"6W+24<@ %]6 C-@$91HO5YE*E^NM'(VT5O:!D?PD50G1P[2S])U[)
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M_^A _NVX*7;EM9'(I.+KP[7V1S//-3?\X/*8;L$BBEHPK,\$1M?K[T(3#F@
M/5DJE!,&ZO<I:%>HSAHX0-6OP^?TH@Q5&]Z$T*=V%U\)S02E3^A3AR].^DT
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M"M8"M$Q!)D7)F'+15V]XM@VSDV>DD&>C#''D9$Y-$,^<&428Z78"CZNF0A4
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M)FZ$%JSO2*;;CQA_OTCCO[9"5+9^JN+*1?Q9[GX[C;7=N:NGC,?]<I=<)7,
MQ4W*.^Y8OP7^5*<*Q"]X)KQ=T". VL-%$!Q&_A XJ2%:?Y\><>6'?B#MF."?
M ^)!] LW,9V$][AXZO/__ @W7TB(:K$\ [3 %B ,[2\H#^%I,XEIA71^N,2/
M+&X;NDVS0:/$P!SO4%/LFUXL%'%36=4X7"(LN<0\KM9>%E)U=7@;[MISA;5Y
MES+]%:X)PH7N!M+0[542RF0N-/&V$"_<KC_-'[3!S=?J9K%[ !<@D=&_0B41
M<C.MT3JE@=3,0'TYVFMZ3H.QRA8I%+V<1V"FK$!%:>F'[)F <O>0X'-DWYG;
M<9W# RYGO!<A[(K2YTS3Q]O[XUV65C68OCA,\R4JIT Y2KKFO<Z8W4*Q@?8%
MFP6V@PECQ\%IV!%BT8,GV/Y#/-OQT.,4!W _>3Z+C@8H&)F7D@E?^14S0<7C
M>.(K6"O;&XP9R(I0Q#?K (/PB(G?[?>Y%]<KBRY_52_%YB]B^M,)-ORN&N:.
MUB3>P582MTW#YB.,9BZ1[3E\?-GCTGYVUV&(S/YJ!*H:.W7'ZW(4A31BSYX+
MGP+M&F8B;M^V-VS=>PO]-5Y;9)^E\7K3M9F:<+R=U:\$T(6QFCS802OXN(W)
M;%/PCX_?U!?L0J1-D(RA[4*_NS0F2O^*T5>H;8$=1NM >(6J5,PP;:7D>&5C
M:Y5<F;DTNI/*7C#$-JM%.6E'D$#E2P/I5.%W7>-\ZZB ]-]!"TC!([H#RB40
MNU!$01=*Q=3GE]H4%&&OOHH5B$C4OAH>0E&/-?+LXXI<T*T)NJTC\NIM%^/@
M4"5#*)G+E*K629NIUD-U/FR'KK<UO[%67'N^81%^L2(^,NFB*JTB5@0^ .^"
MF*U(Q=$LU05C._5< VD_I:]-"$RG+<>\T9EPC/9\IS?_)'T^5V,$MXFA66RO
MM4Y#D6SH]@#F@X:I ,( 6WE=9'AA3*I8X'A^1.P8T<T*OOZ"L,+>L_-NH9Q7
M!M)Q"*:#,YAM:@YF%ZX,;R4??PHSB-8/":9H"Q'I2?^#>]5]K BRQ@)6:\/0
M"M782;E=RFIW)[X9FB07TI;=0^P@D;L[V:P_GKVLX5$/;='VH?9G0DO/P6A2
M'5'CPQ\_929\BLQ5:ZT7".R8J]7[;NAV#-/G-QS4T1+D58S1_NLL?W2Y;DT\
MS[1A#<$*#XE>%H_9[J]GM#P-;)ZRC5XIZ,*=]S]-2+S#?+^ED]HP9A[XZ_;
M@Q4)EK%NCQTH<# W'ZH);^&BBZHIU9114+>-UR=2!+;(T24V>)<+1?\ 2)08
MX3V0M5,C2 B*?11.O:_P4=1F @.S:'[,*G']QXUJ!]:FN_7PSCJ1,WES;U2H
MBQ-BBZ^"QVD62,1]*7M<?P92/ !FL%WQUC^RNRFUK2<=M,L1"^P(JH8=U4K/
M(KD542*JE6Q$3BHY#6;[OH\@ZA1.S76]"U^I/GIE+#\E$.9AKFQRU[B!5#?B
MA]E+9XQ,D%L@=%DA9N.K/=S-6GV3M5M_A^W"#%&W4,QH3G@[>TZ1I5LK>TF7
M?P0<IGK[$.#07%@;X)8:!:&GT8QO$7(6:VU9_\:Q(R7##MQK0R[AV2EH]:-I
M*LL-C<!9^3R"3Q:!B@K!TH\[6?ACH"HU!XQ)H-NADXK8T5VZM<R8)O:*6O2B
M;C'SLMJ7&!'/$6T[FJ_F9KG,%J"%2(DJ-?>V8#[+HT;_RP':W&C,#PD=+8G9
MBS#1BF0ZQV4%6JC@&>U_3YF5[JHC)$O38J+<9 (6JR'-196'JW9%=R+NCG=0
MJNF8S7N5[V@?T136]_4W:?;[Y^"/'<#IN#/F4*N_BB]JA27KT5,\JV_+?B7&
MQ([YK1-W.AJU1=JPZ_ /15%I":$SF(LGM^/%#8>(2WCKL_#Y:W4!+YF0]EC[
MLF4&TEZ/(&U*)YM&?\Z,4E&RQ\>FO63W'L9=&O1%BXA)%;&M>@Y@.V]B055(
M+&?,2Y_0^!XM^+9#P_@3OACJV%7;<+[__:"R%7,(4(*GH"1^?YN"D5O0*)\%
M[AU[3EW;V;!&3<^-=NLDBAS$/47S01_\RAQ1UHGB5/#@\65L,XII@'([[H9^
M$%@Q06&9>F>8BB\&;5N5?'OL*UB>ASFH$AY@/D8(7P2@;F::DJOL'L%\]$PY
M9E74U708@ \R-&=T/[U,H,-%F.?][>!>;BY8Q<AJF*Z@YKX6REO>Q^>3L_TC
M2E\.E2MGC-);IQ+^D#0!F@]IJ7;=/)Z!1 (4I^F$52_5>;!;!KSA,5$YM<]5
M>P*68S80;N$!%VJ5^JL3=!F5D">= L<18$XU8VX"4'EC4LRG[*?;33@#H3 ]
MD[^P#KES127/:A^6,81!#Y,1?NZK+N_@:0-!C.$,,02'AZ)NH1FX,?.0]AQ"
MU00JGKHK@3P6>(>UI-WMLD@^YSJ:DXX$":6,6!4_BPM_W2^TP9(JT>/*N&]"
M5:#I,#!;XQ^@[ ]ZZOM=;_+(:N>PT*+!U_H5N,5'CM<@4 M%-D($W;!.[4P1
M O?&FBCFV$[T#$)IH9@*%@[S9K%286D+>W8]$IZ7E.SLNQ%F9'NGY=L(\7G=
M_JL2TA/4:YQ$4FC.6RS8FR=*MVBIWW:N+/Y7(ZP&%^)^O=!>JNRR.K19WF>A
M]8,'3]*68/;$>%BR -22 0]JTU$I#&D[.[!$W6$L3E]&LT(!)3V/M5<%'1OP
M1KGPY/I>MCMZKQT+Z,9<?T5KJ0[QT(P&FW+L!^0\[UK$B&^5S$#ZB7*78+<2
MO)E^SVS40-)1A_PNH2?42C>1!EB/Q.89/?R*.:C:5WDH5<7+H\]YZ_3=^;3W
M1Q ;U>&'JC$GNE/?ZWK?H^/R_><C4E>S1+&Z1&*XEA ..M]8%9Z)K5+)3X!5
M0 ;;<;_<B C@NTX!!;.1"N8S747UOIJ8"AZ998.49@-*<Y1Q$]VW6?TTPGPX
MDG=QC>3D:$;\  !:QGW!X%Y HW"+8)U'-%.D/85FJ"3Y=&,OZ'FYDMQ$Z-L
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MWNM1D9CR=/';KNB.L,WP:WX<R$@I&9[4CNYQVM4UU>S6^<Y ZOQB7B\^7^^
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M2_<PQ@S6>OB&H$Y!M5O,8PZX((MO>ESO?]]Z#%1<&UB!\# [HFOAD$2&-H)
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MXH+?@<UQT;Y(ZLD)8'Y@ @'TQE@H='KP*9Q'[]N!_F3QW/,.M2& =M:CQA]
M#Y$QFRH\>S ?0A80W@3 CWS_Z4X9O@!,S1:#2DL /X _,O[;+!A(=*()/-A]
M19Y2 ISI.=&N>@';91T2I/V%P*]]7%F,:EUA!CZ=M0=EP.$MN WJ#(<U$\N>
M(/>-M!:9H;&Z"-1-%9M-L_-NS6Z@JG;.;@G-KZ ].@2+ FB WVO^G;8[S+10
M!8C-:5.E-@+&A$SR'&79Z,*8GO1LHFB44_3:TIP;O2G\$T=OX[/0"KA.J^QM
MB$I *"*MP*&=O829$ 93\QM6*>@V0:7,U1&5B/V-JT,#KF<F@JXX3@D[+?T8
M'@82YTOBRJN!-Z>9_0:2-46;82 -G@O\=+O0RHBC5T<#\3E$+5XW3O6 4V:E
M!E*F-?$J[-#'#?H,%A%@EQ(2 R<UZK&^,#4CZS;;C+45M8'=Q'1G@DGY,M>6
M@17TZ:SMZ,42IB0"EK=ZT+JT?1TTJ^$B)_J,N$(7DVY7U HN5Z1FUP3_B-)5
M-WC9U50K=-4X9,.N )L(2M_-SY;?#1^5I\.^*FJK/D&MZ6D5C\UC#@IY<71*
MH (Z462"S'+TX&5"L9*,=E;XQSU&53(P Y_7]T;B<%+:RK/!8E01BWIJ5O$G
M(F;=*O]@8R#-WD44]3#8,1^IPQ<"&J*U)5]P/]4QZ6'$L;7WN=CG'&)"R'_3
M&Z'#3I.\P<0%\M/@37 6.%'^X>@_2?)Z4'&*#H=T="D&\Q^,&$CS+'5KSWP@
M8)7"&7JV]"_W*$Q,G%CRL#_Z0MLXN2+\:'KD^0KJ9$Y*'-B^7+=91[F>@[CC
MYN1S>U_J?GQY_\6-(%?V8]Z]7=N<CCVY^VK[CX&?28D;-AA(JQ,^&*-+B0$Z
MI\_ Z"J*C!XJQ6U1X3NI<E+C7HX:"RM%B%1]OJC7Q;Z&Z%5RRYSM+]IV(=,&
M=FX;2AES1'.':H(WOYUPRQJVL$G16EA81-$/_Y.XHL*%2N>(!S'+K=BO\V;:
MGRO;G%O%K($\M-L>/;S8V1S^O4I0$:19L]QZ9!4T9?H^=EB.V99K23T&$J$7
M'?2_"*Q&Z/8U0!;=!)_/[A3,0#\@51OA4X)%'8(%K"T=^+RA^A<#<]!T)6,^
M&B,NHC3 MM;,JFU5R.)B5=36>FGUTT"1P*7'WSOEQG#]3SOJE'0-GXB<A:IU
MRYE.*F_N:"'BI"8W\TW8G1"\E4+8<XVK C(?*9J!<G5AK$WZ(IHK&AA5WT&4
MFRRCJ$IS6,$JWIP$:"ZV@A]_%XU5F9VJ 9P&]OMH+Z5RKG7X!ZM.W@4U\9.\
M3S5+"3Z#P'23MSO4!(&VK#6C5 =J9GQ%_NX@XE[\UGW12<(ZMB>Y$M!0_$'_
MTRM]/*0W)J9+F .^7_H*J W$;%9KF] CMW!"N]KXKU+W@Z<)_Z?Y^"# <_TE
M,-Y RJ<[L.?B3P1?]0JFLXQ@KDA^W$"R$MBCY/!>W%R&A2 .V0=P<^RKKEV=
M)4AJ#K85X8DB:["B!5$1@@5O9*-'0W.NZP(4#I@5I1DPIWD3/K#:+1_<3YW)
M^@8]![_7:O0/ ,557O5/D=CB>EB:@;NR?M!7X7/CY+,-I$JV%7I4US*PI $]
MI 0S$31-.'GIFZ*%O0UQMX?K3Q?2ZIS?YAPZE!!3BB[YJ"4^=DS6>G2-^L?M
M<];KKP'[0]8.D[$==]:^)9L6?)J?*5O_(TD&TE,>]5W,WV+/2];'3T&_1EYS
MD!7*\$QOAJQ\;3<!$XSC(+RY(@TWSX!%2GL>3 M>H3U1B[Y/N\4L%;,=T#05
MR$VEV]0P+!-X,S%GE=Q^Q%'QD#*CHB%5E;\8'Q,Z/GO@?&GH:&W!NP$BJ:8O
ML&!D _IHEVXC^R45R1%XL%L@1VC/RU15)D_$RQE!^.)+$)?FQUJ-#BFX^70;
M5@1"U^:A8H$7,CM/125MWXX6-.(N#(Y@>J%0JXV>!]=>OCI *U,]Q*%_$CO\
MFNC06+V5Q E4!>#M(/;NUZF;9#SC( 5=1\8/./26$[E9 V!+"@VDKWBL*+ )
M !,8.0 A)A57/FYIQ@.R*$6LF.+T\<MD<VE?HH]+T2"=/\I1NA0@E$9H#AC[
MD)+A9U]PL)B.12$#EZ\Q51)Q0#0BS:YY:N_A)K01540P$T0N9O#+F\>=!VZ,
MAV/6(UJWC\]T%-$KZ:+0/F GFG$#V]S=8*1BG(K^['++)5].$LOMYO!R; OZ
M6"W)_6-DU'[?^I:'!_=X,5G[+GUS2O;+2(KWSX7[[]Y6+<32_XLT9+66O?TI
M+>!O>V&*X_1N11>T$3VDWI,DKP-&OU3N/ ^8X%+=BUF9<B7WY((-G_VPYU7X
MX:]>_/ :<C##K/+PF3(R=N8O">9UJ;[S5KJL)GHUB"UT]-48Z5:BKJ%HN'HN
M:Y7ZI;$VNP%95X EHZ]2UHSB)G"KZ&6 *#BA[ 6VMG!+Y_EG(SNZ]SS("ZZO
MR0NSOAYY=J?(Q*KYQOS%=B%)*Y^,37KW%,UV/^H=EKJ][EKT^[$$QNXO=A^T
MWDP0XTWH2!"^>Q%#);HF2@+IUWV8V-&C!?*1#3K)^UJHD, 6!\RF>@)=K3XT
MQ),Y:4]2BM&?0>&G"&KK6>$/O;R=8O?D[4OZ7['V:GKH#Q+LLC?*MY66LCZ*
M6KP8.H(?E@X2(I.JLQL!*6 B^2,,1L0@QD%P;Z'.DEFN_1FQKU&42V:_C+_$
M$7^/3L [L"65M9TUOWGG.3%F UE)\R;RZAYV>1\L$S].G'&/>:J [6\@_6_(
M;N#6#P1Q^EH92">_^T<]<9F 7\4 5>:8!GU\\([:W[86?:R2$RJ]DJ_AZ5R?
M(JN;Y>;LI2^Q+4@4NTM6Q"M##ZE2F_FVS#9BY+@)JN"$IH'O+P6AX8U3H2*^
MR5"]Z9FK?4QP;5Y807CO6QA07#.0[D&$*NM+:*97%9X&]CV&X@!;UOY.2'&6
M]O%CMCCTK$3!QVRDK6"-5 AF ^1Q+AH WDU^Z;09#A2/F<51[DTV)QA(SFTN
M=4JN-;:#M@"-(F JL^+IZUK9(^C8!'4Z<ZR=\!*?$-IA',R*B\]\\: ?3FNU
M*+K_$0S7%BU_1EMTJ,GUS<'.S)--'LA]0F+\]#$]3>G_F1I>4RQ (CN4$<)'
M[@6L6>L04.BQ6ESW\5N\5;KE^'-*%;^5:L;:A98H+GCS,AQW#UR6FPS+J^2:
MG3#YZQXL\&I@V0OFQI$0))D@%MK<ER-' ]"VP*P)?LM8/[VO7+L8Y>E6XL0T
MUCEHK'8AI<*BI:BE+C8AV@0]Y]M$O)\5>8XGACARAP8G!7D:YNVK!>V5:(;G
M\0K4]+T(M^M-BA*E4F8E>I\Y<F?_G+4J]Y4-KF42-?<Q^ \M6ZJWY8<L^6<H
M\%=WM@1\'ZN^_S=YT >PWV.:DH^2"Z0"G\#*_\N+YGRT?.#['_ _.SY0^6^S
M$8(=ZH+Q<XC#Z/:S-V_H]B5MVRFO,VMQ^%_L?6E84]FZ9IP*%2$@DX"0*@4I
M1(@#@S(DI12B(D9 04%(*2($A(B"! G9*C(/*46E!#$J0T2&**-"2(0$*$N1
M>0I*2*(B K)WB; E4V^JSCWWUNW3S]-UGGZZ__3/:%A9ZQO>[WW7M_;:!WF&
M5]EFX*\%:KP;QZ\5GM3L%'-UZ'_X4+"HK4EH2(^4_OFK7*N1&A&P!!B]QGT$
M9%30<&UB3&+ YD;",EH/1@M1YV><$;9U)W\6NQ*.<P&=^F\$GD'<D&+;YO'T
M<CSQ(,G&WW7*OKQ[KX%_P/Y'NQY/K++2]*RXN4VCMS'][/QMLK'OM2Y6^9"P
MN#0^3O^%SM'>8D7Y7ILI)&]";M8QC;A#]18C$Y_Q+.X(D%^]8"#6N['_[?)2
MBOTS+Q%&?.4,$G@\0CDB<NZ&$F$/K"((_R#P_4\2UFF)_ASK&4: 5BRODF S
M&=7HJ63H88]D++': 2-(_^.QB5!%KSV0Q.(8?;QP>V1U#_ 3?86+*/-<4^[-
M DQZ^-W^"HYI-2FFZ.//I%E;A5&F21VGLJ^]^3GY,_=OJ%7//XKA8_P?Q5 E
MK0*9L''N#/\/*AZRP"G3 (,HK&")K[R,HZKHPZ/9^M#G7<CLKLH ^5.:EIND
MXU*]D$].TKVC(B]2+*.XCF+YC 2A)MNH6.8-&M>Q/H(AQCK5?8Y.$JXZS.-5
MD7XW.M#:L;^'95,*:%!B?EVX1?&;3_#-:1Z^"GL9MYG6-TNSZ52L#@": J8X
MEF$*3?@PYA+;![);>*:DA+JN5Z']T4ZQ.HVH34G@ 6B9*S@>G>G*/]L660@7
M_-#[R;2N>W)FPLW".^RA\'\_H@D+BE4-4:RK\%^K%(:]1%^$]?XPHT2!]XFR
MW^(UD2*[]+&<0W66KE-TX"MCTO!D>L)9.&S6!ZI[UH!-'A]%@+!*0FQ6HE1D
MIV =D"R:R^"L920I4368))HN(G970)BL'J]T;SA>8F&YY)G""8X?W?Y%F*1;
M'Y,BPXL3Q(9$38K;3?DM[FB*< T^Z(VA8@4>>QD?VK$DU!B9\^73L&2V%[?^
M*:3R[(WG7#-#GZ.C& 8T*J@$2?OZ'[NLN6D7E@WP&&LIP3P7:V!5*"+F$8*?
M3FQ(]^^U=I.;[<:M&7!,^)M$Z3$&=B8H47E_U? _RAE(<%S$5Z,G\\"!V3CR
M4,=L/TP6L>B($ 0",0*W6168)2&F %6GF)"%B)6)^T9&DS]PC)>ZDW ;0?3%
M4?CY:+M;$U$'MP;.::M+)T>*"1KPYR:%71ZA:^H+%TT2V!0SF6&*JV6(NQ:-
M]2B,9)&P%S@WFU19"3+Y9-@$@1\LO"'YB@U&C[)RS!NR38T#7[3,3Z>Q%!9P
MTH0[9,4( H+$L34ESK#KOKI'!J?O['(N<0\/7.7YM4VV(_W/)(GY;TE"_"-)
M.'_9TMF/D7\CQH-)&!GR%TL>(1@J@Q=*+7HA3\8Q(M?+%31#JB4<!GZ,@Z./
MRI: R)PY*_,.U=6&;;<Q9UN*VNUVY1R\_.KHI\+J)&C2X+T%R2K">.G5$['O
M3FZU _Y)4O[._HH:'RF,VL#71X#?0JSV_B-6@8/"/R1K+E3? %NT_/KPU;0(
MT%AW/_/E)X'[X.%%.TT>BWYX>TW%*TT1S/U7F. =48<$"%*6+U_P#:EO?U>'
M$%]#UTA20>C YBWR>_@0_5T=X<<C':T"L\5N?%%0YIK"E%]Y[Z)/8@W351+.
M9CY^DCE=L=+)IGNPCO6KL87&?\$4^@AA4'./_ KW!&?E(_DUX!2X<S0)HT+5
M_WFGI--X-('H^P?<OO69/8?\O"NM"><@S^<&"XW@ I%K!EE&D- O$56H06*_
M88".,:HNC>O0@)FBMJ3H]HA/POW=BN]\2;DG]>SSY;V/CY!F;];J>FSU.SK<
M%*X=:?9X@5TML'I@QI6*K"Y5\T];EI9>::[ON_WXET0SWZK0[=9];T+K?.8%
M[LRB_HPTRL./^0ZB<9O)\2'Y"5]6D)O_F0%IQT?,0L6D!0--[OC1?%^L3!M8
MN'OADBRP%,9A$,I1-3=5"J;/WH&OCC+6PC9LLF@Z X>" 9$PQ=@0PC<[M&^3
M>NVOKB+JDQ3;KXVX$SSIWCWEHW6Y%HW&BATO W]G*M8NR-X))$L=)$39'OH_
MLQ0/FQ'EFD(#)4K\(VTA31_BF N$_C5!H>FJ1.6^H-1/*XZ/ R)GQ.Z!,R]:
M ="M(_DQK9\(N@FSB(LF:;JR1;#-0E.'/ON;'V9(^HRH.M.NPANQR)XMA_V+
M*?I6; 23E[\;2;Y'L97NA(R*[TD(FL3VNV%V'(O>Z+#QL2=U?585->:*W?(;
MW-%$>[-)D=25DMQV04CGK*4>@<W#)0P!T,90O3O QDI_#,%7=_ 8<&@^NI5C
M"+4ES&#3:&OEI=5*5,(%HQO%J9 */Q<IWQJ..Z2.)$"+NI-DV6"7$N7D/4#H
MFQ%^@P#V@NJU1] G"T9*Z>KU_Y0W"'48^".#N?!5S#_4S7\80Z/M\_R8Y,G"
M;C35$T$*1-^]%(*$:@7"3)O66D_A#\FO<1#2U(3G.%"8LZ[P%RD"1&(Y$B7D
MU53/)W""]"?8HHVF LN+28*8%FX24><TSI9Z$$'@"0/CRGFK6]&B."DZ]6>7
MT1T55.<8T=1*R[B#78AE5\5.MRI1L$GRE(W4/2Q@ YP.3<Q6PPL/K'%V('%]
MDH;,^I%9NJ.K"'M1P+PHVQ0M%/B)C81I,G-)O&IS.F3!]SH"!XJ2$_-<P=/S
M-I]J !9<+]F=QQ_P[6><*]M;/"A[@P!M(#)8M!+5902Q%":N_]QRP\BT6(J4
MZ4P 6H?_<\>-L*)N(!(/.ZO*IW4'_XE>B)=O9='%1)F&5AL-#Z]0HI:MA;>A
MIVQ$1EOG9B=@Q*!+F;#+?3B)F'BAL9W%2V? 9GK)CF;W*,E^?5%%T$M/.!>=
MOIH2$5>NV]VM1+GF-&L*G9?-S$N'V ,!M\H1ZVISK!9\ZB_]468B?R!#CTX+
MT N%_*X,<?GE%)E&KV,0N$\J1C<C" G+0:!)J.(8#GJ)&9>UQ-C$&KJF&RY!
MM-WL$2*X"3J4X".=S)L?X]6;VP[55_=5 QI_,SI*KBQ$AZM" ZF!N;R%DC;6
M@I>9 [*7%WRFXI#U'I:7*E&G\1GAD)^8.-4WVG[JQ<&<63N(!.)*P&!Q ^(5
M,A\[U. /%M= 5NBA'EX7K><L!2-B7J(Y3-CO+I=@-1DZL(4XF-]@><H=PZM%
M(EO2^6V?62\7T:D_ 8,=OO*,:J'@(\\;^G1+TB\OYI()@KC9YSTG>QSQT:(O
M8-)5Z4XX>]] &749M>Y";5ETOAMO_8%KJN6T8:GM@,?GSI8BWU]NO9=%_%MK
M1S*C"?@T&!_Q7X* _B>@8?[<ZJ3\FQGW!_RT?:E7HF;0"-BO1/YW&Z8& WI6
M7T46CAE>L:NJ3K9MFG]-QR=&5311&YBH\NGA3;.[!]VH!?0$;@0&-M'+Y. 0
M[J&/U#[RD$3BT]2QR&[J*!C<A%^J1(4)+S*JIR=?%"IZ&2C<=C^9.1<1BY>5
M*%TMGAUG!XAD7A)MHVS=R1J$>@?,O)[P79MS 9]LL^>T=3QA;Z\5DBDOZ0*N
M8H6-=+G,6GX+YR3;"08W<_5(G$T@L;E#%\[FU2<.M!&R[/MJBEG%I Z;VY_'
M?=OXJE/8@VD[4"1+&U6'O+VMNB$F/QR2ZP%(M"ST,:):XN-64XV@)WLJ/IW(
ML)O2E.[2/;3W[6%/ K_RR,7-1ZX=D?&O[;5G6^D->M'[H;4/:[R+OI@,1VC?
MR*64DE[$SX:YO>Z8L&DL>_?EPM[ZJ#[%H_D#3+ES;,.'D[Z(%^H$Q9G@"S<X
MLH#6KW ?N\P=S26J*5&!^&2,QFF<'D'$U:$$2N::A,-Q1^1/.&MI7><U!?"$
M-WU/5Q37R']\Q*@>],^7]S?89I(!,]D&J_DKG75WCP%-7$%2#I@G837CERDZ
MC0VZ9LCI2*G )S! 0KJ;M"-IOG#@I@(/8K*HSM!Z,:9-J&%"VS;\X 7DTV:\
M"7)-MP'4_5ZH]=4^%:M.Y/17'-[7T?*_J+ %_[J8!7UQ7*!5P *M&B0N;,1U
MI $P@M5??Y'WRG\&3K"&>F9-8%+0*&9H;I35C+TR9W^3+MJN, G#J](P(;AE
M.6+75)G-_8J;5#=QK/6O^.J:5 &IQBW?UBG,L_=M=\\A=IH@VLYNJSM\3\*
M[7ZF[H&F<C+8'M+=ONFJ0GAC\-0V:035&:S(&[7<I;9>#$PV2=UEAV!3**\5
M4XG/6 1=QMW[#JJ;G ,A8>N5BNN6)_O?)C1?;3\[$=T._)VU8KS^V(,U0^KJ
M?25J[@RN!BE+7O\H2VW!R.R^\VF;7BVS3Q=U) /A^5H\FEX_-U2(*!0)PLQ8
MBT(9JQ3F'X6J.),/W-K&V?P8$1EVH^J-T@7K1>[<-#8@M<]S/S4GFN38,EKP
MZJSH#CUBJ*_P,K8L:JC:G^:^7K'<0E*^321,8Z\65C,3-]1#"SO6" R">[__
ML@7L.4*LI-!=H.)&<0ENZ\\C6V.)O!Q;P6_CR4W+/:71U3XJ 9JMM6,I?Q<;
M_@-S_B>\-6O#P'9S$B'?R&[V#IC#ZQAV$[4E<(QI W>6(5D5/K[0+Q #0UQO
MZ ![@8U?/D_Q$0U<9F\[-PKH'Z$&=:X'A0E4<N#H=K9[V7@]/9'MPJJHDC/N
M#87YGLJJK^DO_U+7,@V;U"&U6#^,"'H"VM2M\HI"V(-%>P-@@" @8]Y^/,
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MK?#6#MA8W:][?6,?\ZCD^J/5O.ZVW]_U$/ZR>OI?/N6I9% Q4=3MEE2BR+!
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M_A;MF7!>P%@\\;O7;)7\)LX&9LY>[N*2R!=K 75V;&R%XJ5BJ_PJQX9J"-^
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MC 7<4;BPEMHVU,> 3PXQ=@V@?D[(7 GY QK.M@)F9DV\0;#$0H@?_M[*U%C
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M<PE^448-E&-$&T"9N=T_CI7T,X# T;*UW\I"A4$M =$C(=?GN,))B3^JZ5N
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M]9\L='NR](9H692^P+%_.'W *<(CD/1UT<D_W[Z("9KF?XVD $',V"-T&(T
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M>+&W:+Y !:<,^C2X](8,]*=R3O;MZ,HJ>]/E\%T'G[D'5.#!0 _<":)L(RG
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MXH/I1N $SU_8F*D#O>=))T!JM92X&@(GGGN\F;RWVJ_(H*W0Q>O3:B-%[O5
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MKO7%\DXE'NZS!0/8=AO]AF5?\2L:MV%4B.Z".OI'D32KVN8X"WOW8IAG6',
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MP1%!P,-6;I_4WT!S19NGY0L!%46%%=750POG+77ZW03TC'+%N+\CJ]8&MR5
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MJC0P!W.TPA> 7#2X1X+(\W_(8!= AR2(B>=R__"TQH__]Q3\L<AN)$248\I
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M(F267HI<&JB\4^B!;DMQ)/TBLW^P:=@4)+"9\<!:[$@V?1T63U"95&)NP6B
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MSH4ZTM=_#A!"\>!<+;!:HOJ4A =MGZ593#2)G<@MN#4T&AD#W7NMGXZA9!@
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M"TT>^C]]DXGD51Y54F!:J#,OMI.AEEE(VBI':1%_R9#^:NSQ5[2%933$"WG
MEQ>B$N;()$ZR"?/_1NZEVS:)Q$<=F>02O@Q5-"E$'G]:,"P-:\''X3',H<?X
M%^P81,#V&M2'J$]Z@XJGWDGDA<G#VB_Y4J<VOD7T[I?@8&HN^0V@2C+.X0J4
MY:]_/-WO+EAH3,GB6!MO?S_NDIA]5\VC_O6F!?'?3)[^H\F^+J\N6R>I]89,
M-B9TNK\I["3&W7&6<D\=W=OQ*5_,P:O\30-2?_X/W5?TAU R__^<^'^@9OYV
M(@,4[H)0M&3201FJ6 WJEZ'R!2)RGCJ\\MM@)IBO;^A&X#Q*E!P\R/Y%\KWT
M"?8[<CL VE-7C.._PWXO,84JS_& WG2^E!JK7;6([W>@_H57<$A.$^&F[M@O
M/G>\BW^\=Y7;<"%T5T& TO4['<&.G/O:ATA'-X\8*9W;^*ZP1<,A=SUMHJ,R
ML,,YQ*V$ECU[+"#7]N33K)/I_H6:NPZ53HP;7'PX0.GB[,DL;PV?GH-7'I_"
MU* 76:I6^5-+/2=6CHZ^34I@EM)J,@L*GNB^V+KF\)(U"E?E3G6O,.RBHQ$V
ME=I/_4R3ZC\O@U<BD]\M';(3F]!Z564H5X<AMY^/#E$A-'SK$=F3(D/9-SVV
MEK+1_L7U?FQNUMP#?;_)+9.@P]A'A]^8TMROF_E9G_BZ[Q05-K80/46"<U@+
MH9&+_0%H\L02S/04961!V+4&=;C1L.WE)+<W-,U?<*VGOY(0&B3P]!>%/<QL
M+GTX^31=X.O-=C/J_9=#MMF6FU;.M'VIG6DR-<S:"IL>N)TA\:0M-K$/IL].
M A .E'[77,;[PK;1[W3UP<-=70A#W/4,&/)KDZ&V9(D=$#Q^=.^Q#'6S#">Y
M]NSB!1RUC(UD4O?XGM]F$=4L0]GE#(]ZD5Z[#>S*\A]3_]3OQ"V\U5R6,6 \
M69;!,0V\]J],M&^#D#QOC=,6,Q$9_NN9:_A@R7=S?[H)PTFC2I?0T1*%<AEJ
MF'[L'^Y&\G?[GV_?X5/Q:$FB]0DYRGQ8^2QFIB?7X6_)JAC&=:<53ZM8IQGI
MQ)DJ3^OL^#35QW3H<D:D9REYX,A\,-SG(BYW;8Y\SP7?<HLJ/I_?J9KND_?A
MPZ3C%M3B<<RDC1U\RR4:7O9>AA)RH%3>M>+KO&8TM,<N9D9TM,O$4&PAL1>N
M?O#E:/*QM*1H\39R2UIA?)5NOKGNKNXG/X)OGFJ<T#V^\L#B+VT)3#]J HRH
MCULD 19+!^0Q_3M8V+5"1NSS<G"R)&--*9NQGK2V2OI4XB;,@M>,/76U!E9!
M.:+SG3/X>.P&<*8UT!JC2K(#E5F5(_TF]]JZ1D_E&]?F&YX;\^$49ZA%E&>D
MF9^9-DWV-KB^<S[KY/JQION"B1P'7J7/@2M%GP<^WZDLNF;;0NM%_W%6.+H^
M;F&%#P92#9"AFGP_XC?!G0N8<)+Y<+PG1!"JGH6N@^D-&0J@02,N(<2$BN:#
M=BS">JC?&K1E*M%;8PN@$4OH-K]%O4X- Z4.8=9(S(5RMTAHVIB[8@?I."EW
MMMJ.Q?B^LPI'X7$Y(RP79FS@I($+,O:.&GAE#W8/^1UW62 UWGU/<HW"4'Q;
M#+[80J+58L%7N%MQ*7(XT9._X3Y/0%E)4H#2^3:+&SAEMPIF-%F\T(&5GT+=
M+HT<*^LN$BD5<#5]S9\D^U6^>E*>7&EIN?ON [R!%ET_2$/=WVMVM"?^FK1?
MTX^Q<%8L_Z<TI_S1'Y(Y*%%\6>"^$=)'1%A,B$4-.E8%$\/DI9%WPQW =_NP
MN]PENO1VK 9DS6N-Y4D)IZM[SH,Y#39VSJ Y-SH0O0FRYJ-CL&I0(["<]$,W
M:6U OK?[QI(**#S+UWU#^^,>&<H7O5EB"&4)6T?XZG7X6!VPF4>KX?;Y\CWC
M9L)6 K<6'C;5Q.,Q4)/H_COR3B*UOB*[C#*I V_7'[P_A)/SS6$!JV?M8MAI
MEVX.(0)Z8,R(3,T?!"X1\^ZI5,:G5#XI'PYNGN@JG#I#W_N@U%;2?@5*CK,M
MW#D9!%AX9'=+^\?I_9<R6D=&@_]YZ0F7R%!E^-K3Y(/CW,7#%=8#OM9"9KU=
M).O42R&[5EPIH,4R5THT^6U*4"?+!BS"Q(P,W[N=V0O4R?.Y\BZDHT(T:XMZ
M34A.0F!,P3YZN9Y- $MM!_MGDH68"!%JJ2B)IM@28@\UU=.62'2%GI'^V.VG
M7P]C,.2W[LI"$^[J[:!!%'GK&6*R.9A4+OS25*^FQ98<?B182&!LAL[QTK=8
M\SU81#N7<!>P*7I6P;F6 \0Z=PO&B)9X\^>?V5-]>.M">I>2BTU)MK)_3^F8
M?X=K)8$1S67^89XE@(\/,+.N"P<>1$A]$ONU$672_HEWACX4SNN#E22VR;68
ME60CHJHH#(H6)LE!(8REH R5B-WM!<CIX^5\OA]-)1O1H?3GD.,4P^CKX2!8
M&H(DBWS\>)N"5M!-CW'\]K*<RCM#[*)DJ!*+*,9NKD2W?0:_BOB<Y2I$$A&[
M!^*Z=P2=:K\SPON1*U<%9))V"7/"X:VO/?(&^\WYOS$TQM/:;L[DNZWT.\]R
MJ@8-DNCR-L=L#'[PS8\8[8Z[>B7EWN<Q#NC@/%="*C3V^MQA->F66SLQ7&$U
M]K3_FD^KZ3[NZVHZWO)/,VWF*LZ:'H>[F2^GMQR!BHAX47EOX^>A(CD07_=3
M[>G?K*)J!FX=N+'Z!]H3 2*98KE?@H BM!3A&W0F_!A8,6;?<Y4I@>IQ:=G&
MN%3;!DN=8'.)E9LRHL(^A+E)<_. W[$@PS1JU_H_/KQ;9>].KAX]E$%K?KL]
M=6^[7]_U>67F']J1UY\@*D]OG9Q+.F-J"OADK-W\&?_!_5]B&/F^Q!CS>"(D
M<';3(KF<*[<_FU:'"3NKE<?"0O'X"MAWRJV[69L;!:?Y?F$(*A"8^6?MT2?*
M CMP)5G";,.;6=M..08'5516S#I7S#_NNR;!#?U+Z^V#!Z13D@:/OK!F23SW
M[SE8\;76OLQ--.3Z:%X7GYKLTDD-GKPOO-_O-U#W^1HXQ?)[V_N+_X6;=Z[:
M:HX9S8>*+FYU)W?-(]SM#83PR6=3K) >3%WAV-?3V!=N[RS/]6+L+6L/S$;O
M&/^7\YF?&Y-0/H2M_NX'@8#2E(2SG[_9\^V(#MBC[QLZRU#_O$>8[=C4MOF!
MJ*8-9XO^8''"ZSWN1WCC;Y(:]?GI!I4Y(%2&^KYH$@)JX*_;^?US_ZA&'>B_
M/?\SX+Z?'3YVS&)FX8L%)F;'N(+*/.*UNN:RP<+Y[#+W@<O_DKGX8T:X3TT#
M^C>U;%)[1-Z>Z,XFIWZU8X(Q!2W]%RZ)W1JT-<S; &W?IE82VL,HG4(83I$X
M=5[Y7UF_Y"8<&B+%M;GHHN=A=V:DRCR\+2?U/?._4,'3@SNZ]7&0A<E17 E]
ME4'T;$W-X/M?#G<0=)=/7Y=[91(XH^2[%<"-P,M>5EDBA&<DACF!9YO*4)\4
MKX_9&ER-$GVR!O XP;/N2JU*[;;?OJ#[Y$YV.8C,I<GM0?(?CDI_97IVG[*N
MC'!<S%,.O^$HOQ6%_/IIT<VDI6'H/]F"Q\ M(2V?*>(=\&^XBZZ7#'#%ZC64
M[]^;[V2.8]= :QX=26ZX]6-;I2&L=FPYX:P,%='I*D-EA #P8AL9ZG6W\/Y(
MS&;<G4N][XLW3RO%U759Y3V^E>)CS<EUSFEV%NC=I5EE'YRT-2E\I4\LCCP_
MVG$B(OW3J3'W=XSG*=H5[N+W(KM_RD<:92B>'H*8(QE4&>I&)_ E" .F^0+3
M;79?][AASAM54:&X*@U)7QFLBI>A#D:S7\A0@\AWZ(O_(DFJ"+"B#0&^/H;H
M)@4#1#C;RU KGI;)4"8S,I1D63HBAYXA!""_CMJ2#O#H,M2T5U@H&DE$U/^6
MR?C?39:ALB=Q?S.Y5 ![T/*MX7 2\A,I'&QU-%)UJ%#U?UYO(^0M0I.T%-89
M?,'^LUCW=IY%DN'QCT,>UR]YI'KI[O#O'=]I4YEB)LJ'PZ#-L&D(E79.=.9@
MT(VV%]^_U>5TY$<_&+&R>N*VM\O7P3<C,40[(,4H3C?RZ(,'GK8^5Y)C.ZT*
MC=I'HO)$P7$V^A4#,\5N4Q\+_T7))"J-#WRK] /6_UY7;C?G!L\QI^6_W4VJ
M%E\;#TDF(ZR<KD=XAC?"U7#5HBPJ7WG\%'C_ZB:7(\NQT3MR'M%H^EK.IXSN
M/7YH?8*_, 7C_4/?CL A"^Q&9AE><C]U$BF5B\9-U 7O>XS*+N##+B1Z[%DV
MG!32@Z^)HD%T(^;\K,7;=!VO&3PKIQW0DU1%_Q&0VO]4&Z>\"IY_4Q[WG=R^
MUG'UOQ(WF?'?H&G#_Z?OK@BR^?$[H(2^.AIQ<1A.4(C$Q]$G+1WR'/(*.S9?
M!W.H+P_<F M>M3AG4@><R+IQ\9 '3K?,\?*:PRAVA]]_=WBICTI73EC8&#"6
M.Y^L5ZZ>"87J?,K^$/:3OLV)&[;9SP(Q7\0!2"FZ_9>V*O\N3.Y+=H'__XK$
M/R#G7["W;I4]W^#KW)]1]O^X>RGIV -?"Z<=\Z+/[\A\ J"$-=6[./!^PQ'@
M(B'QN)7B[E-W@YVV)N07/8C:*CWRNZ<OWJ3.]%/M%@3X/:3_]FQ7>BYH'W9V
M5W W+'K^X;"V3X5.DJFR9"'Z-O#/U5.6N<<WBM.,0.U'V'SJG[>-]6Z_\X/_
M4VX>QJX<<',#:LTD^_S]/5]IB!5)+BL]TRRMPH730XQK4Y?Z'ZP:WE33=MA-
MZZ_.PT6?=F(PR],EWK>L.?;7G$4OG,OL2-++F7&:K::*TU-_]3Z*? CN82HS
M](GQHDH0F+@/#O/5&^S"X=4=2#=L4X-[L(;=@"=S,636A"]I:EI193ALS5SJ
MC5F*7>(-&[?K2S>TN16Y[1;4+R2D.:4 ? 5_PW[+A#&GGOQGF-XI2 ,G29^[
MB9OXPOP)WPRK.@PY ;8IPKFFJ3YK48CTV5:P"K<9WN0-ZU>!^@.S4[<DYKXT
MJ*D&U@/O<JHV@#Y"*+@)OUIBSL-L&G,RJCHH$N1[.W&^>+LDN[K87??0;\@N
M>+< J=P=LW^\]^55BOBL8]:FJV]L;R5T>7Q^W3#0-]IFH+3)]N2)5$VZ<E76
MV^1G[Z]G=B8NE/0\M(<^"@WX-$J5GUB7_!:SA?$=W ^4[;[OS0<XPSQ@PI//
M$BI:0ZI#%"6!D[LF)!Q^*-](UA9&1P7:1870G^#62[2RQUV";Y:XA72>>/F.
M,$-;XI4ZN TT]KTCT.7^+$.5!M?+4!SQ$+41S3G H]4!%.0:D+!/AKK$[),?
MHC9H[6AR46BJ"2/\ /;0\Z#FQJO$83YWTC'+AXO.ZC%Q'(JITLQY6W80LZQJ
MQ3-?>4PTJ9^+;LJQN!*L,^ET7ZP,OS72J:.@2.AVAF+O&&XEK"PY!8XT3BV&
M;%D-U#7;W';PF1$2LRO\%G1C:HA0> '*J@^)P&ZOH#I4%PN/E16,+A17<,8Y
M03!UU88K/TDN2L-Q'AB.7--"6STW7H9:I6^G3&36#VX&1\(ECOLP&Q@'B=8L
M6!O,B?!_3I,8\YC*D'H-=QUI_Q!-R:LB;'*RF]VK+T.AN:P@D[=S\3^_>6ZZ
MDOA^GX^OK?MK(Y%MU*96^X<_&F=O.M296&C[D'@PQV,RY=XH/T.MY!$GS7'7
M1'+)>/_[')<#17='/K<Z:C#C/NNY309Z]Y.N09;"A%ZXC;P)FL_ME7A#R:#9
M82$CF4^-5$,+K\7FFC\B=M:$V,5=QNXE'1)BXDF+:*2#'1Y5G?JA>"7(U4RX
M[''!>,AE@VMIE_(?O1]W8CO%S]\?"M7IMVCBRN.&'KMOE:8SO;@<U^%<,*=^
M2@[^>L+N*R$SCKRR=K@PH)Z[DKQ'8DS@Y//9T2:6ZK?@S233HJ*D5L(F(H8W
ML?#HH+**<Q3)7G_:)ZWT\9,::J7+*?M1ETNIF:.WS;)&*Y2>4\]E>E6<W=_K
MM6 >E;SD8(5;TOULU^4%^_:5"'R)6@5^6C_%#;9R-CZFQ^T9-L>GS[3UR8F"
MVYF>_4"?IR6H($H%=5L7;)PZZT(\Z^WB7*[1_0JLA\L9N[%E<O7I:)5^D@/%
M1<WH?M4/:47$7OR^_LM+N+W"YP_/=EW1&]/(=[,J7+'KT)%,^T3/DP7W;B?[
M?Y^SU"Y#H]%QQUM:4*&5;GI\@/N$CV:CX[;= WOJ5B[D-*L;3A^J?//]-:=@
M26>)L&EROS!8=,I-670!(:8$0%ER!K(37Q%P%0 ?&]7&#%UI2@F!TU_CO@D*
M'6KQP.Z0Z(.TA(\=,[@;:8,/O?E:9C447O,D[D?V%"W(U/4$0<>>?H/E?O@9
MW VLQQH2<;4J.A-"L0/Y'8 V403%\ J*V([\?DQHW%2A4RN@)6'6,_9)MD--
M?+NH-. &0]\2=X.NL\1F2(9""<B;A J4F,"V16-&6LS8$B^MW51[8F9Q-:W'
MFM9K++(KAW"/2<OB>4<YN#H9:C6QV0F*SO&"-T#IPNA:>"NU";NU<]9&O=Y=
MDPUOAYSYJRE"G8:%MIB9%H)#YZR8AM3 697JA'=GQE<$$'*\+<^A*;B?,+W]
M?.<(LC(DW\!%56GBPN%5D+\,50LHS.#0 O=#X#XCY5M!L3]1W4";V9$;$D?>
M0[N&C-5"I8\5X^1=8%O"%,DL"XH^0[7OF8UW;;G@U$V8"D[2E-L4$*JAZ91_
MB'XL6L^[[<[[GL1QJY,1=W\:V7@BQY[&?;V7HL$3O+;4>#)PR%P\;>^_[EFY
M8PJ/V&(IL;K:^;Z442XVE!SI@;7@-CP*UH32WB@8U#/78U>0-*!HOJ;\<35.
M1Z>[D'I3#[W.=XV+*Z[%SZ<B*?>*R/4"M;C_U\SW#98TC[Q2)Z>0H(<9#W/.
M](UQKE$]?7.\%\A4WZ6)4=2<WL-;LB,C(Q,+?N;TG>YS:5"B/WQ88N_JXMJ@
M5%UUA:6RG4/3M3&T;-C3\,9VOPU]8[F5?1S!N7G3GH&I"Z4:SQH,KF6M'ZR@
M;WPZRPZ<#:E<NM[^Y(G?W[<'Z<-?MZ7\TTG=U%LANZBQ4SA_[BH?G8 -5#Y2
MA4WNJET>17?VT,YW2@Z+->"W+J8S]TZV*+S=[[ZK\$.+[[X>]EJ+GW=<W_I0
MZ?$=PEIR W6IB9G'\*]!RTGG"*%"19$90QHW6^C?>;8H^F099)Y']+=;/CZX
MK?WQJW;M$DU<G%%KN%QT2;5S8X=7V8GQ@VK+0-L4;+PTY9$,Y?G>'C+E2]&\
M83*B$]=([$54Z)C)(O$)R0_"MEARD^?NQP@76CX7SKPH0_4EUZ>-]$YLW^XJ
M+LX>2P4\BA)BM4>^3 YO^[B,<012+R1=A;2$<CQ<N$E 0!"NGL#I8 V5<.57
M<==*\,*L.JZ2B?(0(<89IXCSP<=SUTY5F?.=.QD8<KL3M9@2GYCO!:PLZ02M
MX"E;L!Z/-O$36OS8H4>1DQA.1NQ]X[C+-NM6A%<I\W[>1N^V(']'6VT;P<4G
ML\76B59ID?J'!H5T3H=&:Z;-P;)*<J)/I72 3^D+K\5J"8/CZ,VT]1*;%R"S
M'M@ '6C"KX?1HPM3T5F0L]"NT7W)"_!:\B-!QKY.FF1++G&PUC^0%IVQM+,*
M_XB(;F+(@V7UJN@5O7U$@9EP:6D6?UOA6!_<PEP]42#9DCV(6>NK MPB'R0%
M0P)"MF NQ&8VHYK/Y!RPA:1/)!;O2 X^>JKG<HF[;7"B.U#L,DIF__.'N:X6
M!-ZK61O"F3B6@PJ7*KF,'L9S5$4AD!*?N0:BL+CR)F%#: I\L$N/(D]DU0/H
MS[ .Z4?(-Q3T::[#K-3'*1%Q9\"Y./] 5;NE1 $?J)=:\SY'/S^-HRC6O'3W
M_64<7@UZQI8D6I:QU0Z"A'IY=%^\Z'H7655B3 >=:Q-=AZ_ET"0(>XLL%C[T
M#Y02^#HQ) -?GLUF=])/(#4^L&4QJ^)C5&$^Z8BPL7C83O&TY."[62:*Z'L8
MW'%&X%28]<;QXT:<3U=U>DKY]7/K'_""'5*87M59916?JKL]-HX5CC4ZG/VE
MZ$XXZ?7KUU^Z.M9Y[QDPO5XP.W5^\*%XL^00A>62$U[E.(Q+P"B:Z.C4<%7@
MEL%U'8SM1-:1+CR/6DN+J=A-X3$W$EUKTYJBJ[;P$H&3W?0P>9:[4H<'=%.H
M@_0^X9;+)@8Y_1;\[KBY^OV"T 7:1#E/1Y%(&#X8RV]3(9T0AG&;".%X-'DE
MR4I(I@%#OKBU@Q">5\)5^O!.OWD;#XC.4 -+D_F5GY"._"L]'B+I!JJVG^--
MG^,-Z%J;VL]2?@%X=*P)1*LU&FF86DQT'H+#AZ1R=7C0CJF8PV)BQC!K]'4V
M^"KC2Z6TFP5!-FI 3(A<?. 6'=8]ZJI9 L:;TW.[D!*EIDYM<G&G7LD<\')7
MO,??$E8(Q?.5F] ;R>]P2["JEGQ,A A0(BN3$53: LNK)VF9K!T.U8DF:W4B
MS?BG>+M$CC]3AEIY#M9R@S)EJ/J#*L[UP> "<3]9+RQMY!0X36S%K.&X[(,W
MW1K8Y_@AQTDSQ7)LEZ;5VI&>[[-##58&_UP9\J8E%Z]O8O2Q9,O[K$L3R2>?
M94X,6!2^9VCNO$//O(/MZ"0O&DLSB#,)HHU2US#VCF'70.%\7(R:EE"YSMC&
MK*:8I!/?""A-SGJ;!/&UMM$QT:DRU+I ;])AOL*%,\+WC"UTZ*[)6KFD( 6+
M^FN#Z^U*SW(L/ZH92Z-A96BZEJP&Z@T>A)@\/\Q1:>H4<$$L8,H)8+G2GBIG
MT$ILUCEC6%(8<%*(9E'7O7[BVZ&@.PB+ZS%HAYHREXF/)6V*YH70>7D,FD-J
M&48PFK_A]M->DD4QB*OS<^:G1I"7D?M<E"4[5P_B*+4N<[$,.7B06^P\49U[
MEGA>D["^69L*5O(O#)Z%9B?UY?'*Q*8ZE7O41Z,A=@FSA0960EVB8-3-89C2
MP%PE0+!\+9%2#ZSVA[4A8-B.18UBRL]2%TF^@QX/$^&=_9+#D-9U82EA]1CW
MNT*RH8OOZV',*HA01UV3PQ!JR5"-4O6:?!X5;<:O]MFR>JH5_%C#B[.Q["HN
M*OID^T:CTR^T\(V&_G5]X#K6M313XQS']\X8A[/SP<.GF5R3LVX3W3. GAO8
M-E$6^EQB(WU492/<T>!N'%^+6P/XM"TG^8 R5%VB:OV@:CJO+&F"H291D?ZJ
MU[8(HC:I$,'LN:09J<-AB Z&VG?M!FG1$@(O#%T/0KBZ &(G:W!GQ\ZD#O%+
M:09YG2\9+?1LXL8S=$$^=*"!JX;=QO&]!R_%K^- +TBFH$[43)\-)3J[.[!H
M04[$3B#O(:;RYQJG-K!XY<]GGI',A.?#M.BFYT?,?3_-R[-P&-B(Y**V!8H$
M"DDFG;#:N SU0FY21ZC31%UF<:O*.=<;NTT(L' Q\6"G?=?E*K>GI LEZ4?I
M;/K&R_XSKW>4"/6;(JNV/"-2:TLY,E2,/FWM&'5MB78'CN/++WT()O.5$2TB
M-T:5"Z1$XXO:6%-]<[ B$&7$B!VN=FW"K?ULX@>BA]B-6G:V(#HA$XKU\ ;K
M6D>.0CDY)$-(G<"G+B-=[(*W2HZ!G[*?^KK0X]P*[G6?S-AK=>)JM%Z*D9^%
MK:.JNHW[:DE'9K;&F>K.!SL^9]L&*N^[DV8_<J>O7&/G?,&'SUF;WO3K>WJ]
M[L-U%(2_#^A@_ 0]E*'4G<5;9:A>FMA5AAI7!C.J^A&:I@;K#TJ.OV.6;8<L
M#.JFUG[=@[LD=2+RPJ-16%E8F%IO;8KC;:$T53O7X=9-F7@"PP-F=5_&E?U
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M^ 2XC'*!-R7GRUQ'^K^X>_.H)K9M?32VJ(A1 1$0HJ(B(,8&1&F2K6Y 0(B
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M&QZ(?B@]6A#SQZ<XRY9M3;_QHP/G#GV0H;31XA4R5+LCA PB)TZ8SG[H'CJ
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M!MU*N$7D,7[;R*D<^)?B%.MR*!A?*T.M(5%7-N%T8%\HYJH06\'>UV@P%M8
M48>K-7$E+; "W\RUJDFB(]:&G2&Q4+'7+@,,JNLR:#;4$F,@U[KN%3*49_GI
M_LHNU<9O4).0B(3A&GQ[?DW2Q&":4M-DYX*30'M2Q9INC;)@ON^\H@B_);XR
M%(D88>-[FH>[[WU*+6W-I= 4/]YM)=[)MORCR21K'9;.\?"]]7S_HQD?//?L
M;0U+=;C-U+F2N[%E;-/8^9'&L,=-^?;YUTKPMN!<!N0#L5^HG?@73]:AH0/X
M"YIRF D]> .SQ/M'>\>33L6+XH\?GV7KV>@!\QFV,4^2=!N U4GF<^MJSV"N
MHG:1,4EB6[NYQ/'8G0'+4(J.V?<WGTOOR/L.Q^3E-5PHP8XKSF6FVW.)Q$6G
M_?>%-M?_GG@._!*(?F-_<P"_P<;\CVRSK11;#/SZFV;HN-+<.8<&\Z1ST]CQ
M/Q;SV2+W$ Y?.W>NP/[W14K^6#QK^2][TN2^FGD+T)\?HT>Q'2:T&3;FMF4:
M\.THY$&\A._$1TPH@YB1C+FM,;4/2TK+S@@Z/0C@6#A%6WP:OBXTBO*7N'PS
M,<,>!*4W>P@1+L]9.5Y.5Q*CVPB-DQVN*1T=]]=:+BI8;?U5-\&UT2DSRLJM
MZ);5YFL=N9O/QE\<+<@I:O!.WY&6."!B$0E\[[XF<+QI[,O?%$=$,WL+!=?P
MO4SKS#-R795()0U7T#(&*_OX/W6M,8K>5J P#W;,=?.,_*@ &Q,C5DUEMZ__
M\H+T[F)J9*VW%G^LEAL&K/%AN7)O<58A,>;M)D\ ;^7F$/BC7MPC--M&"M"3
MJRXP"O%W+8P^V$=*TP6-(OT )4^74/3+(6/;H2^N'Z5'A]><C,]/TNIS93N=
MN]98VI=7:NM;XGWUHJ?[ET\<[UJQ-FLLG^"3'&30S>CYJU-.UH64>?/QD=(5
M(+T:.Y\<>ECH<1,.X)?+U^(4A'915XI*L%$4?8'/GFYG<#K2(&@@7_E[8B[)
MZ%[RG0?7E^[H=/YR\+*BP94,S?2$V!1;YZPFY$A!I  I*YDTE$QJ?S30Z-4:
MR#AWOC37]-.?G&[]NU\7_>[Z/V%GZ^^@V?^[Z\/^IGCN1?\!FC]6<-WP?R=C
M^BA^<O &S9T]P)ML@6;WU)*RY\^+B1K F[A>K%AY3L)DQ;SS1M@@&O^7!6&U
MOG$_JQWJE80A=19]U\^'$3633U;O=,(+/2@JJ1>UUGND^G'-O(=]<1W2H/TR
M%( (&#78"PR[S!G1D:$6\KLB/TOBV"M_V95]B8J&M18NIQVDOPYJT_N*!)#I
M(QF*8T-,$5I&$C9P)TQSSZVJV;9GXQ"G34,%[R-'=/%6L+=,XET9- JZ2@K"
MJF611LX^W69Z]I$=K7Q4G^JE=*XH_QIKE&,S@RF2!A?!HE"IU%)J<%W4/<%#
MBV<P4)M +DX%'H^02O0U?R9.O,.()UD]0+5+DF0)TL\(56!"E2ZJEZ$>>B(U
M7YL,]8[6@12\?QJ)J=AW9E1. M-@;^&"-S'2ZXB)J/=H&[$S?6C)K M>H&\C
M#5N%U,&W.3.W\85$R0)+&6HQ1WJ4VCWSMUXT]'< 7$_\V%>@EQCYUWX47%\%
M<+<"8XT-,M0J+^+D>IITW3D9ZOTI29X,-:"&APP1*LH0(65SH0R5]@GH?B-#
MU=+^BY5_&M^(G#HB0W5G9OR];U", U*=+P3 7JST#'HT28;Z"7E$!5.&2OS?
M6 G_>^\XX1CAFDRDD%XB0_%KB7 MI@,KO9DA0X5B9"@]_*7$]$O6!A?G5>@>
MN['WX]*%$R$KC'N:?B?7<=<>;O4P/9RJ<P=ZG$_V/K:#1TZQ+;)/*CKN'WJ,
M15OK<]!ZE]6VK0\-.[._?'Z)OKSP!?7Y8)LH\$%BVJ-3_HOZ$J=RC.X%'/^X
MJ:B$]2IV<XA U4EODT/UT,!K^%W5*\/I,OV:O>Y;*INS[>(K!>#4OIU[C1QY
M[U+/?AT\'O9%I^2N5ZV^SA/M97&)^S*_[YL]<?B8Z<EU&<I+*WA^WU.LX%TQ
M>67$XXVD3D.6="LB\))N_+[%8^&:Q?A>#'L3,!CRC2UXO>GK B[C!?Y] A$-
M5!S&]V&Z"U4D*=/5-,F.DVU?#F8' P^9+^*)QS.1#$&N]B-.#*._DC#3T3&,
M_$P&X4[13W\*SLK?8UF]_7^.SKES.I[I_X=B'W(4(<DI_BJH)>5FBU;*4*TY
MD"OQFM,/MF!H6Y'4NG6@*,D<3C2-?):4EQ;#I\WE.T^Z/\*-[_[HD-[F9VUN
MQ&_U5LZ>A6XJY_Y9<EHZ1Z06<^?TE9S_[:GOG[5N684O>(T!FV4HT&[#'3P_
MB'*E5SHRMUY__=P=1 5J$V;<;^XL5KR]>QUGZ@X;W_:EA76T^!(/VW-T@#.P
MA1&W$GHF0\4"@Z_^]!3EV-\[M?W_P[$=7*O N#D3U%9MW 8_3N$727Z;KNV6
M$(GY4\'LO^Y;IO;?3[F9:>N1Q-'B0,==3\OPPZ,8B>ZC:04E>X<+E'WB8!GJ
M[68(\; '4DDNA!!H\" T,9D(.J 74)Q %5A)BX\=];X* @).#3-L#>:E4XUO
M.\(,A#O25?"B9HZWSU717DDVQ;:7!EF-X#WU#XHN-)VS)5:7.$51UI9XA&TW
MI"E4&-;T#I >>1>5&-YONK@=L %\.3.;.$LX(\@3>^B8V0[BO.'O*_?*W8YK
M6S=N=C55<=9OU,T@VWA5AN&29MO3@Q]7)X3S'?R.IIZ_FWKV[H7'"0UO#9J3
M]WG8\,2'KNXM&+#;967=&,$BO2I,<.HTZL\X)'6EF#^F?@8P0,\#&>K%1PZB
MS?%W:+79:$B/.#(A\%U)]K64)(^Q52'Z84B#S^4%G6SN@:)Z"6%4U4_?2D%T
MQ':*80 ^INS<,^_65E[P_59??]^57@[R@_[J'$3'AK!@#>B#@-@A)QILA%7X
M:%Y#V68A(%*3I,+S>H E% 7)'?BJL(Y/&#7KI2\A#PN,(D]#*D)%0< M6-X8
MU@ S$Z>ZXJX*:',31KB5A#4#)<?S@X)]!'H=DMW6#=LY+W:\>EOY]:O'NKC:
M759O!YMPJ4(+M-V.P-[U2#PR H<8R7:)1-(Z?67EJ9C]^[;6.&5'Y!0[WLX=
MZ8NPM]V,[;*MJ3Q^=V>:7)J^<?XWK]C^>OFWC0R7N\7)ETN>JGUX5=A+-B\8
M]0 9E<P5TM;D8;+\:QE*F:U$?=>U2G*/!;1W5.+4A-U59GK5F)6LL6CI6F$-
MDNU\M*R$$55[_68,8ICAO+JJ8$77%!<PES5$CO\F0QT!:U@Y?>=>)?_4?<.%
M,W)?>+62GN<$*RVHX"APSA,PSK 1=%6&6M0*1M0%FX@"P8!*,Z>J82%1=!"R
MR:9^X(6W)%7,O5+Z7&*7(E1Y+;KFOM;6J<J8$'K!7Q]-Q"TN:RPS3;[#.*<1
M [BM7X1"H31NH (G4>C&9$?M??VI05>"I@: !9]:#78V/>S;VAC^S.YVWR+N
MVGT.V<>9!DFF':F2G$>ZS&XK[?/?TUI>O'SV,/5;JI;#3N\XUJA.4S@KVGJG
MR,M:SZ;3O;5H',EYRT+ZW:"#8BL*!8KHH4%;54;$?$P,'G3"*%';NO,RDT:F
MQ#K#F%52/.3AV(#W"*+/\P14J%K2CUU;H&-"12+H&TK5);/K:TKJVF%OL-N\
MY1;'*.0B[ CP:X0K.<RU4 2?UI'5BU2&"M2]5!X^CU/+N<U9*35!$K<JX$W[
M+&VJXBRAHABQ4[2ETB9 D6I ].Y6T(92P#'^M?M//.GSIKJC\8L8X'XA-\K5
M>D[:FPC>E%GR/_PT\)*D$GB>+HD>T0!BF@.%W0LG;J9=?ZW]\.%ZN=NH_1]1
M<MJA3>LN&?=G^JQK?>S6JIGB%._TU-[:H$]MU=>PYJ./2*>>?+Q2UDFRL'UF
M?27F0\_I)O?&P%H=\8O+=^\^LTD^\JWOVC%MM6NW3VJ]2[B&NR*Y0UT'<7MD
MJ)$$\798&[HSK%V-O87/+ZH@1+"-R6.GF]-Q.T"/*MH*<D!UC&;&PJ*50ZOJ
M<DC3<9GP[@_*@F=?++4VW:0U*MTX4US'8#2]T&QF?7MG=R6U[VS_O@_MSNY7
M[CY(,K]NHF\P<*U6=]7MXPVW3S.S"TZG/^_*Y>F.=H8KV1\Z=2B0J@?7Z/^^
MM;02?8ACH)T_B8A9/N?SM)R  "MM6I4J_1*0(7<#Z%7$G_V(WY8:@&I[0E&5
MY% 7P=26*3<TORC2<'BX'%]%U1"VWM>.,EW4RUU HNZ!@GH5G$Y\HF"%*OQ"
M9J_OB@$U0K7O/._9PH@G[:2T+>"Y;ZS,+P>WQ#S-R?A9Z!MFJ!_4#]RTZATD
M2I?%J51&P6;>0FL"KZAN*=C87Y-]63L\5[H>/^(JWHX-]1!N.NXU?65@)10Y
MV.B]LT/KRY[DH@/*I&L+9OA\3'M=KTH(O!],'W[-R5,9M<F"UR=5TU%E3N)?
M$/)(N@.<'].@$-IP6Z1<NJ(/=2^LW *<MW7H[AWMBN5S4- 9T4W7;B7*68C$
M%W/F2;DNQ%#_+2W .6YXUQHACB54:W,;>[#7+C= 9_RMKAV]+-[VE*>UG16+
MZJ]LMT9LZZWQT?CJW5,V]U1B1*FC69WEY4?ONCCPOML-.FNSZ[ZKU&)HQ.6X
MQ2>@\P!FR(7?0KGZ_ OD^MI]!8)^TW-"+8'V'?B@3X87;B.GT50#1+*'-$+@
MJPK=G.R4LV@QE%#'JRP2#H%=H0SWX:Y-G$8_;Y,8J*0[ H=O8&M#)M;"PO!T
MJ']_TY1'\YF80U ,**[ER)>=.[/G_C/W02/O;+*68$4$GZ,\N-$U6[6_Z;FO
M7Z2^?_EV;[.KEL6<!G\]A0/]7\=X6E6 (JPJ/B3ERE LS$V<$I30RXB YX%T
M42BD,+>=7=K"5E-E!GSH4P$WEKT56M3[05O@&W(!MQ%*>"U5$FZ^%Y$-SXNI
MTMP'?A)2XP3>G5HUO.,<?K;/-6!9YX :\R,>4Z8L(,1R5I5AA):]^!$5X551
M"+0O&T8+,:%EJF+<,*]M9/IR+SZD6UV?O<'[M%@@%PGKY\(!>9!'II<,I0++
M84-[(1^$8HDK6;1U%*67(+N(,4P &Z?KU*8*OC0PEEKL"7RW^FXF5WE,QW#D
MZ+KT>_<HX_%0IH]R6N/=NYGGTN.CHT-;]C)&US4FD PO'E,?*>.V_?2R?\.F
MC^ )_JW^>4=,UL56+SKVY<J!)X[C3$V/7DP,;@5H1,.MA(W:\ 5MU1QU%F<-
M%/3Z+2F+]3&M3;H4W%,L7.!LZSYX]N<F_;:JDL7I%QZ3^\3F_8F>RBZG>\$Z
M1\E-JIDW4AA_SQ">>5U"K\'PU"T;@9X$MOHGJN$@U32NS"EGJ'O91>I:LJNH
M7DBO B*=<)O [M@R_3VE_(-"W2J!4=1#S>7"@.KN1=V= T:# G6;&+>EQC*4
M!K6.O1Y,JO$QL2V0T R)4=UYQ!OXB[1HSDH#[$W<O 3^,4[(>D@1T1_:Q"J:
MG%L]GQZ.VP[=Y*,7>N%0+7@OA$HCD]3:*DE-A*(64Z?+ JQ*58_DX*CQU>$4
MB4.L#-652+@6T&<?89"Q='Q\XJA5E]=2G:U9.:GQK;MU6[#GS#/)!9W=)7TJ
MV\\^Y%%2Q6Y/#;,&)-6OA+;E1;%^M$4:\C6.W!R(6)VF0UCM2J;.^BX>;""?
M<0*?_SJ[XJ4@#-,^&Q UE20\&TB[569F(E_N?>@3Q>DICQ'WT)WE5_>+"26?
M5K:X;OW*/5_/A"]<S?#M<MB_4)'XL:YZ[#-']*"-J@AI5>[!+"T[<2].^I%3
M6!=:X+O(!38'O\YV5^*7PJ<0-1(I?0NHXCTX-W:3L[AU3%]O ?86,9\0PJ(I
M5/GW$!6'TU:"]I!',)^Y$.H_TC1BJOYD6-HG#!"=A\+!68!&7\%&4]]T+16V
MC?"%1J+?H,T";]JM?$B>SZC&SA](4Y2A;EUO\6%K40Y# *A8"ZR5HBFX5E.;
MZT)N%6:% :#L3(YQ>M$$%,!6 M_;L\PPBO_30;6RDH)Z!;NW.8=/QO/JC[U/
M[\JWWDUI.^(4;9_XN"GF=+:)26/0Q8*R')Z+)7_:W]?U5;:;"34!.O,S9 _N
MKL-K8,Q;#$==!9@Z?>]J(LLRQG2I/'HEF6%/E$.$A EHXT1_G:;9E*,_EG)(
M6@\%@6);5D.RMU@L0ZT95CG?-72(R2]X\5F2QE:&KO)I(;[,R0<'$2'&DJ&B
MT]9CUE WD.L%PSQ:M/MVX1T.OWO%P*<N:*CN<$.98;JG,3/"5)7/64I>7%>E
MIG(+-DN'B#^!MVC\8;.-W6)CJRVP"Q0L5H9/-/@10]*V0*'B[6YDAF"*,8(6
MGZ%^+$PS;HZHX"J2IY&$>*>[QKB,,]_ #*C=32Z>4L#;MN!6>;EK0;X]&M[\
MUD>"6)6J5K76C!ZQF"8/^;I:-.]!^MANTQL\%E%FSB\/$IT2$F\#GMA5D)SH
M5 /G+(&7AE:E[/71$^GAY"%E\&JEYJ:FBZQ<@F#[?:$<W[^NDGNG:RWT5$BO
MNX8@1TOP (\P7'C9Y2QH3>\1H="8$0+CKV00^">R)ZQW/MUWA0?>?9B5\3$A
MTVXGPV':X;*#]0,KBQ76AIN%QJ9E91^7:OL]SFA+9#G8?MQ3M#VJV#+YN/3F
M-.U[49LOADZH8YSZ>!GDULI0,SCF9T=I-:U#7H:R!\(,QP,J:>URM9H*4"Y8
MU6M-V?BJ@;H5J'HO0_F@U<DRE&#U$&\W](!S#ATU:SGJK1VJCV6=@ ^:-7.6
MFA($MMX]G"@?MLIG@WO'N_86-U""GD&[ZFKN&7\L]I@*J'T!\(MEJ%.F4S@Y
MR0N"*G[N7>['I;465_:_?E/Q^BECR0%F\;&CWZH$S._CXZR()(.  *=[L>UL
MIZS:^(2[3@;77;(M;;H&6V+3WG$[6[Q+6H:"F\L),](M#,>_[M/=ZXHEM*3X
MN4=N38_^Y<_3Y?Z8V<1\4V^K=;Q-ACKG"^D]#W_HR:-'LCJ]!<!H[F//DL51
MC*XAWL?B;"]@'L70(VN 9Y&8577YR5!@VM/K!GN.JU'IOF:CHU\^=;B8;QO?
MY#/[[2]%7)4,]?*(#!65-)IR8S>B#*N$$:K(OQSYB7Y'$L+T/FSZHAV:3#A&
M/KVOI:DAN\+-W\G-SNO9U-/MPASVK#Z54>\248&FX32A%+'*L+LN @/OWHOA
M63 .&B8]&> AU49$R>+[8,<1I$H^+^XTL4EP:&:KPL;@QTQ&EY=*HU%XCL&8
M$M%493;\G3./]S;GH"\MV9\00M<LVPT21(= 3A5G(7RH<3OBQFY(NWN$*UY$
M_1002 @U+&C#+1BF+F\RW?VD0NA8&W=]3Q%QQ<4R15!>X#$:E^5&#JU92>K#
MZ9$#>B*JAI^>:3&,U6S%#%Q"F2S_==[KX=')K[VX@O#]W 6IH75'+):83J0>
MR_$Y=G:PTLI(C[2V*/".SN.D"IW:].,%F8M4/3OK;MW)W9<U<_S.J/.![1\Z
MA]=>Z9K5[JI1T+9N,M#'VC;XV<C;8BT;MVTK*-<[_#+$Q%7!Y'!3;GK!BQ=Y
MK/#CZMXV)B=.%Q46A:_>>CIVE9+N31<#^Y/)Y:X^Y1V=Y1U4GZ*K#)_"@9)-
M!7G_,"_S'_9C?O;<J8XXOHE<+ZTAKI2A!M/'[[R4H=8!._!:,$:&VO+[.U$9
M*M\2PLM0SP"^\E7# ;Q"V6X!896TD@/:/>*/H;V3IS]SSOJ&$B\8[TD,?AKC
M>!D,XCNZQM!>[L?'>X@-I(>"L_8K95[1\IK[N:I)X"11Y*HC>DKON0PUO@@P
M@2)":UM[MXUGKENSBV7D'G),Y]3.8[]\N?3)KHEQZZG<^>1K"2V&#?3-,0S'
MCJ*1(8-!/L]+D<3,/N)DMR,^,.M!6JQSZC%EG@Q560 ERE _3R A#5D/<^";
MEK >(8HX23#UE:'"GI?*4&^4A4![<9)$/A\#KZ\#)E0_C P!W!(ZM'UNL[R]
MS_00 @LG"?6D4?U(B@43VX"9^33H.'TU9R"-W"U#+74+D*%^W2K]\)XSX/8;
M,H;%2)[^K:H=@23='P^Z$:3'+Q]U\O[!,#%@+FXST& JY$A7EXS)4.OM)2GW
M@4^E.Y%N+T<:W1F1CT0O;@CH*:'#.8(GS]NDRHQJYJQVFA%RA9.;#/5U&9[O
M0K&6H=*O]P+P9O]NZ4\98J-=,M2C:V>0X:T=DYY!>SA*@Y&^5/CC9YQK[-V8
M_S!^): R'[H+?$LC?PE"VM5[+I2AXN?311?/R5 '1I 07K*S&Z[%_[F=ZI>O
MN1J6VFO7(?GID'IP</9DD<BM 7;-I)C$PI:[GR<^/5GXB*^Q7;!K^Z1$[:OJ
MV60KU2@;6Y?!;B1EOTM8OMJP%<36Y#(_$!=1YWNS-PL/=$%C527/H_BQJ_@E
MK_):)X?+]_BN=%^#)64=5/BRTVI/:JX*/?O=O"C^^(C2(=_S0<3&H[>WH):A
MW!X=/?73VM='=LR_L4-EK?WKU\Q6TSW\G'/+FK@O7^:&(_A0"*NR-O0\RE2M
MGV:]-!@ZD$@X([<DQTRWH/&!A7 /+3^]?_3<"9>XNR\5OX4WA:V?2?_&'+,F
M3=JZ+,T,>-_!8@KE8*4JJ;U$? IHYU .R5!-BSX$5_^^IS 4(%V&B):M4LD+
MSDCW7U^]:K@.2Q916[#37D31JDCD^A-7FVCB&L+LM(T,99.CKV1_0F.>N=*1
M?SB(2Z7=]'$[ZD*@?8I:B9EMH<M[?W\'$7[PTM,%"< NG<!Z&>K0$P\GR!%!
M%_*@NX12A-YK?": %/T+Y2I?0Z*W9NU(C]Z*^F_' CZ==T9J1Y<NK4$8OZ,W
M2?JRK6Y6G,Q6E63AOP[*4#VI1)$;>Q\PK$$!F,79+IP5ZM*RHS)4<_*M2W]]
MH[A(R=Y9[4<3RQ6 $@#]34^@X"UUL 4[I.^#>GVE3&;[++O[GYUY1J_#S@J)
MXUEG',E &P\_>^S@=[6MZ8\_0U=%XH7P9LCR)AWZB(>TW_9^HG80YXT#\]Y.
MJFK?\/Z^\A**]V5>!X^SC]/SA+?FO@!HIU5I:K2FEZ98M7*\.9\M#S>??M$R
MQ41WFSV8'KT/&K<.^AAR5@P96Y0__F*PVKCF"4GMP:T,SZ\$#_]%E9:Z\&W@
M+.'&?;QP Q1O["?)!+RV79F'!-BG8*!J?ND&"^4=D^=TX\/[(_-B<4'/ ^U&
MQ8=<_7(]NH;/Q!_;;/?X[B^9Y"9 +;S@24G3 QEJP;1-@%A_QKY4<@_.!O.E
MJHH]6 F*O0D1#-;29B(\,X#HT9\A1&3\A(W"0_$<E@H2\8&X;!MIB"[00Y-^
MQ^;,S4A!D".'E3I0![\C#N/H&@%YW8G4-4#51LHB&>JA2C4=MB+R8I +S3#@
M&_H\8&"14%N&6NTD2I>A^KF6+23@DSD!7B5#=58-*^/[&Y$X1K!SEUX2Q&GW
M?1?;/5+41PRG_^A6>)?V:^+L/(J5#%6=*'G"F9EHF'(A3JY"(+<0F+XT6XU<
MQ?OW-5=#F)GD@%=DJ#[M[VEC(M?QC#G[.?$]?G"C#+4\"E21WB"N!H2; 2^L
ME#(9?#Q)LA Q6 5&\@7W$F$L++R.,V,E9LPYX*EJU+K%0VBMIK3.8;#H'WTQ
MB!Z) 97F R^HFT0R5 KR%$DPVP#]%V]<Y/35>0 S".D:NOMDCB246G_,*\S=
M?M=QN!,32*U[YRAP@I4P5W9HBP2EORS[]=+<G)_?CMWZ:<;YTL$52]:'1HM#
M _*IQ^!/E'F2)-S2(;:.)/<7=@-UO;$GD76OZ-%@>H<H1))1T$H[3!.1)<E3
M9Z._NQD).A_SRC]S6OU55^3FE$M?B,8[/EL]P=$9@X7W (L? < [LLKA@;.1
M2V!M6EJEJ'PYCMM!8GBK.C"Q'NH.QULR1^.[KOI*3TXG3(U0!SU2^?E<D#91
MHW-!Y/L&.-GVOS3T%*W%4X;BSC[ ]]7Y</IF&*VZ #=3A@I-DJ%T\'[Y([VI
MH-G;NJ:TNQ[MG.WE^R1Z/S+XC\%/='PT]V*X27I*[*9O5EZ Y*B(9K,R!#Y_
MAZUS_UX@:R_B);,!;OX4E] T>(?-@EQ_@(@?F0C_K,&)=7V8(S9NF]L/]V\1
MP9!4X/VFYV)+?0['''D\/PXW7X;Z)"\@2#<Q1\V1(:?1((0?.)/SH01$V.J)
M[8&)_HRA@D+11+X,Q=! TC@!_LS^$_0RZ>>'T^BT@<LSI]FJT.?'TD[,B_Q%
M%[ A^ L*=:1>W%KH0,;>=6?!W<V@R3*(\(]6&NXG1'+R^BM,"#RBZ%C#0P0R
MV^FY"#,^2G&\0^#)B>X4E\3;*E82ES.:;+.>7A5><7.U/M''+O9^4A SBM.W
M=]G*.LN^U=JZUS\C/%/5]ME$:091>M(UT% 1J L<ZN(5,!_M9MH_89[E1-E(
MW9DS8H(TE0F=F75;&'(%W6/V%N]>;FEO\U\IC/H_>9$[5'"/?N)I%OV[J*.^
M(X_]THB91X3V >,)TX3_EY2(.3$GBY*D*XCP8TE3I[2>>O3B[[0(;_OAK3_T
MXC/$XP^CZ9"6#%4:\5_1^_\, 9R!C0SI$AGJ.W\JFCXQ"/3TR5#O")UF<V1H
M,<=DS$KN#V[\P?AG<[&S2Y AAN#%KX)/,^#9O]C-/$IK'L&^^1K7S*2MFOCR
M>%\SYT+GFRI\$;IV=9GF48C CUN^^P[ZS*<IU75M%< ?]+O@+_2;,4>_Q)VP
MO"25XP'I<[QBO6LND4LM/U%4Q$=@;]=R+QE*]*ODD>GNC '-U2 WW%0^VWTH
M;4-+.E23Y2Q).)1G-'OKI8"^ZLN'ZQJWT;B7V>4/[N+/\]+4Z'FYRBX95_V<
M0,/&;!8'R.TH.K#9G3*9DJGLX=0E*F%VUHY*O[W=',":G@%LQ7_/$!]EJ"IL
M&#W/J%;=QV*"+WH@K+-G-:D<2B;!YD(MD0BZE-0:"*LXN6S)YO.%)K7N"KYK
M!HQ9Y8GO"S4W@LG#@0J5M?.]S+]&G>7T$D,P>455HTY5/)6H2>9M^[FEZ\N
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MR4*<C5[%NZ&\-Q8>O'/LD4W[\E_<[?^W1[@26$_$UP#S>Z)C8HSDX3RG35^
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MW>&<EC_48Q;%F1G^*I<I(?\\RK[F,WR$+CW3+2R4P:JT)]@2TVZL[S1F<=L
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MAZ@V?1NZRT_-6,2MBZ!O(AP>$\,-\?0SX"%(V":';:+J!Y#60\WM3>4I_J*
M'J/8HC,7*4B5B+/]IGY_-M:#GMY[<HKB;2V<W;.Y8CW K-I]<8KJNLAW[R_(
M- @YL=NX*QF@M/]4-_Q) YGC6FBOL;#>+_[-]B\?DI2S>A9V9^_J"-9C@"E:
M60Z6G>=U;KW+WGBJ>]_;,EKH_D_XB)Q+#YQNO/MT0^H]6(].HJ]>9*5C#"X
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M&W,C_7E"[PJP:=B]";!D.+#4:RJJ"$8<FNH'2&U<N)H;*ME=F9ULC\RI>2U
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M&Z\M.@XU NJ"ACRQ+_1EP:L.<&[S(UU Z^&'%5BI+]M"<*CO+6$[AD>#9EX
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MYTZ>X9B[)*[#_I3[F^<^OP_S^:%=]ZT+[5X:KKS>OJ-M6,\P@WP_?U09C5Z
MA*@4["<G-]$-<-%6.X[K\\KP0EAU]><7YM7XSRR7W<^/L5+3N]N;QD[D[#_S
MXI?-QW\SX/0WU-8/BMC[KKH[M;;T& ED7NXK3_3B=B4S0]XH_Y[\:H,'<4+"
MTDWM[,NOSBKWM-FKYAG]9.R3YR67AKY[1>G#837U_E8B2:-^CF +,!3BOZ_T
M1O)^\:X]#[:Z/GC9KW&U6&-^QW1S;FUD_8EX\5@P!VI"C!?MG>ZCJY.B6&D8
M@R@BBD=  *1,V2XHR%)O"E%GVHX9FEL8R^LTMVSS)AJ XTRXO@45Y'1BM @'
M^&C]<(RZH[M BN!/<;EXAW;NYVM5>/A1P'V1MS'6"86V\L=R4 WNOQ,=8YVB
MLP\I3_WH:$0\)7U$. ,TB^+2NX5%A0"BW0@I?4@TQK/:,*MD^J\?XK%M07I0
M.6@I@&?GNZNTTU3[B9:!$]KQ<ZG\CM[%[LG8UN#39*_G?8YVQ6XXH_L$WGEV
MZ3<CTW8WW9PW**[5FPD/YBE*)M-KN;OPA,&V2>_BDSH^NBQUKVF/%+5]!(JN
MUPK/397^R;N=2!.(XOG-GGSRQHG!U-6]PIEIFS=6C@7)^TZ@11I[ZE_D:50(
M =TB.TWF16;($-'OYRR7-&;HKR_/E94R?$]N8PB>CNW1N44,O2%9A-+X<&A'
M4'.LV!N?VZ5HU'IBIK"RU>?[>Y$WXXW;-A8B^"9=UVE;)+Z SS6B#KZQ7;:[
M 1JI"$\C 1R^TN!ST.X$QU%58>XYS$!3?[:CFV5'=II]SKSH9-I3#$AFD(<;
M&:<@!5;)-H)=LP<IA-TT:95-C]9TA_T[2B7A*#0<"Q2T(U8MZINK=Q:M36*0
M-6A*^!H&G]*!SK+3$U5>+2/8@5\9W2BUMM()MTB<\O4Y1[<2+.(@/E74"74_
ME,"@!3"?<4*:1MP22%CA9A[7L4>R3?I4<A1T8 0SGD\0=S>#\&2J?C:<8*;7
MF(K<-83EHE,64:H3Q*U))X#Y=,[9@2B?@%[G5,=6]&NB ZGM"&T_\1V'N F@
M,"DIY+IC!: 5$Z.\Q,I"C]6!&8);QA[O4RKXL\JOY+#U!)-HT_:KU,!@(>56
M;!=(O16D+VO'K1NJN:8JA)X,E7Y@@?@G%T5&.:Y0E3A]Y\[W9SZEY3B>%\XL
M&%QQ4-7IZ=I3>? =S12.49DY7=%4_VS/C4!=KTL*"^X#C%IVSGPUO/YZ'T)9
MEGVUT/5 U65_W=5FP*Q];1<0NO9BV25/FO:ZS#%'K>B4MH_?ML?=&5^T.AOH
M> RQXI8@35"W;OS>U,&Q75.H#?2H0.4V4OUX5HL3J"[* WV8Z-11'4@78(FN
M  UT0>&^7D*D5@[ :D<:?,\F+C6MBD=P!'%,M_L*Y:#B!5P_&['\+BU..+\V
M7&^14V0%6A0^GC9^>UY:A J#IX_:0(&(#O@&XG N?<TC*:UT8+>CDP"1U<1)
M0VXE[(1LQEA)14;/(!SH[#LX3]PY53O$PY*TEA(Q'5S6+4=C@?L9F8Y%MF#$
M\I7E11MW^.$!5%!+('@<C^5KI\FV?""O@KR8H]I0@G)&RV$^.2W(*8DA,X)(
M5:R2@R1D)NC0P;6]31G%1[N^IZZ[P%[JN<QA:',V-"4.3\:[]S"<H^@/_+,E
MFKL"M?ET1K4S$[D&\N.C$!(WT+0CYKVCLV ^K<BVCQ2:D7V#IV)3;7<H0SA7
M(*C$)/N7=P0FO*)OLFGUB,&L"-<C,5"SV.E$8V:1U0"NGKQVXO.<D&+;#46O
MG'"V8D7'QP1I^78=JG\JV+,T*8>%\\M&C;G!!GS/JG)GRR*ME@GQ\7/YA?&^
M;W>/R8(9678@.R,L%%^D!!0PW@:%&HA251WG+1AC+TCVOYDAUP@<]UW=O4^F
M^^A0C?*Z&X^8CE@+X^ZM#WS:!77QM&Z+M_C@M"]51UHR OKH8P_C&]LQ:[A3
M1NNDE!CR)GS&:>ES@H= :JJ004R,$F35^4SV/L@,7/1!U>7C[W;&9S/7SEN3
MAS(8R,T#G[*ZQ<8>J8>+Q.U]AZOQ\4*&,:,O@EC()Z>@&J/*P>A7HU8@BXG+
M;FCT1E'+7Y'60,6'WCOZ7"TAJ-(@0R!XS"A##E/I%F1V7:_V-[?]RD @:&9#
M$=RXU!E*=;UTUV?!LOMQ*#'6['8T_$6W.&I:1*\/J@8.^Z*'AMN;XACT5.0F
M*!6T\N303"1'"IC$K6PV_P1"6V;I)G8:GN2I(A@(]?KY5*0.>=9VOAJ?VNY/
MJSQGP/V8?\(^MJ%82AXBOL50Z5E(>[P$[]"%4HZAI&C)S*5%!&VQ%V%/HEU7
M8]#>P:[V;".(Y0.04F)X:2)MI#KP*3N%$%?%G1RD6=2Q8_1G26[N*J>P!^;5
M2LL_).T_JW;82S^EO>LF/J4U+K/X6O+.A(C3GS*Z XWPG"*]EG O]*8-1TUV
MD7W*GN-;SNYD&&Y_KI,(9:2W8-Z\"-C_#HLW'JMQO^><#$J\;G:>JPC!2]I3
M-X"M&]I+3>Z=L_J0P^E(<,Q W/T<>_'EF9_8FH>WO7[AL+<S^,N&8_JZ=X3(
MZ2!R^:=7T^\N*@>AO7K,M^@@9#04:D%2@5U\E]\P4A#)G:T?CGIMUCPR9!+W
MV/4U:47D5QD=F3O2B ULC+-T !H_*+3^S$^@I8Q,F4Z'%+)QYV8 +;VOW0F7
M8GBKL=3_XS<63W3+CL2B9M3AW\[!.VL1W\P42O;<4.JG;-2IL,?I$D!Z#S*3
MK3>3P[:A^.72(HI$_:L<%H ;<R=4B%UE'70X/1RC3=@+D>V8J$SZ2ID-03^)
MV81CL#+I=?3L2!I"<JROQ4ZXH[H8=+X1J]+J]2-X,KD:"CV3<#PJ.:7TD?NE
M\A%IQ>+P]'&;R(AACV7*'P:+X(P [9[=9?GN]DOJ[MOS+Y;DAY?EARM<EC4W
MO!K^!A)4NQYH6%^Z\XUZEI*_!Y4S/SYB/9AQK#JF:-(&"$VECQ625DK,%>0>
M *&*I^4PC>$V7FWJ+*)<-D#4C,0PF]3J*(3C$*,<2[0!3]BS.D8NS+<'X6Y&
M!G0$.0Q(?GP/74&L&S'_5)2Y>33#856DW4ZP3K:N'! +*1VX;)0ZX;#X1QF;
MMHE-"J<K29R@<+"9GZI@.H(9\/6:! L,\QNN&247X]7%Z-.0DP"=%H0 1$]"
M!JDX]6$(*UAS%_FR E\0&)"1S"ZK??9<:O28EMEN/E(=B5VBLA>F[G*_NHQ.
M!@@&S3:6OJM$Y[-]O@9072K><3)<%VZ%Q-P]N??3)1?C=AO+(3I_#S!748J'
M,_Q);22-48(]FZ85QM.A;0HC;@;&.^6P-9##X?<*<H2BT4 7<P3#"#+FN.(3
M#@.LU)C6?3RFNT ?_BPL/Z1TMO"C]Q69S\]0M&@=V]$4WH'>-(&AVLUBL>"X
M$'U3IC=-VD2/T&TY!]Q9$%K4E1!,^I9ZM!64"3=?;"9?KR5HLXEZD[E&Q@/<
MZ?9!S+H_1_K+!"JS;IXO$AU.9+'F_7=\3"F:8N-HLN:2K]2^2%M7IG?Z':\K
M=S/NY)3VO&&[GITZZ=$TN#FJH/EDP<GNL4!+V3HQGZPLL:F%(@&R*$]:0]R@
MP&"(+>ABHC/H&QU7@,:O[DK<I8]:XL#G]<<4SC43N0=?W(58+PE>/6I>(%93
M N@WB8A))*Q?HM7H,\]_/3,WIS5G8=:) 5SA0W',)E,&:QT^V ?J!4BO9.ND
M9/A,L0"E+-D.I88_5 "^#CWT0$L$>1,5D<S36$J,8R!-P<">,KHPW"82QZ3M
M % W":I"]T2"FR#0RA-<S;U0(3J.<ILH>:19&RB+)WI[S]QQR]F6LSO(Q,[$
M/\+]I6W5@Q(!O\?,>33"]N.XY^E9Q/F*@+.SQL?["*B22?\U266^$_EJUTK#
MN5I)C\.O3(:63G"W9X>L*2R9M(\L">ZN9R^.(+G<-V^XJ#LJOC^D$4_K]#Y.
MKRML;ABM;AA.:!B.I-L.XWJ>?7_+[Q_=RL;GI2!7LV4[PU& )R)YF591'9;O
MS*1S0P4DQDB '_!!Y$W[H2^&K$_L0BF\=HJ-D]N/3?WU4A\T=7!F)M9OSKJR
M<L3J5$,C+6M=:?V+3"-=9!9(;J,K09P30-'M2]CMR>?X" 1A(RC9A(]2W=4>
M>84TQ.OT)V73-*%09MS=R;R\.)F&0J0M9MJ=IK+OA$55<=?]F6U9M?GK*3NB
MAWB?'/;;M#B*-#2E&-OO=]J%) ;XLF^%K,EW/]!_<KK<,>\C=_&GB>H#QXH]
M[GJ?#BENH'L_,DRH=)E8;&U&Z$R1GL,9TH C',G.6%!?N!*R/2U];$G4@Y"J
MF%<-37:OYG6(_5J(S?6L-/)&F>$(5^*DP"_6K1@QXA9&XR>B80\8S%1\C%X1
M3G, E5+N/K9'WK>XSX4XHO_%WIM&-;6MVZ)Q62 B B*@($1%1$"(!8A2)$M=
MP@(61*324&0I(D6$B(!$"8F"@)39"H(B$)$B(D)$*D%(A!#8BHB4D2"08BE2
MR9P"<4JJ%_?9Y[:SWUVGO;//:>VV^^X]?_@1DCG&^/KW]:_WV<8<TP.*$OH'
M? N(]V#+=(?. -C9.=[$RC'H_#RK!M$^*,TCF1*RA?#VN:B7P[K?DJVDNZ<I
M0ONK'82&;O9E@]W 1&JTVCJ(?*3IW=DZ?]=Z>'E(I2>/'C)_^=M,W)?EL?'A
MUK'YR\?HIU\TW^X7#86^N7VG;OIA=NMB\[,72#\%DK,5?+(J@=.&U:R3PVZ2
M-:M)QH1@ :)#+<U@%_BI"L4:<_&&: )\:L!:@,S"JQMG6C:1#!!)T?X'7"$R
ML/"2M :(8;9/J!%MFP%*HF3?FLPRK!G.P/#%T/="%Y$>9%TE.0#% 7E^@RU7
M'A,<^;39*L'\R %6N3_.(>4T4A-D2DR:8N9O<O)+D5N/6;.;K-2N,U2&JI:6
M&BFL0,\\OZ)O[=; ]'DN_%E(\5&5H)$8QGU<W-1 _5C5Y;LS7A&2>=<GMQ6*
MPSW#N] V_/$[@*PJ65O?)W$$J.Q\A:I!Z4$+&.A %&@A;L-53<'7$4V*N6%P
MS6AS%87X(P/I"N&) [ZQ&OJAN",#Q"-!_%>6TH-O@[(%<(I%?45,RN#BW45$
MC@Q!:B]#;B)P?H'00FSJ^ YP/7PM,Y22((>M)JH(J!N)J!K NKW54/17T")1
MH7(WANI<9J@!C-9',W"U.B>B8PQO#,<., ?5TL+M$+M*^+9F56>_N6<BR$Z[
MMQF4H# !K[6=CN]L\&YEB*?.#[VP;O2NT<II:BT)?_%BI%Q:^MB6IDVUI%F$
M5U/-^Y$_06RQ:9ALQ[OZWC6$P  H3\#4E?CG\29NU%.Y@1U7N]K5E,=E;^6P
MM<S@B;1\'39E]11656+&0VV M(>[V=R(1H-& 2+Y%N3(=ZA94PN:?N+X06QA
M*ZH=N0D(2,=_4TJ2(/B]JPC!+)(*<#D]D,]4@FQ9RX@;$F-^SSY]RWDU*)B5
M']Y >?"YP<S0CGFN?_&%F>\A@U"CY[</>4WFGH[]=?3NS "3O[R\T'EXLLK\
M4/N^UF8Y[': #YYY[T#EX<Y]V7W6QE7SA_'F=^K<TYQ?^1ZOO$#/^?%.T%=C
MI$Z4R)3TGKQ\@[B=7CGS42V-^3466T.1IE$;X+)B^-J0HCXY;*.D=!/#A,QI
MGE@."QYB_6U76O\&:CKY@(MW\-#R4[HM1 .8[0K&;5&M)*) BJ@%XUT6QQ^+
MZ/8"QJN0UP54%4)M&\FXKP7/P^H1' ,:G<[UM9SF472AV"-@</*2LOG\A;-#
MB^DA]>&(4_W&S/YY^XUINLVA2[H1YI:S ZXHRR]UH;21\GR<PQ,B2\ <8?F#
M;,KU/#:V+K8S,Q@+18+!K(G-1"/!E19K\2$,^HP OAXR[I*M?3I0;6==2ES5
M+]&IF-(\!FJ>!,T'PHJVM@Z=!<^G\^-=?AU<3-?7BJXL]#\@NFIC2*!VV* Z
M\>D-$]H2_"."&WX+,8*1SC=H$I+5"5$O&\:-Z@$*RPL8;@2*Y#"^3C)2FQ#?
M<D;@[^$&I%QCZ!&.N@L*<:?!LO&:*T*X.D0-X#!2'Y:,L!H%<E@O\+YO^-%0
M==7EN>Y5U5S\\4WUH0>K*IT6O;\_ZQ9%M[RS0T:KK9*0H(^\X.%ZZDWD;BA3
M8*Z-NKY,367LAKH%EVL4Z431@Y*_L9FK6IP"^61-]B$J&G@/^9=#*NTRG3YC
MBG-_B\5?0C$JH<@Q'E.)$,R?2+33!Q;:,+]AE!)D<,B%%; :N)RXFOWQ@PW\
M1HO^PU,0GF5C:7TUD_VI)%;[SL/0W(,:'Z9U8GTXRA'/QC[T7OSJ+#7?-&BH
M?[(A-\ I-&C4Q=QF9_,.H\-.I^N6+D%GZ^->/*+1L7F_/TPS3?W[IC+01Z$M
MMH0P-]B9B&,D#N">5)UDF;YL4 ZKZZ)(CN^I-DPS7]F&W?#CC51AI[>VG E,
M_ZV_^MSE4'53LWU!G;@Y;QG\6\H2_29C/:34/J%EIR^.ENP#WU(/5O'H-\GU
M*7.:/.KFT(/+N14EW94$;(=L+80OF>'^.A3MVX/R?DKQZ/_RY8F%\0"]*H+1
M$VD9V6OP-<P8=!B=61;A%AP&YU[YY'\Q&SF,X3RCKYF+1P25+<;9JR6606)Q
MI*,8%2J'U7XI$Y#5/U/K&$E".6QDGC6AA0ISF5CU6;NA9DKANS(8ZOZ2[8I<
M<-V%77^,5X47V#,JP$I?A4(<A>RLXL[P$,G8VM@.LB:4UOL;R,F2Z89=3>DG
M:S)V2GPHO,DYOO@TY")TS"1:Z;SLO<FLTR2N@8BYC-5#C$TS10;2W!9$L<1^
M4*8/U;*XC8DQ^K%^]5"3^&>)+53_8%IW/%-0:-B5JR:80Z)608D.S/[HRE^9
MQXEG>+T;"")A6YZ!64VV!TJ-L2V$JBDQ^6D".W)Z2F8)?&R@XXNGHT9.?1CE
MAEU>#L3%Q@XWNY6I#F<;5.++PIAGK9<=J)%*-PDXD0-DR$_NXZ6X@>/,8D)<
M5SZ-K;^RS< *8H*^G<P-EM2;S<RL&'QJHX$EA=^52CSS"#)TY\S*ML_DYV4N
MJHQ%'1M")Q%]C!IOMNS-=Z@OF[(>UGAE6_FJ?K@?=_E^?^_Q9Z[<GM+^9S8&
M.V[4B]QO9$>\+@AS</:X4:;WJKQ)J*-:I66R<RYTJS[SIB1>;2Y>@%\A\0)[
MV?@4F\M-%9]EQM)<.[,'IR36<E@2 CS&G[@ATX$P"T(UUKS63!Y2!82GS3,.
MA<#5@Z'K K@.1/8!=9(19+X'EZ##)J^:_Z/F'=+DPZGX<ALU.<QGBML2>!1:
M"4S\#'ZD==S-[M*=2(M.[]6;-M#"ZTJ\H6+AG,K+/.;&B///P:&N:W9F0K3.
M3)$N<"Y?XF-M<T+6UC_;F<+OKF0J$\Z%%&UJ;>VSL"^J7N=DM:NH&2.^,M8:
M-UKU-JSV1L%AK9S?LYU-S>Y[<_WZ![PX#]R/:YW_AY< G"HR%K(,=B&+MG*8
MBP-7?&-2!9'4]82[5R%\ /R[4\L#[1^[&;Y&*7JBQV%I!I/WEY5***#[LASV
M%\A*O&=AF<0HX/ ;A H-7$P&K:0O(#V1I;20C*.^GQ1MP%)D2DSP 10KWB/9
M@E^K@M C"-M*7)'FD"U0*R:_-5 !-URS0C4@DBW=-P_*AAN2AWH>),Y9'PW#
M I_HD#%:JCZF&%H-W3DA(VB)==824K+/V:&NO0;O^KTM-]X 6I0"BQ<''DH9
M%O6$W:\)S2?#CS[\U+(CI[ DNIIL#UWG&ZN#CCKGOW]2TLON:Q<:IWA.G9TY
M*PQ ^;".J5D?ZFOW2CA9X>97R77Z6CH^K= 6U7]?B64$DKJL(X=I8D=])(<K
M9<H#<M@OUGYR&&L ;)3#BE;#_V2"BTQ0^WF4[%HM5;*KG;P0"3+!%8=J9<E^
M*$7:;$F1P_92_TL#;")W8/B]RS^])0/WE>6PGC8Y3%TS'?4YB"6'0>YWR0O*
M$N<O?[^LP_^ I)[,RE<87=3BL9A>B3U*C_R=YRZ';0B3PQ*BY; ^50X*6)2$
MRV&3UQTEQZNWRF$/]DS*8<I/J9(/\/^>_W]J_DPQ<NS1JT4Y[!T3RI<]E\-P
M5,C(<=8,^/$"K >D701-GHA> @V\I*XC8@44E; !R6GH1>5Q&NZJ6_XW;9U+
M4U<;,^<M6X]LOVMF55T<&H7;N_I\$B=MV4$L6]LCAZWZE+PLVBQ;/9.^U3I6
MPX$)-#.L:S2ZS![_U LJW[MY8L7YG46EV;=]),<96UL9907CBM^\.'/0%;&\
M86&TH0P%>UY_'"UV27GR<3==E-'Y+2/0.&9)Q3<W,O9%ZQRNG*P11Z')DA3E
MT/=\F?P9*W$EA_])06[ZGX'Q4#B.>A9U<76!0K <U)3#[J<J/E%F4Q?W\^4P
MR>XWJ.\W9$:Q<+1410Y++8G\UQ!QF?P>+.!&7=[>/"DSH&8R)<!N.2S%BMQF
M0_Z</$.%KI(.RF$++TMD.S@;R.^T%7.X\1XMBU"#KA6<EL..6<#EL/8,!0QW
MT0*??[VJ]=^'H<]5RK8.*:*F0/ZA7C69/P6-*@323Q0HRD>B29/=C&A2C$43
MXN4PNW4H@?G%2>F*8!3D>D,.^\3[[^G_)Z>_/W* VO5=N-C%*2.'.\K6_FT%
M,"KDWCRY$O45\R]7I%/EL!!%;2!FC0 Q:T(Y1DU9HC^T.,K4^G$*[@3+-<()
MN4<2,*@]WT;6)!V"$&T!EOTWKE*R+$H:LKV!\=I'[[LJ,.:,RG*G_>-3L0UY
M3]DVQH))U<[].4^O#)7H&%\XJ/'B^&%;!!WW,.C82P/S@AS#>Q>7_IC3$T2M
M:FK>)7OP;9B+$;^7'?^3J#A*-/[."P?\MB+0F2B]R->)G:1MFM<+UM^.=RK[
MLQ#1Y# -7 KJL]IA14@N&'M2I4J7%0O\/Q?F_Y[^OS/]GY&EE$_U7\BU^-DE
M4%-$@[H5WTO KJ_:Z$]F6X=;E%2.'8M$IO+FUTW-K6<8@HVI1>^5$H\ <P65
MEH\-#B^%N\4C6/F!+E4S5_VKNI;F_TW+6\]1DPXK C @@-%IY&"U]TQ1F/0V
ME9TM^0D*AR?,2R(-\O"">,Q"Q[@%F%SSZ-1G>LS!PC+68T*O/X<>W:,0A*/I
MW9FV+OG]_;)OLYQ8T._#J5.O\.R[4'VNG;91T*D];><WENWF&V>4I="2RS 8
MAWI'M!8&_UX.TU;WY!:>.IGQX?=/G)(<@DI!U_ZVWL-OGM%RC[:8!FY/J,S(
M-:W:'!"1:>RC[*8>4[:YO]#'(LQRVK/2[4#%NDB23KED)10CMB0TRI1? "[\
MK(+A(BT@KV.>N\::\>*4WBG0FWE%#"=>>@ZJ94B<(M?MC"5M4^B\(&8K81#S
M_N=A[JYLK?+4\M#A@Q/%W4$A]]AUZZYNW/$S^K?)E8-QRYQNK-YS:8D<]GO;
M%!BE<%.-DI&)+HNAI;@8E(=D!@@=JL1J!+2&95=BZJ3UF'JXE7,]SKG*N=YX
M5^'DX5=-F-?+QW=W[I:5T5**$]M_?_K<>2^+_Q0*><=Z5Z:U+CK$/6)3Q=%]
M?::1:9FC.6465V\73)[TR#L@^.LQ @Z3M?MZ\ !=RWT3\<WPU]6P%0E.+^%Y
M5SO1F?"U%TZJV$ZDRE;6-3<FK(TP_V*'+CMNMY^-WWK)<2?ZDK[^UOW/GB64
M;LVZ,^:RT56/O2,YZ[CI])55!AVQ^C<_'Y&H*:/:Y;"5']XL]#XX]6IGQNF1
MXJ-O>A*<C)R,#>W$'$I^T-XWTA2KTR=%!OT?;F44M#YTFKB/?O9DJ3$XZO.E
MK;(K>NQ#9_C^ J^=WS^>M&.\&HSUR_1GQ(6_8/PU6Z:3UT9>-E5T=2;PN!_U
M?5<+7DB3'#">6\F[CUU#Z!5J4QXB4P2]JI(C@$^&1 F$.P&]%*0!\2@0T\$)
MT &[$JV$TN(U5'JH:DQ\N$;K0(R>\I,EE>?5>\IBTT[9XV5:CM=0GWT51#K?
M098<AP./[5;(84?'%=Q/,I3#!&:LCHN7-;4<JN&:F*HPK0=30V4G[^BL^TN>
M6>1M-S5"NWMD@=&6 =HA-TV:,FOV*UYKX:U!SR7)@N')UPL9E5KK(_SO\LV&
MDHV5TFBZ@T+O[ H7#6>?LE3VB4IGAIY6<L>9&D+++H1R>IMPW]W??#H->>C9
M]$@ *YAH\P\6I3!!"RHX*7!,ENTF^H.=-4)J$@!-=&(FDJTHL.E<C!V--:[R
MS@Y>2O#&D5-TUZ1&EGPNTG@:TQ\1<W<.;_XE1JV.K=2%OXYZQIQ3 G6Z&/9@
MRIR[H$H)#97QX,K$/5 ZL-"&4B=I3AFH@E@6?<U,'FG74R#CVU7ZM?KYK2'<
MB#*!BG@,[9?-0N[KLYC_H^FVAN6)M8'I<WC("PE3J%6<FQS&U)##0$LJ\)CX
MC[%[4\&O/N*=P/)\2#MBBANY-)@66;8G>JKSTJDATUN?>@X8N[M=.I5R-]#
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MGU&:1 0@Y&/3&;LA W@R>:V=/1C5?C7OFAVV3(+J;S'A4]=#UTM27F):%5U
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MR6%4 DJBZ2&'Y2DM4VZ).N4P/E8.BT09D_\,;L?_.>\KE]+24,/$;EF\ GK
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M@(> ?!VYB=#=CGUF<2=4$4WT,-YPR.X8D"#"CZYTDR:25"7..(AWO8ZJ(7&
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M-3!\5]]DV3N2PL9,9,PJ!%,G4\W.G$]=+SD!L+]<!W7:J8UJ:7;^?,2-HD,
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MCG)CB9D>L W+=12QD$A =D>@EFR#9N.ORV&U$^T3W'$Q+^7&PQ]LLYYH'?L
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M,K]%\EOK$ :Q1O+;(&,OY#:/':IN";<H$T@#64R-F*JH#MV#3,%,:Y3?P$
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MC[.>;]S#D!OOJ],OWVHL->4=!YI/T'ZU8602S6%R+$2=M^E:S40-\IP3X_[
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M*M#,,.2T>ZV'[9H5%LDL/+/^XG'^Y:+(&1?C$Y)=%J9K=I8M+U.9O_1DB#J
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M5W%RH(DBB.XI$$$W( 0:.UP;"7R7+7CP]0P:2*#'$@G@3/^G)6P LA>E  %
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M3"=_<M,SR0R%RF")L;\?H:4?K&O8> Q/IN,=O#BLH6V+R')WQB@@5XH*$RB
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M4(5W_?T4"MM,_(*"(<?Z3H]#1AB^"=HI#KUW[$$\<'"CU\>M.ZDU6[V;^=J
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MC^@/C,*T MQK1[JDH<^<!>[V/02+EN#"I2F+]!0(W>(/])BD)M* $!!S9=7
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MTF*PT6P)E%H]&IKKQYAB'EDBR18IQUC7A%^L#N&#6^GCN;_Y_PB "I;@3&Y
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M_Q#^QA0Y^'MDG1LZ9M?@OH]52/$'6<4@RTVU!MH $SMDHG9^^$\J'!($SDY
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M,T.QGK@>T3T?XU[U.U.*YD3OVA$QW)&X):'ZA.;X]%=K28GS] 4>XEI]!>$
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MBY8,F8X<82UZ=!IFH&"I?@\):6@/ 9&6":; <.38E#!<-:^ *W9JGON=S)R
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M5%__"XDB7 7LP5(6T\(H@K^%!UL\JMQX$1=R! S@>*",-WD#2/W&=^NA^]C
M+/D0(=F:@7BYQWAX-.PME7?/KG0A\"B?B0K.H&I,]8[7'6#H_^=KII_HORS!
M.>/7[5 C,&)?.,H\$(89*U!OF_MMG)258F<<*-WHC9E-BHV&_I+84<?>PC\V
M.M]_TL8>?3/Y?5*N&;(DXW;@=4WNO69RL2]$L.JN!E6<O1G1Y9+YY/0I]RRQ
M0'>M*Y#K3RP;Z%&]\)F]]?SE+K0@M>=1<=KHZ3NFB 9D/& ,-(Y7T>WE;I<5
M_W%3RC!.NIEGT'!?3+3P8$Y+-6=10ZO/]D/\3\<*!&NK^[_J0:#@0I>22:V5
MEC]X/&TDP?$B^((,8RY_.:TK234/U?0HZF*D(PNNGPQ@1(3Y$O87WJDL,N2"
M>:"?.RG)[SQ"+XS\QYJ52&E3" ^O_0;1MA<T?EEGN3#,QI@O.G80TR:^(B@8
MOOGU.%8?[RA&1TW%Z$[K92 W-&@VW^>)5*J/$21>\_-POX=^V EM"UA)?^]2
MY-Z_I8L##<'<N-_T8\J9#JXA<<CW;7/4*]609F;^MYM&1/Q740R;\K]$G[))
M''G4=EQ@SH=_ UFPQ>\,Z(*X+_.9\?)BOUGE#F<7J:!Y)H]QP1E$FA"ZHPHO
MKE])W<)$O;DTL(:6'7\[WX50:*5D$==^ILH/+!#__JC.7V&=^;%51D#YB"_D
MMP>CJ)5 O'>GIXD+27]+&_4>L'6JO' J+T0&083,@K768MUVP(X6MI?9^8@8
M5FV.##(KX.9E;NNDK=!>W<) 7$W/1M@:B?"1HD&08851BV;Z!/P1[!XIK:3&
MR]R(9^3U9Z[Q1'OCI._D-<=&0,JGT'(Q-[FC]C?VKT@5!BSC83M8A!9^;8NR
MDZ_U :X]R(P6[>$(\  Y,9 >]ZR++>%/F5%:[<\0=,9+N7A5 C']1$\,-S<!
M+RA-F?N5UM2-KII*_)B,9,;I*J$H"0EU")4C!9?3=\J+@"XLF'UPSSA)C/MM
M@XP/7V\_OQK91VTB.IIH:__[;SQ!G>IWN!9) 9S\A8F?/E>M!XI[&OA)=YAN
M>5S;HUAS/UZERSQ1'XM<'9Q'#I<5=37LP1*>>YQHD**4:_=V?+PI]9)20SOY
M]%3)M!OC+K+MHB NCU;.:5UZ3.U)'/-_%?>507%VVYHO[AJL\80F$!H)[A:"
MN[L$">ZNP=WY:()#<'>7X.X>&G=W#9!,OC-W;IU[[ZDS5?-GJFO]Z^K>LM:S
M9#][[<@;+)GUR?KYDS7!?B<S=.<;'D[DCBUPPU25^0PS$_,MZA83(KP9+>P
M6[$2,FPO0+*&4=-2WWPI&:IS9Y&FE:0TVY70W(4^]NR\3F%-U=.J>+<6])+J
MN"6,I:.G-V0<0ENGS=QR8]05ZQQ@T-JS>5N&;8ZX<&CUO>J0Q'ERTZWEY NV
MZZEYGP&Y]>IG1&F!K1JIDFJI//+3TPEQU]LA'Z$+W_T@EZATL@YI%KDZSU*3
M\(%7_JC==#.M/Z\O58KXKI)I+9J*Q'0LBPN8>B+I*YUZ(ADPIM]5-^..U,CN
M<@V3?2-W4)P)*:M^-6W >G$]$)4W6,(2?GO?BL40'EB>M-DRBHSA3[*-T&'W
MX#V8=M:V_6CS9E;K()M'6PX[A,#%29="T=[KYF@WN63$6N);E6\2S/KL]GV,
M1WW[I,R?8'2,^S\*8[=/.%B6*E9\T='5N>CPT74U!P3NG"5Z=-$^"-^L/^^K
M+#1DJF"8]44'GMNPXL+O,+\7_GE;P*S@.NGMVKB5?)H[+E_QP'S<-^V1<>!U
M;. I<2H5=&]7,I@FX>W /AMYU@[:YE<$+:WHZ<+D;>ZN;#QVNH_8_L#D57?.
M@\QBOX8&=(UA3E-2G\_4<N%ADZ0UF\7M/1QB9L>E_F#P,\+F$YY]L07I61G3
M-_D]1-F93PEA* Z#@JP&L0PNJ^ ,,U]>7=L?UH4#!+,JJYY90>($FG^Y@!9:
ML9/-2B:+85JBA#N_@>.WZKW<%1;3XERP%=NF9F5Q@N"_@ST"R@QE*0_0@ 7"
MWBB36%=BP:A'=K\!M:WA*=M+;@[4D*G3.? K!6OD3S*))]:IFVMS<*+.2YHP
M[0ZX[NUT?<9UAG$[FR'HH>=H]99@\08#E9FZ-0L5W*!:D^M#$H7WJSH0=5)O
ML>G![_ST%]G,N<!>^F1]I")K_&O?(6R96&1?),#R'VB3GS"/!_?Y,P^ G9_F
M^NEA4%+?N4<G,Z#).LS;G?4C>>4A?&;.%?L$CX 2\E^MR='8);0K&#029FIL
M6&/^IM444C\U!%<?+X6#6=Y>O/P490P?);_J;7Y-GE%R/'A=^>$WT.-5L1YY
MHG68WT^WM-H ]R;(EERY=918OZOQC'50:-Y]@,_D@7M3HIR#Z</>LI:P7QU%
M0:P6? < Q/(0 #YXB#XL-9A./5O;='./%081!LX7K%'/#+.IL=)I3HHO#58W
M5O^9S/0N?-\1WOS^\SGECYO;+>:TQ[6\6//$M[Q>$V +!T&Q1D"+R:K3Z98@
M0S'58\,KJHOU%S_9WT#^U7S1E,LAYRN_J9J,H=K?0(5OVYP1U\KI!,\$+P'<
MI&25API:14A'5'WC)2/T&\1X[&.ZA\'CXR+US]DS'_%-3ST]O65VI-4W8W>#
MEDD FYV _0&JX+$*#NJ!VR*: )>X/M?)RW5\,RP:WO$9X[9?E1)E%J8&]02[
MU9D:0?VK4<=$63+7O6D" :']2&!N>GO&+E=>5[XIPF^:A-*JD*2*G&K(3]U/
MUL/,8TW*Q"UZ%_07?M&<EXJ.3J^9-6$]N@;]HE5@7X:OXMMF0W+8PYXA[J'M
M9HO,4K1GNO:'T,FW<E>:E%FW'>@&"S[M(_Q'-Q\5]$KO6@X()PXU+PY;A4H\
MG71'XI1:)N89!]GB 802<( ^[N&DSE[]0_G>E&OP',"5;=MJZ235$X$V(4E#
M,B%NI)WM7?[@KO9DH].8)(1;(F0#!J$S-%..=9HK#F3]W ]IP+"P71NQS)%"
M=#AK-,8^,:857N>7I'!J( [+OXB+.CFCJ0[=[&.S2YI(%(^O8XAY:C+=H=[G
MW:JT^BD<YM+QSG:G)4R.3?HK+53%D<Z8K2NK(WRP^%AM:W;76B4#7#"R4&#-
M7X5BI9.9F:&!%U5N%P,.^R2AW%-]A$U 3B5S"L$0OVC,+& JGSY/.Z*_2P\\
M?1K[#>"!N@4V7B7%WK:I2/U]A4D34N)1U=MHP-0P<[:]6L(U)]T>[U.[[NKN
M"OK5,*\AOAAR8[UJ1V&\-<#+LCDP+"W8BL\>*&D3V<Q3=$ZJZJBX]HSE1?\M
M9^S_:-^[)!IIS/!HPE0I3$T>GN/8FY\29A^93PC53!,=@!P<HOD*5PHZ_2C)
ME/X+6;<-]G !)H1RD5"S%=&-^"*$DBK)*9,PW0N*<MF2ACENMP*_'[:XC<9D
M- Q!9WBS%.&5=+J!@WT:FEG<4PTQQCUK[S0GB18@K"T6?NI03KLN=B<>:F_-
M+YMDOLR+/3JF.HP#MCPBI&C2PPZ>C+[#X&PO8(/S._(/BZU/=W&D*Z5OS_G(
MKDS(W05%*"9XJA1GZUY2+;,Z9;Z,RO\Q5^&HA\Z.8Q:EFKIY%M.0AN.O486#
M]8&[!'A3EX$K+]9B\K.OY"*V(KTC:'A0$ZO?T ) *4!"0@ GN)O<F&NUL!@/
MOF!5F6X>HI7Z](B+LZF.$W;C7*)G12?7P)W"ZLDN9TR6KY N?<9#6/ GWZ5D
MF*E_>;4);3$KU!&SM(*JXI%#ZN%%AROM[_Q^ XFFPL=WAB_0MDF"T]] L*;:
M.E.?[)WY&/3R,9&%0MT[VVK+#S&$"F</=8;O-V Q&9K@5@,B3UAZ4D+)4S2S
M=NHN:@S50 "&28Q1MN7DN0;>$6[7-DJJQH_B!PJ3JY>^6[TGC/^C"J$$FL+;
M@G3*"\^<@M 4USMOJ!DOHQI?T$@BW^>""VCJE[P'JYE!U98G\3FC,]_^:C0P
MLZ(>-L.C)M/Y%4NRD[.AP<"JL4=<3YI]I$F@H'AE3V^;15.+AW,;:&*&?;;#
M=H[;[\O2_A/S>KVG[:[=81NY^66);KQ'S&"/]"G3?L.LB[[H<*ND]NZ"NIA$
M18:MGG-L\!5:99'L@Z>U+T=9B67:>+!5B^2?!0C4;J*20]ZJ[R2/ WGJA#W3
MIE]V^,1QVYU<MY%]"2MDZ,S<I,*'^<BW+-+--QW::05?HS'F^]2<'L#_?/)>
M+-+ <\KD2XK9JDQK:YO]>&:4/IU_RU_&KW5BDU,?W!))TF>A/\H%= T+))U9
M>=%7,:[\0ZU!8B4:0- <GJPXX+FZ'_JL3=<WY$K"\D8?E9"6&\AEO7ZML)/U
MZ]?\@55I5(,:/85_/Q-AA]55Z;<">U==Q<6V-^^5.UK_)-U:1 3_4>7X6P@3
MJE:M-.*7A3)^>GW>)=I8&U%";5FMCZTX@!C4-IQC6PJ]K9$5-![A;\;KBXR5
M@O.G$?!^)4)I6&;923V?E[BP+_?P1;!H66<3[XS"S_G9W$[(F#5;Y[;CO11'
MF2A;5V*XJA?L-U"&8C&D>.<K6+8O/B/ :K;Y(B8^UXY7RAV9IJW!CM162\SH
M4QN-#0]HQIDL= 9/46<M]K::=<SAB3H2EDLS*KWT&>40&AIY$,#EB1/@ \,"
M2G!Z<7U/CJX7Z[K^DYAD&X.I_+;BCV&J^GJ)^8YU;4!I0<0=A;R1E?MVGQ#>
M'/CBYDZ3+=EB:O6U15!L[E_1ES<YV-8;6H,]F3RFY/+"-+]:.;T$/=>[@=Y-
MUW ;N^LS]MC4:YT._/\\-GQ_6_6(\V#_ZSOM;V#&T]JI69C40]5PH5TUQ^"0
M;WX^,X,=SY/<Z12U37$B^Q17&V?.>Y'F$OTWT$]$*2C-<?IAE2:"Y@E,944+
MHS9G#9C0I<EJ+@OFS8QYUYNY=&>Y'[FP)KV?8!+)R7PV"">RDZ3=2ASA4H4O
MQMBJ/YE1P[6())-PV'UBW4O[$+8-N_0LFB3\*[RFN3FZ!V>(QZ@+,^#X4'^P
M>W2(V;;A8Y1T;']"'F//P=B,*972>V0>RKV&9$HM;J;Q M&>=">%WT# $8>R
MN'-&/K<#YWS&%..,R,QK949SS.#8O!5-I(T.,L.+]="&EG951\^R4?#,7_41
M'T.VAX?524:%I =\(5,'.3@8G9>(:\3US2T7ZV$^\GE=W>X5$XD%H+KY?&8I
M$A[XDG%?]VU^"'^'M?RE[Y3Z:WEH? BOP&:3$\]QY!V3?<_%<6V=8O$1Z\?I
M1T7$5Z<Q8;PCVYW60A!?XJYSS)36EQ5'J4ZY]ZLK=M%PL5&Q:PVSI+'+PMZS
MM_PTZLN7?O>%WSUG#D<B"G7R'4?)K=&18I7#E /\U[8[M/,E-,5=C$9ZJ8/B
MQ9F<R3_]*W*/LEY7BD8M;#B;68U^Z88&N:!X7YMR[6/(G<S0!R'V^NT@$4I'
MDT(?J8N[5.*P^N(;LB@,CS&NQ>NV\@@J\15_HVK*5!3R14G+36F7[V$HO:2N
MUY(.C8J([N;4$23DW\GCOB8-RNSBQ/GH8TY[*#WXDO7'DC"-Q>*/;U-=K5 6
MO4Q/?&$XR9^^Y:^"U[,DC2TE4\F:D2KHC''S/\$90R%!$%I!!RX=-Y^D?P-;
MDBA!S_S8%4VCI(''.2=^619*[OL" ;$--UC!^,N'"PO78^9I],F4JO-+ (8?
MYU;%AKZ.K? 3]8-JM\-G8<B3_%N;*I)K^)?3U9^W59:SI\NS"@V-EFEND;1B
M$%<?@)NJ M#^%GG]Y975\EGJEJVK\=S7@32,59UN<KT//2)MEQ-[ PI?9(#S
M6SR/9=>NV33:#M9LVD+$'#]8S7(S56"6PX79_;(,Z#?04.G3D^W2N)GA_3E)
MYE+]5\J&K;MZHZ6/F'WA:NOR)&.WSA9 4&<_0&;)R![K&&G>!:MJ\L#>._\\
M*:S:G/+9N<D1!?1L@3!S\!\.?/_9O,AJN2BTJ&':3B"JT8P76ZDV:"24@EWE
M0690==:'T]*Z7,_SOAC[?KT-@0Y!\.(]NZZ+^G6G@<KC.AWUGQP>\;\?X(+8
M/++%PPSDL>4_$,YEF!G19>N9%_JV+C0XI5#AU.MFDPQNF5__6B@'LX:]P'A(
M,"78$P+6R34U=1?45.)J;0\KGAX]\2AM/0,CZ<LQ_I-*\+>(99"[%E2*;;W]
M7G*@0_'-8@ \QXFQ5)X+-5NI29G0BGW^LYVCJ_:&3V1'RREQKOK\IQ"W4(+@
M<H>5OG6F[Q3<[Q!Q(>O/O*PM%P-)_&B]TN:O$AQ@^<,B?B:K';['(SOS LZE
M:^L/()N;T1>5$1?/V]0<P[?T/P@3&O%^-27%%6T;=!3!QJT+EV$K>F016R'X
MTE^-AKH W4N!OTDUEXT9RT5!#;(NWCF_@<\)\TP995+=TFB#X%>Q*#KKW_P%
M2J]EYTTO.Y/!;MS?+7X#8AXL\%0,J/A<K_+(-_"U'+QVO#0F8Q:5+K)[TO>G
M;Q$(=_.-)5H\>D%H/BW4.V:U?JF55RTXD4J<D[WR3@06\VF8"(R1D4*?YK_Z
MTR/0;)@0/Z@7M9'7R?,*W]^639=-""%%^]#/AN77_08.!OZCOOD/:<E4[&J5
M*-N2XAR-$]#K4_M+LX?7L%5JP.-.L*SP6RF;XSPA:(3YT@W"G/VY3IYMN0N<
M8:R)%]U\0]<A67A(ZA:'T5ND+69-UKBG%<^L6*'_+7FI\N[/!L4'YG18A]0T
M6XMKM.#51.CF^CC@;*M.B]!$/7QQWVHK\Y[=LLAT:[Z22RCE?A)#J-Y.F[Y4
M#+Q9)WKYNBYP68\88J$%KW:+0KTH*6YQ)&1G<7A@==3IYW%X(&F/Z-8XK=O'
M2BZ%AY*# )__+7)LZ%^Q21G(&M;-^;XNRPWT&F<0;><(QLC+I>KGND;T2*F%
M&+,'+6WY"[DLW&1C62CW.Y=[8/1Q/66;OI77U_X19P8W2M734=7;:IM\[E_!
M\>@R6B;[[E3.UMS]M:4RF3"$RSF#JL*1]$LO"_&2M>JQ_%8FU[7:7Y>NGD4@
M ]:#5!OJG^@WI\R0 XXAFKDSXY8.];XZ<2IHI?,<LP(]0NB,$):'SL1PSAPC
M]*<HY.L>FU3,;E(R5F@WM6/60Y5H(,GI1BQ)BHUC\4?0 =!5137_K/H;(#1H
ML2YY%FN>&J^83$$JZ$AK]=0517%4A0[S4I0MVGP5#&ECW',P5GE+@ZP@="?X
M<PKQ9I:4>$U9UL3NQ#E.QO5/%O<P,#MVP5QG:8]'=K*C)F7"Z"1ZD%<UI4EQ
M@<X5M=DFT14J^_A7* EU3(>DU0V6'X)KCF$7$[B=363TSF,7KSZ5RH7U*?_G
M(L8%ES"D*X7U41Y[7&'3I]"V_[WDB**3H 5"VZ+$-Q>RS?QDTK#$=7.F:/M!
M"H_*+YO+#[DNO-\WW[%Y_G*\^M@O%_">;WN=I[(G<HVS0GIF5Z?^W-;E9-CQ
MOJ7R3UADI/3?FBS\6]'DWA9&8XFZ@>FJ%BM^HFT861D4 (@TE!RC7ZSS_UC9
M"$X(:7+#Z>H)I= B34L[@QVM4FX^P_N6G]B0Z?(<;UTR;T]F<',B_3RII=!-
M,":1T'Z%XM_1F=YO(*;BK%* K#1*%A8EK;(LS0T+Z&@LX1>EWA;*2P/6P?3@
M>& G28OR=8)K%:H5@ES@H#H+&4,O^QX(52#T3;.^FA5WY[O:NNM;I+0M?JF<
MCVR>GW]L.3KU^<Z(#M+%?]AJ_?K,7WD@A)XB-U5E^W8.(^Y=Y38$GPZ(AE<4
M430H]&<70H47(M8*S)7*V@Z8^IL;"AD2X-[\$FE .$TSXW+\'9O,8G55KH2&
M2SN*4H(_27'1U3!JF3"#&SN-< GJ$F1645\YVO80/HG.GP;<CD#&GZNBJ:YO
M-[\\W=(]3._^_<AC=A7&;V"]1'C 7_!-Y#7O;V#3OMN><> +9G4,AJV6&7C#
M'#"O4)FZQ8E:WHNQ+Z&?8OJXD8 UWU[RQBCA&O-RQE_P\Q\G!ME&>7[Q,/SU
M(OV+P].01'C_N.<W<'^D>)F#(_6M/714ZZ'-=PM+4DKK1BJM[S4W_O)(C6RS
M^8[-=>QMQ;\8QC__'F=*Z=%W8I>R<:X?21^:N6<?7V\T)D-9[C+V \Y%*%O$
M/;\G7P;]\FMG^0WXY?\&2!7_>2Q_-WA+/DHQ)*[O8#AZR>Z=C?(8"Z6G3LZ\
M_"'AR7'*]R7J9VRZK5>MAQ.>@"QUI 6MIEST9JC'&W]!F?_KK*(DYW\Q'Q.3
M1C.D4=34-+\G:FY(1FS^!>;=]3W6''GH_@T(&Q#_!KZK?(D!O,0)]]8T!W >
M?UY\?_F9]&S-?*[YT&:Y189%71A&8T#3W!R[H$J@Z\UO'NBMA%(Y;6#[7U>E
M31B;N;65#P=/,/V(/]VS#E&R29B9?5(&6/CG<_32Y6!B8C[7,:(4B84]J1_&
M&=3V3.&;U5[;,^73(N3,N1OK!/IKLAR4K%(T#N_#9"*&^$4$DI(2T9ZM&YIB
MMAHC><'7%+@0H14[:B?'Y8*_76RQ70XW5VW76R@5J\QC CG??K-@#"!> I/W
M+5C565X3S+_ZF_\:72_G]9[R6S-+H.,P<>"Y"525(Z)TI6Q$ B->0NO%:C'T
MY%G<_&*>J3XYED*?F?;J-U ?E- T8:?;,G)?Z=V[1OQ0L!F%5G[S5(5-4MB<
MN!M=\II_9>>GHPCE=W'/_*A+/_HL,<?-1#S93\;Q20%3SMIK5/-^S ]!$F$J
MXE/E?2%A2>ZVC$[,:.2!OL4(B_15W%>=[[],+H;\!L[GLK<E_ZM^ #>1D)%;
MW>]1RQK)KG[CF\<!]J"DD4 T \E!,]#.S&&*,'&#(//"HV%O-48X5)3@0J8R
M%=2+>2$.>&42[OWZITVT^"]_\X]77"D[2GT,IERF/8YS]8,8)'>783+GU^3F
MH /^A:]1VW"@)\W__';2_]!<@7\RSBF4?&4#Q6(K*N+ZIU.^^>_5;[EKOP;U
MVT,8M?1V)SS(38YU*/]Y* @S_WW:TO_=KMY&7O%R&D;5/$ IB.V"=62=A9?%
MZSME-K8M;5[.K>;^YV3^;\.3M2[Q,6A=N,5ZCX7,5:>U-'$W$[Z[AM;#Y4E#
M_E,CY7\N.UDO9(MP)OR2?:GC-Y#F8),<:-,U:/ X;C/U+RX"_ !+&7N:N4I-
M$7TV\0>.I'.0W-4^G'6K2TC3 >B3K0LG%9P8D'?DJ<P[K#34(V6G*X1QQB(\
MM_U.R^=Q]645G!7UGB?VX"SQIH3*7@P/]2L$V0$W;@82!^EC+:@0D*TV:_#)
MSF5TR"RF/,MXS;5LX#F/[5) !#-78".@'_"J( A:^Q,F-;E4G<:=Q)UB?#G%
M:NN<;+<?8)]=)-_R?Z6S<')#QE*_FDKF""-_G^M):V..F@?E07Q!TIZ]Q9#7
MZ"$[!LUX6_XEX/1ZB.;YKHJSG;0HW,?1MF"M8R#;&_#,D&1&1,\IU=-IH7KO
M #-@P^ED35KR$.YEV4PG^[J322F;VKXO%8"7VX7H+\W+LS+80E< N+@,%T:N
MH=&EB<?2S[6U92 IL4D+AJC.<W:P?XSD=>4_8,*76(J!;-,]WU?R;[TM*M;5
M14U&UUIAJ.CHH;@8AYC)$6,L<V/Y;T13;D<"1RZ*^):=U-P0,YH(IG6;!)D0
M*I2SSMF)!?*@%8T.1TK*"XY6C0[D"L'G6I**]GS-OX:I583GV3.08X3#HA.=
MY-W<B7&7=8<='1G$,:VT5R?@ ^:21/ UV#V*I!5QWT;.)K@\JCL5C;(!:%%?
M%-D1*3H<U5V9OIQF4=A*BL!*8*'OA'_0]I5FA+'^!F;%CPBVFO7)NN\-F*;%
MKZVB;<^8Q](S$O:1'C5V!EAW5XS@%D$@&H&_D5$*F0 S*7:O3J*M:&5=WQ*J
MN5!K%9_[=C4[7K*2=\ QPR4']7;]S\0H0L#?$Q6SXQ,D]'NB[9SR,DNQI4\@
M"FA;+8&\&PFTH>*8L6$,73?4]X2[#C"K+,9+LQ4V>=<B0VT8NUP,\V)]0G6G
MG@W*N5$\\_F=8S?B5MLZNH>/A_6'. 5\R*<U^9K FL'F?6-X:71^TRGD55%O
M3]NB'Z/N[FQBB&+,9PY_H#BTK<"2'=9;; B#23NX]=4VZP]2?V%#V=;CCK-K
M0+LE<8G8, L]4X\<\PS6-2@S\7%J9,<L%77Y=,":E"!"T1A6I?40.%QIDR9B
MXDQ>/19"&Q%VT9JE=E_!M_/,O7'H(N]VK9JM##V3SL.S=Y)+@HOF*,K]%),'
M $(-,P;K.H>-3OIK$_&Z VQ7O%T$<,8U%0*J!0;'B8>X$WXSD=H8[]"X9L3"
M87F$ N\I("Q]K=NRF_ES+B6FS3.%&D_B9QE/14URCF#KH#;+I]Y*]GYG ZH+
M];4:RSQK8NZCJ+V7NM'(#Z-DQ.N=N#S1P\\B4 1GN(6_?>:_NS,%$;Q=91#\
MQ!$VQ[2HY+K2N#MP)935O$]A 2QP1LEC=ZVN/D:S-[R)P!B&&&46_VU,VTMS
MRVYYEF66%^M:$TDPN;;$CP)XOX3F]WY^G6]8)],Y)';2T](KL9099,;#8Z-I
M:4RB^H*IO$T=B#9$85UY\24$UDNDJ=R^)<W\^5I?E9]@ UY"FO^/?=V#+^@1
M_J0,HW'ZL^=V9S<O0K_^9GNC60A,J-WL4]1U#\H G]NVY+E[JP=IGV,1,DYC
M,&ISJ#F"L3\PBS(M-[R!\FY)&[LF<BN-'#F14 93;K47D@FJ]F?1=S:E;9WU
MG"VOI.9Y-C;4Q_F;Q/B_G+8'B'VI6PKJ]T()N7F].8Y,P2%%3L/^"0XU/8(?
M%U]*.0.0SL%*HP<#TCSPU;"^]T<Z9B>=I&F3JNT-/._1JM&. [U-S5%R<U".
M_-[-N,3(K U<;>0GL94XY.?3UM6-V44T!R)[I?VH>CW+0?8=],5FDN*DAXK5
M=L1PAV/#9QQKS 2IO;8/ H]&[L1;I3IS(I&:OZR%EO]5MZ?&LY:\[I1D^#X'
MPT7M7]BSWEW9%D[#@V,#!<JOMQKIR_S0VJ3[Z4+4S]'NKANG''#VO_ [J#U"
M7%0=Q&=WU4>RF?+)OP;=7 /4I\>1RU7@Z78JUZT.+);8DE\QKFZS=KQ]N0I$
M!]2#*;P80Q-PPP,>53H( .:>/U%D6;&5AI=ZNO[ZRJ ]?#Q&2]?P >3KI5\'
M(Q^B5\A?,[\!$UF0):>@P&.M+B6Z=%W\Y0YNEW/<@#_GS3KA(6EEA5"JM8-\
MGW4'QCL,OJ!0"UB>OP?8A;/!P'+S_&_>'7*1LTM\/J)^E,4.&X8YG:,4V;>\
M_3T4=RKZ[;2;5H"!=S]R&8TNZ__@*D*B]$UI6F%#H46-)'.1+U:I%$RYP ;>
M.OHAHM10S*HZ_/*32VGC;,DZ4E],,M<]PH-RKQ&/ *7S+#6%0=B6/G<?E87N
M.S ^K/''FU1,.[BGJOKKAK _2%.EIQGVC,.5O(7**7V^DS+4=!4O_3I1)1]N
MM^X"](J*!03>23NU^)>-*\JQ/,LYYSLOTO79]%>U^;]#V8P_N(4*JWA07%@5
M1?H8VN87S,>TQRZ6V,W(,LJ B1@DB+0U>6&):%T"IC?EPJ@/=E?7*E':<QH_
M$1 =.?"E?>@\3;NOT9LGC!SK0P0'1'2 [V:;F;JJ"TS,S[+VA:@GMK1U,&LH
M<>2FZ%H^4'*U0R>P:%.*!U\,)]*%4%U03D5@];,RV1HTXQ(V]]GH;(,53ID8
M[(#&Z$5_9@%O3Z!WI)%%UM$\HZQSQXGD'"@RM")B#&?40OTJT-' O,BB=3&B
M@4EFM7(SU&(_U',/BDOE  :/E'YQ=H"W-3U0*Z%6?Z$2"5*:>ZW_SI4LAMDS
M\!CWB($08S#1/=#]$79'B3S#M]<APY,7Y9Y"6K@-769-.K* P\3CJ!FYS),E
M>0UFX&;VVK@;EU9WA;0PNHRF%U>8M2:2I,Z@=MX$8Q-XIUUC++;/W_(606%J
MU9>NW[EJ=#;S+.;8H!$%/5^'7=<'G)  M;DS'^EBCZP!C+T(.ZRYJ0]5\(11
M;A+S0!('H[]G:K>*Z%V5Y,6"_[)D*/6,?1I9?$%$]#N+!%DBO,J3Q+)X9&\X
M#0ZF-Q0L,@U1)]"+E>!UUG!3SXJQX%>33&GS.0@YE3A;*'=UHCQ/&EEIW/%$
MWKJI4!H'DOA'YQ&\*UO(LV1:V9:MW%%*3.%#D$Q'_53[58W^FSI(\UO.:W\2
M-<:-DDEU4(4BLH6F,NWX6IT]N"Y:5V?<!Z]2:*SYM>FRS,M)%B\-:,^?^H(H
MIGB0W?H^1493J2[<T_@5>6+"4*)CAF<.18M!7I75J7$H/4$^:[Z55@UJ#F92
MHL>9O+3>8!2GK\:PQJ+B#'-E3N(;._,FNK$84*#? > NQ6TW2/XN!PL'[S=@
MU?CUE71;X,3G!+$5&;BKV8Q3K&YC!][;*OXI#GW-/KZ$#'WMWCLF469F</AC
MMSD#J41CO N^:5CT#D*&^CF6AQ]&A<+4X;"K\V:HL)5IAQ*-]AR22E3F4R_$
M'I,URS'+>F:&(\;M&T.E<P@) ;#^AD5X\BII E8WMLQM.^&8+7=7PA!;X^EJ
M4C JF)RNOQ)81D"][<R.A)@UPI[H"U?%F@A9U51*NQK 4IGM3P]O;C(2J'H7
M+@KU^;Q^;R.JW,:HJ /4"657'FO&=Y=*6K\4@55I.X;B)NK:&YF@C=GVJY]"
M7H<Y#O(2KENT"M]]":M_8;M3]KFK^99*J[>;D@NZ.?&ZU.1XPM!G40P<&$$,
M7$9$(Y?B4=:P "HQ!M:79_4G,2\>?U%<&;.])&&Y6S-?:6P2.'5+Z<791&\$
MI5:M<X>S$,WVD6H4%77)5J:"0?R[QNK<YNAU/JD*CF&55=W+9JL5T??+Y23S
M=CM"-C-(UUFTX(]@V%4HQAP+:+(#8.\1HNJ<WIFKM*^L,..>2+1IB,B+KD8$
MR21=M>W8(43'>1U^"H5X0.E-I+:50SXJ 91=J@?_SC^_ZFNM+"K0&OBI\-=R
MR&C-HRRAFKI*7R(<+\\RSY$X(+_%>PNQQS%4S/\F>"792KWTK C&#$AD<\SX
MW%[9*[,@H%YJU1CCBJY']5;;/ NKHOL-;V/NR_C(Z6$&VS:U1FQ*WF"9P8<T
M/9V_H)ILY5ZGC3FEQ3)0-_R=\VL_TP$A%=:,R%NIW$A<G^($;B>W8M"I"$H"
MF8 *'V04][6I&5GH/RQ:W&F->8%3EY"HD51\=0Z_SV]6L-%G:#Y<<17 -@6M
M!@6$'(N\>A@XUJR?SDN28HXU5T_3RM,VC67/^$N"FG4"61#M7(\NZ,964;\U
M\'E%1[<B-M\\?51E+!&75!2C9&"8^]/4#L0<5$&%9>%@8'67:)DPZ;AIY+=4
MYD+PL0E@*/O(_MW!Z"D(TVX8@?.0M9_\72U836_?*AH=$/C:?BT,S;+4#Y7/
M<UMKGBP0BMST,2E?B3"?/7=)W]R\K-<WU(6P;^"\S\QQ)D)>X)U\Z\_1;OSS
M2+?OI_QI3#E][#79MQP9B??!37#HYXR2-.2:G!L4V&=[QPJ+-&GT-DPF:6L$
M0'T5I4QX=-!N(B&-$ROH\%R'$O?B>+!4FK:/3<^2R$)3QGL\),F3_[DZ_]=)
MY51;IXWC3%N_NCAZ*:%(%V"$#AB+$=C3#))"AMSY&?RUMD%"[>B)D==?"-8;
MJ[R6W<,YVHX%<>6&D<:LQJK>^C2P8WY2JX,/$Q2A(X"S'CPM"S]SU[?<%K_Z
M,&XN,(JA4$[">HW#T'4":_JN4[/ABZ/<U)*BW]ZFH?LD%3H)'F3,=P)GF%-:
MH%A"%@FY@USXB_-:VA<JUF0+/R&U+[;I;, JT2.X$G/.AK>K0'MMZ$ LB7&3
M?'Q?0J&LK3A@FI$T6%+RCN14Q4$!1=1 NW1%?DOVP62Q?E57K@WCNZRNDA8[
MN13P&4[#H5@"K0N4@Z5(R%PE5.*,M: 0^3;HI(E(A',BFP<H[Y=<DQ]$I%P;
M:'RFW82-8\^\L.S6.[L[?'ZO(Z&"..+?K[9/%LXH*9<4F=3]4W\B.\]S^2_4
MM I8JMT.R?KK@X++@=,<4VRX"4AN#K(X@4-?PL?(A!STXCPXD0/@5+&T-7D%
MRF<V/L=5JR^+:7.(:.CU 05=J&&/N^=)8YZNQ8-3EXH89@KKMT'X:**DZB+_
MEJ!/ML3OA1[^5YE]Y1%I5^AS7\7=C]"D+XA^+H[8:K"5G*/8O*H-!Y'*JEX#
M*EN:7E9+[CV,9,R=OK*O>2K]P59DX-)]!*%D9]%9FAD.:V^UIE TKO/43\.J
M$*=]NB0H79*.VK\LDRZZ1'(E2J!'8K"S=@&N;YM3A:B7#0]U0M8R]PHRB*G,
M^ )SXD5D=N0N?<]9P,XKSK-IIS_4Y\KHS3X%H@Z]J?U\L1MUO/!S3/3T+"^\
MFRY11#:\ID>JN1?PI!B<\><Y1WIPO'TGT>)56FI'Z:%-#F6C@GY(-&>QI88+
MY!DZG$*_<5&/(<3[4!J-A "@__D   _@5O[BK-TPQ>$=(W.1@$EM3C',@P #
MQRHB= !*EY2UU?MBM7-OZA;M*_*M$=C,9)F%,:]X?KE.//C)ZVK,;4[?\NY*
MN3PY@D=M^=D]@PFOS.-?[H"S$5RTR9QBCIV.2[\\7^O*)5&P[=<"=66*@:]=
M9W'604_]-LB:!K_F#QHO29B^A0]=_272:1K&N$2AV &(%EE"O<2_-M3XBZ$:
M+R$F:EU)TX&3CJP$3;1JIUQ:&I@D5 G+>:[)W]FV4)LC'&M&H+-)(<PM)J]Z
MA!J^\IC[#1B/I-3\Z,&PN&<VT>VH'!F_QH%^M*$41<1U'@2(6#B%\76L4AQ>
M6GD_S9\E,.8'W _9+IGXH+,5FV E&O*W\))KNG[*L?SI^J,]DCOQ]IM6UIXE
MJ:09@)U_F6&Z#1*8=6'"7Q=K@)*)@I7&7W_5)5Z)?W4/%1:?4.!S<HR<SX%O
MOU>]I%BH<K0N?_!6:^ 33Y(E/,_01GR%#9>,#%JL5HZ5LA,WO$R)>CN;)<\M
M]UFV>5OZG/GC!U5S.!N03ZUHO.L$>[3IW"_2J13?PAK!#"[28&7.MI= .5%W
MX@M>0P5W9D^]A!G_5[T_9:Q;Q0LK*FG'%E6'6(C6-H=DG0<(E8QL21#M$.\%
M%G7%33W"].NG. 9:VGQSESYD>Y/!7KOCHBDIDK4I(9M'NH9]U7]PENB4\OEP
MU[-%\O6$3;(Y%'7?OP\"> ZBD)2OXZ2?XQNNZEHUX7,V!+^!;W1J%8,TK6F:
M7'-$-(%0J+@\RK/1+)T?TJ4BSH?FF.@P'.TK)1V(CE:G,CYZ90[U^QLYB/)2
M6,^I?1(!9V":WN>@VI17U!_S5#"]UK+=(E,FSB'4U%KD.(5?AF0J;.AV,XX"
M"0'+H%;3.\K]R [&$D06QC"K-U"3Z WLAKUIC]BG?M(=)(XGZQBF.6FDD#$K
M^3&47>OPW6&RN0R2"1ZA0G]\T+-"RG'.$?</7XG;T7'+U]SPV-^T)B'D'DKI
MBF-L"D[6G373]2]<>WM["UAU*QFC$'Y^;@.VO@TG#W)GZ3Q+7 LO*RV=47[8
MP."(=K9GC/0FG, I!;*W1@C 9JF""DX3"XZ191WP0'C;OJ]^R97KR"%$/W5+
MIEW_ZG,/"T^U>+9 WL!W?GX'E'L'#W"D@/L60?O\23M_D57@Q-,DW%AZL!,T
M[MVK+Y[D^/E!R3S;LT479Y&-LYV5/SUGJIB_X:TL]?)X2*N&^,#%/(F *)IY
M^X&W,3FB@M#4XJ,H=^?BG*</Z3_8IMJN-"UZGENH'?M=7/[=E5T-OX:RY0,^
M\8$"KWZC "<'OJQ>&!T"79P.4%1E':\]2AE'^*R1UIF+&=A=*)<;CRU8E\AS
MKE<41K?(B:4R*3;/_%F\)FBR%5?.0/2MXZZ>=#37*6Q@S'?%!%#E^ TT>7Q7
M[ZQ?=!GUK("YO.I2DQ1*8V]]*PWW<E0-%U0R9)?)<R,KA561P;5G^9F56I%+
M-<4'TRS.R7L*D=0@R21/)]T:%9&5F'F=U7C,*[$O4;&%TRVR_U(XG$E L("S
M?_34$B<9E1<84CO%%.$7I?G?"LM9PMQ_'\;!OTD5KH*4:30)O?JH.$;C1H(5
M'7W=1#U/A9,^^6K=0+QD96C!C37*59?;8R/U*SPLXO''+,D0S[Z@-:1'1Z#S
MS0RU]Y5]Q0[,T[JJGT<V/\$!T8:7/V5/191!<FZQ6 G)&P*QY1HAX^?1(/-0
M8W0L$B<TCMQKU]W2=K$@FE1HLJXPWGM'N8R$P*]F]A5>Q(GO!.6M/[N 6*7>
MT;6T^6;'!Y9Z2TV3)X75E;YNUO@?1TJ44H;M<$"0XA3C9%0Y\WG#('0+9/9^
M$)Y_T.801"T5U8O[R+NB6"03U\NG<OS.LDR?46)KV42PLL)8(,DK;C2"YHA-
M J0( I%4[OF3AA='AN>J2P!_X-N5</\W@"N@B,AD_TWG&*?0"E\>XZ78%'7^
M:XA@4(D18:@3'%T#P*UZ2;A7)9C5M'FJLOA$.CL>>S[)&(@FVL5&_9B!U_4/
M-+(^()6Q]A+,*JL8=&6:F_&M%G5^#4,@QRT-0K#HHG&@:]G+W!Q'^I:%I7(L
M)T^C%$EC"R9*"@MUH0"%\G8/ZUW![;6F 0P8H\TVC'8LS"3E[R5FAD0F""44
MJ415%[,]ROHUN36O+$G-$Z&7"DQV9\S&^!]G:G>-$IQ;\*Y04J/- T0(;Q7Q
MCM^O26\),E_-7(NW-"A6T[!_6G_(16U_+)?$]*!RI["NG'GFM;2Q.6?6V;M6
M"F1#ZE\)R2 :%J9_%'T,'Z+@.93.L9C6JF\-U)7^Q'E%L[)4'O M5HG7" 4D
MB$;A ''R1\\KM[K3P4[A*B@>,:X/L__Z) U+)' 0'"HK[Y;0\A>4]]1?#,^_
M%(Y6O".O62O(?YTMV6I"NAKB!*KNW4GD J(#4<__.! [3AP\F%4*U_@7\AIK
M8BMH8M=N =<9@ . U*ZZAYDRE^AH(L_*.2B$%=J\AXS=VSP6Z)K3)!)^2/ G
M#3@F19O.<C 18>$O2%4$)_1"'K\M#;=0TYTS>#$[.9[KU/^;(U9G2NK+8%+*
M)O-"-F!&PHX.JA<B)=J-%I *!OL3.GEG_0!JMA1Q=0X_8[')3M:L'4F#W5(P
M6V)Y@8V:TV&22=5^)R'2IH5;V5%?,H/&3B)H;GYSI.IK0TXI=-+/8#V)S=1J
MUI@\F@:K91UKOJH(>Z9GL6\2/_57XZ!:4K4?RW'$A[#; D"(KDK.^B$Q&5Z^
MP42.'#'D]'ARE?KA%&R*;_U!A8>-K?+!7%R.?S6%N$D41.'FY0SOPT>]R$S*
M:\FO]BD]7H6_OB:S\,1VJ_158.B;E;3'3)([)E<N<7?C04<!)QT:V#MO81B"
MK$I,'',Q3FGUT7O?U.J=N/:L,NSC$(])2$(6(X'0]7Z^L(A<>^SU7GNLU=U1
M7?G]#Q5WGPTS\]Y#5WJ-,VNST+J[*F$?+AK3-[<=;((G/B<7(&^)022; 76M
M*X)3%)# 7!I7 '8RP6=+H55/?!+H3X_%25;S70D'MB42D*!CDD[?QJO#0Q$,
M ]NJAZQM[2RR..Q1E^," P&^D%((FBHV@?QN";(IF>$N"E:VC?KQ%]*5ATA(
ML8NL16%RU*/2XSCYFDQB] E,IN_IUU$C#F+:U,5$]#VI74SQ,:GWLK4;_45=
M*/H$&O7YLD-WYR_A=F<1W =K,7T5R!=<:[=[*ABEM339T$F6SD8.:J8RR)/>
M>7B?AW ) +I(X*'5/JI;'@+<12E79JT="105IT8?SIXD9(V<&SS L8'^[#Z?
MMB[S#U->6=:!X\R<$HZ0:*X-YD&R\*HT)<ML"H#-7?F0"\PP_)YX42><Z!)F
M6Q^M/?K4YR &?5726S*R88+0/,[?^]/8>K%(^PI_4!D_PO1[C9!998G=AL]W
M;N40H&27Q'&AK4R77Y?,M:FN*70-Z:FF)X# %]CRI["WQ<I_0T^C-66ZJ8:9
M-'>YDI979;U@0#8#4Y[##/RACQ=MV1S3A[GA')"1X5;:";DD?;"7C_R$"]W;
M,VMJTB8S]3-Q81/^J!PH_8SRMKK2E<)9??Y&]YB)T^[&Q#D(; =8C)PR7P[!
M(6G9:>CMF"_XLYID]R59S1Q6<.[V9Q4X@>R9HFIEK7:RV7@#8'#B7;"X=! *
M6/.;I=?;[&_Y)46P<!JH& VUL8@Q $:8Y0$-JHZ3*L28Y78S=03;$N#+S'KJ
M1J@QS='_PLMRX-E9" $T.SH:9VT*V]M3/S6&R [3W*A3C#OH%,6=W738*S=E
MH6;],)%F"AM!Z(&)I&HUG?L9.T7" :[@R*2^3N8HI4Y?[$F%..4&V]'W7Y-E
M&S]@=&/$8D;R4E\XQNFL33VS?C(C<0WO2'5MJ:UK"Y&N-F;[8)Z\WV0W!X<<
ML&&-1;K+DF_/==-3PD;?WWD!:\J7?(T*WJ8L6F@M_;?%_;1+NFBF=N'BI:5F
M9=HNR_Q$%75\ AI/<K.5'2311.F;'+1GV2U^)EQ=';U5,NE;B@N87NT>3_X@
MTN2G1&1%$.?  >[Q<L%N9T"5KF&4%&CMDF2XOC:AB;WFC<7.,#\RZ]0%Y/."
MH+W:I6QAP[>\@WLW%CSCS2W#=)I=(PJ,=[WO*-2<^UU;;8/Y##+M3>Q,WW<%
MO!IW.JUW0<R2!]ZF%^I8$N%I_9 P^8,/ P51MGI)T8D*R!X4I:N$05O9KWHW
MV["VT.S.337>Z_2T909&U^'R+N<E?BDA@$O?6B?.9%CJS.2P8[*#,HG/"PPT
M8+;HCR;X#UJL> !)$Q"N=>FFAS!']^+UO6G;%9T!QIV^$K ->5-&$?Z[D7C6
M@$DOMX "\<K5QJH[UYKOUV*CWI]]1FU54"B$;'8=A YW4;<KW#4:&^\T#NTM
M[0G;T>Z-(^ 97H -)83<0#*+8*6/"1)L'[Z%(-#1!9RK*.M9/_PX:RA;A<B&
MKI[EQ,/$"'OYVNOH,1_1\_,_23T.=8.-_=\]]/:]LA*VFW8ASFRPY5*#>G.Z
MA9Q]^]$<OH*KP/V.&M=CT,LO)#^;,**!"K?7%2+&QI0T%&<%?""1JGG5RCW,
MH.")$(NEN'E*M*]:3=.G8[-PWZ@3I6C-+U>HPL/@7F2 W7M$8*II*8(**/L#
ME'.C$5L-C= M=S1,*?V5&W4$\"]U6H<UR*4#M^2'V8J<5LLHF,(]HTE 1J7?
M&)B<L1P'M&&JA$@ZV ?BZ' @D*KD:&'LG+<8.2IS\C?[84:'%$82C9FQS^DN
M<J$?EFY;J5\-O;)8W8D%L\*:XT-!(;5P).073FR>9:0HH1R[34\?M 7X;(=D
M@Z?/J54:D]S-4/@5B\G-$Q9:_Z[L%^AZ@%-_[5AI;4]ASI$6YF$G%:Q:$;^1
M"%UFAX3'M^$B>R"45%+>]_'=AS^S0RR@#O*.N^?)MG:B%EKQE_3& BU"2@C%
M@D,$<-G%#REJ<U45/I*;/RJ9.5ILHRW*"!)?H$8D)U!$ZLQ'Y?9]^RTL-QV4
M,"8FFL:YO<945VWJ-YM[&4,[+6O*<1+H*]@\IY$-A99$":N5M5")D9][RQS-
M(60878C(RMUFA]D*$ -_]#+?$AW+'IR&%7&TYK]$<;["Q(9$7XO>\G!R7/?;
MVH.OAVIZ\5/<3?Q+D:7I9@GWB?E.FV(XU:M;IQ:>)*6)<8= S.JF*B4N91D<
M=(YD89#%!D"SZ5(C=TLMJ3<M6.-27U\_W;)]20P5/>:4*CESC"LH AN.KL"=
MCSCD9AW'\S=@HJTW"I$AW1R+H3PQ4X\;(X[>IDM+DISZ-K,5411O:- 72MN9
M17L]YOFHGH&9@8EY/V"MX_]?*)G_3=A=.YP&16J(-2?4M?LL2MDF!JN?X81%
MK/T-ZSUFE1/05U:7!2\39U5"YC_51< M752#KMT_:7%YWU5]G.<H8_K<?W*>
M$VN1GM"!8/MI.E04B!U(DIZQ==$79"R?#[:2)7)CG.C;J7LUES3, >=(4,H
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M;3$P+7%?,# S+FIP9[6Z=50<[Y8UW 3W8,'=@[M[&@T:W!,([JYIW"5X<+=
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MB1SG\^SY0S8I"RV9^28)FOU>]IZ<%B-CPX;1\G+^%G\Q5S2X:/&=B5)  =8
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M&J]", _#-D B+CDB^$@/'PR(TA_:LQ549BB6W1/U+<"'1L/IJ]1CUQ6J9]X
MON YSK-?RW25Y2TC868FBA&3C3YXOJ5GHW!O'#J+R#'H7O^[6%ZY!\G/UNH?
M! :.V;Q1@4#C;$0-XMEZWEDM6N--4 -B F-:A+NG>[&M=@,45K\X[$$9%*>>
M.OK#(Q 1_^)']>''R]T#&/:[4<AG32 !WYZU)V^2YUZ]R_7,/=B?&F8DB&"_
M*K9GE2%S7Q1>9C.$C_HDDO'S 'AG5+/M%H)9L(/3%8?G[-[?7]:Q'W'U[:0
M79(?O"3F_2DGGTMW-LWWG7EP\F'3D7+9J]!GOJ==R9X&GLK*92X MXZXP*?/
M>&LWA8A:B/)?+2=\_N<;J?!39Z=<LAWVPEYAIUR2/6/]=QF'RILN8"&D/N#4
M_'@'FQ ?M&3(]B)+MP9F F5PGJSPG?P]^B6NM6AY<-$8I.T/5A\+EBCL*';V
M96VVSWQ5T5:@(4VRKTL<-Q4%F;\%[2P=1FP[CQE=:L'S7AO_%48^5!]"6TNY
MCL2X&S[YG9S2-1:[/F,K3XXJ&Y"/D?5]=2/\Y="\5>!XNR/Q0GZZK61\NN>/
M+N+A"W#FI'S*)#)U#C(.HZP([H$AS[BUY83^5B)IZ"C.UF*.>,1W:;5_BWQ_
MF1;D/&S 7.;)H=MWIUVV#JO397Y1YR.FXDK?5?R8EU>;=5^++4W\SQ(O/>]K
MPM9VO]"=FG#YVQ]?Q\A05>7^?*H($"EJDQ_[6[<[,OOQ&Z>XK*$LO/3-?36%
MXK%G*S#]YY6V<19">:%4_Z9W5"XD3Z<ZF2ZGVN]>?(*(X_L[83QB>^($CA+K
M>1<(,T[@JYB0_\M8@8R?Y[_I%@(9-P9"YC^U\OYTE#EM.W^"IU\N[FT*!BW-
M6R)5J02P<<UQ2*/Z<1_FA./!^VO]OS:3[RT!@\>/.*=WVNGQB.6]'7L<M*M=
MOF6L&/\:&Z33?&Y8G^I-9;WY4YP,JZVK0*Y$__@(7@6Y%:R G>J!TLP[\0J-
MW9XX#(JB&39,BC+M$N8.I_< <4#^L,)JS2."-9>&J/#1&&BHDA&:FHQU3,N]
M3* WGY^J5?O+WP_LQ.VD(1OT1BT-TQ-Z5I^'[D^I.H"B5.Y@Q1.7MJX %-/]
MZ!V>AFD4P+Q/M5N3N&7U4CQ@SQH"+WRY;D.,^#%6D5]=53MF'T7M;^ZB'?[@
M1M@L>V5:%>&:;=\IJKD"V)C^4ZE4&TJ!+J7:P68<3)X8$?@MDM8N6\S'+V5P
M$-B2!+4+Y,[$PJ,QZ2W?ID:G3RVB+@^0Q"EA(%%HQSUSO^T&H2M :>*_U#:/
M+@;*_3ST2$;*<?(H7%]+:G2CLO-WD/%WT'/OX(>XK$NJE^A^56I+(VSOKICC
MBX!4&Y%S9SYC7@4W'9=^/,\5@%2B;IRN'"*<94VC_>N8T988\87>:EDIYBP=
M ]ON6**/S>1I3R]W^F&I3H/Q 5.DL?7M?%(,,G/O3)PA1R,ZD(B0F]J6$4$-
M_N-J7\556QH])MN^3/T\YS4G_Q/"[,$!FCBU%AS:](527HJL SD(0%>,.XU5
MOT_!$!^2^T!C)/W>.UT21_+)UN)N(% FFZT[1\RRS6+(P% <7?%JV&YL)6T=
M64<UOP=""R2"TA/J]HX5#2O3W7G:4EMET];O?U)G> 3*O0&[F^0L-IY.#R8V
MXH<8_'YC,@0\85]./8:SE#19 Y4%62\F[((S"B##BTP$PSP]V2R9]T;%4CHR
MW<<D6:,.CPS+Z "H[N0F;O.R#8NI#ZU0;$1O6F!]"0I253QOX]QE-G9'4DK4
MJ5S@D3(E;4/<V51E1S[*0OM.^"C%'6(BOLAG1.L ;N]2K<_@3R5E[,E+M[I2
MIOBPN2F8$'/KJ0H9*)G,=HH5RF(=%9SID_HGN7!@>S6DYDL?^P'Y[R=!W+:9
MAWLQB[7T\4HL'D4RB/>[TJOC20O4!M/O*_/FNQL>6]SYZ=9@+J28AF0Y5&JV
MKMU7YT\;_L5/+OFPNS!?I0P:C2UNRWQL/A O,/O5[6G K8C$$OX06D PH@A?
MW -E=+V\U07%9+7Q*FMV);D$^J065L4$R4^S"EB6OJ4M'I,9=#F+[*ELP8YU
M/W I-IMR];Y07)"@GM>4R/8<O 9FOVXMU2NNV$ZQ'!.-O9*[LZ3.\%7G+V5P
M%<+!JT$E9WQR5"Q3UYX5^_$;Z9N4WUSYIN/"FZI4@-/\Y9,8_@GI';FGLH&P
MZ\SO*NKYPMG<%"C[[$#-RXWOM]**MTF@HXQ@M S^<#$.(MZ.G=@96#',7YBS
MUGRH.T2[\ECW7/=U) =:<IQXLCTMRS <H\N?N<!1&!;;O=_+D>^^=R,0Z*&;
M:5\K-2!MAM/A7SZIK H=A;9Z'$"DB7"3;:46LHG%,"87.7.A2Z8(\Q&MGI5Z
M[#Q(=TAL<.;IJ]\%)<\/D2P-0>AX53/<;CKF8[F/B*'&08>4B]?'M903/PV9
MYZ+R7%BIL5*9PYR4)1XVK9'<4;'MVRE&#4FKX2)?NO,$'43U=P<5; \'WF:Q
M?[!>K^SP=?,F23T\>TK>@Z@Q^G@$H\-_=!BK$, 9S7H;BRUDY\YSF#U,$J=)
M=Y6\H?!!24CAI]*S1<96+>7$^&!-U? ]"8'D \,DF1>K 9D&"B0;JVV=8?N]
M'W0-6P]ZM4*\I#GE(K;W)()C>>Z,\8:,;W%J GFL^X@/9/I?$,SQ7M"24]9V
MH6%^Q(0DYZGY_0SQ(-(EPA5 ,[.00\]:+#9.4&" )4_E97/SRU8Y]'E*>?</
M/"2HU'M'+"W 56;#+[3]\5>&;CO2E;@U]HHL9;/]H'F';1L75IN[0;0F6]VL
MHP_#'*I"CQ][_>Q"FW/_& @)E,XB24"15=6]6'K-S_C%G%%.]4'<*][61(L!
MG&#D(91APWP252!96#$*1TV'<60\6R&';$H.9\;*Y=T6<VL0EO@P"8I*0U46
MBYHQS6VT+.[0,6K6AE"J'*TL_DB=>W YH,(3?S=^)09<T6'%U)3QX3( SG11
MW2Z!"H9@YT\Z%R-1#M^6>0R,&J.VGB)&/F=9^D16VS+1<;2\XMPWFIXZML?'
MX]@T)GV"5-DV%^F]_7Q8>V?\Q- <-!XY )7LK84H.A&*-3.KYOSUC5?"%^H3
M%2KF/M_.PD+*IYV'3Z<:CNNK4D(/'E=50@J.*MFZKP"UT"Y5<J377?AR".NP
M93VR!_-0)/"UGFJAOTWZ-7-%8S_OJPM^#'Z-@3&&4OJ[^9#O9YI.=*XE!)G[
MH:'3!DOP]Y!?BOZ*L\9M]9Z=NZ>9YK[*LX)DK2<TTEPG64IK1J2&[<X-Z^7!
M*>>.$)39@B).._6;/^>6T52K5-& :QFM.C'PL''^B^ M.^^!D+'S^\%&XRKW
M@V]BAV)EG.[4C[LO.63*2_U@\;61.H1_N0*\79QQ1R\DNJ/CO0Q&R-)]@BI>
M;,A)OH3L\I$DOVXW)N@H:X5\Q-:@5Q.QQ3_/0)&U[#D\(D:)=M1\>Z\H13V#
M]@U],6M1_A8>!=E#.EQ*7!TF\10MI]F>"<63V8:F7\>^]ZB\^Y]M"\)QGD6I
MEQL%'DCFAF%Z\8O"=FX;@A6>?'F(?&/PYM-)Z8R*G5]*')*IY)MJP/A@2ZS1
M)948&A$*H_:6B$8P!E-BXNE[>;D;. .J(XQ.Q5\^^/8I6<%]/$<*].ULMZD8
M[Z@',YVHQ%2-[?QT=G-\]Y%]D$QOR5-M;3*W9;C6U>&%VY[T@.K3;#6GM<QY
M ??G][IOXF-2=XNB2_?-"3>G.BZ%FMKQA3C+;D62!>8(9&#9_+13RK=X3)@G
M<?5RN#K\6ZOM^2." CYHF8N>$A_1R^F;"K=A89S1[Z[>E==8H:T*#V3CDT'D
M$S2P:Q]:]<KQT,>3HD>TMKJ/+H=KZC]+S;J1E-7+DT<@+?#]QX,XV/M@,,YL
M<:GR2R9K? 4^8KNA70*GDL=(6_C^"<]K'66[M^^(EBN>51[=E9T^6SU81H1N
M0_A[EJ@369R'\>VZW1$&SBJ0 "JC>3J=VU(IT^:#0.QS,[%SR6[**\"7HU#>
M*T ;"]IBQ=?#_PK0K<+TD>92/F69)?XXVVUDKR5$QOB&532?BME/R%M, V*I
M5%:5#5'E)NXF4>N 5[TH?'6GSNB:+TKM<=4@#6?VC'(;'-=SWAL=DV4DY*%$
MKP"+-UK[ET^ZK@! _('A*!I+'W\%0-,TUG]IFSWE?=T8EP!0;H(_P>*!TX%.
MY.QUL8"SMRRYOQH! 1UEL7^3DV6*Y9[HZQ)*+@JO /9&B8'P6.\9\2($_LO&
MFV<NLCVO&()7OO3U#8)G5!@@ ]!:@>A0;XI7>)C$^S3V4$4E+"4M0@'UPM$G
M9'$E*2%H9"794VT)ER RD6-OXMV6$G.>Z%+D858H88=IQ^3$TPX4I3J2_NUK
M:8T12 #'MSR")V:$[J0,V%@E2*;,CI9N<>8Y<]H?$4I&-9W=3N@8['X\%U4[
MP;22FU\4U86P=8!FTQ5]PY@;/&0F(JLW?]OYD[C>IFL\!5''!:9LV*BC@5I
MM/R=/,_G-7$><X2B=O>FBQ(EXP"WS*A8-!=U/*?)2)=,;P%C%_*M.#]-X^7N
MLZ PZ\1N!-=69F)7(CD>UA588,',=A:5<Z+GP>"7S&'W=#AJO2 E?@ZGQHO@
M>I#&061TNX7>O4)9P'.7@@2@Z //D ;%G=4E]HCY7F-%5WTQ)C'+IZ.NA^>>
MR:66MOL-G\C^]O6[#](7.H,1=76589CI0V%O84Z,7C BQSJN_1WM&W9?YYI$
M%\"94$WDX+,@WD/I F%^6YXA39!<XD=5!ADC8J? MH7BH@VIKF6Y,1F*\G&#
MU5FQCC@-+KQEW,WQ<46Y[@O;GXNL=0:)K)O[6Q:\Y5,5!98;;#?^NMHV]/Y-
M9FA)35@BTUOA!)P9%[ZU>_< L <KO/?[#[,MR;&R!T@>'XL\BR_NL18/<N?X
MQ19U5)N) DDYIA?IVIK%R$;O%61;_E$5ZCLJRY3K 3)L\)+@4N.:YU!1<$?X
MK+.OWP'SEX*;2J_T[8P^AY=/'_(_)1_C#?H>^LS3]VBY4"C@P3MROKBC@> 6
MN6[7-[0FKKX'W6<%DI;XSTZF&ZQ)W=C9SI>OS3*EHD7_;/K!/>E=>G&\WS"+
M5'@OC,S?A@2?"[/5KFZS0,,"$RN-"FYW:<OP*BL1AA6[XQY "*1<;2UM[XEF
MBV!=\"F6#_,7-5"*!_6PI9]DSEFT3OZ@9'%TNK.4F^;4VQDX-2Q9OSU,\CE^
M-&(R@^^5=U\N_5>H&^Q40)'M(I[3_3(>GG?["O 4L9OX%R0/F3M) D:BF'GM
M-$PQUHH@T3[F;:;]N9S4)AS\&($/P2H.LL./'DT<_;(EX^%Z? ><\4#^5.?Q
M^91+H>+G;^R5Y8?/J5*=.M3=%M># I+>VS<^Y_XT#SB"9T'D+N=LZ/'@,KFH
M6NH@&)<_RH0O5F^4N;]NR'"[J2= O^=< S*=7)4*0P.[FIHE[IRM2FTMPCK;
M8_""YP_\@<<!(UGGU(_E,G-H4C;3Y=,V?0%KJTIGV'NIG-ZJ'_;$>W_'<ZOB
M%J5;)"9@F1;7D#\&(GE1Y+TU;] Q5:\X,0AWK[1Y4=[_P;7UKT!-2^ZNR+$V
MXXG7%+$,]C.T]I&B^XY!"?YO*^FR[*C]B';<-^GT!]+?93$::T4/I^90SX<1
MU>%_7R>S9,I\TKF'3N>3?ST].7TV^#TAK5IN #S84O27ZR6_U9.*HV(JK;TG
M<"&LQG\MX,=R$R?4G6:</\=3'YMA0=V&9I.S'7(@QG8Q<$/U((HLI50?T)34
M_U#_>3CR@$G_ GPXG*#.<PJ/_X>'D53AE9=5>< VPJU-.!J+2GB0[#?/81>:
M_('4_G;ZIP^0,0GYZP$2V_;70Y>O ._),4^R<:I(-C,+N@9W3[?:(4IG<XWG
MM;_19GJ4#P<IE\PWF$%^\L0I/Y7,?\&H$4M9(.IVINL JX.#)$(QPG6&=]UK
MU=(58UOM3X$/3K@/X>5)X5^3R0*I1E+&_Q_,T&)VBF.()0ES3(\6<R=773=-
M)$2-1P5_NYY+T14@Q2K]LO=?^U>FN^VFD*I8?:_$&4^C<_8ZB0L>D-U38DEM
M6I48@!-[L;$6@/F_Z%TOK5NO0H1$);^.-E)G:BN9FJD%,CCY6=UX(AR6#7>6
MM;C,4,DJF=4*L/6,4JA84UO?# RG)VM_= &#4/JS E$&R\SO_$T?:V$O5C-1
MSJS]L0[^UEG]P*X^'I%-!,]6(GJ1 JQ8#C"0B?S:(,PE2YQJHJ;Z =Z/B(36
M(;HE& CFN/O8].C#QF"]Y?-8[_AB7V$7')^0^W$H":RS[2T+U82SX5B@C_)V
M"_6';I.2#66F\0LV?#]NK0-!="A_!&3>?$.Y)N J^L;D1,YH@]LV!:32@S:*
M5:V7Z9;C%6)3I;ED;J)K5F[9'I>1'H0&=GTV1;*LJY)> >Q<53MS;O'*X!;@
M'M?._'"S<G7<1W5!TPE94A^'S<G@QK2_UY75E\7*+]&/-CW7]W='!UM? ?HP
MQ[78K1.+7SY7 +Y8+*)SB#:8#^_GD^MOKA>A/X:I^^0:'^#U@S 86'4BLXKX
MD4=T+N/_*F+4\ENRWA4@;6A,9K=Y:_G1>/H_!6#)*P! !@W[\?$*$ ?&HG+H
ML[VA^P_'FYYX"PJV..4X#]$K& 3!Q\\HA SSBZ7?N_&_BLL9QW4<K2:E TY4
M+KXGGVV^<_>ZGOWLS6X5<=R3_$*\K18>C.%QH14QKYEX4NK,?K^/S[6'^0P'
MTB'<PK6== /)>[Z[V'".!PMZCRGI/)YX)KK)O"1)7%59J9:[PR>_L?BN="<\
MDM\19@,N\GE66F)I6^:SK.B277_70LC"8E5'R%B+^>=_Q7?@BS'U6XY'A>[-
MS@F>T4J)^F;$L?@.[)XVO@';WYU#AR/^4NOZ9J"B4L!\VI:#Y+[@-QHB@LB!
M>?>E]$5N.Z6+#<]%YA[!O7 ]D*Q&LFX4PC=OD,'9C:UR'^I;CCQ:>36U;K0C
M"8SDQU,N>RSW9\T:47 Q^2A([S_"=35!T#9>7R$^IT[>$M,JVZ0I/;R*&>:B
M'[:DWAXA@4]"2G4\#E7U5.U!,Z".*T"-1+0,M2&U,0PT)2.K5Q?R9G7Y3^:J
M<3(E@)#/OSS5%AC5@LWO6!!L23YYCDV++EO4.ZF$>^,+DW[(][-<IY;K!^TP
M<>F98"\8:VDY)>/:2S9N;N$GH'+<F74%X$X".2([PQ8JDN/LL9 XF;ZZI((7
ME7#F.PL/T6[MGCH7/_%]()=3B4NJRN)+CJ@'/Q/QL!=+=-$G$?OP6I%EU?]6
M(:Z-"O%"_X3^\.Z*1ZQ7O5.D_V26[>CO=ZEU\>\58Z=A8M^1^FQ=_UP9X:$[
M6B3P^Q>_\Z5N/ !P#$VV!UPNX-7.(-7 GQ4LW7ZE]YQKG,/<)/ZF^'8QY;2$
M0M,3I+9 FE:B>R1YK/L.]JX)VAKU]XN!-N#5"NBQ%PX4(V,YQ.@R[,2FF&G=
MX=FLH11K7]+JA,L07+[7 \S#(0,!VV*M4"R.H%7H[[#8Y: @+D9[(#+SWE(^
MFX.C8&C^5)-XQ_Q0-?:2!.< <RVLSY*I_])PWQ+5$>)@^W'\J_H]8@)I.N ,
MT^@,=4AD +U8/Y,YS)0^'D$RI'??B\LL+!.I"<D1! ;>K_A!3% X*JD#1N3<
M"Q^<G#6.06W^_5LULJU:W?5&Y(7C@07&S"T.P,Z;%ZI\//O3@C8QIE+) )S_
MLJ=R3C!59K^7) %AL[#6)C84VJH*+1DHL7%*8PM\/T23/&_H5L%7"]K\DJQ8
M[*X_7V]2XNGIOS:U4)1+YSG[,Y,VTXA;4;E,2VSQ.$(P[?Z4PJ\LX*+@UZ,!
M*1U\2*Z3S9UQGUE:IL&A%^. <ZT5R3#^KRLKYR='E9DQ@!5[O".Z].A\P,V=
M?F-_\^03%SCKURVS %LE9L'A!.7K'#IUO17I&L(E6L6*-X;7F^UG1:JG;QE6
M5E8F)C[M0Z3Z>3\EY[P"4!%D_##4( :0DQE;^ZTP!JBSP8W3\LW[W+BIT^?Q
MMNBAZ*,+*>.Q.EK.R7VD\6?# )H2BDPU=3HHBH0NY'M9P9Q4W# 9?22!I]"?
M[S&G6T31-8BRC#TUZV,QX"U?*#B;'!?^P4LAF//$Q4*(B/+&][GL7_LY1_S(
M!O0AG/ZB] K@1'%)BJ=0CG,X[\FL"8G6&LOGNHY'@*1UQ<G/Z'O)Q@FKM:6_
MR\?Y6E18K@#A25;0SI?GNC,OG09D"\5AA9:S5K.SR?TT>R*?2>B(&;1"Y,Z9
M(;_;>;&@4&\$"Q[6:0-*=&O0\[A;GF/W(WM%&+!")SEDL7\%8"(09RU-;?\M
M!"MNPUQQ:S%*SXL6P>F[E $<Q7-53 %$4L-^\&'=*4K>D?!<NW/SFI@>>;0P
M>D-,XONA2C1'_#/LTRX32SF_N=0[%)149/[+A;<_-O)]#3SZ3I-;*<SB,1:#
M#3'Z LXR;Z*(;R#C#J([$M7O[Q!,R)#>E>J3SEW>>!X46=>HLP#3Y9*NC?JO
M>5([D.YH?VVG_]QDAD""#ZK8\$W\/N./,!V]FZ4[+BI&\V.VCXZYY= F!+SY
MX 'Y\-308GU#_"6/O^525%,A07O2;OAPD4GM[)DY:QHF*'M@:'>,>[E"<UVF
M:0C2!:I[GH[<BVZ63?$^ZUF+]9X7OP8'FD^K);4\;O.SZJPO1@9!>Q8_*KIW
MJD:?77-[U07UXI^#]1LG:RE ?I>'-=PTYOVP:N1./-:$FIZ(< >K?%E3N5EE
MB2RRM#8J9,]\I*:7K+V=WQ;DN',;JV.%[[?-A;[V;P;16*_[,=F(4KNE]'C=
MCBLC-UN.^_HN<&)(PWC%#%1?'!MLA!U#1QZ'+5VHN'/Z#R)-)A*R_'QM&VIK
MJ]_P/_SQY)@=P'LZ$&04=2GMI,JHZG@NP6WHXYYK <Y\%O=I\R:_AH+L?3N2
M'-U7@;[PM&"!<_%@!SQXB3Z*LZ=5EE<4YQY=>^&HW3)BWVCIG8 ZW:^LMJ5Y
MBH[)@;QU:/.\ AS?P\(^J-J[4_W39WISL]K? F7P-ZW3(=)LO2#RPZ[.H#9]
M;MEHUWW$TN>=EF/+-U3-5X!.K5)7^Q7&-1_>B6,U=A9< X$I1J#^(I65O?=.
M+&C<-LY1WEB<?!]>K:5+_3^; ;68WR\]);'\\<!\'RXW@7!*C$+)Y@>\ABY;
MWQG='35EZ7Y@5>+TU8=VB*R-92:,?0\D0+#%/U\Z'T+!T9]-_1WUTFB?\&A8
M[AQ[_&A\EQN^S&X[Z.EE.?+>\6[&2'3DO5&/TB!QY(3BW3I;#,^]*9,Q\;RV
ML5U;IBX/8C<]YA.R)O@U#& F2& 3N\; [2(3K\9$\X$BNHM*\1?C(,S=UBP,
M<D<"O1CN"EY*)-VP[5Z0\N_VY>4<??8VS"OR0!_'SC)$N'^1)N/.B4^>Q4@@
M1= 8(Y:T@_)#[K4GHZ8*CUZ</:3;#LJ<E.9CV;G7(M&3S=C529V37QOHYWAO
MF*![T2!Q&_SEB#X:1,YJW7MKE4?GY9.9G[^U0Y0WT[=GSF7PY'H7A9?\L:X"
MHT;D5M,\?"?;9D!9<HFC7SQ;VU!&ET5L##YP_XQ6)0CM2.1=4V4X*D\<J05\
MDKK/]G,Q-C,[';G(Z^)%4,%9R:K<;ZT^YZZ>WC'PB>?@[A_Z_6 ^H/*+^5>T
M +VO<@+J1<9$H1ESVW1A]?"YF60T#Y[0GLKG34XLPQTP'^[G-3X^3Z;\,',_
M<]??ICB38(^7=,9%&U;7M.#HVG+%6ELF#A^.N8TRW==<\E3$69W\')I)?(2G
M#'B'XFV"VZ#TZ#^G*:8>&-(H_<UXED ILQ.DP__*<33)M#*@(J3\<P!K[^_:
M\0!%BI@;:Z4E?P4%N7/RBBAC$HS:XCRVK 8WG)N2%]9ZK@#UD]'7L(MBT6E!
M%#O5D\C@[S;V8J*\UC9OEOF^UJK*V!V/3W-K8S%GT*7KZ"@#C5Z@C=:94K(L
MP4\9Z_$LFDU(KLD+1OX$O#+OOP)@3>AC%CBQD.@EY9LFS:]+H)WJCF5UK<[)
M8NA/'$#EJIQK^FR-%^D^\XL/EBC:0FG];!D]8F?"+'@0G+HB0.;QQ3$)QI&E
M)MGY@F(!)FT5KJY^XYU*E9[UJYBQ4O)"L>!F62JAO"^D_W*FXU^58IY6.JYX
M\NL\K>"SHUPZ$0PR/E@5NX@>^J!D@,FM]O<RJ'/>RW-Z]"U_R74:<OQ$_@3^
M&\IQ.05AO_C>JEF"?[/<K0+$LV&S[S=XWOV2[-*<"?70_S:3$\B8< J?2F1P
MLH!^K(VMD#"KCC >$T^Q.TX7XE4P;Z[.H1@(Z+Z&8O".64T23SQYYW"_R-L$
MA;??3(6)\U;L8(4"C0O(;$CWT+DJ"F_P=+B=W,;2A?%%N>.S9BH,QN_6=L#+
M4,%O&S_A)7<&>WX-\7Q/P1IUT5,0Y-F$T2#:C1P@F_Q!%.QM5<![[_FPP0?@
M"N-0E=3'GQ7_#SI>G6G.]KH0^Q(;L*,MMLM0$>V:UH?7!.PRXYJ 54'7;]0Z
M ?)BA  %A7FA-X'Z&I0]BC$ E\JYL9+_?/O)\)4JKMZR^*\)[^?>Y=R5,>H8
M+M[#R4^[O;1>.0]P>]&MQ&#2H0]UL<J\"QAU&A/K/WQ,"NOYRELBG8NL!+[E
M>/W5?G7<W:PR:XVLPIC1=[NQ7^WB<,^^W:U,TO^ZTI0\/(7;BS^$1T.8QUNU
M*N8JBC)>4QM*5WJ$DGG@#^')5P '*+$+K!;6/;N7F/.P/D/ZKQ?]>^G8<%_+
MGTV\D(6L+&[(W1J( %CN>OL.]2[BS2WX]&'4K8+>0-#X4OI*>W; "W7N!V<)
M05,HE'BJZ[<-W\"0S\+NSF#V**'\IRS/  " ]X:U^T5:#HP;01+H6B[ %=($
MH< "9S\YHN6B#ZZ!S7N8X<85P!J\WJBS^RFPY/+Y 7QG#-F930X\E':&G<FV
MQT1_R;\">$/O_79MOG_D*&;HI'Z*&/Y!SNQ;F->4H/;/ZE()_7?E<_L"SX Z
M+T:@%GLD/D"IE(S0.ZHZ.*V&R*, VXG#>/5QY'% BEV"(GK<+FRR/9.C#]ZO
M&KK @/]5&FQ]D1O\&IO>>U^\IL ?M;^PU1GX4^)U:<_JPW>G%W,1N2JIU&8R
M=4/J>!^L):8R]OPQGJOKUU*\5-<E _9N(=2W7:J&R&Y25)PC4Q[(,ZX()]Q
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MQ?7<:??#$%;K"?HE#BIXF3>K"'R49'_N"K$4--;J8;[F<# C^,L!K![@J6$
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M)79!K*N0,Q';O1P;A4WM;(7%MFNX9MEY%T,>M'/[["P43[OSB.DJ#=C59;<
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M81 "'"]*T,"@9E5ZA03J"2V84-G^X)WT[>E@KNR0/W\?_VZ1H#ZKH5KG/!4
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M^6J? >+2-3S>7P)YN:/@:9X6Z7H-8JXA-)GW&4IS]ND<X$YH#UR"Q4P5\.%
M$>V690[.,UO!U8MIV@GCN&L'A\3.I,MT)Z;5&GL7H$9G2*AE"'9]*351FW_C
M]<,%PIQEWIWVT6/-R&QZ2UMJ5P UZ-NFO3;7V1>R,%264(1C[X3Q*Y[Q_AG1
ME"=+UK5@\4L(MG/ X 4@3BAGL_^;RS;H"SH1*K;L.[/8O<#KY>@)IH5$FKCW
M<(_]IE=I3ZH63:M\^=*_8SW"T;TW=4:C%\1Y#O \!W 18@^N7<6RM"T%8C>_
MV6<>?FKVL?@;>H<VMVZ$@8)QVO+D<:0JC)8P==))YFDC!&!LH3,WI&ON!<X&
M)+Y,;V./U=!5Y55:)=^@,)-,R%<3O=X"&>S>QZ4WFMS+0_=F^I?SK;#]U9XC
M1;OO; QU^^[050?'=5)J8/+D NU7++@[YP94I!2BT?U5K'HZ@6M[..]![?T+
M].I%F?O;3H&?R'TH-C(+(=MNA"2-12RC>\#,BY[H,AM(7L_/3UM]DOSB$GJ'
M:@X?GKP5/ ?T@&?1&!\4;K]#B(E@]GGCY!261+J>^Z=J]L?7LW2(]+H:G>@U
M\F6U(<A^+VI6 [/>@Y[Q7RF-">@LVEBXB=7"S&R?Y :YV;<I/Z)[I[L<O[+I
M?+=IYQ@S")L#=Z N[QY]TQ[O;)6- 1F^M[M7\>6G?W2"R.%SWFTG[[*POG/
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M;:;(G/-;OYB,!Y5'^MQZ,[>6<8?Y9&^C1?5]ZF>B*=<&"ADQPNK/HY$A\![
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MEP>2%,V)E+OZ*OK"USY^N$\0PY9P_%;-OI[_HM_2M_\ 4$L#!!0    ( "2
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M:UFMVPT:'3[5-<?8VEZT!/H;VK]$]M\++.'_563_'MC_%=<@,%=515D\53V
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MEL3#I,1&Z_X&<FPY;+8'+,^>)B>-J/7]>M]M?]W$,ZN10,UW>1[7:AD2L?L
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MB"LXEUP]B1C&\E!UT+)(S,$$1WJVLC6XX1V6B&,W/E9(P>389X@^,D3<C)%
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MXV$])30R1$RTZ+P.<%( OC8-E9N0!I5$!=.>P86?$D77[#MF[-BU6!3+,F%
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MC#6==SRC;"K>Z# 4W.U*G9X6;'41O4S?OC#PD_E%BG#N._VY$<\WNZQ02LC
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MO:'Z#1LV_MSW/%YFZJ1HOCGK@7$:/YB51SQ04[."ID$ZRO&!:*-Q#C5.KWF
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ME%>\S]VENFJ/<2\=3R5>\ID[83^68FF_VV.E\'71\-=@B?W*GU:'A4O@P.(
MOV&B8:*/_HLK,E!]^X4QZ259%P@]M4)?PU=3FUU?M^ 3T'I5T_KC_6[]'!95
M ]Y\P>R:/O7[60"7_'IB]DH[=0M6 1N,'W(5U-5*$0D;9#F( E6&1TD1.ZEK
MR*;@+>"MP=)8LCS ?#&![Z?!2G*2U0VB4Y*W3!6*/1PC+FPT"P=BG:#"4>Q:
MD@*+B_S3Z%I RF[37!A:]2KJG5UP!;75FJX84KG);7O*RD;M._M+]G"UC@>)
MD3=VO&[2M"&Q[]IT'/+(<O^XU<PG;M.=A8":>WETW _<TS$5X J!UQ&:124
MZ96_CA<<W?EDH/J"E?I=S_Z1N=?Y:?=<(DSH?0EJ'OA*^MB1_X=-8O_/C6(9
M4QD\$YP:I5.*T)\3O?%M]U&OSF[EH E' TBN[3'<&]6;_75;AN!\3T*,VM3%
MR&A\OMM:VK:XPJ<I] N<??]CCC< +R(Z D/$05?!*_@HK17)&N/1:#K-I!Z1
MKLA8HH*''*)XC^Y*OHFYPK%O&J(9:':Y2L-$+S;XO$S.,&3YV4MTR).K ,[_
M_1>7^]GSG)H0N:%G_S4:RZK#CR#9!KY-<3???XOX]8#/E+>+NDKD,X8=A/=
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M(34LRB&:\;M Y'"TJ;>Z-6J*>/)"@<1);_DRMM^I,\RKHQQ%X/4JHWQB>V_
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MX:["CN9A7[ G0:(>7AY[=OIZP-JZ*O_^F&H&ZZ/",5"'VL"8>$$8V7BA+GS
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M@=R Z@N_E*5\-KV/AO'+1ZG@KR?:M2+U2>KW3SU.CI2?%1X^TVW4,<:Y4NS
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MYG2T+K$!VK[O!C?KP\__ 5!+ P04    "  D@ Y;4(SW5JH,    E   %0
M &=T8G M,C R-3 V,S!?8V%L+GAM;.5=6V_;.!9^7V#_@]8#+-H'Q[GTEK3=
M@9M+82!M@B1M]ZU@)#KF5B8]).4D_?5#ZN+8HDA1LB0JV&(PK6WR\'SG(WD.
M#RGQPY\/\]!;0LH0P1\'>SN[ P]BGP0(WWT<?+L>CJ^/)Y.!QSC  0@)AA\'
MF S^_,\__^&)/Q_^-1QZ9PB&P9%W0OSA!$_)>^\KF,,C[S/$D ).Z'OO.P@C
M^0TY0R&DWC&9+T+(H?@A:?C(>[.S![SAT$+L=X@#0K]=359B9YPOV-%H=']_
MOX/)$MP3^HOM^&1N)_": QZQE;3=A]WT3U+]0XCPKR/YOUO H"?,A=G1 T,?
M![+=M-G[@QU"[T;[N[M[H_]^.;_V9W .A@A+L_EPD-624HKJ[1T>'H[B7[.B
M2LF'6QIF;1R,,G56DL6OR%!^31.&CEBLWCGQ 8]9+VW&TY:0GX99L:'\:KBW
M/SS8VWE@P2 S?FQ!2D)X!:=>#/.(/RY$3V)(=H1!^MV,PNG'P1V_70A!^Z]W
MWQSL2C%_'!/1/P>>%"!H7ZDK"B*RF $Z!Y+LD?Q]E)8=-=3T)Q!*LUW/(.3,
M4H5<G594N0048CZ#'/D@K*-73D!32LJQ!.=",KN87BSD\!<=S-9PNLKM*E?'
ME%:2VE#[FA/_UXR$@9@W3_^*$'\\@5/D(S[&P1?X^S? ",/DAQI0*DEO ]XQ
M8+.SD-S7Z3%K=9M2[8+>"<B_8W:%"3X3X12/B1A#5'P$X2-#MHI:26K,HM%\
M#NBCX!/=820(!)B/?9]$F(MF+TDH*(76)K84UI3RJ6PQF![!;0B%L:Y@*%@.
MQ.BR[M1E0II2]@>@5-CC'(%;%-J/.;5:<X-),X*M!Y2V?E,JBN!O3G#<4&H'
M)OBY6%3Q%"4RFE05\7A^$>+%>)5=7D3']J/'**$QTN&=;$'&M*)Q:0-;M@LJ
M-C<)W3+X5R3$GRXE?.OI)E^MVUFQE=FQ^5G2KMT;.?DU"R43V<UT7PF G:BV
MIOY*JNHJM^X&JO6(,BF=N(1**EM):F_>K69>;?4.X]<3R $*V5=I+(Z6L+EX
M5I7<F-W]&0RB$%Y,QV)N&@8HC&0#U]"/*.)BDDJ;MN7!6ERWLW=-:NH*;X&=
MS0FY-BL:,:TK?$/6'4A#ZFN$=N-/:W:IJD*;9R;O,,>,1?-D5J_+BXW(]H'<
MB$\,^(TB*9395MQ3LTN5BVG>]F< T3C)+V."<1BF^>^+Z5?(+RGQ(0QJ<U!)
M=NMA7EW782^OM9$Q%OUVB>I/MSHQK2G,+B(>[XX)[RJX/WV U$=L&X=G+[AY
M4&FHO"T+.C&M*;QIJ_3+!KBH*KZ3)5'-X5U19@=9M"V 6$MLOLNI"[>ZO<L@
MJ:T\7.U519F8385]$/I1&$,Z%Y\W%(</'.( !IGJL@&K7=U4".*R?+I)O^<-
MY8Y^).TH_EFX_]NL,KG]W2*E]H4FJ[VI6"O1!&8P\-+*7EH[53-35(0-&\K%
M802AFQQGQQWBC?@I8+?Q;GS$AG< +$:2_!$,.<N^B;M#W!72+WZ*2%>T?1Q1
MN5V9R0[!+0SC%G^FY7+%1DYTE;MZ<HR+OV1$L@1A/.KYL>AXCV+4QS&7'H-E
M]3RVM0XSIKY'J(B(/@[VLG8 ]3>ZB7HL(BTQ8G(Q+L4,D>@,6?TI)7.3J5.S
MDCI0UBD16@R\>XCN9CS6W@V%5Y!QBGRQ7)2ZEW8[37$[BO:=4F1$VB=*1%@/
MA7+!Q53\':?NV--4IE*B*6Y'R8%32HQ(^T3))84+@$24OY".0L9E? :IY51M
M5=F.KE=.Z:I@A3Z1EZ4Q1 !:RE5163=:Y])ZY0&!IKQK[ZFW?JYWF0'WJ4,)
M36D$@RK]RE#%M>^L0I 9=I\X.D%+)*+ZP'K\:"NX=J36_)1 ;I ==2'[^>;3
MY<]\VEAO<UE<6]JU*RPWN%']_HT%-7.L'P9%99W%7$ET&*M4LI0L+.S:]>GM
MK@96.JA]ZD=K*<JRE;U2TK67L^9"![)/1(R# $G((+P4\?@$'X,%XO)4NS;\
MT%5P[=RL:2F!W"=VKF3V%</@%% L%K5,Q$W1/(JWY%?G=?7YE?*ZKOVC-6?V
MAN@3?6ON7RQQJ_C.\IJN/9(MMAR1SR/DOX'S!:& /B98LM3K>"Z7E6/.*;J-
M>'+*)WD82,]D#5&N'5Q-:FL;S8YYAXNE*E8P%#3"_##*HSP7G[O:WLH]TE:T
MUW5@N=?EO=@0]K+=33K=LX1%"%YI$3Q)\<C4>Y+CO?B&023"!1B\=+.'E^J"
M[R988(;GA!GR]X6%744N2X@C>"9&E=RWI\#G/Q"?'4>,"\WHZ8,?1O$I"\:@
M^"^X 0^F4*:&,-<.TL"<$MS4ME6?G.859%!H(C<O3P2BD"SDB$I3_,9]0%,U
MU\ZP"HT6^ L(&[K+YL!0B+M+7N 0R@.-P1QAQ'ARUJ.4.MOZKEVY/8?5+-(K
M,K\23#9QEO)GJ.(&PP1S2"'CB3+QGJ!>^\+"KF?]4A9R'<Z N$]S^^K8\SCX
MGW!+<F)[.K^JIZBDFNNYO2I95E;HU:3P&2#,Y'P'V04^?9! (\1FB>8G\-:P
M<+6HZGI>K\J?M37Z-/3B.:'&Y%Y6SW7NKRIY=G;H$W-? /T%XXS'TS.&WS"%
M($2_82 [HWDY9UO?CLG7O6&RFEWZQ.A7R&W6X;EBSF.2(JWSH\L0(F^1GFO1
M=UN >E:SQ0:@\1*@,,F5KNTBIFG%3X AW[+WV0CJ5?^T1YXGN[!#](C@S:WY
MU1&;1.E5!G(R7P#?? 2T@I1>C=+:U-:Q7$D8WGFZW>I5<D59Z]=;9:W=9>,K
MO62N"/@;2^#K#?T;+ A[[R5BO1=IBR\]@ -OU6CV\T9VOS.[K+V_K@CU6TO4
M4HP7RW&_22%&N53GDA(Y,H-/C]^$OA.\BBG2QT/C-R,9O):UC!XXZ.<4_%7D
MYKGYU6LQV*!P'S"0[QL68R5]PYDV:ZTIWP-?N1U39D.T?VAWPE@D-X*?<F)G
MA'ZG_ = R\)$KJQ55LEYCJDV*S;H^C>:7&9Z6TPV;3NVZJ9^_Z\SORVFG+;E
M<YM4<.UTOF;>E+I<X&O(11QHY$>6UA6V8^1-#QDQH>KAEHI4K%X^M[RF'8EO
M>TBB-<0>,BK"6Z$G@R<P^7N"-Q]/-6U!E]6T8_1=?QFU-4[/&4V>+U;>;Z<^
MB%B%[ I"[?K!X7/J!Y5-VL$*1%4R W@N/U_)5LDT8C!YU%RW)JDLQG*5O]M#
M?NL![N&@UYA@@I>0;9F%*I3A:!<!/,8Y0+&.S-XW* ^.)AK.H7&19E.WI_DJ
M XOYS0)K SV'WGN&,,#^=KVW4(:K/; G1M+5<_IV/1,N<ZV>]E@#<\KV5KE1
M^I1:V!A668*+7@/YIKNR!]MLZO8T$5N/4+.!>D_K])B(B9-R)(*[S6W8BAR;
M!/4TQ[LEX>6FZQ/[\9O,-M\YM_F:L_AMX.M?K)6\A!210(TBTP=73A_\&<!W
M\ IP>#J=0M/YAJ[U<.T]W-A=W>.KNGKHY:&P/AO3%,'V\@'8/AO3-#7WZS%;
MJQL!-PZ"'!X>[N[)IVU/$/-#PB(*Q8=U.?%QEEB2EXKR=+<+-GR.Q?*20!7/
MJSR>5%1\@.=)F/<DS=/=IM4LI+(K!%4HK_-0,A%>*B.F)Y7B%=Y$V"P$]9I!
M5>DW>:732I[V<L*F3T!I+QQ4E7VK=);U(UY_O-O?>ZN>\6K[S=3&FPA5#._R
M&!()"93,^BSN*IK[#)L'H+VA4%7_L$C]M'ZLM/&.PX;[3L'UA8K&^[M*ITFJ
M>89K#YN>'?-W&JI:[JGS8%;)*[X)T<4,;IC)]_?KS^3>B^Q?;9^WK'3'H8I1
M\;Y5,"9B6T9H=PFBBDSQP^7.JR-$NKL250R* U9\64<JEUZ<J.JN^&$;U]81
M'*M+%55(BK<N]71=T:.]>%$%H;CK N_1D=JU[EQ4$2D>W'(%(;M=+-U;B6^;
M)^N+&164!ZK73X7)J7I#G/<D;P6Q%V[(@LR#@K#!WB$YY%-SI:,*4(TJUGG,
M^ZBN^*MXN:,*2PTD3+ XR7O>;G!6O?=1Q5DKK'#7+VWNA%1!*G''.IEJ#+(F
MM/L.:W57I I1#4^,$->E=H6Q_$9)%982HA1$C.YZ8Z4[)55P:NBRQME4R/:6
ML?!X"(*5>/DKAMQ;I"UTUD?M+Y]4L2I!C5WX['RF42Y(5*"],D8R67_-Y#B;
M4"PNJU2AJ=&+"HUY:Y+CKKHFNWNXNHLM57#&R"5;\+CCK>K%EBI 8PR3 <R3
MEWWO@,2*UU^J@)5@QF)!V_4,4^EJ3!6B$LH8T[LN)U##U9DJ+&/X4KBB[VHA
M6':KIHI%W03)9XKUM*2[G/)_MX!!\<W?4$L#!!0    ( "2 #EN9.WRW(3,
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MA6B$GB>G)MF-GIV3>T',IF48Y%ZD16NC6^>$CI^\))B2D13)K+7O?B%(/&:
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MU/?*-4T\5AZW(H?MS"Z)H?]W1Z1"?O._4$L#!!0    ( "2 #ELH_^GO@FP
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MK"'S:V4FQ@ZG;K,TK_])U2;WR,Y?R^R9QI6<Q5F2K>*PN$Y#N1NF%'?F>QF
M;ATNA:QW!AD"Y+:!&PW4JM!PH:EW6#ZE,;M45;[.EQ_C-"654 9RJBC%G5'%
M '1+%84L#*KH 0ZILM.@,66MSM14N<&K("$K@.<XQ,55G*_E-)&*.J.(!FQ+
M#XD<#&JHP0UIP:11(XZH_-24F)=/.)^%8;9-RX(XZP%9#RH";!32[N)JM)!W
MX31241CTT.+C@F>H FHT4*TR-4D67[+%4[8MB">T^$)6<*\+(HZK8\_:@U=$
M9=EH.R.1O4DMJ<Q589#,&N^0=(00[U%]R-TH^(T0O:=["9*HT,YOKB)!.3A-
M]&?[@W<FB-"( MWCHHQ#,@E]Q$&QS:NP]RE#I30-_3%XB==;L9\B^-U5@PMA
M-8W>^Q%$PXL0<4>"E8R?J>0N"4+&M=F*!N>-G5,TQ7B>7(R,U,PRRC*\<VU/
MX,)YIU5$E>;A9R KIHZE)C NCB+?\;#-G%Z._!F+'>@+_%A>IT69;UEWD>\T
MBP1=[BC+@79WCGDI[\310ALRA0JBG224V/&.CW:=;K;E@GQ+P1>YN$O6Z$!W
MN2.3!<,@#4 ^[&KG5#-Y1!6@THD=X][E<2C>$#)7\TDOF1$JF@UUP-)- E1+
MNQ/$-!%3A3/S#<V[CXO?KLAL?IV6F%1E>1^4=E14%>"3E'K#5/24:X,EJA:R
M 65I&8@6@II2$"T&+GU9[_J<)4$9)[+09TM=GZ15FJ/BJU 1+%55: U86@VI
M.WVX]*1W_<,J[YEX?\U&T2<QY8:H6,EK@:6D%*H!'QM=1)7];MI_C%/U7F[_
M=V=[N2)8[5YN]T?O!)$AXGA0R< ?>RYHZ@F<1M:>G:H "&.1W#"3,8G7]DZ]
MT9!MQJBF$&".'5VDSY>="&;%)HM$UB4GE7"[]!,*@F&:"AU_ SLAVEF=Q:BC
M4R4YZOR["J HGX(4]94F#>>\(Q7S%!1XMB+K%XI#?GP@%75V8J !VQX22.2\
M$\@ ')?HH99&K?C4ITO7:;2MSK7T)TIR66><T,%M22$3A,$*#;HA+7;BSDX=
MJ_M9,QMZ:%4<7[[3@A_<NI/*P^",&4C)/;L9\L:A,WL.*50<<T@+?L AJ3PD
M#NE 2CATYH=#S=5C"]_%0,DACPP-Z#!)HP&%2V8P>3:UE\G=NSOUG>4%3N\P
MJ8BT''_7W*(,U[?.K<T;WC\W+@ *%4>AEMY)?_OF?SBYERXAZ0?2&=+B*</W
M\>I)-5M*!)W130FTY910"@9Q5-"&[&AE424,9U^H?B.CGI+G.<.GV!M2R#O-
MRJ>#W<O.)Q/V3B13A-(G2YJ[YUE>,6OB&[V&MV4\WXLQN@$#]ZZ+Q:V6J2ZT
M2-K_,R[*.%WI"2 1=,8 )="6 D(I&!Q001N2H)9UQ@)]\WMK=TV#0VQIHR:&
M%^']L'TLXB@.\M>'@*;@USYU)I=WFDY<![N72EPF[)TYI@BY50J1.O1+9P=(
M'QX_!^7N=HWR$%TF[#:%N IP/XFX2!(,?93P^$3B3+ASF6GB>8:NG+?T\4?]
MA",5=7?@J :[.W 4RWFGA $X469Y)@WP M+L2Y!'FKLD QFG:4Y%\'J)2;L"
MWLFA0L4E_Z0RA[P3(DOZL4[CQRU-:$2&HOB9#F+BO(I::7=)/[20=TD_I*+>
MR6"&3W!1\1VJM5"K1B<30#D4JX2W-.<C38F+TX+EQ&5_+6;;\BG+XS]P](F,
M>7DGCR2UH3A[O7S!>1@7U5T667*'2;_DU)&>KJIZ+OCA/^.] TUO&_=R4"U<
M1_8S\6E'9_:)>:I(PS24<#8*BZ&U(V__9^]DD6/B4CVR5B6+NT%K$[VI/77V
MZ<673-/:'0FWK<U!Z[=V^S.@UAYB,FUMHN>FM6F* EU[=V4<MS@/;]#F.P%(
MK<ZA,FYWJNFDY:^(S9J&[XJX;7<>7+_9=[\#:G4.E&FC4T4W;4Y\=5V;=T0<
MMSD';M#F[>^0VGP(RKC-6:"_@S9_B%\T3=Z1<-OB'+1^@[<_ VKO(2;3YB9Z
M;EH;/V/%_@DOX[C%>7B#-M\)0&IU#I5QNU--)RU_2>-&-"W?DW';\@)X_9;O
M" !J>1Z5:<M?5G$\#EK^-M8NT+LB;MN=!]=O]MWO@%J= V7:Z%31S;I-.\HO
M?(WQ'+3!B@W@^#[$9+Q:<S6V)P;3>E_(\>@N #@8WA.0,[L EO$ GSB;VQ=?
M<*)=N?6%7._,\0"'FW,["4#M+X!EOD5'51WMTL5YB?5#_D#,]5Z=".1PNZXK
M XD'(F#FFW:5LM^<-C=Q&:_8V=,YO8@ESD@O$G*5W48.L$EQPTMXIX@2%O=H
M2BN(J.2T9W-_FZ?XYN9</B8,!)R-!D)@[3C0^]5[\THA#9OV;^P [H:^5CKU
MD'^>/;X^Q GYPA+'BC%?+.?P>H8<9N=Z!B\$H]$5R/CK&8^O:"?K=YA_")]P
MM*51PLWCZN53%EVGS[@H:3@G_U>,;X.U;$+8KSA74\<AC&XFF7W*\D[= QG
M9Q=IE$\0%8424WZ/"TQJ^&F61A=DM95D&V;@"PVS46=I,])T^^BIL2G]UTZU
M:MY):8^5?]^TTF0YLCJZJ%;V\\#&PR9+BRS'46N8/N_$V)(\/\)A:JKF60Y=
M,=ZINC]VX=,=K2YJF>PLGT7'FH?XA:Y#[X*2?/>&+$U3HUPIMB7XX*J%:2*.
M&JB#XZ8Y9IZ3;W\D0V>8; L6G<U*0'41$S#S,/<\+@A,W3V/G8SS>QY#>-P]
MCT; .Y%4J,3W/"Y8DM,I=RNZO*;[YI399-C-MJLG;C@V&ZE,2_$R6MF9*!RQ
MS(KP3K;]< M&KK^@LM)$A$5OW'M^JOAGE;1'#TX:%RT7!<<;,;XA/\[P*DY3
MFB8A3A&[C.2:'^H82J6X/X8H8BL5LD YHHVY')+DS\Y)H@G#4\O[HXDJ/$\E
M#)0H^K"](5/^XI ILP;F/,5[K-C,B_'!*ULC170S+0,<"RV!"W86WG96<=,M
MWXRG/E)+'\K':K<D?J'C\-]PGIV3HNA#W8L\#I(Q6V2CRO4XF8ZO!L6L:U\H
M.+[O:XF@ _P)D8^<OO_QSV]04P!B);CK!K/H.2ZR_-6 V5)19V35@&WY)Y&#
M02DU.&X'HY:&N*_U4))AGT(Z(V-XBHOB :_H/PM53@&UCM/L ";P>_?\50K>
MR66#DD\,7(E,NTO6?$4^Q PE'.:5%D'K9(WN_NR]J>68Y T[[312)ZA^^Z;.
M3QVL\/C$XU:EN$X]/L+$8?)QBR*<4HT ><P*?"-GW$CXWO.0'R23)/Y]2P_\
MZ0:P)FF75-IU%DD%Y&$.28&H]W'.#!_'KE8:,7%0;[\/3%%&^4AD/9)('LDC
M%(1*(/7@-*3/)(-0@</O5]GS#Q&.*]J0_]BQA?SCU_.,#(NSQZ+,@[ <V"7X
MW04KI+ H$[@?O;>^#!$? 4MDR !12[ENZ(LLW*[K84U@0?]G5\TL M6T<O<W
M$(TL #1LXT:$30:.&WA&/AS1CU\EP4H ?_"[JR86PFK:N/<CB$86(>)V2QH9
M1(5\-?,%+L(\9HGP5';TQ)PWN@ DU_8=&5@4X(')F="1]32PW^-53*<6ECFQ
MV9U1#&,2>==#OQ+V<"X0"H,@C0E"Z6S154*MEB<>S=)T&R3W>)/E*OKTQ5RS
M1@1R2):N#"B."(!)J5')HDK8$R/^SS;(2YPGKUI2<)*N>2&!.J3&0 P4.\38
MI 1IQ?UR9)$':1'3 4Q+$E[4^7)# I9;>@SD0/%$ DZ^)&GE_3+EX0DG"4WS
M'*3Z 44D[)HM<L!#OO"2H!@CA2?E#-- M0H<VK =,QIO;VAL1]XG>3C8*OZT
MPF I-$1HR*)JNY/J>6+2'<[C+")N=J[C$"?IFCT2J$/>#,1 ,4:,3<J52APQ
M>?\DN4PC(XJT<GX(,H IID<M!) <?60Z:ERFD4]B7,5%&"05EBORM^'IK$;6
M-4&D<(<DX01!$46&3DJ62J'A#%/Q2IC_P$%N1I>.I!^R<%#%5&G% !)EB$U'
M$RKOA23GVSSOH9;/.')19X>R&K#M^:Q$#@11-."X4]M*O$<43S/095K&].96
M@F^W@G@.L8@K;LC -9P8_@Z""Q)0W)M13 Q1.50)>FGYYI0@+6EZ(:DY0S&W
M#!"#[+.@+P.("4)@$C;L9%FV)R^,."<C4QXDUVF$7_X=OTKMXN3<<D("LT^*
M@1 @5HB126A1"R,FC8BX%V+<Y?&:OH0=AYJI@A=T2PT9T#XWAE* R"&!)F%'
M+8T>KL]]SB2+X.4Z(D2-EW'(#ITU+)'*NR6+!G:?,Q)A0-11(Y0PB"BAOI9/
M(EVG899OLDZXPWFV)0/@ZWD6R3T4C99;4AF9T*>64@40P4QP2FC64SVI8E)0
MEJ.Z $1+\,*X6121BBKJ_[F)4_Q6:K]0UBV[%'#[G!(( F*2')V$/[7D2?,?
MB.K0],] 2//.PM1W_DGSSI0T[T"3YMT8TBR^9$!(\]["U/?^2?/>E#3O09/F
M_2C2T,P)/FES3OYSGB^R+Z+@;*FD%\KP4(6$V8G!HPN'34<6JD#]&:KBDR;,
ML9KG=WGV'*>AW&66B7LAC 2TD#4#67C4$0/4\:=UB!L]KV--Y91K.TDCYF>4
MZ8,4#S&5##R2](%I!Y=*VB<E[K*B#)*_Q1OE0EPL[(4>0L!"DO0DX5%%!$]'
MF$H'$24?"^N:KO1 0WB5;/"[NRO  EB[*\"='T&00(2(OP)<[9Y40JZ;F7(T
MQX%D1.C_[*R1!:#:-N[\!J.)>4!<"[-^361\=.2;C,9(/66I/$" %W'5TC)P
M36L/?P?1XA)0W)MU&8LUHW*>=N-?2IP6XN&[\YNSF7T(IYW(FQ] M.X0#3=-
M-[\[;LV?\[@D7S[/UNMM6I_RB.(&)7*N6ED)LVEQH1"(UE<A&S*AED5]8<>T
M>,B2.(S+.%U])(M/FL!38)5(R!4AY  ;-O 2(*@@A<5E[6D%42/IF 1W.:8D
MQ*0AV"5 G$8XGR^7PME>)>R*%'K #3GDDB!(HH4W) M1. T[&JA204S'+VVN
MBV*+<ROR"%0\44@*7D(D3AXBG60@M:2J%'URZP&'6S(_OKY]][B(RT2TN.1%
MG,U)$G#MC#3X'00W)*"&7&"_T;?4W[[[]O$[U&@Y;O[;;)$'$9D2'U[7CUDB
MR3XEE')% @7$A@<"$1!4D.,:LN$V0[4HJF1]9*?J@168,_C=%0&$L)JF[_T(
MHM%%B+C.WVMK3T/^Y4OX1$!AR84$L9CKH5\$<CC\=V5 4$ !C,]S7(FB1M;'
MA83=E+72.P$K;T[ 2N,$K" Z 2M3)V#ES0EH/ENE""'CTOPQB5>!)#FA4MHU
M*120A_P0B(*BBAR?=,QH5=!.QW5&2Y;B[#I=9OF:??^*_(? 2HF<LYR6*IAM
M4DN1$ B.J)!Q:2VKI',=842E7?-B&\4ECBHP5W$:I&$<)&UZ1-&.N%[%&5L,
MP;?$T<C#X) 92(Y.E5J3R[!5W*6Z=+V57@5@_(R3Y-_3[$OZ@(,B2W%4[:6(
M3HK4\FXC9C2P^T$S$F$0=#)!* F=H4JGOU$MU*C5.V%>F/0Y2[9I&>3L+GDN
M&IDD<FZ9(X'99\Q "!!3Q,@D#&F%427MYX)VE3VB=;+H@"=, :,6=WQ=6PEZ
M<&M;* N(,TJ LCO<=<Z/G6]<:7FZ8EEB^EY$_(PO@C*HL4GME8F[OE2I CV\
M32F2!40A)4#I_<E6AZ:*"1I.>4L9DY\35VN5*:+$!U+N$\=P$/G<,:T(('J(
M<"DRR.2HD?7"A8=UD"3-FXU2FP92;KD@A-CG0D\$$!=$N"1<8**HD?7"A<LU
MSE=D>ON09U_*ISH_J]0VB;1;;B@A]SDB% 7$%14^"6<:%53I-"EU_9#G99=0
MO,JR*+=4(.J8-E*P \YP<I ((P/'L27!(=UON<U*M,C0IP*C\@DC%LX:D;]W
M,L%7Y?AZ:20,Z86(RBM/HR 744@E[/S5$2E@[NT13A($D;3PY.^0M!JH47',
MFCGA<-Y=QS$0UR5>2V\[Z%5<,<@4?,,CG3P(-AF"''**J?47UTP144V?V8RZ
MR>WE+EY/R+%G+  X<(P[$B X(H4E<XN[;P7XR9VW?4SB\"K) ODN2T_&<<8\
M'MX@6=Y. ! #>%2R%'E,$#%)+^U_%J2_Y=M-&;[>Y5F(,8VR*MK12K?_9JCM
MEC-6)O799*0*B&<V>"4,W!6!.F6<=&8LGYMY-&B<9G/+PM\>G@)2@?-M6= 9
ME "3[X(KE1P?+Q@8,#AD4&@ HIX!3-F! ]-$3/4$5<JHH^UI?5;LL@#BZ.SU
M'B]Q3N\=+/!+>48^])MBA6&@ZWKU9FS.<#&G501!0ENTLJ5>@;H%H$<:(U87
M@7ZAA2!6RF'?+U\&Q2.S<UN<KH)@4S$3)V71_&5'T?H/O[;1(XO@D0LXE0FY
M()T:(&676,([C92PN!#"1HBP@HH!(L1-G&*ZF!P><*@$O1"# RHD1RL%CR!#
M: J24%&VQ"_\,V56%+@L9H\T@7\X=.9E0BX9(@;894=? @PSA+"X@,"'A\O%
M Q 6U,Z\$1DX6?><D,#EJ3$0!,80,3K9ZSL!T_%.F/.@>)JE$?V?R]^W\7.0
M4']I5IX'>?Y*_/3/0;*5.2*&NBX)965.EV!&BF (9X.6(R!10F01AD+Z'WBG
M[IV+]YCTG)B>\U&,XFTIC:Q+KBGA=KDE% 3#)16Z(7=VLHP]WAES09=Q.8Y8
MC@"Z&985W"4*C:Q+QBCA=ADC% 3#&!4Z;@E>RZ*L%D8AE?;.G+L<;X(XNGS9
MX+3 9"QE1WB]B5QBO9&F2U99F-+EF($:&,:98Q4D%Z&:"%>J!9OY,G9<&\+R
MQ$RXYY%E6C[Y8TZ9E4%R8^J?RRX=SQ>S&P1D&7<3!X]Q$I<Q+@C9V2;Z4Y9$
M."^HNU>^:E9VYNHN&61K5)=<IKI@1BQ+P%SZS>O9V?7-]>+Z\N$$?;S\V]]F
MM]>WE^CR_WRZ7OP'FMU>H(?%_/S?_VU^<W%Y__ __^&?WKW]RS^CB\NKZ_/K
M!23ZFFU%J!0\4=1@4T(N#9&&=ML3R4[1.YWJ0+WB+GBEN_*:*5(B['2N5 +N
M39I"23#T4<+CMD!K8;2II"'P)M_BB.\#<FME\H[9HX8]()!8&!*'E @%-*+R
MK<?NG487\7,<X30R&W^DTDXW&M20>UL-8E$P]%'CX[8;:NE#C4&K\K%BQ)L?
MW[]AK/BP.+O[]><@I\]D-YQ^%5-"+>J"#R9@*1E4<MZ98 ".2VY=2;=>S&'#
M;@_C$AM[;+Y=8#/7%]:*WWBV6="2VNOQ-X"\W@5>TX"E_+5:,#9'.[,U=;*N
MTS#9TCBZ.QJ_F:6SLLSCQVU)Q[Q%=DN:.4M+4E4$T(I=W,:%-CA@R@^Z9/#T
M%=?M"=-]S?O Z\S$8:?\B/_X(TAI<$WU1=A]L6_Q7: 8W$>4 Z;GJ,PT[A"B
M0HZ#YPKD_)M8Z3,FG8%(HKN\.0 KJE#H39"C9WH\C_[QS?=OWIZ@MW\^>?/F
M#?U_J*C"I(-M^93E\1]$Z0'G9"Y"-^@4_7CR_LU;=GS1"L8T/514'6GL0JM1
M4-#DF?_OEO2?]V].$&4SD[G (:8WT=#[M^RO?SI!I)0-9CD]$O^]S'J?&\K.
MMMU>]A'L7EOO5W<5FMWH2A%]>X&7](61[[SSJ^V+#*TJLDDHZ?A,5P9U<(8[
M% /#(3FVZ<?+<S)>_O7'DW?OO]:ALG,Q1QFAQXDY#<:3@.S%W0UDP-!7 HSG
M+KOG)"0K9>N[/[^1T_4$O3]Y]Y=W)W_]:\6Z=X2Q?SIY_^Z?OE+6SJ*(Y>@(
MDKL@CJ[3\V 3E]R;7UIIIYOQ:LB]K7BQ*!A&J_%QV_"M-&(!-'&*PDK!.XWN
M<1F0Q6%T&>0IO<<Z"\/M>IO0NUVUKR&I 1-%MQ&DIH;TPTEU6F H9PQ5< C4
M"**HDO1..]XI-O:>?2]'S)8AL+9PI?C$6[A'L0+1106-#":"%<<U)GX+%O4,
MT8I#",>%;GU;_?X=F!BNP6;879#/<W;U,6+N\!W.V:5^LZTTN;;'[4V=28I-
M39DJF(G7#N^X!3DTBE9))F;MZLJL:G@MCY24F:"@XE %*@4E.*VHQRV@85*0
MO=I@1;]&PSOU^M"UM*O$85.NAW$,W:I-&)A4DV=*,E?S3CI)MB13'=CTTV=,
M,N%@-E'FI/V/42P=0U-E?X<M-FZAF288@EK!%=RD@^H(]NTR] -U2OX8:.(%
MJC6 ,L[0!SP"OT]DE]+M4RGX9IK<Z9-+@V:8TN4#[N:)[-%[>5HMWQS3^'@:
M%=!LTWMXQ^#5=<Z[+5TZ(TU/<0<VSIR!&A@>FF,U#%B Q#]#!TZIX8EO)JZ;
M0APBOXPW[KJ\@N>Q<18IW36IM%=>R1TUB2A</FEVY01< N*?620K-U/QRBB-
M6P8Z3;D%2"."0?+&:+[J-6Y3S6KBX*72+KFE@=REE404#*/4^(9DJJ1W+[^C
M7QH%_UF![_$S3K?XBK34.;V'14#]')=/YUM"_37.+U_JRULT0Q+YO]$B>)&&
M<HTHR6TPW6A3^]%UUL6 X>UX['RB1U:2_UNP\PW. _I"29W[37>)52'ODHQ:
MV%W*287!$$N'D'L/K9%'C<)/WIETCPM,JH_FS;T@[$ZR#1VL:WS2#J74<9QM
M5@]_D'56K@"&628H!5EHF0Z[\Q#MM+Q3[ &S:\X?<$KHGQ"39M$Z3F/:5>@-
M##773)6=1A);&=2++C;2!$-#*[C<Y<=*^02M*G7&RZ!7 /HV;N[)HW_\$[L-
M1(7^\>V[ZFH0K?9J.8*(,TD_%K#';)=9SAZZ+0E#,2)KEO*I0-63M_SU'_[&
MSTGUE;_L/OCNW;OJ@W7!1?QB7ZS_0.IV@JF<[YN,>_E=*>G%%>"A"IV G1BL
MH&@Y0"YY)?FI8G2MDZ7^'<G;+,WZ%C39A-4.I8&>2S89F]'EEE8)S#ALBE3\
M &^]$O^VUO$_3#4)3RI@#*1TRT$@Z7;[1@JUOW7#B8$ACQP;OV532:*8B7KG
MR540Y^SP;A;]%UFL4V=VOJR3F,DF-HV.2^X8P>^R2*G@AD]_K?B4XA4].55-
M?"9@N0WF)_(O3"_-+HEV?2<\6Z(OX!+3?0CBM* S-B[FZ>4+'7BW<?%467F!
M'V7SHH&>2PH:F]&EH58)S-!FBG3(0ZJ'Z$D'+LNDVITF+'PFKC[Q_Z'DZ64C
MM73FE[FC&B6G+KZ1 3UO7ZD!AG9&,,6^&)"9]6.0_X99TJX''&YS=J?S4YKC
M(*%1";1[*-:.ILHNN69G4)=S9II@N&<%=\C!G2!:-4/@4Y:7I\3O6Q-N/N-J
M(@>\+K5=(0%9AUJM/V'M<-@.=%7B ?'2\P3=8O\;T@2#=H-L(..41")X/>)T
M!8"110!M2! B@^C/WGG0#UMN4ZH/XARNUQOY/IA=$?["S<V,D\>>J_6AK4U'
M8)>ES"_H)+GI1ZI[)VZOE\V>@SBI\J]V8K[JS!QG01&')GW5I!1O@Z"YB=)A
M4E\$X('4&+QLJ$5!)T\O*C-ZG-:&^O73 WDG=Y,5JXG85U%8(NN2J$JX73H*
M!<&L*U3HI*PBPHA)HU/$%,"1YR).MJ4TGETJ[9-  \@J"M6B8$G4QV=$HUK%
M.Y%^QO'JB0"9/9.ESPK?;FD&T?F2"Z56C4Z69;@DW2CSNE2T*@ ,0<>@YE[1
MJ<M 055(.Y=R\?*$SH\@1D6)V75?,[VP85T* $+K3#2@M*P(Z*36X-Z+UA&0
M47J6L')K*TFOQ=%Y)U!,O6=HJNPTL;*50;T\RT::8$AK!9<++:0ZIX]4B1[7
ML0,\=H2\8@O[D^:51!4_IXP/'9MI]IW3YMG@/,ZBAS+(2]5*5(%SV"YG ?EG
MZ/]XRW1&\SQG&<U*?N<=4XX83C(U09K+A9[ZYR3IUD#V76/4\K?&<)4M^A%B
MR[EZBNL8VM;"#-/&GNB96#:A5#?=+[8Y?2./&<R"R2Y?<![&!=Z%DEUE^7E0
MT)LPUVFT#=D$W_QVBX6/RQ[X \Z>I)VD8MJ'; ]:NG<_<C*3AIVC*:<3IUBP
M>R(A*8O=!(G;TEJ!$Y3N?\YMUWVJL7W*_C/Z"[X[T)Y5H^M!(XL'W87VL^EP
M?<C$WW#WS(EDJ*E2U19DV3I??DIC:6RZ91G.'T>Q-8];S9H6X)WZ^Z#F[SG6
MCY&&G8S%@X@!QO&6^?7[94T'.,AD,17!JX%@3X9+"P% <8V!!AR7E "=Y&K8
MT[#\Z(;S3A;R7;SMGH.)I$P ?<'._#'#O[! Z#W%R@IQ'GNJ1[T?HVX4IX,(
M':C=A1]"#M!?C L%T&$L*V#49'*47<;.C"GZS*&FFA&;6/3/=/^,K))V*R@:
MD[JEN20Z2ZE+\L4K/#R?G*!\WROPO:K%: ?+MG#O'6@JB[A+W74QS#G#G87X
MIBFJOR2_O)F?HR5VO/F[2W\Z4<<9^P'?/6>_BC';NOJJ^LY>)AVJ\QS%.J?Z
M,ZD#,L$^Q^&H=8V@# !NF=H\TW4+5X!WWN^#6DIMPN:NW]1?Q%-2%W5!4,G<
M39T]FLW20@#066.@\:KBZ BMAKT_HX]BF%;E1S+0 \!?W@S3(1A6)B53I"IB
M]GCX^7Y!_A"31:UW!K;W'?MW)R4U(95VR38-Y"[')*+0[JVJ8<JNJ-(;JB9[
M)-XYMLL452RR613%--(W2.Z".+I.SX--7 :).!R85<-\PW(FWM,@I2(N<3T=
M5)WP'H?9*F4ERB*.77W=:;RXVRKM!9R[^328T=^MO</.?M5+F$83M;1;G]E&
MFTMT0@9:9JMP&TJI:D\Q+M$EQ>0 R2KVV$;F-RX6V0/+7/:992R[JQ*6C=U?
M-"[>]U;8/I5BM8=L6+9W)D]DD,I]%>Q[Q=/FT=NKXW2R)<S2:!#$-KXV-<4"
MZRA&E6#9091E'E/',#%D_$;#P<*[1IRF'+X7V!7KNQ>,J02C\Y*OH1>,,.0
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M[VM[=U:HH^A^H^=1^ )RW%)?H"D"/;ZB5OT(_(&K. W2\ #^@+(@ $PV,-2
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M["4>AKLHY%PUOQ)FPP6A$ ABJ) )+G=4LJ@11K]0<=?,N$XC.G5N@T1"B:&
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M/1T85XQWVNZ/W8:MJ,P.F[;I@ /XPQ-9U- 7>2[P8\DLU?9PD8J? 5@.7CS
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MHB!VEQ'X57W ,CI]TG#M\CH-LS6FUX#$L=@=@5__Y*9Q_EHU3HI7-'9'=4=
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MD-0*+W>K^HEF1J7;UI-'C5V^T'1X9/'_U/.71!."5-193)@&;#O)2N2\L\,
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MT+:=A5(P&EP%C3N,W3:B:#5Y?^X[F?^!@YQ,#8J5RE#0]4)/#'2XTNM+P:"
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M]A7AC!L6:)7\.TR6*FD6 [S$>5X_TG9'*N")+'3N\IB[BJX7=YC)0 NZD\M
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M\IF+#YYNFM7&G16MS([#SY*P[\[YY#>L*+LFQYGNC02 -65KZC?JJJRR]67
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M C&3V_PFWC,#PRB9?3[0YQ&EB'61[CSU--.A*;PW$L9CV$"E5'BC:TH7Z\
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MTUJ,(Q-!4'BY(R3^$$?9)K?> !A15@!S,;RMV8 +@,QCST:YK^NA8UH6E!7
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M,RAJ6G8G83*Q+L8\+DT_VI25D(+86A3E/2.+&UHDHF#:!4M&7U=L\P:1!R2
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M=ATR.;+B;O0P$TE=Q_K:@(R^CA7.UTD-AK65=6"IL^_")C?$/:1>G%J(51C
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MBDHA]'S(8U+1 L<J$^29A  NJL70T\^.RD8;()M\7/*SHIZ/6C'TS*1C\B$
MR"8?MQ1RQJB60L\R.28;;7BL[FXA4]7<?*)Z%2MX"QRKTU0 6S?JY=!SHXTZ
M40D@LGL&)P%DAULOAYY*:]RC>!LBNZ=Q&J<$-&DU2J(G2!KW4"Z"Z9BO0]H0
M?-IL2)S_=$/75/&BE]VO(K_%#7,4L6F5EO#@J+*]I@ )?//[@-IG/5F,8UZ\
MQQ+0@/^LN9F2H:=W.;+9KCV6>#JX^9.G1^*>\$U(_F1DF+M:9E[ 7YFRD=_
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M_JYY>5RT.,F;/#SQ5KTRWET33_8-GRZ,N[O,>VGNY*"[X&V4>ST7L@W!'+A
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M5*_)&$"RGBMS;^;N8OK,E.\N\/Q< W7+AZP\NA\@6 ,;)*D!0)_N\OC6.?N
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MXJC)+G.%&C*MKH5^FV9&,P2"@3F6W]Z4?^'_[Y&M$.PW_Q]02P$"% ,4
M"  D@ Y;_E"5'NT%  "#-0  "@              @ $     97@Q,"TX+FAT
M;5!+ 0(4 Q0    ( "2 #EN2'T(9;P<  ',M   *              "  14&
M  !E>#,Q+3$N:'1M4$L! A0#%     @ )( .6S'UGF!5!P  #"T   H
M         ( !K T  &5X,S$M,BYH=&U02P$"% ,4    "  D@ Y;?&[>8A $
M  #C$0  "@              @ $I%0  97@S,BTQ+FAT;5!+ 0(4 Q0    (
M "2 #EOE+\D7" 0  &H0   *              "  6$9  !E>#,R+3(N:'1M
M4$L! A0#%     @ )( .6_]4;D, H $ Q.D4  P              ( !D1T
M &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    ( "2 #EMM@<\=*:$" .\T P 0
M          "  ;N] 0!F;W)M,3 M<5\P,#$N:G!G4$L! A0#%     @ )( .
M6Q<7\UQ:_@  5PD! !               ( !$E\$ &9O<FTQ,"UQ7S P,BYJ
M<&=02P$"% ,4    "  D@ Y;NZN5-:\U  #A.@  $               @ &:
M704 9F]R;3$P+7%?,# S+FIP9U!+ 0(4 Q0    ( "2 #EM(E5\_.8L   B/
M   0              "  7>3!0!F;W)M,3 M<5\P,#0N:G!G4$L! A0#%
M  @ )( .6_7,":CTE   H)T  !               ( !WAX& &9O<FTQ,"UQ
M7S P-2YJ<&=02P$"% ,4    "  D@ Y;8KYGQ/@M  "!,   $
M    @ $ M 8 9F]R;3$P+7%?,# V+FIP9U!+ 0(4 Q0    ( "2 #EL@2^"=
ME0\  /BV   1              "  2;B!@!G=&)P+3(P,C4P-C,P+GAS9%!+
M 0(4 Q0    ( "2 #EM0C/=6J@P   "4   5              "  >KQ!@!G
M=&)P+3(P,C4P-C,P7V-A;"YX;6Q02P$"% ,4    "  D@ Y;F3M\MR$S  #[
M? , %0              @ ''_@8 9W1B<"TR,#(U,#8S,%]D968N>&UL4$L!
M A0#%     @ )( .6RC_Z>^";   4VP& !4              ( !&S(' &=T
M8G M,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( "2 #EL5;'9*XDL  '0L
M!0 5              "  =">!P!G=&)P+3(P,C4P-C,P7W!R92YX;6Q02P4&
2     !$ $0 1!   Y>H'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20250630.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_SeriesLConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-14</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-14_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="From2025-02-262025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_InducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-11</startDate>
            <endDate>2025-05-11</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember14125843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-31</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_VestingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2025-05-012025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-06-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-02-172025-02-17_custom_ZOneLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:ZOneLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-17</startDate>
            <endDate>2025-02-17</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-07-08_custom_CobySilberfeinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <context id="From2025-07-092025-07-09_custom_CobySilberfeinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-09</startDate>
            <endDate>2025-07-09</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember14126828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-18</startDate>
            <endDate>2025-06-18</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-18</instant>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-13</instant>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-27_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-27</instant>
        </period>
    </context>
    <context id="AsOf2025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-10</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-06-30" id="Fact000004">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-06-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-06-30" id="Fact000006">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-06-30" id="Fact000007">0000109657</dei:EntityCentralIndexKey>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-04-012025-06-30"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0282"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-03-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IssuanceOfWarrantsForVrtWaiver
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:GainOnSettlementOfDebt
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:DividendOnSeriesLConvertiblePreferredStock
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_SeriesLConvertiblePreferredStockMember"
      id="xdx2ixbrl0757"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0797"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0800"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0886"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0888"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1049"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1051"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1233"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1235"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1237"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1239"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1241"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl1243"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-06-30" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-06-30" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-06-30" id="Fact000015">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-06-30" id="Fact000016">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-06-30" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-06-30" id="Fact000018">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-06-30" id="Fact000019">GT BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-06-30" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-06-30" id="Fact000021">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-06-30" id="Fact000022">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-06-30" id="Fact000023">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-06-30" id="Fact000024">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-06-30" id="Fact000025">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-06-30" id="Fact000026">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-06-30" id="Fact000027">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-06-30" id="Fact000028">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-06-30" id="Fact000029">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-06-30" id="Fact000030">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-06-30" id="Fact000031">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-06-30" id="Fact000032">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-08-08"
      decimals="INF"
      id="Fact000033"
      unitRef="Shares">3557502</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-06-30" id="Fact000034">505 Montgomery Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-06-30" id="Fact000035">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-06-30" id="Fact000036">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-06-30" id="Fact000037">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-06-30" id="Fact000038">94111</dei:EntityAddressPostalZipCode>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000046"
      unitRef="USD">5228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000047"
      unitRef="USD">3951000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">760000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">1043000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">7124000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">4232000</us-gaap:AssetsCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">1374000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">608000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">1797000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">85000</us-gaap:DividendsPayableCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">240000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">2307000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">5902000</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000088"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000090"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000092"
      unitRef="Shares">15000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000094"
      unitRef="Shares">15000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000096"
      unitRef="Shares">6301</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000098"
      unitRef="Shares">6301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-06-30_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact000085"
      unitRef="USD">1956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000110"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000112"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000116"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000107"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">3272995</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">3272995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000126"
      unitRef="USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">700378000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">693554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000148"
      unitRef="USD">-697521000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">-695227000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">2861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">7124000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">4232000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">363000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">1784000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">1462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">2561000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000177"
      unitRef="USD">4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000179"
      unitRef="USD">120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000181"
      unitRef="USD">7000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000183"
      unitRef="USD">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">1150000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">2122000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">1983000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">4436000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000185"
      unitRef="USD">-1513000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-3906000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-3445000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-6997000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">38000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">105000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000197"
      unitRef="USD">70000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">247000</us-gaap:InterestIncomeOther>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">114000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-117000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-12000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000203"
      unitRef="USD">-775000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">998000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">156000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">156000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">1000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">-1000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">80000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">196000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">1236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000223"
      unitRef="USD">1021000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-1433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-3710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-2209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-5976000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000230"
      unitRef="USD">85000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">85000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-1518000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-3710000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-2294000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-5976000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">-2.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000246"
      unitRef="USDPShares">-2.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000250"
      unitRef="USDPShares">-0.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000252"
      unitRef="USDPShares">-3.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000254"
      unitRef="USDPShares">-3.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">2771765</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">2771765</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000260"
      unitRef="Shares">1711955</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">1711955</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">2559604</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">2559604</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">1546294</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">1546294</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000272"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">2536397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">695019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-696003000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-980000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">235000</GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">436000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000290"
      unitRef="USD">436000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">3389000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000298"
      unitRef="USD">3389000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">6611</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">2052000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">151598</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000308"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">-310</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-04-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">300000</GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000320"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000328"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000336"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">85000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000342"
      unitRef="USD">85000</us-gaap:DividendsPreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-1433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-1433000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">3272995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">700378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-697521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000360"
      unitRef="USD">2861000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">6301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="USD">1956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000376"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000378"
      unitRef="Shares">2234328</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">693554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-695227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">537069</GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">1051000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">1052000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">3389000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000396"
      unitRef="USD">3389000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact000398"
      unitRef="Shares">6611</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">2052000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">151598</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000406"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">-310</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-06-30_custom_SeriesLPreferredStockMember_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">-96000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000416"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000418"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000426"
      unitRef="Shares">300000</GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000424"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000434"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000432"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">85000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000446"
      unitRef="USD">85000</us-gaap:DividendsPreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000450"
      unitRef="USD">7000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000452"
      unitRef="USD">7000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-2209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-2209000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">3272995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">700378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">-697521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000464"
      unitRef="USD">2861000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000470"
      unitRef="Shares">6301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000472"
      unitRef="USD">1956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000480"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Shares">1380653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">689641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-684331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">5312000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">740000</GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">2975000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000488"
      unitRef="USD">2976000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000498"
      unitRef="Shares">13902</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000504"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">120000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">-3710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000518"
      unitRef="USD">-3710000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000526"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000522"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000523"
      unitRef="USD">-688041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000524"
      unitRef="USD">5508000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000536"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000538"
      unitRef="Shares">1380653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000531"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000546"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000540"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000548"
      unitRef="Shares">1380653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000556"
      unitRef="Shares">740000</GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000551"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000552"
      unitRef="USD">2975000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">2976000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000564"
      unitRef="Shares">13902</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000568"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000570"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000578"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000583"
      unitRef="USD">-5976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000584"
      unitRef="USD">-5976000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000592"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000587"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">-688041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">5508000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000596"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000604"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000597"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000599"
      unitRef="USD">-688041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000600"
      unitRef="USD">5508000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">-2209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">-5976000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000615"
      unitRef="USD">7000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000616"
      unitRef="USD">222000</us-gaap:ShareBasedCompensation>
    <GTBP:IssuanceOfWarrantsForVrtWaiver
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000618"
      unitRef="USD">44000</GTBP:IssuanceOfWarrantsForVrtWaiver>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000621"
      unitRef="USD">-12000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000622"
      unitRef="USD">-775000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000624"
      unitRef="USD">998000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <GTBP:GainOnSettlementOfDebt
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000627"
      unitRef="USD">200000</GTBP:GainOnSettlementOfDebt>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">1000</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000636"
      unitRef="USD">225000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000637"
      unitRef="USD">-67000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000639"
      unitRef="USD">-1623000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">-1231000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000643"
      unitRef="USD">5000</GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000645"
      unitRef="USD">-5216000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000646"
      unitRef="USD">-7699000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">-12893000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000655"
      unitRef="USD">12893000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000660"
      unitRef="USD">1052000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">2976000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">5441000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000669"
      unitRef="USD">6493000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">2976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">1277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000673"
      unitRef="USD">8170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">4044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">1079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">5321000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000679"
      unitRef="USD">9249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <GTBP:FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000696"
      unitRef="USD">3389000</GTBP:FairValueOfVestedWarrantsIssuedInSeriesLConvertiblePreferredStockTransaction>
    <GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000699"
      unitRef="USD">672000</GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee>
    <us-gaap:StockIssued1
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">718000</us-gaap:StockIssued1>
    <GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000705"
      unitRef="USD">847000</GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable>
    <GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000706"
      unitRef="USD">810000</GTBP:FairValueOfPrefundedWarrantOrCommonStockToSettleVendorPayable>
    <GTBP:DividendOnSeriesLConvertiblePreferredStock
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000708"
      unitRef="USD">85000</GTBP:DividendOnSeriesLConvertiblePreferredStock>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000711"
      unitRef="USD">96000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000714">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zLEV62EVlkn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82D_z9TKPvbm3UX3"&gt;Organization and Going Concern Analysis&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GT
Biopharma, Inc. (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#xae;) platforms. The Company&#x2019;s TriKE&#xae; and Dual Targeting TriKE&#xae; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#x2019;s own natural killer cells (NK cells).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Throughout
this Quarterly Report on Form 10-Q, the terms &#x201c;GTBP,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;the Company&#x201d;
and &#x201c;our Company&#x201d; refer to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
GT Biopharma logo, TriKE&#xae;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Going
Concern Analysis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The
Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future.
Historically, the Company has financed its operations through public and private sales of common stock, the issuance of preferred
and common stock, the issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30,
2025, the Company recorded a net loss of approximately $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zpENKaWznPqb" title="Net loss"&gt;2.2&lt;/span&gt;
million and used cash in operations of approximately $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zlO6G3zoUVT3" title="Net cash used in operating activities"&gt;5.2&lt;/span&gt;
million. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of
the date that the financial statements are issued. In addition, the Company&#x2019;s independent registered public accounting firm,
in its report on the Company&#x2019;s December 31, 2024, financial statements, raised substantial doubt about the Company&#x2019;s
ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated the significance of the uncertainty regarding the Company&#x2019;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#x2019;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#x2019;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact000716"
      unitRef="USD">-2200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact000718"
      unitRef="USD">-5200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000720">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zbhqx6OdlYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_824_z2ZMo578HY9a"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1yDj5UG7pt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zR6OwY5RDU07"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules
and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zhEdzgSn4ROd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z7BcxPB2Ntg2"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4SjGrr2hpN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zC5etwP6Mndk"&gt;Cash
Equivalents&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At June 30, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds and treasuries with maturities of three months or less, amounted to approximately $&lt;span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_zlw5dHhPhBak" title="Cash equivalents"&gt;4.9&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zTHlkxQTmVR6" title="Cash equivalents"&gt;3.8&lt;/span&gt; million,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zuLfr8H4lvzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zpLohf8KFOt1"&gt;Restricted
Cash&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The
Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the
same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zrw9QSB92Pmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z9tYdQmnwDFj"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#x2019;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses.&#160;As of June 30, 2025, there was $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250630_z39qRWhw9aui" title="Deferred offering costs"&gt;0.8&lt;/span&gt;&#160;million of deferred offering costs on the consolidated balance
sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBNOjN3ZtlO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zNr1pr6PKkog"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_900_ecustom--WarrantLiabilityCurrent_iI_c20250630_zeY6Pis1mQQg" title="Warrant liability"&gt;240,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_z95d9INiBjZ6" title="Warrant liability"&gt;252,000&lt;/span&gt; at June 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zzjREssO3MYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z0SMOmeygsmk"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--MezzanineEquityPolicyTextBlock_zhhC9ZWZiqCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zfB9zpdQRTsf"&gt;Mezzanine
Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#x2018;mezzanine equity&#x2019; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z5VdWMBCHuWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zdDJNBitkyR"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVFnZfwbYQCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8B5_zSKXQcRn5Ve"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z79HEwK8goC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zTcM4jjU8cec"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z8nUnOa1arL9" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible
    preferred stock &lt;b&gt;&lt;sup id="xdx_F4E_zNIpjxvAfxFj"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,084,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,751,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,133,762&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,960,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,260,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share"&gt;2.043&lt;/span&gt; per share, as of June 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zHlsfpWsJME3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z68Myz1d8pI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_ztAeaEzQPvtf"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20250630_zxroiafA4Vy7" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), a related party, and the University
of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2yEebsh9Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zp5MBuogswXa"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztoQDRMqA6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zabjQIR5FpHc"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_854_zSphDe2DYUz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000722">&lt;p id="xdx_84B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1yDj5UG7pt2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zR6OwY5RDU07"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules
and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-06-30" id="Fact000724">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zhEdzgSn4ROd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z7BcxPB2Ntg2"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000726">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4SjGrr2hpN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zC5etwP6Mndk"&gt;Cash
Equivalents&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At June 30, 2025 and December 31, 2024, total cash equivalents which consist
of money market funds and treasuries with maturities of three months or less, amounted to approximately $&lt;span id="xdx_90A_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_zlw5dHhPhBak" title="Cash equivalents"&gt;4.9&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zTHlkxQTmVR6" title="Cash equivalents"&gt;3.8&lt;/span&gt; million,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000728"
      unitRef="USD">4900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000730"
      unitRef="USD">3800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2025-01-01to2025-06-30" id="Fact000732">&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zuLfr8H4lvzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zpLohf8KFOt1"&gt;Restricted
Cash&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The
Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the
same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="From2025-01-01to2025-06-30" id="Fact000734">&lt;p id="xdx_84E_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zrw9QSB92Pmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z9tYdQmnwDFj"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#x2019;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses.&#160;As of June 30, 2025, there was $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250630_z39qRWhw9aui" title="Deferred offering costs"&gt;0.8&lt;/span&gt;&#160;million of deferred offering costs on the consolidated balance
sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000736"
      unitRef="USD">800000</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-06-30" id="Fact000738">&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBNOjN3ZtlO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zNr1pr6PKkog"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_900_ecustom--WarrantLiabilityCurrent_iI_c20250630_zeY6Pis1mQQg" title="Warrant liability"&gt;240,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--WarrantLiabilityCurrent_iI_c20241231_z95d9INiBjZ6" title="Warrant liability"&gt;252,000&lt;/span&gt; at June 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">240000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000744">&lt;p id="xdx_84F_ecustom--WarrantLiabilityPolicyTextBlock_zzjREssO3MYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z0SMOmeygsmk"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityPolicyTextBlock>
    <GTBP:MezzanineEquityPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000746">&lt;p id="xdx_84B_ecustom--MezzanineEquityPolicyTextBlock_zhhC9ZWZiqCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zfB9zpdQRTsf"&gt;Mezzanine
Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#x2018;mezzanine equity&#x2019; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</GTBP:MezzanineEquityPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000748">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z5VdWMBCHuWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zdDJNBitkyR"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-06-30" id="Fact000750">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVFnZfwbYQCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8B5_zSKXQcRn5Ve"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000752">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z79HEwK8goC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zTcM4jjU8cec"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z8nUnOa1arL9" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible
    preferred stock &lt;b&gt;&lt;sup id="xdx_F4E_zNIpjxvAfxFj"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,084,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,751,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,133,762&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,960,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,260,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share"&gt;2.043&lt;/span&gt; per share, as of June 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zHlsfpWsJME3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000754">&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zNjAPTKIlXdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z8nUnOa1arL9" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250630_z26xAVbiW4fb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zaxsk1CNP4mi" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;June
                                            30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_zYkXvFIOnN39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible
    preferred stock &lt;b&gt;&lt;sup id="xdx_F4E_zNIpjxvAfxFj"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,084,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAie6U5NWaE1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr7zx9CFJ4Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants to purchase common
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,751,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,133,762&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z7akplv9wzw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,960,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,260,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F00_zJzWt9tKvRl5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_z4PVt3thr5Ve" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb" title="Conversion price per share"&gt;2.043&lt;/span&gt; per share, as of June 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">3084382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">124600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">126265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000762"
      unitRef="Shares">16751669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">1133762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">19960651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">1260027</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000769"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-06-30" id="Fact000771">&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z68Myz1d8pI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_ztAeaEzQPvtf"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20250630_zxroiafA4Vy7" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;), a related party, and the University
of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000773"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000775">&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh2yEebsh9Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zp5MBuogswXa"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000777">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztoQDRMqA6u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zabjQIR5FpHc"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000779">&lt;p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFyidnjsY8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82F_zeNVb29eQlfi"&gt;Accounts Payable and Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLoADPOTcSZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z5xdaPWmqwL6" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250630_zqT9xxd4ApCb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zAQeoUhxNx27" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, &lt;br/&gt;
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zn3m6wkeYMui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F42_zWvCot73Bpz4"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zlF7tyJeMuH7" title="Accounts payable interest rate"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zn43xrZCRtr1" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zNbhlRSfuPb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable to University
    of Minnesota&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zD4p7hdqONKa" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;712,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zx9a0O4DQCL3" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z3qTuviRILM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal services firm&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zYBl9cG3c2xf" title="Accounts payable interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zi6GWXtUKJge" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zRjY8xRkQrs5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zMdk2AEfa6f1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;344,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zcWnGQ4VuzWb" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;453,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNUhi0cHgKul" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zyUoH1ArR81a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,374,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630_zzldxFzUBNx7" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,853,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zfUyh2Qpl2Hg" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F02_zzW27guC4jY5"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zS1vfydUx7A3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_zIHPIENRySpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zfPzkRmitlG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_z2szJcyXcmNk"&gt;Schedule of Accounts Payable to Related Party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250630_zeZOS0OUYWXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240630_z5rRWGsXn3Nc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zbQUuhGvsRSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,515,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9GeCP6JTmU" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Invoices, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;626,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;778,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTM2XvgnEZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(364,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,641,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zH6PoVGKIThl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in common stock,
    at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(810,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIcmYJ9ZRH57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments
    in pre-funded warrants, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(847,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zBF3iIgEViI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zIhslV6GwNO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April and June 2024, the Company issued an aggregate of &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB8ZdmFhN50d" title="Issuance of prefunded warrant to settle vendor payable, shares"&gt;127,597&lt;/span&gt; shares of common stock with a fair value of approximately $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_c20240101__20240630_zXo5H3a32y47" title="Issuance of prefunded warrant to settle vendor payable"&gt;810,000&lt;/span&gt; to
Cytovance as partial payment of accounts payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjDXuHDRqfm2" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares of common stock exercisable at $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7vYly99QAUd" title="Exercise price"&gt;0.0001&lt;/span&gt; per share
with a fair value of approximately $&lt;span id="xdx_909_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zzVzGpSsxzn3" title="Payments in pre-funded warrants, at fair value"&gt;847,000&lt;/span&gt; to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#x2019;s prior year unpaid fees by approximately
$&lt;span id="xdx_90E_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zpLm4km7m4O5" title="Prior year unpaid fees"&gt;1&lt;/span&gt; million. The Company classified this transaction as other income during the period ended June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000781">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zLoADPOTcSZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z5xdaPWmqwL6" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250630_zqT9xxd4ApCb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zAQeoUhxNx27" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, &lt;br/&gt;
    2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zn3m6wkeYMui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F42_zWvCot73Bpz4"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zlF7tyJeMuH7" title="Accounts payable interest rate"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zn43xrZCRtr1" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zNbhlRSfuPb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable to University
    of Minnesota&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zD4p7hdqONKa" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;712,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zx9a0O4DQCL3" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z3qTuviRILM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal services firm&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zYBl9cG3c2xf" title="Accounts payable interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zi6GWXtUKJge" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zRjY8xRkQrs5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,505,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zMdk2AEfa6f1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;344,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zcWnGQ4VuzWb" title="Accounts payable interest rate"&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;453,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNUhi0cHgKul" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zyUoH1ArR81a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,374,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250630_zzldxFzUBNx7" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,853,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zfUyh2Qpl2Hg" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F02_zzW27guC4jY5"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zS1vfydUx7A3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000783"
      unitRef="USD">598000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000786"
      unitRef="Pure">0.44</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Pure">0.31</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">432000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-06-30_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Pure">0.31</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000791"
      unitRef="USD">712000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Pure">0.18</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000802"
      unitRef="Pure">0.39</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2025-06-30_custom_OtherAccountsPayableMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">344000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-06-30_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000810"
      unitRef="Pure">0.25</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">453000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000814"
      unitRef="USD">1374000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000817"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000819"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000822">&lt;p id="xdx_89D_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zfPzkRmitlG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_z2szJcyXcmNk"&gt;Schedule of Accounts Payable to Related Party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250630_zeZOS0OUYWXg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240630_z5rRWGsXn3Nc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zbQUuhGvsRSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,183,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,515,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9GeCP6JTmU" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Invoices, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;626,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;778,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zTM2XvgnEZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(364,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,641,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zH6PoVGKIThl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments in common stock,
    at fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(810,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIcmYJ9ZRH57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Payments
    in pre-funded warrants, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(847,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zBF3iIgEViI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">3515000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">626000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">778000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">364000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">2641000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">810000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">598000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">842000</us-gaap:AccountsPayableTradeCurrent>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000844"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000848"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-01-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:PaymentsForFees
      contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember"
      decimals="-6"
      id="Fact000852"
      unitRef="USD">1000000</us-gaap:PaymentsForFees>
    <GTBP:WarrantLiabilityTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000854">&lt;p id="xdx_808_ecustom--WarrantLiabilityTextBlock_zOlz8YeTr0Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_82E_zyauPDLekUS2"&gt;Warrant Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate
of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zovNsnTgRgDk" title="Warrants to purchase"&gt;216,667&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;2023 Common Warrants&#x201d;), and placement agent warrants to purchase
up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zWtWlFYy0kL1" title="Warrants to purchase"&gt;13,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;2023 Placement Agents Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#x201c;2023 Warrants&#x201d;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_z4lKmWtLNMLg" title="Volatility amount utilized in the value calculation percentage"&gt;100&lt;/span&gt;% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#x2019;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrants were initially recorded at a fair value at $&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zsyEGhgEAUGl" title="Warrant  fair value"&gt;5.8&lt;/span&gt; million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#x2019;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zvN0uJtHZ0Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zj5GFkPO6bY1" style="display: none"&gt;Schedule of Warrant Liability Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zMRaoSHMbGci" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zOEchUvwyMma" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zR4NEA7W5L54" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zUghOTnWsWWi" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z7DEEYXKYyrh" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zUiUML0kgpkj" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____z8DPmaUwmuz6" title="Expected life (in years)"&gt;2.5&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zXBAlpEzUHif" title="Expected life (in years)"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zP2IqcNqlPej" title="Expected life (in years)"&gt;3.0&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zb5TRxpqlamj" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zHDWhiBMoW8l" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zVd24N3s9O86" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zSBeyTu8ftGi" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zx5PEV1dsO5b" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0B_zMY6SPzd685c"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zPSDqIoGOGi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F09_zbMpmvqZUpyf" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_zM3f9fFjxWu3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0F_z7vjk12pZ6Sa"&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_z4fCAsr4Xz53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F00_z6cW6eqbfiDa"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_zfI28UCMF0N6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A6_zGCiIYluZunb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLe24w7itmB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zQqix48w7G1l" style="display: none"&gt;Schedule of Warrant Liability Transactions&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20250630_zhVN18dsfG8j" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630_zPEwsW5r4H1e" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zH5wLvB2rDkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,052,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_z94fK3t2S4zf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance of warrants at
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zn1u4FH4ak8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(775,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zcihmlUBCKf7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zd0T0KijeE01" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zcMXOpmsNzE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">216667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="-5"
      id="Fact000862"
      unitRef="USD">5800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember"
      id="Fact000864">&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zvN0uJtHZ0Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zj5GFkPO6bY1" style="display: none"&gt;Schedule of Warrant Liability Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zMRaoSHMbGci" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zOEchUvwyMma" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zR4NEA7W5L54" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zUghOTnWsWWi" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____z7DEEYXKYyrh" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zUiUML0kgpkj" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____z8DPmaUwmuz6" title="Expected life (in years)"&gt;2.5&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zXBAlpEzUHif" title="Expected life (in years)"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zP2IqcNqlPej" title="Expected life (in years)"&gt;3.0&lt;/span&gt;
                                            &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zb5TRxpqlamj" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zHDWhiBMoW8l" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zVd24N3s9O86" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zSBeyTu8ftGi" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zx5PEV1dsO5b" style="text-align: right" title="Fair value of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0B_zMY6SPzd685c"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zPSDqIoGOGi3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F09_zbMpmvqZUpyf" style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_zM3f9fFjxWu3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0F_z7vjk12pZ6Sa"&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_z4fCAsr4Xz53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup id="xdx_F00_z6cW6eqbfiDa"&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_zfI28UCMF0N6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000866"
      unitRef="USDPShares">3.58</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000868"
      unitRef="USDPShares">3.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Pure">3.68</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Pure">111</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Pure">114</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000878">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-06-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000880">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000882">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000884">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">240000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000898">&lt;p id="xdx_898_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zLe24w7itmB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zQqix48w7G1l" style="display: none"&gt;Schedule of Warrant Liability Transactions&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20250630_zhVN18dsfG8j" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630_zPEwsW5r4H1e" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zH5wLvB2rDkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;252,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,052,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_z94fK3t2S4zf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance of warrants at
    fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zn1u4FH4ak8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(775,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zcihmlUBCKf7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zd0T0KijeE01" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000901"
      unitRef="USD">1052000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000906"
      unitRef="USD">-12000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000907"
      unitRef="USD">-775000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000912"
      unitRef="USD">240000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000913"
      unitRef="USD">277000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000915">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9LePaa2nNHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_827_zspFBQN2pBwk"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s authorized capital as of June 30, 2025 was &lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_zmTL5pJtTJIf" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250630_zpHuDjFmZ4fc" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, and &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250630_zEVcGcYZERth" title="Preferred stock, shares authorized"&gt;15,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630_zmtZZfO8SmW3" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Private Placement of Equity Facility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#x201c;Purchase
Agreement&#x201d;) with investors (collectively, the &#x201c;Investors&#x201d;) relating to a committed equity facility (the
&#x201c;Facility&#x201d;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to
the Investors up to $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zF7eF2GrWFK8" title="Warrants to purcahse"&gt;20&lt;/span&gt;
million of its common stock subject to certain conditions and limitations set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the
Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market
conditions, the trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of
such shares of common stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and
prices at, which the shares of common stock are sold to the Investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be &lt;span id="xdx_90C_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z7ddTMl6SBce" title="Weighted average volume price of common stock percentage"&gt;93&lt;/span&gt;% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to
purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCv1LOuVrsOd" title="Warrants to purcahse"&gt;300,000&lt;/span&gt;
shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Warrant Inducement Transaction&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2025, the Company received gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zZ30HP9Ugi3i" title="Proceeds from private placement"&gt;686,000&lt;/span&gt; before deducting placement agent fees and other offering expenses
of $&lt;span id="xdx_90F_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zge4LiRJJlec" title="Other offering expenses"&gt;70,000&lt;/span&gt; in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zW0ZQlglhOAi" title="Issuance of warrants, exercisable"&gt;302,069&lt;/span&gt; shares of the Company&#x2019;s common stock at $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zectYv7kG3tj" title="Share price"&gt;4.35&lt;/span&gt; per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zep4Qz0Hgg6j" title="Share price"&gt;2.27&lt;/span&gt; per share in exchange for the Company&#x2019;s agreement to issue the holders new warrants
(the &#x201c;Inducement Warrants&#x201d;) exercisable for an aggregate of up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zYlSb9FEM1fi" title="Issuance of warrants"&gt;604,138&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zb96CDLdLc7" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of Common
Stock at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zGQqpzO5dZt" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zD47LyZzbrhe" title="Warrant term"&gt;five years&lt;/span&gt; from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zczLTEjo14Ef" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zXylTgIAvtB7" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately
upon issuance with a term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zbzA4hNPEAXd" title="Warrant term"&gt;eighteen months&lt;/span&gt; from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_z1OESNPFBh17" title="Placement agents"&gt;21,145&lt;/span&gt; shares of common stock at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zRlrlaV0737g" title="Exercise price"&gt;2.8375&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zcTUxLso45Nd" title="Warrant term"&gt;five years&lt;/span&gt; from the
date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#x2019;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $&lt;span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250630_zD6aQk1WrWEl" title="Equity issuance cost"&gt;1.1&lt;/span&gt; million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Private Placement of Series L Convertible Preferred Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, and as amended on May 21, 2025, the Company entered into a securities purchase agreement (the &#x201c;Securities
Purchase Agreement&#x201d;) with the purchasers identified therein (collectively, the &#x201c;Purchasers&#x201d;) providing for the
issuance and sale to the Purchasers of (i) &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zarCk86s68qi" title="Issuance of shares"&gt;6,611.11&lt;/span&gt;
shares of the Company&#x2019;s Series L 10% Convertible Preferred Stock (the &#x201c;Series L Convertible Preferred Stock&#x201d;),
(ii) warrants to purchase up to a number of shares of common stock of the Company equal to 100% of the shares of the Company&#x2019;s
common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock (the &#x201c;Common Warrants&#x201d;), and
(iii) warrants to purchase up to a number of shares of Company&#x2019;s common stock equal to the number of Greenshoe Conversion
Shares (as defined in the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the
&#x201c;Vesting Warrants&#x201d; and together with the Common Warrants, the &#x201c;Warrants&#x201d;), with an aggregate stated value of
$&lt;span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zIctUc4ICvI9" title="Aggregate stated value"&gt;6,611,111&lt;/span&gt;,
for an aggregate purchase price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zys4wTWv0qE" title="Issuance of shares, value"&gt;5,950,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an
aggregate stated value of up to $&lt;span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_z1KC69dSYb51" title="Aggregate stated value"&gt;24,018,349&lt;/span&gt;
(the &#x201c;Greenshoe Rights&#x201d;) for an aggregate purchase price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zKTNo8NprII9" title="Issuance of shares, value"&gt;21,616,514&lt;/span&gt;,
subject to adjustments, as further described in the Securities Purchase Agreement. Each Purchaser is entitled to exercise its
respective Greenshoe Rights for an amount of Series L Convertible Preferred Stock equal to the ratio of such Purchaser&#x2019;s
original subscription amount to the original aggregate subscription amount of all Purchasers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
filed with the Secretary of State of the State of Delaware a Certificate of Increase (the &#x201c;Certificate of Increase&#x201d;) increasing
the shares of Series L 10% Convertible Preferred Stock as designated in the Certificate of Designations from &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zjqBiuyFCbG9" title="Issuance of shares"&gt;28,056&lt;/span&gt; shares to &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zl6BkDZuGUL4" title="Issuance of shares"&gt;30,630&lt;/span&gt;
shares. The Certificate of Designation creates and specifies the rights of Series L 10% Convertible Preferred Stock, including the terms
and conditions on which shares of such preferred stock would convert into shares of our common stock, as well as its liquidation preference.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be
converted at any time at the option of the Purchasers into shares of the Company&#x2019;s common stock at an initial conversion price
of $&lt;span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zCMTE1mMQBi5" title="Conversion price per share"&gt;2.043&lt;/span&gt;,
subject to certain conditions, as further described in the Certificate of Designation. In addition, the holders of the Series L
Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value
per share) of &lt;span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztSReXVKfFRb" title="Percentage of dividend"&gt;10&lt;/span&gt;%
per annum until May 11, 2026, increasing to &lt;span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z4PBmYYRKa2l" title="Percentage of dividend"&gt;12&lt;/span&gt;%
per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first date after the date of
issuance of the Series L Convertible Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation), in
cash, shares of the Company&#x2019;s common stock (subject to the Company&#x2019;s satisfaction of the conditions set forth in the
Certificate of Designation), or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right
to require the Company to redeem the Preferred Shares at a premium, in accordance with and subject to certain conditions as further
described in the Certificate of Designation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant, each to purchase up to a number of shares of
the Company&#x2019;s common stock equal to 100% of the Conversion Shares (as defined in the Securities Purchase Agreement) underlying
the Preferred Shares issued to such Purchaser and (ii) a Vesting Warrant (the exercisability of which shall vest ratably from time
to time in proportion to the Purchaser&#x2019;s (or its permitted assigns&#x2019;) exercise of such Purchaser&#x2019;s Greenshoe Rights
pursuant to Section 2.4 of the Purchase Agreement), each to purchase up to a number of shares of the Company&#x2019;s common stock
equal to the number of Greenshoe Conversion Shares (as defined in the Securities Purchase Agreement) applicable to such Purchaser,
in accordance with the Securities Purchase Agreement. An aggregate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zeKMbz6a5lf7" title="Aggregate number of shares issued"&gt;3,235,978&lt;/span&gt;
Common Warrants were issued with an initial exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z0aleKWOeapf" title="Exercise price per share"&gt;2.043&lt;/span&gt;
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zaimnRnnO2he" title="Warrants term"&gt;five
years&lt;/span&gt;. An aggregate of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zYMPm5YBwpI1" title="Aggregate number of shares vested"&gt;11,576,406&lt;/span&gt;
Vesting Warrants were issued with an initial exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zZ9QsUoJyeJd" title="Exercise price per share"&gt;2.043&lt;/span&gt;
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Shares and Warrants both have full ratchet price protection and are subject to other adjustments, as further described in the
Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise
of Greenshoe Rights, a floor price of $&lt;span id="xdx_90C_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zy4EIPDm1CFb" title="Floor price"&gt;0.454&lt;/span&gt; per share (subject to adjustment for reverse and forward splits, recapitalizations and similar
transactions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration
statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the
Series L Convertible Preferred Stock and upon exercise of the Warrants. The Company has agreed to file a registration statement
within 30 days after the initial closing and after each closing of the exercise of a Greenshoe Right in accordance with the
Securities Purchase Agreement, to become effective no later than 90 days after filing. If these deadlines are not met, &lt;span id="xdx_90C_ecustom--LiableOfLiquidatedDamagePercentageDescription_pp0d_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8uPmJVJoJf" title="Liable of liquidated damage percentage, description"&gt;the
Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the Securities
Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than &lt;span id="xdx_908_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc70S6wPsKbb" title="Common stock shares outstanding percentage"&gt;19.99&lt;/span&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the date of the initial closing (&#x201c;Shareholder
Approval&#x201d;). In connection with the required Shareholder Approval, all of the Company&#x2019;s officers and directors (each a &#x201c;Voting
Agreement Party&#x201d;) entered into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting
stock over which the Voting Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company
seeking Shareholder Approval. Shareholder Approval was obtained on July 24, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $&lt;span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zfxeuClwKSj3" title="Dividends to holders unpaid"&gt;85,000&lt;/span&gt; were declared and unpaid as of June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
C Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025, there were &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqQixzlzdl4d" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAc1AjdiuT45" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt;&lt;/span&gt; shares of series C preferred stock, par value $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9yvFiItTky4" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share (the &#x201c;Series C Preferred Stock&#x201d;)
issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4vBEy8ioKVe" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt; shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Mezzanine
Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Private Placement of Series L Convertible Preferred Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
May 12, 2025 private placement of Series L Convertible Preferred Stock and Warrants produced net proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfWHUntL7L5j" title="Proceeds from issuance of Series L convertible preferred stock and warrants, net"&gt;5,441,000&lt;/span&gt;,
which was allocated to mezzanine equity and additional paid in capital based on the relative fair value of the Series L Convertible
Preferred Stock and Warrants at issuance, respectively. Series L Convertible Preferred Stock is classified as mezzanine equity as it is
conditionally redeemable upon the occurrence of certain events that are not solely within the control of the Company, and upon such
event, the Series L Convertible Preferred Stock would become redeemable at the option of the holders, while Warrants are classified
as additional paid in capital. The relative fair values and allocation of net proceeds is below:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfConversionsOfStockTextBlock_z4eXOwBTwrta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ztAV5Hmk04k2" style="display: none"&gt;Schedule of fair values and allocation of net proceeds&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250512__20250512_zoK18SsbtBfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Relative
    Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZUKKfTWedoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series L Convertible Preferred
    Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,688,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDixMPeB8Pji" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdz5utsYe719" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,089,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ivnyYMac1a" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zBTmFcgTcKBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512_zE7CVK7xIZxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49F_20250512__20250512_zYihwjyeE2e3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allocation
                                                                                                                                                                          of Net Proceeds&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; width: 16%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zxyeobCFgYGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mezzanine equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,025,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zORHzGTl2Fi" style="text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zUZLCKFpD2x6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional paid in capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,389,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zEkicuT39JCl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_z5DFcgIRmWW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,411,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512_zjp40NXazyE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_znFb3FxML5fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
Series L Convertible Preferred Stock is converted into common stock it is reclassified from mezzanine equity to additional paid in capital
based on a pro-rata basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000917"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000919"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000921"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000923"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember"
      decimals="-6"
      id="Fact000925"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:WeightedAverageVolumePriceOfCommonStockPercentage
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000927"
      unitRef="Pure">0.93</GTBP:WeightedAverageVolumePriceOfCommonStockPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000931"
      unitRef="USD">686000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000933"
      unitRef="USD">70000</us-gaap:NoninterestExpenseOfferingCost>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000935"
      unitRef="Shares">302069</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2025-02-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">4.35</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000939"
      unitRef="USDPShares">2.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000941"
      unitRef="Shares">604138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      id="Fact000947">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      id="Fact000953">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">21145</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000957"
      unitRef="USDPShares">2.8375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-02-26" id="Fact000959">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact000961"
      unitRef="USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="2"
      id="Fact000963"
      unitRef="Shares">6611.11</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000965"
      unitRef="USD">6611111</GTBP:AggregateStatedValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">5950000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">24018349</GTBP:AggregateStatedValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">21616514</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">28056</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">30630</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000977"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Pure">0.10</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact000983"
      unitRef="Shares">3235978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      id="Fact000987">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact000989"
      unitRef="Shares">11576406</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeFloorPrice
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="INF"
      id="Fact000993"
      unitRef="USDPShares">0.454</us-gaap:DerivativeFloorPrice>
    <GTBP:LiableOfLiquidatedDamagePercentageDescription
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember"
      id="Fact000995">the
Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the Securities
Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</GTBP:LiableOfLiquidatedDamagePercentageDescription>
    <GTBP:CommonStockSharesOutstandingPercentage
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">0.1999</GTBP:CommonStockSharesOutstandingPercentage>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2025-01-012025-06-30_custom_SeriesLConvertiblePreferredStockMember14125843"
      decimals="0"
      id="Fact000999"
      unitRef="USD">85000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001003"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001005"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001007"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">5441000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ScheduleOfConversionsOfStockTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001011">&lt;p id="xdx_89C_eus-gaap--ScheduleOfConversionsOfStockTextBlock_z4eXOwBTwrta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ztAV5Hmk04k2" style="display: none"&gt;Schedule of fair values and allocation of net proceeds&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250512__20250512_zoK18SsbtBfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Relative
    Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zZUKKfTWedoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series L Convertible Preferred
    Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,688,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDixMPeB8Pji" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdz5utsYe719" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,089,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ivnyYMac1a" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zBTmFcgTcKBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,777,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250512__20250512_zE7CVK7xIZxf" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49F_20250512__20250512_zYihwjyeE2e3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 16%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allocation
                                                                                                                                                                          of Net Proceeds&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; width: 16%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zxyeobCFgYGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mezzanine equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,025,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zORHzGTl2Fi" style="text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zUZLCKFpD2x6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional paid in capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,389,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zEkicuT39JCl" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_z5DFcgIRmWW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,411,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250512__20250512_zjp40NXazyE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfConversionsOfStockTextBlock>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">3688000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact001015"
      unitRef="Pure">0.377</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-122025-05-12_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">6089000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-122025-05-12_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Pure">0.623</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-122025-05-12"
      decimals="0"
      id="Fact001021"
      unitRef="USD">9777000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-122025-05-12"
      decimals="INF"
      id="Fact001023"
      unitRef="Pure">1.000</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-122025-05-12_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact001025"
      unitRef="USD">2025000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-122025-05-12_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact001027"
      unitRef="Pure">0.377</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001029"
      unitRef="USD">3389000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-122025-05-12_us-gaap_AdditionalPaidInCapitalMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Pure">0.623</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-122025-05-12"
      decimals="0"
      id="Fact001033"
      unitRef="USD">5411000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-122025-05-12"
      decimals="INF"
      id="Fact001035"
      unitRef="Pure">1.000</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <GTBP:CommonStockWarrantsAndOptionsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001037">&lt;p id="xdx_80A_ecustom--CommonStockWarrantsAndOptionsTextBlock_zyfxNdUrAs64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_828_zwzcaLLtxo4d"&gt;Common Stock Warrants and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFRRZXXlycMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the six months ended June 30, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zud5tta1Phy6" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_z37492ouCh32" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,120,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zOovBpyVmDqc" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zc0TWRY0dmE8" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,468,308&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250630_zqmgzxUN7Rcg" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zvQUToGaAPGb" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250630_zxxH4NlSBGu1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250630_zZvR0UJDo61c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(837,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250630_zCiSDQpCjojl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zsLqmRuPauL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,751,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zEwamcGVBY01" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250630_zgV9Z5EFy2zg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,995,263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zgeMLtj4NIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zCEVbE2Ypu6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of June 30, 2025 was approximately $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20250630_zz0TLJTEWeT2" title="Options outstanding vested intrinsic value"&gt;25.4&lt;/span&gt;
million and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20250630_zP6ZPMjgl5v6" title="Options outstanding exercisable intrinsic value"&gt;7.4&lt;/span&gt; million, respectively, in each case based on the fair value of the Company&#x2019;s common stock on June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3p9I5hmQML3" title="Aggregate number of shares issued"&gt;3,235,978&lt;/span&gt; Common
Warrants with an initial exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zHtH1CeWQp2" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, they are exercisable, subject to certain ownership limitations,
immediately upon issuance and have a term of exercise equal to five years. An aggregate of &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z6YQFonayyNg" title="Aggregate number of shares vested"&gt;11,576,406&lt;/span&gt; Vesting Warrants were issued with
an initial exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zPy6JRbP6R9b" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, they are exercisable subject to certain vesting and ownership limitations, and have a
term of exercise equal to five years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have
full ratchet price protection and are subject to other adjustments, as further described in the Certificate of Designation or the Warrants,
as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor price of $&lt;span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zBcTMq3MsIF" title="Floor price per share"&gt;0.454&lt;/span&gt;
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zk2w4UQL8WXe" title="Issuance of pre-funded warrants"&gt;300,000&lt;/span&gt;
shares of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and
subject to the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance and until exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2025 the Company issued warrants underlying &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zAGNxBhGigk6" title="Number of warrant issued"&gt;24,390&lt;/span&gt;
shares of common stock exercisable immediately upon issuance with a term of five years from the date of issuance at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zlBIbiw8cwJ5" title="Exercise price per share"&gt;2.46&lt;/span&gt;
per share with a fair value of approximately $&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_ztFQyDrIsnTf" title="Fair value of warrant"&gt;44,000&lt;/span&gt;
in exchange for the waiver of a variable rate transaction (&#x201c;VRT&#x201d;). In addition, in May and June 2025, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkeCHpbBmfg9" title="Number of new shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFBbUCKYyIj1" title="Number of new shares issued"&gt;50,000&lt;/span&gt;&lt;/span&gt;
shares of common stock and warrants underlying &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA6L0jfQVNMl" title="Number of warrant issued"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsYxWn1lQWze" title="Number of warrant issued"&gt;200,000&lt;/span&gt;&lt;/span&gt;
shares of common stock with an aggregate fair value of approximately $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zW4KDpCWe4Th" title="Number shares issued for service, value"&gt;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z36O3KO3ZV2j" title="Number shares issued for service, value"&gt;718,000&lt;/span&gt;&lt;/span&gt;
to vendors as compensation for services. The warrants underlying &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMvHrysfUdb" title="Number of warrant issued"&gt;200,000&lt;/span&gt; shares of common stock consist of warrants underlying &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zw1jvb7eTYbb" title="Number of warrant issued"&gt;50,000&lt;/span&gt;
shares of common stock that are exercisable immediately upon issuance with a term of five years from the date of issuance at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zh0FfPcN2oD2" title="Exercise price per share"&gt;2.50&lt;/span&gt;
per share, and warrants underlying &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zPrzYOKWtdq8" title="Issuance of pre-funded warrants"&gt;150,000&lt;/span&gt;
shares of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSxQ4PFox24g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of June 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zNDak2Z2iooa" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding and Exercisable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zylrlDxZCov3" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zuYvvvqyDxh" style="width: 20%; text-align: right" title="Number of outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;476,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zghIcncxrhVj" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfU4RWPBx8J7" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKKvqqfA0Joj" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zzuc7Zx6EXGg" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHdVGYCivtmi" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zBNZitw7tIs5" title="Range of exercise price"&gt;2.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zbQUmE4GKwv6" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,235,979&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zeoCVFtVgzT8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkdQtMfLk4F6" title="Warrants weighted average exercise price"&gt;2.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zz0ysIDCUmb5" title="Range of exercise price"&gt;2.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrEB11Xg8Dyg" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoP2g8IYBLHg" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zqBrf3XirNg2" title="Warrants weighted average exercise price"&gt;2.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zJF1hkVJEhSl" title="Range of exercise price"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zwbhoc74cPLc" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqZdDvhLf5w5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z5UfSuUciCKa" title="Warrants weighted average exercise price"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zQMTaL6JPi94" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF6bgnAIVp6f" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYmlIk2k6y5b" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zACP4rkJEKG7" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zvUWzxuujET5" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zwIrLvKs5OB" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437,931&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmknRphKmfT3" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zG83qSeIN0e4" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUJe2w5QLOC8" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5e8u2NRi155" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zExMoAUjLOak" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaKdZo99QDYc" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zppRZrBCYBzk" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBXJIl2OnPT1" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zrryqog2Rby" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYtInJW1Lnq2" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z7j6zJVIJ3x4" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zCKNI3kWO8lf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zwjwtx0iFxg1" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z6B5pnD06r0d" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z4oI4QSW5qpj" title="Range of exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z3gz1puzc5t9" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zqa8Z1DriZgj" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zpO2RIcwnqZ4" title="Warrants weighted average exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zFJVlof6TBW" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z8EfT49bILWf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,316&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zCsUMQtnxai4" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z4BqBJBXNDX5" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z9G6Qdw0rz31" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zxZ10meisyhf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zr9HRA4NQ7O2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zuA3IsDxnvud" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvJFIU9TLJR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,995,263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zqK1AUGxbcI2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsgL3EuScUFa" title="Warrants weighted average exercise price"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zH8srVfQWY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;). The Plan was approved by our Board and
stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our
employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards
granted under the Plan is &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zXHJBhMXSGr9" title="Common stock awards granted"&gt;166,667&lt;/span&gt;.
The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant
under the Plan. As of June 30, 2025, there were &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630_zC2cmFxSpvv4" title="Stock option outstanding"&gt;124,600&lt;/span&gt;
stock options outstanding and &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630_zbeK7wTiLC6j" title="Rstricted stock granted"&gt;25,935&lt;/span&gt;
shares of restricted stock granted in prior years under the Plan, which left &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zreB7M2SrIU7" title="Available for grant"&gt;16,132&lt;/span&gt;
shares available for grant under the Plan. Only July 24, 2025 shareholders voted to increase the maximum number of shares of common
stock that may be issued pursuant to awards granted under the Plan by &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20250630_zbU6w0Ao5lOg" title="Rstricted stock granted"&gt;583,334&lt;/span&gt;. The following table summarizes stock option
transactions for the six months ended June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zo9LxrT4uavb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_z5y9KBqzLE5" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250630_zUURxTu1R4j3" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zuPebCPWWmG6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250630_zMmIK6Rifx81" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zHZG6IFDTYFk" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250630_zNhmjR7FiBlc" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_z9oZJEv9WChk" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250630_zauh4ESFfEDa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zWGtpFYrQJv4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250630_z4h6eRIePgZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zbt7vI2z4mDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250630_zLBTnyA2eoCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zn5qNLzwgCQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z9OhJspF4mn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of June 30, 2025 was
approximately &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630_zBAMadCSyzrl" title="Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term"&gt;7.75&lt;/span&gt; years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of June 30, 2025 was approximately $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250630_zFX8K3ykdbch" title="Options outstanding intrinsic value"&gt;34,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630_zUlVJiX9m8y6" title="Options vested and exercisable intrinsic value"&gt;12,000&lt;/span&gt;, respectively, in each case based on the fair value of the Company&#x2019;s
common stock on June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total fair value of options that vested during the six months ended June 30, 2025 and 2024, was $&lt;span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250630_zrH3wffxZ8xa" title="Fair value of vested stock options"&gt;7,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240630_zSZ70SgSEmZ3" title="Fair value of vested stock options"&gt;222,000&lt;/span&gt;, respectively, and
is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of June
30, 2025, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zot1fKQQGan" title="Stock option, exercisable"&gt;109,692&lt;/span&gt; stock options were vested and exercisable and unvested compensation expense amounted to approximately $&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250630_zS9I3J08jJsl" title="Stock option, unvested compensation"&gt;26,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z96AsrsqRwN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of June 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zI9fjD8kVxV4" style="display: none"&gt;Schedule of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Options Exercisable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zpYk9IqrLm69" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zoi5cG4IlAhg" style="width: 20%; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,428&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMWsSxLQDVLg" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4ansmC0W0hj" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJXNKmGxXa72" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8ojRqMnqIgc" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkcTlyi0X7u8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6XQifpXUYjk" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7hTzr1wd1X5" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zw60N4cokNUi" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdMMyBtv017f" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGkicjYnYiK" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z72dsDauQvu4" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPLmfno1S0Eh" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,598&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z106bEEQ6gJ2" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zOTbkAruaQWl" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630_zGceyO43Ed7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zNwNpKTRFaK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:CommonStockWarrantsAndOptionsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001039">&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFRRZXXlycMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the six months ended June 30, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zud5tta1Phy6" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250630_z37492ouCh32" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,120,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zOovBpyVmDqc" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250630_zc0TWRY0dmE8" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,468,308&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250630_zqmgzxUN7Rcg" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250630_zvQUToGaAPGb" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250630_zxxH4NlSBGu1" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250630_zZvR0UJDo61c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(837,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250630_zCiSDQpCjojl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250630_zsLqmRuPauL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,751,668&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zEwamcGVBY01" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250630_zgV9Z5EFy2zg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,995,263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zgeMLtj4NIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">1120429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001043"
      unitRef="USDPShares">18.85</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">16468308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001047"
      unitRef="USDPShares">2.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">837069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001055"
      unitRef="USDPShares">2.11</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">16751668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">3.07</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">4995263</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001063"
      unitRef="USDPShares">5.49</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact001065"
      unitRef="USD">25400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact001067"
      unitRef="USD">7400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001069"
      unitRef="Shares">3235978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001071"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001073"
      unitRef="Shares">11576406</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_VestingWarrantsMember"
      decimals="INF"
      id="Fact001075"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeFloorPrice
      contextRef="AsOf2025-05-31_custom_GreenshoeRightsMember"
      decimals="INF"
      id="Fact001077"
      unitRef="USDPShares">0.454</us-gaap:DerivativeFloorPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="Fact001081"
      unitRef="Shares">24390</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="Fact001083"
      unitRef="USDPShares">2.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-05-31"
      decimals="0"
      id="Fact001085"
      unitRef="USD">44000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-05-012025-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-06-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-012025-05-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-06-012025-06-30"
      decimals="0"
      id="Fact001097"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001103"
      unitRef="USDPShares">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">150000</us-gaap:ClassOfWarrantOrRightUnissued>
    <GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember"
      id="Fact001107">&lt;p id="xdx_890_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zSxQ4PFox24g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of June 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zNDak2Z2iooa" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding and Exercisable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zylrlDxZCov3" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zuYvvvqyDxh" style="width: 20%; text-align: right" title="Number of outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;476,251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zghIcncxrhVj" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfU4RWPBx8J7" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKKvqqfA0Joj" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zzuc7Zx6EXGg" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zHdVGYCivtmi" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zBNZitw7tIs5" title="Range of exercise price"&gt;2.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zbQUmE4GKwv6" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,235,979&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zeoCVFtVgzT8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkdQtMfLk4F6" title="Warrants weighted average exercise price"&gt;2.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zz0ysIDCUmb5" title="Range of exercise price"&gt;2.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zrEB11Xg8Dyg" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoP2g8IYBLHg" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zqBrf3XirNg2" title="Warrants weighted average exercise price"&gt;2.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zJF1hkVJEhSl" title="Range of exercise price"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zwbhoc74cPLc" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zqZdDvhLf5w5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z5UfSuUciCKa" title="Warrants weighted average exercise price"&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zQMTaL6JPi94" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF6bgnAIVp6f" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYmlIk2k6y5b" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zACP4rkJEKG7" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zvUWzxuujET5" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zwIrLvKs5OB" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437,931&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmknRphKmfT3" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zG83qSeIN0e4" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUJe2w5QLOC8" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5e8u2NRi155" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zExMoAUjLOak" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaKdZo99QDYc" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zppRZrBCYBzk" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBXJIl2OnPT1" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zrryqog2Rby" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYtInJW1Lnq2" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z7j6zJVIJ3x4" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zCKNI3kWO8lf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zwjwtx0iFxg1" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z6B5pnD06r0d" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z4oI4QSW5qpj" title="Range of exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z3gz1puzc5t9" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zqa8Z1DriZgj" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zpO2RIcwnqZ4" title="Warrants weighted average exercise price"&gt;102.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zFJVlof6TBW" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z8EfT49bILWf" style="text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,316&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zCsUMQtnxai4" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_z4BqBJBXNDX5" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z9G6Qdw0rz31" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zxZ10meisyhf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,780&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zr9HRA4NQ7O2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zuA3IsDxnvud" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvJFIU9TLJR4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,995,263&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zqK1AUGxbcI2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsgL3EuScUFa" title="Warrants weighted average exercise price"&gt;3.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001109"
      unitRef="USDPShares">0.0001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Shares">476251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001113"
      unitRef="USDPShares">0.0001</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001115"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">369138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwoMember"
      id="Fact001119">P2Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001121"
      unitRef="USDPShares">2.02</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001123"
      unitRef="USDPShares">2.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001125"
      unitRef="Shares">3235979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThreeMember"
      id="Fact001127">P4Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001129"
      unitRef="USDPShares">2.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001131"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001133"
      unitRef="Shares">24390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFourMember"
      id="Fact001135">P4Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">2.46</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001139"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeFiveMember"
      id="Fact001143">P2Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001145"
      unitRef="USDPShares">2.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001147"
      unitRef="USDPShares">2.8375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">21145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSixMember"
      id="Fact001151">P4Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001153"
      unitRef="USDPShares">2.8375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001155"
      unitRef="USDPShares">4.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001157"
      unitRef="Shares">437931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeSevenMember"
      id="Fact001159">P3Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001161"
      unitRef="USDPShares">4.35</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001163"
      unitRef="USDPShares">5.4375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001165"
      unitRef="Shares">88800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeEightMember"
      id="Fact001167">P3Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001169"
      unitRef="USDPShares">5.4375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">30.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeNineMember"
      id="Fact001175">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001177"
      unitRef="USDPShares">30.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001179"
      unitRef="USDPShares">37.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTenMember"
      id="Fact001183">P2Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001185"
      unitRef="USDPShares">37.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001187"
      unitRef="USDPShares">102.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">1867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeElevenMember"
      id="Fact001191">P0Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">102.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001195"
      unitRef="USDPShares">165.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">52316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeTwelveMember"
      id="Fact001199">P0Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001201"
      unitRef="USDPShares">165.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001203"
      unitRef="USDPShares">206.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001205"
      unitRef="Shares">7780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember_custom_RangeThirteenMember"
      id="Fact001207">P0Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_WarrantsMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">206.25</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">4995263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_WarrantsMember"
      id="Fact001213">P4Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001215"
      unitRef="USDPShares">3.07</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001217"
      unitRef="Shares">166667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001219"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact001221"
      unitRef="Shares">25935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Shares">16132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001225"
      unitRef="USD">583334</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001227">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zo9LxrT4uavb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_z5y9KBqzLE5" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250630_zUURxTu1R4j3" style="width: 16%; text-align: right" title="Number of options outstanding, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250630_zuPebCPWWmG6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250630_zMmIK6Rifx81" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zHZG6IFDTYFk" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250630_zNhmjR7FiBlc" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_z9oZJEv9WChk" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250630_zauh4ESFfEDa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250630_zWGtpFYrQJv4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250630_z4h6eRIePgZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250630_zbt7vI2z4mDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250630_zLBTnyA2eoCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250630_zn5qNLzwgCQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001231"
      unitRef="USDPShares">32.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001247"
      unitRef="USDPShares">32.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">109692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001251"
      unitRef="USDPShares">36.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-06-30" id="Fact001253">P7Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001255"
      unitRef="USD">34000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001257"
      unitRef="USD">12000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001259"
      unitRef="USD">7000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact001261"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001263"
      unitRef="Shares">109692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact001265"
      unitRef="USD">26000</GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001267">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z96AsrsqRwN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of June 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zI9fjD8kVxV4" style="display: none"&gt;Schedule of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    Options Exercisable as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining
                                            Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zpYk9IqrLm69" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zoi5cG4IlAhg" style="width: 20%; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,428&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMWsSxLQDVLg" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4ansmC0W0hj" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJXNKmGxXa72" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8ojRqMnqIgc" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkcTlyi0X7u8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6XQifpXUYjk" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7hTzr1wd1X5" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zw60N4cokNUi" style="text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdMMyBtv017f" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGkicjYnYiK" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z72dsDauQvu4" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPLmfno1S0Eh" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,598&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z106bEEQ6gJ2" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zOTbkAruaQWl" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250630_zGceyO43Ed7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001269"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-06-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">8428</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_custom_RangeOneMember"
      id="Fact001273">P9Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-06-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001275"
      unitRef="USDPShares">2.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001277"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-06-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001279"
      unitRef="Shares">16666</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_custom_RangeTwoMember"
      id="Fact001281">P7Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-06-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001285"
      unitRef="USDPShares">25.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-06-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_custom_RangeThreeMember"
      id="Fact001289">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-06-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001291"
      unitRef="USDPShares">25.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-06-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001293"
      unitRef="USDPShares">74.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-06-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">34598</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-06-30_custom_RangeFourMember"
      id="Fact001297">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-06-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001299"
      unitRef="USDPShares">74.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001301"
      unitRef="Shares">109692</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001303">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zRwcH9vnzFt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82E_zEtS4yWleeua"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Litigation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ohri
Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#x2019;s termination as &#x201c;for cause&#x201d; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#x2019;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#x2019;s violations, and attorneys&#x2019;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#x2019;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for June 10, 2025, has been
postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not been scheduled. There is
a status conference scheduled for August 19, 2025 before the AAA. At this stage in the proceedings the Company is not able to determine the probability
of the outcome of this matter or a range of reasonably expected losses, if any. The Company believes it has recorded an appropriate accrual
for the matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TWF
Global Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 24, 2023, TWF Global, LLC (&#x201c;TWF&#x201d;) filed a Complaint in the California Superior Court for the County of Los Angeles
naming the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes
(&#x201c;Notes&#x201d;) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was
seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for
improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF
voluntarily dismissed its complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently
filed a summons and complaint for interpleader against TWF and Z-One, LLC before the Supreme Court of the State of New York County
of New York, asking the Supreme Court to determine if the Company&#x2019;s shares of common stock should be registered to TWF or
Z-One LLC, as both of these entities have made conflicting demands for the shares. On February 5, 2024, the Company filed a motion
for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of
Z-One, LLC and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice
and agreed to reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024,
Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing that Z-One, LLC and TWF have settled
their dispute over the entitlement to the Company&#x2019;s shares of common stock and there is no remaining dispute before the Court.
On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. On November 14, 2024, the
Court held a hearing on the parties&#x2019; motions, at which the Court found that the motion for entry of default was mooted by the
settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February 17, 2025, Z-One, LLC
filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that
Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder, either originally
or by assignment, of a Convertible Note in the principal amount of $&lt;span id="xdx_90F_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z4oV2pdd3nY2" title="Principal amount"&gt;150,000&lt;/span&gt;,
that the Company breached the Convertible Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it
damages in excess of $&lt;span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z7lwpXbW28yg" title="Damages sought value"&gt;500,000&lt;/span&gt;.&#160;The
Company intends to seek dismissal of the case. The Company believes that the claims related to the Notes are without merit, and will
continue to vigorously defend against these claims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Silberfein,
DiPietro, and Werthman Trust Matters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 8, 2025, Coby Silberfein filed a summons with
notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages for breach of
a securities purchase agreement and convertible note in the principal amount of $&lt;span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zyAE3ocpukJ7" title="Damages sought value"&gt;100,000&lt;/span&gt;.&#160;On July 8, 2025, Justin DiPietro filed
a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant seeking damages
for breach of a securities purchase agreement and convertible note in the principal amount of $&lt;span id="xdx_904_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z5TI4FLoa1b4" title="Damages paid"&gt;100,000&lt;/span&gt;.&#160;On July 9, 2025, Phillip
Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of New York naming the Company as defendant
seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $&lt;span id="xdx_907_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_z994mWnajMli" title="Damages paid"&gt;100,000&lt;/span&gt;.&#160;The three
summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that the Company breached the convertible
notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are seeking specific performance and damages.
The Company intends to demand that the plaintiffs file complaints and then seek dismissal of the complaints.&#160;The Company believes
that the claims are without merit, and intends to vigorously defend against these claims.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Significant
Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cytovance
Biologics, Inc., a Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform
biologic development and manufacturing services, and to produce and test compounds used in the Company&#x2019;s potential product candidates.
The Company subsequently executed numerous Statements of Work (&#x201c;SOWs&#x201d;) for the research and development of products for use
in clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and
allowed for future invoices to be settled in in a combination of cash and issuance of the Company&#x2019;s common stock. The
Settlement and Investment Agreement also set Cytovance&#x2019;s beneficial ownership limitation at &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z4T2TkzC9iMf" title="Equity method investment, ownership percentage"&gt;4.9&lt;/span&gt;%
of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#x2019;s
beneficial ownership limitation to &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_z8Tjn3xaHaM4" title="Equity method investment, ownership percentage"&gt;9.9&lt;/span&gt;% of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zersJaECbUn5" title="Equity method investment, ownership percentage"&gt;5&lt;/span&gt;% of the issued and outstanding shares of the
Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2025 and 2024, the Company recognized research and development expenses of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znbHdtNB3Dff" title="Research and development expenses"&gt;626,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9MYdmclaWi4" title="Research and development expenses"&gt;778,000&lt;/span&gt;, respectively
and made cash payments amounting to $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zRWPp84O2n5j" title="Cash payments"&gt;364,000&lt;/span&gt; and approximately $&lt;span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zEKl3SMUjXx8" title="Cash payments"&gt;2.6&lt;/span&gt; million, respectively to Cytovance. In addition, during the six months
ended June 30, 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zCtadGfp2tna" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares of common stock exercisable at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2XRPsD35Sa" title="Exercise price"&gt;0.0001&lt;/span&gt; per
share to settle accounts payable valued at approximately $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zM2el97SdJg6" title="Fair value"&gt;847,000&lt;/span&gt;; and during the six months ended June 30, 2024, the Company issued
&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z7XLV7yAPkcj" title="Issuance of common stock in settlement of vendor payable, shares"&gt;127,597&lt;/span&gt; shares of common stock to settle accounts payable valued at approximately $&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zJgiOdJ5R7z" title="Issuance of common stock in settlement of vendor payable"&gt;810,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025, the Company&#x2019;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance
for services that have not yet been rendered as of June 30, 2025, amounted to approximately $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znaoD4J955Zi" title="Stock issued during period, value, issued for services"&gt;310,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Sponsored Research Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#x201c;2023
Sponsored Research Agreement&#x201d;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zbdtHhXCfvE3" title="Aggregate research and development expense"&gt;1.7&lt;/span&gt; million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#x2019;s TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; product development and commercial
GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; constructs in support of the Company&#x2019;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#x2019;s native NK cell population as a result
of alteration of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform through formation of
immune complexes. Most studies will use TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; DNA/amino acid sequences created by the Company under existing licensing
terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zQp9HhDP5Fad" title="Payments of research and development"&gt;216,000&lt;/span&gt;
were added bringing the total payments due over the life of the agreement to approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zlwkkGm14Qw7" title="Aggregate research and development expense"&gt;1.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense classified as research and development of approximately $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zYG1w6TyPNVa" title="Research and development expense"&gt;431,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zhqFPEv9vlPb" title="Research and development expense"&gt;862,000&lt;/span&gt;, pursuant to the 2023 Sponsored
Research Agreement, for the six months ended June 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately
$&lt;span id="xdx_90D_eus-gaap--UnbilledReceivablesCurrent_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zDCuAOKtFUCl" title="Unbilled and unaccrued amounts"&gt;431,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2016
Exclusive Patent License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#x201c;2016 Exclusive Patent License Agreement&#x201d;), to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $&lt;span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3dp4KJ2aatg" title="Proceeds from upfront amount"&gt;200,000&lt;/span&gt;, and license maintenance
fees of $&lt;span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_z3GZvh5j68yb" title="License maintenance fees"&gt;200,000&lt;/span&gt; for years 2017 through 2020, and $&lt;span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaCVDRw5b23" title="License maintenance fees"&gt;100,000&lt;/span&gt; per year beginning in year 2021 and each year thereafter. The agreement also
includes 4% royalty fees on the net sales of licensed products, not to exceed &lt;span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zbd7pNuT90rh" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zGbQNcMrbYyd" title="Annual royalty payments"&gt;250,000&lt;/span&gt; beginning
in 2022, $&lt;span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zf5G2uYyERf6" title="Annual royalty payments"&gt;2&lt;/span&gt; million beginning in 2025, and $&lt;span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zhcDVBExHAri" title="Annual royalty payments"&gt;5&lt;/span&gt; million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zpJB5wwXQGL1" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone
payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z0LLtoK0ipI3" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zUNVR4MRrhye" title="Sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zoJWoJwdn7w1" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_90A_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEqAH2gnSqA5" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative
gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $&lt;span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZ5y9iD4Zrl3" title="Proceeds from upfront amount"&gt;145,000&lt;/span&gt; and amends the license maintenance fees to $&lt;span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zLjj4h3AfNAf" title="License maintenance fees"&gt;50,000&lt;/span&gt; in 2025, and $&lt;span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJOhnQTyBdij" title="License maintenance fees"&gt;100,000&lt;/span&gt;
per year beginning in year 2026 and each year thereafter. The amendment also includes &lt;span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_z8zCGU12T8s" title="Royalty fee percentage"&gt;1&lt;/span&gt;% to &lt;span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z92NnLxxsmk3" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed
products, not to exceed &lt;span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zjsU14Uk98L3" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $&lt;span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z3WdKZYMWcgd" title="Royalty expense year one"&gt;250,000&lt;/span&gt; in year one, $&lt;span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zT40GpuLv7Zj" title="Royalty expense years two through five"&gt;2&lt;/span&gt; million in years two through five, and $&lt;span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKESBNm0J6Kk" title="Royalty expense year six and thereafter"&gt;5&lt;/span&gt; million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $&lt;span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zaqKmtkYxFZ8" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone, and one-time sales milestone payments of $&lt;span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zC9PjtiV1NG3" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zXAY4L0eGXj3" title="Gross sales"&gt;250&lt;/span&gt;
million in cumulative gross sales, and $&lt;span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zRiwWSsZFCH5" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z9zolMcdf4Fa" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense classified as research and development of approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z8wUl3OBYMQk" title="Research and development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zNVnh2gFO2Hj" title="Research and development expense"&gt;150,000&lt;/span&gt;, pursuant to the 2016 Exclusive Patent
License Agreement, for the six months ended June 30, 2025 and 2024, respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021
Exclusive License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#x201c;2021
Exclusive Patent License Agreement&#x201d;), specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. The agreement requires an upfront payment
of $&lt;span id="xdx_90A_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8ogOGCqIc08" title="Upfront license fee"&gt;20,000&lt;/span&gt;, and license maintenance fees of $&lt;span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsCAaaCMn8Fl" title="License maintenance fees"&gt;5,000&lt;/span&gt; per year beginning in year 2022 and each year thereafter. The agreement also includes
&lt;span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zDxt4LCKLsH6" title="Royalty fee percentage"&gt;2.5&lt;/span&gt;% to &lt;span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdvZmN6pcEil" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $&lt;span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zjyziXdUWq2d" title="Royalty expense year one though four"&gt;250,000&lt;/span&gt; in year one though four, and $&lt;span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdDxgyYhn8Yd" title="Royalty expense year five and thereafter"&gt;2&lt;/span&gt; million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zRhIjtymKXs6" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million,
and one-time sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zqAdPQXYB629" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAucye1sF9qc" title="Gross sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z7tipI69XMK7" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching
$&lt;span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zST948NdUWc4" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
six months ended June 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024
GTB-3650 Clinical Trial Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#x201c;Agreement&#x201d;) with
the Regents of the University of Minnesota (the &#x201c;University&#x201d;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#x201c;IND&#x201d;) application for IND 165546 GTB-3650 (the &#x201c;Research Program&#x201d;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#x201c;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#x201d; designed
by the University (the &#x201c;Study&#x201d;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRYccYR7t3Nc" title="Annual royalty payments"&gt;2.1&lt;/span&gt; million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#x2019; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the six
months ended June 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant
to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of June 30, 2025, amounted to approximately $&lt;span id="xdx_903_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zRxKtdeu7nFd" title="Unbilled and unaccrued amounts"&gt;1.9&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;b&gt;PDPC Advisors Inc., a Related Party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2025, the Company entered into an Advisory
Agreement (the &#x201c;Agreement&#x201d;) with PDPC Advisors Inc. (&#x201c;PDPC&#x201d;), to perform certain advisory services. Under the
Agreement cash payments amounting to $&lt;span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zu90pIWGqo83" title="Cash payment"&gt;100,000&lt;/span&gt; are to be paid in six equal installments beginning on July 1, 2025 and ending on December
31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC on a pre-funded warrant to purchase &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zixTaOnEyvc8" title="Warrants outstanding"&gt;150,000&lt;/span&gt; shares
of common stock of the Company, which had a fair value of $&lt;span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zMNuYOa3ADJa" title="Stock issuance"&gt;537,000&lt;/span&gt; at the time of issuance. The Agreement begins on July 1, 2026 and terminates
on June 30, 2026. PDPC is considered a related party as its CEO is an individual who has voting and investment control over an entity
whose beneficial ownership exceeded 5% of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Contingency
&#x2013; NASDAQ Matters&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2024, we received a letter (the &#x201c;Notification Letter&#x201d;) from the Nasdaq Listing Qualifications Staff (the &#x201c;Staff&#x201d;)
notifying us that the amount of our stockholders&#x2019; equity had fallen below the $&lt;span id="xdx_90B_ecustom--ContigencyMinimumRequired_iI_c20241121_zAnRIH6l3Tnb" title="Contigency minimum required"&gt;2,500,000&lt;/span&gt; required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#x201c;Minimum Stockholders&#x2019; Equity Requirement&#x201d;). Nasdaq&#x2019;s determination
was based upon our stockholders&#x2019; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#x2019;s Listing Rules.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#x2019; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#x2019;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#x2019; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#x2019; Equity Requirement, so if at the time of the filing of the Company&#x2019;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#x2019; Equity Requirement,
the Company may be subject to delisting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember"
      decimals="0"
      id="Fact001305"
      unitRef="USD">150000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember"
      decimals="0"
      id="Fact001307"
      unitRef="USD">500000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001309"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001311"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-07-092025-07-09_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001315"
      unitRef="Pure">0.049</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Pure">0.099</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember14126828"
      decimals="INF"
      id="Fact001319"
      unitRef="Pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001321"
      unitRef="USD">626000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001323"
      unitRef="USD">778000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001325"
      unitRef="USD">364000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      id="Fact001327"
      unitRef="USD">2600000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">847000</us-gaap:FairValueAdjustmentOfWarrants>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001337"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-06-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001339"
      unitRef="USD">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="-5"
      id="Fact001341"
      unitRef="USD">1700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">216000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="-5"
      id="Fact001345"
      unitRef="USD">1900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">431000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001349"
      unitRef="USD">862000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-06-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001351"
      unitRef="USD">431000</us-gaap:UnbilledReceivablesCurrent>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember"
      decimals="0"
      id="Fact001355"
      unitRef="USD">200000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001359"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="-6"
      id="Fact001363"
      unitRef="USD">2000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember"
      decimals="-6"
      id="Fact001365"
      unitRef="USD">5000000</us-gaap:RoyaltyExpense>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001367"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001369"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001371"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001373"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001375"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">145000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="0"
      id="Fact001379"
      unitRef="USD">50000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001381"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Pure">0.01</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOne
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001389"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOne>
    <GTBP:RoyaltyExpenseYearTwoThroughFive
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001391"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearTwoThroughFive>
    <GTBP:RoyaltyExpenseYearAfterSix
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001393"
      unitRef="USD">5000000</GTBP:RoyaltyExpenseYearAfterSix>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001395"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001397"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001399"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001401"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001403"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001407"
      unitRef="USD">150000</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <us-gaap:CostMaintenance
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">5000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">0.025</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOneThoughFour
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOneThoughFour>
    <GTBP:RoyaltyExpenseYearAfterFive
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001419"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearAfterFive>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001421"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001423"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001425"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001427"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001429"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-5"
      id="Fact001431"
      unitRef="USD">2100000</us-gaap:RoyaltyExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-06-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-5"
      id="Fact001433"
      unitRef="USD">1900000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">150000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">537000</us-gaap:PaymentsOfStockIssuanceCosts>
    <GTBP:ContigencyMinimumRequired
      contextRef="AsOf2024-11-21"
      decimals="0"
      id="Fact001441"
      unitRef="USD">2500000</GTBP:ContigencyMinimumRequired>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001443">&lt;p id="xdx_80E_eus-gaap--SegmentReportingDisclosureTextBlock_zQm378o3rbs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_822_zhvK5xGCmHLa"&gt;Segment Information&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#xae;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zABlW2L8AfH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zxXs1bkEkkQd" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zFeVxiSmIG3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zEoob9Bsoco6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zGRoSunlJxNd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zbKmzSCnUx03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_zkUepjTp0BX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,805,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,462,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,561,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_z7vNPeh1kNgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;287,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;632,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;765,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zbqVlsr8oBa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;121,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;152,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zTDYqOaL1fic" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_zDwtSMBk4wQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,619,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,223,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_z8rx2N03qgnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(197,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,236,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0XwqDwv6666" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,433,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,710,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,209,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,976,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zN1PMwuDq7V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001445">&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zABlW2L8AfH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zxXs1bkEkkQd" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zFeVxiSmIG3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zEoob9Bsoco6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zGRoSunlJxNd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zbKmzSCnUx03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_zkUepjTp0BX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,805,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,462,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,561,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_z7vNPeh1kNgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;287,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;632,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;765,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zbqVlsr8oBa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;121,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;152,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zTDYqOaL1fic" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;222,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_zDwtSMBk4wQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,619,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,223,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_z8rx2N03qgnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(197,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,236,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,021,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_z0XwqDwv6666" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,433,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,710,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,209,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,976,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">363000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001448"
      unitRef="USD">1805000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">1462000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001450"
      unitRef="USD">2561000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001452"
      unitRef="USD">351000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">287000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001454"
      unitRef="USD">632000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001455"
      unitRef="USD">765000</us-gaap:SalariesAndWages>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">61000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001458"
      unitRef="USD">76000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001459"
      unitRef="USD">121000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">152000</us-gaap:InsuranceCommissions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">4000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">120000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">7000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">222000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001467"
      unitRef="USD">734000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001468"
      unitRef="USD">1619000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">1223000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001470"
      unitRef="USD">3297000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001472"
      unitRef="USD">-80000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">-197000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001474"
      unitRef="USD">-1236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">-1021000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">1433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001478"
      unitRef="USD">3710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">2209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001480"
      unitRef="USD">5976000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact001482">&lt;p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zuQEn7OkIi17" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_826_z4bvuP9xMyX1"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 28, 2025, a Purchaser of the Company&#x2019;s Series L 10% Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;) elected
to exercise their Greenshoe Rights and purchased &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfWHD6Dz2LS7" title="Shares issued"&gt;222.22&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock with a stated value of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4QcKmhQquai" title="Shares issued value"&gt;222,222&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_90A_ecustom--PreferredStockPurchasePrice_c20250728__20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUZyxu4udV2j" title="Purchase price"&gt;200,000&lt;/span&gt;. As a result of the transaction the conversion price of the Preferred Stock was decreased from $&lt;span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250727__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrwGwhaW4p7" title="Exercise price"&gt;2.043&lt;/span&gt;
to $&lt;span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250728__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbFA4VXVKfp" title="Exercise price"&gt;1.7766&lt;/span&gt;. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Conversion
of Series L 10% Convertible Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
July 1, 2025 through August 10, 2025 the holders of the Company&#x2019;s Series L Convertible Preferred Stock have converted &lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcIjFuAeFgh5" title="Number of shares converted"&gt;543,273&lt;/span&gt;
shares of Series L Convertible Preferred Stock into &lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20250810__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpWddUlZ3Qxk" title="Number of shares converted"&gt;284,507&lt;/span&gt;
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001484"
      unitRef="Shares">222.22</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001486"
      unitRef="USD">222222</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GTBP:PreferredStockPurchasePrice
      contextRef="From2025-07-282025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">200000</GTBP:PreferredStockPurchasePrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-07-27_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001490"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-07-28_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001492"
      unitRef="USDPShares">1.7766</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">543273</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-08-10_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001496"
      unitRef="Shares">284507</us-gaap:CommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-06-30" id="Fact001497">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-06-30" id="Fact001498">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-06-30" id="Fact001499">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-06-30" id="Fact001500">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000756"
          xlink:label="Fact000756"
          xlink:type="locator"/>
        <link:footnote id="Footnote000767" xlink:label="Footnote000767" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Converted into
common stock using a conversion price of $<xhtml:span
  id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250630_zKpDJ4kG8aHb"
  title="Conversion price per share">2.043</xhtml:span> per share, as of June 30, 2025</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000756"
          xlink:to="Footnote000767"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0757"
          xlink:label="xdx2ixbrl0757"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0757"
          xlink:to="Footnote000767"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000783"
          xlink:label="Fact000783"
          xlink:type="locator"/>
        <link:footnote id="Footnote000820" xlink:label="Footnote000820" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accounts
                                            Payable to Cytovance, a related party, since Cytovance
                                            owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
                                            7 &#x2013; Commitments and Contingencies, Significant Agreements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000783"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000784"
          xlink:label="Fact000784"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000784"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000786"
          xlink:label="Fact000786"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000786"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000788"
          xlink:label="Fact000788"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000788"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000870"
          xlink:label="Fact000870"
          xlink:type="locator"/>
        <link:footnote id="Footnote000893" xlink:label="Footnote000893" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000870"
          xlink:to="Footnote000893"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000872"
          xlink:label="Fact000872"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000872"
          xlink:to="Footnote000893"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000874"
          xlink:label="Fact000874"
          xlink:type="locator"/>
        <link:footnote id="Footnote000894" xlink:label="Footnote000894" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000874"
          xlink:to="Footnote000894"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000876"
          xlink:label="Fact000876"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000876"
          xlink:to="Footnote000894"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000878"
          xlink:label="Fact000878"
          xlink:type="locator"/>
        <link:footnote id="Footnote000895" xlink:label="Footnote000895" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000878"
          xlink:to="Footnote000895"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000880"
          xlink:label="Fact000880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000880"
          xlink:to="Footnote000895"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000882"
          xlink:label="Fact000882"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000882"
          xlink:to="Footnote000895"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000884"
          xlink:label="Fact000884"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000884"
          xlink:to="Footnote000895"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0886"
          xlink:label="xdx2ixbrl0886"
          xlink:type="locator"/>
        <link:footnote id="Footnote000896" xlink:label="Footnote000896" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on no dividends
paid or expected to be paid</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0886"
          xlink:to="Footnote000896"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0888"
          xlink:label="xdx2ixbrl0888"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0888"
          xlink:to="Footnote000896"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
